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Abstract
The NF-kB family of transcription factors have previously been shown to be elevated in many 
malignant diseases including breast cancer. NF-kB activation is strongly associated with signalling 
downstream of the epidermal growth factor (EGF) family of receptors in both aggressive EGFR-positive 
and ERBB2-positive breast cancer subtypes. These observations have led to much interest in the use of 
NF-kB inhibitors to suppress tum our progression in breast cancer patients. However, as NF-kB controls 
numerous functions in homeostasis there are significant risks associated with sustained global inhibition 
of NF-kB signalling. This investigation therefore aimed to determ ine w hether inhibition of the NF-kB co­
factor, B-Cell Lymphoma 3 (BCL3), would block the pro-tumourigenic function of NF-kB, while allowing it 
to retain its physiological functions in normal tissues.
Deletion of BCL3 had no effect on the gross morphology or function of the mammary gland 
during the pregnancy cycle, although a subtle BCL3 dose-dependent effect was observed during 
involution whereby Bcl3+/' mice had increased apoptotic bodies in comparison with both 6c/3+/+ and 
B e ll1' mice. Loss of BCL3 in the context of ERBB2-driven murine m am m ary carcinogenesis resulted in a 
significant delay in both the initiation and metastatic progression of mammary adenocarcinomas. 
Further in vitro investigation revealed that Bcl3 suppression by SiRNA in a murine mammary ERBB2- 
positive cell line reduced both the migratory and invasive capacity of cells, indicating that BCL3 was able, 
at least in part, to exert a pro-metastatic effect in a cell autonomous manner. In addition, SiRNA 
suppression of BCL3 reduced both the proliferative and migratory capacity of both ERBB2-positive and 
EGFR-positive human breast cancer cell lines. Collectively, these results suggest that targeting BCL3 may 
be an effective therapeutic strategy in the treatm ent of both ERBB2- and EGFR-positive breast cancers.
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Chapter 1: General Introduction
1.1 The mammary gland
1.1.1 Introduction
The mammary gland is a highly complex and specialised tissue with the primary function of 
producing milk to provide both nutrition and immune factors to the mother's offspring. The gland 
achieves this function by developing an extensive network of secretory alveolar cells, interconnected by 
epithelial ducts, which transport milk via the nipple to the suckling young. The developmental cycle of 
the human and rodent mammary gland can be classified into three main stages: embryonic, pubertal and 
adult (reviewed in Watson and Khaled 2008). In the mouse embryo, m ammary gland development 
occurs between embryonic day (E) 10.5 and E18 and involves the form ation of a rudimentary ductal tree  
that originates from the nipple and extends into an adipocyte-rich stroma known as the mammary fat 
pad (Figure 1.1A). During the first 3 weeks after birth, term inal end buds (TEBs) appear at the tips of the  
ducts and invade the mammary fat pad at a rate that corresponds to body growth. At the onset of 
puberty, serum oestrogen levels rise and initiate extensive proliferation within the TEBs, which results in 
ductal elongation and branching into the fat pad. This continues until about 10-12 weeks of age, when 
the ducts reach the limits of the fat pad and the TEBs disappear, resulting in the formation of a complete 
adult virgin mammary gland.
The adult virgin murine mammary gland is composed of a variety of different cell types:
epithelial cells, which form the ductal system of the gland; adipocytes, which make up the mammary fat
pad in which the ductal system is embedded; stromal cells; vascular endothelial cells; and a variety of 
immune cells (reviewed in Richert, Schwertfeger et al. 2000). The ductal network consists of two layers 
of epithelial cells, luminal and basal. The luminal cells line the ducts and form the secretory alveoli, 
whereas the basal epithelium, composed mainly of myoepithelial cells, forms an outer layer that is in 
direct contact with the surrounding stroma (Figure 1.1B). The mammary gland maintains this structure 
until the initiation of pregnancy when it undergoes further developm ent in preparation for providing all 
the nutritional and immunological support required to sustain the mother's new-born offspring.
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PRE-PUBERTAL PUBERTY ADULTVIRGIN
Nipple
LN
Rudimentary 
Ductal Tree
Mammary 
Fat Pad
Lymph
Node
Terminal EndDuct
Bud
Lum en
Stromal
Fibroblast
Basement
Membrane
Luminal Cell
Figure 1.1: Developm ent o f the adult virgin m urine m am m ary gland
Schematic of the developm ent of the adult virgin murine mammary gland (A). The rudimentary ductal 
tree extends into the fat pad during puberty as a result of an increase in oestrogen and the extensive 
proliferation of the terminal end buds (figure adapted from Watson and Khaled 2008). Schematic 
representation of a cross-section through a mammary duct (B). The luminal epithelial cells line the 
ducts while the myoepithelial cells form an outer layer that is in contact with the surrounding stroma 
(figure adapted from Visvader 2009).
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1.1.2 The pregnancy cycle
W ith each successive pregnancy, the mammary gland undergoes cycles of proliferation, 
differentiation and secretion, followed by extensive programmed cell death and de-differentiation back 
to a pre-pregnant state (Figure 1.2). These stages of adult mammary gland developm ent are similar in all 
mammals, although the actual number of glands can vary considerably, w ith mice, for example, having 
five pairs of glands. During pregnancy, the mammary gland undergoes further development and 
morphogenesis to prepare it for milk production. Progesterone induces extensive side branching of the 
epithelial ducts, the adipocytes within the fat pad de-differentiate, and prolactin promotes 
differentiation of the alveoli, which are essential structures in the production and secretion of milk 
(reviewed in Watson and Khaled 2008). Upon birth, progesterone levels drop, and the secretory alveoli 
expand and produce copious amounts of milk to feed the newborn. The final step in the cycle, termed  
involution, involves the removal of the now redundant secretory epithelial cells and re-modelling of the 
mammary gland back to its pre-pregnant state via the initiation of programmed cell death, or apoptosis 
(reviewed in Watson 2006).
This process o f cell removal within the mammary gland must be tightly controlled as 
insufficient apoptosis can lead to hyperplasia and the initiation of breast cancer. Furthermore, it has 
recently been shown that the mammary gland microenvironment during involution shares similarities 
with inflammation and can actually promote the metastatic properties of cells (McDaniel, Rumer et al. 
2006; Schedin 2006). The study of mammary gland involution is therefore not only important for gaining 
a better understanding of normal mammary gland developm ent but can also be used to identify key 
events involved in the initiation and progression of breast cancer.
1.1.3 Post-lactational mammary involution
Forced weaning studies have demonstrated that murine mammary gland involution involves 
two discrete stages that are characterised by the expression of specific genes (Figure 1.3) (Lund, Romer 
et al. 1996). The first phase lasts for 48 hours after pup removal and is reversible, allowing pups to be 
returned to the m other and to continue feeding. This phase is characterised by shedding of the now 
redundant secretary epithelial cells into the lumen of the alveoli. The second, longer phase involves the 
expression of a gene set that initiates the re-modelling of the gland back to an almost pre-pregnant 
state. During this phase, apoptosis continues and is accompanied by re-modelling of the surrounding 
stroma as well as re-differentiation and filling of adipocytes. Re-modelling of the gland is largely due to 
the activity of a specific set of matrix metalloproteinases (MMPs) that are inhibited during the first phase 
by tissue inhibitors of metalloproteinases (TIMPs) (Green and Lund 2005).
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A) Virgin
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Figure 1.2: Stages o f  the m urine m am m ary  gland pregnancy cycle
Left tw o columns = mam m ary gland wholemounts, middle column = schematic representation of the 
m am m ary gland, right column haematoxylin and eosin (H&E) stained sections. The adult virgin 
m am m ary gland consists of a ductal network spread throughout the m am m ary fat pad (A). Epithelial 
ducts undergo extensive proliferation during pregnancy to form side branches and alveolar buds (B). 
Lactation involves the expansion of secretory epithelial cells and the production of milk (C). During 
involution the alveoli collapse and the redundant secretory epithelial cells undergo apoptosis (D) 
(figure adapted from Watson 2006).
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The major signalling pathway implicated in the initial stages of involution is the Janus kinase 
and signal transducer and activator of transcription (JAK-STAT) pathway. STATs are activated by 
phosphorylation on specific tyrosine residues in response to many growth factors and cytokines such as 
leukaemia inhibitory factor (LIF). This results in homo- or hetero-dim erisation and translocation to the 
nucleus where they interact with target DNA and regulate transcription (reviewed in Heinrich, Behrmann 
et al. 1998). It has been shown that STAT5 is activated during pregnancy and lactation, but is almost 
imm ediately down-regulated at the onset of involution (Liu, Robinson et al. 1996; Liu, Robinson et al. 
1997). Conversely, STAT3 is specifically activated at the beginning of involution (Philp, Burdon et al. 
1996). Studies using a mammary-specific, conditional knock-out of Stat3  have shown that it is critical for 
initiating the first phase of involution (Chapman, Lourenco et al. 1999; Humphreys, Bierie et al. 2002). 
Mice lacking STAT3 showed a substantial delay in involution, with the first phase being all but abolished. 
Furthermore, in the absence of LIF, involution was again delayed due to a failure to activate STAT3 
(Kritikou, Sharkey et al. 2003; Schere-Levy, Buggiano et al. 2003).
LIF/cytokine receptor
AdipocyteMyoepithelial cellDeath receptor ligand Apoptotic body MMPs
Milk fat 
globule
Death
receptor Dyingcell
0 - 1 2  hours 1 2 -4 8  hours 7 2 -1 4 4  hours
1st phase I I 2nd phase
Figure 1.3: Signalling events during involution
Schematic of a collapsing alveoli during involution The first phase is reversible. M ilk stasis induces the 
secretion of LIF within 12 hours of forced weaning. This results in the phosphorylation and activation 
of STAT3 which induces apoptosis and the shedding of dying cells into the alveolar lumen. 
Neighbouring cells migrate together to fill the gap. At the same tim e, members of the death receptor 
ligand family and their receptors are up-regulated and induce apoptosis via caspase 8 activation. 
Transition to the second, irreversible, stage occurs by the activation of downstream targets of these 
pathways. MMPs break down the surrounding ECM, resulting in detachment-induced apoptosis and 
total collapse of the alveoli. The gland is then re-modelled back to the pre-pregnant state by the re­
differentiation of adipocytes. ECM, extracellular matrix; M M P, matrix metalloproteinase, (figure 
adapted from Watson 2006).
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Several downstream targets of STAT3 such as IGFBP-5 (insulin-like growth-factor-binding  
protein 5) and C/EBP6 (CCAAT/enhancer-binding protein 6) have been implicated in mammary gland 
apoptosis and involution (Tonner, Barber et al. 2002; Thangaraju, Rudelius et al. 2005), which is further 
evidence of the importance of the STAT3 signalling pathway in this process. Interestingly, AKT/PROTEIN 
KINASE B, which is normally down-regulated during involution, has been shown to provide a dominant 
survival signal and cause delayed involution when it is constitutively active in the mammary gland 
(Schwertfeger, Richert et al. 2001). The transcription factor, NF-kB (see section 1.3 for a detailed 
description of NF-kB), has also been shown to be up-regulated during murine mammary gland involution. 
This signalling pathway is activated within 1 hour of pup removal and shows maximum activation at 
about 3 days involution (Clarkson, Heeley et al. 2000), suggesting that it also plays an important role in 
the involution process.
M icroarray analysis of the lactation-to-involution switch revealed a number of other genes that 
are up-regulated early in the onset of involution (Clarkson, Wayland et al. 2004; Stein, Morris et al. 
2004). Many of these genes are either STAT3 and/or NF-kB transcriptional targets. An important group of 
genes that have been shown to display this early expression profile are the tum our necrosis factor a  
(Tnfa) family of death ligands such as Fas ligand and TNF-like W eak inducer of apoptosis (Tweak). These 
are NF-kB gene targets that can induce apoptosis by binding to their receptor and activating the caspase 
cascade (Ashkenazi and Dixit 1998). Interestingly, reducing NF-kB activity by genetic alteration of its 
upstream regulator, Inhibitor of kB Kinase p (lkk-2 /6) has been shown to result in delayed involution, 
which is due, in part, to the transcriptional down-regulation of these death receptor ligands (Baxter, 
Came et al. 2006).
The evidence suggests that NF-kB and STAT3 transcriptional pathways are essential regulators 
of the first phase of involution and of apoptosis. Identification of other molecular mechanisms and 
factors that control the involution process will not only provide a greater understanding of normal 
mammary gland developm ent and apoptosis pathways, but may also help in the discovery of factors 
that, when deregulated, are essential mediators of breast cancer initiation and progression.
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1.2 Breast Cancer
1.2.1 Introduction
Cancer is initiated via a multistage process involving the acquisition of oncogenic signals that 
accumulate through genetic and epigenetic mutations in gene expression and /or function. Hanahan & 
Weinberg (2000) proposed that there are six essential alterations in cell physiology that determine  
malignant cell growth. These so-called 'hallmarks of cancer' are defined as self-sufficiency in growth 
signals, insensitivity to growth-inhibitory signals, evasion of apoptosis, limitless replicative potential, 
sustained angiogenesis, and tissue invasion and metastases (Hanahan and Weinberg 2000). As the cell 
acquires each of these novel capabilities during tum our developm ent, it is able to successfully overcome 
the anticancer defence mechanisms that are intrinsic to every cell and tissue.
Breast cancer is an important disease not only because it is now the most common female
malignancy in the U.K., with more than 44,000 women being diagnosed each year (CancerResearchUK
2007), but also because of its biological complexity and heterogeneity. Although the early detection and 
treatm ent of breast cancer has improved considerably, still about 50% of patients eventually die of the 
disease (reviewed in Caldas and Aparicio 2002). In most cases, death is due to resistance to therapy and 
the form ation of metastases.
1.2.2 Breast cancer initiation and metastatic progression
The majority of cancers originate from the epithelium lining the mammary ducts or lobules and 
are histologically classified as mammary ductal or lobular carcinoma (Bombonati and Sgroi 2011). Several 
linear models o f breast cancer initiation and progression exist. The model for the ductal subtype 
proposes that neoplasia initiates in the normal ductal epithelium, progresses to flat epithelial atypia, 
advances to atypical ductal hyperplasia, followed by ductal carcinoma in situ, and culminates as invasive 
ductal carcinoma (Wellings, Jensen et al. 1975; Wellings and Jensen 1973; Oyama, M aluf et al. 1999; 
Oyama, lijima et al. 2000). A similar multi-stage model has been proposed for mammary lobular 
carcinoma and involves the progression from normal lobular epithelium, to atypical lobular hyperplasia, 
followed by lobular carcinoma in situ which finally results in invasive lobular carcinoma (Page, Dupont et 
al. 1985).
Primary breast tumours are currently being treated with increasing degrees of success. 
However, many tumours are not completely eradicated by local and systemic therapy, and will relapse, 
often leading to the development of invasive metastatic carcinoma. Metastatic disease is a complex 
phenomenon in which cells must detach from the primary tum our, invade the surrounding stroma, and 
enter and survive in the vasculature before extravasating out of the circulation and colonising at distant 
sites (Figure 1.4). Metastatic progression is aided by the process of epithelial-to-mesenchymal transition
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(EMT), a type of cell plasticity whereby epithelial cells acquire a more mesenchymal morphology with an 
increased capacity to migrate (for review, see Thiery 2002). Secondary metastatic sites in breast cancer 
may differ between subtypes of the disease, but are most commonly found in the lung, pleura, liver and 
bone (Lee 1983).
Breast cancer initiation and metastatic progression depends upon the activation and inhibition 
of numerous signalling pathways and their downstream targets, many of which are currently poorly 
understood. A great deal of research is focused on elucidating these signalling pathways to enable 
therapeutic targeting of the underlying cellular mechanisms involved in the pathogenesis of the disease.
Carcinoma in situ Invasive carcinoma
Extravasation
E M T
Intravasation EM T
 Lymph/bloodvessel
Micrometastasis O '
Endothelial cell
^ 2 2 ^
M ET
Macrometastasis
Figure 1.4: Stages o f m etastatic progression
Carcinoma in situ is maintained locally by the surrounding basement m embrane. Alterations, such as 
EMT, whereby epithelial cells acquire a more mesenchymal morphology, lead to the detachment of 
carcinoma cells from the primary tum our, through the basement membrane and into the surrounding 
stroma. Cells are then able to intravasate through blood vessel walls and into the bloodstream, which 
allows their passive transport to distant organs. At secondary sites, solitary cancer cells can 
extravasate out of the circulation and remain solitary (micrometastasis), or they can undergo MET, the 
reversion back to an epithelial morphology, and form a new carcinoma. EMT, epithelial-to- 
mesenchymal transition; MET, mesenchymal-to-epithelial transition (figure adapted from Thiery 
2002).
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1.2.3 Genetics of breast cancer
A number of risk factors for the disease, including early menarche, late menopause, nulliparity 
and a positive family history have been identified (Claus, Risch et al. 1990). It is estimated that hereditary 
breast cancers make up 5-10% of all cases of the disease and are generally attributable to high- 
penetrance susceptibility genes including BRCA1 and BRCA2 (Miki, Swensen et al. 1995; Easton, Ford et 
al. 1993). Disease-causing mutations in either of these two genes result in inactivation of the encoded 
proteins which, when functioning normally, are involved in metabolic processes such as DNA damage 
repair and cell cycle control (Venkitaraman 2002; Bertwistle and Ashworth 1998). Mutations in BRCA1 
and BRCA2 genes account for approximately 16% of the hereditary breast cancer risk. Germline 
mutations in other genes such as TP53, PTEN, STK11 and CDH1 result in cancer pre-disposition 
syndromes and are associated with increased breast cancer risk (Easton, Ford et al. 1993; Lynch, 
Ostermeyer et al. 1997; van Lier, Wagner et al. 2010; Masciari, Larsson et al. 2007). Although mutations 
in any of these genes confer a substantially increased risk, they account for a relatively small proportion 
of hereditary breast cancers. It is now thought that overall susceptibility to the disease is likely to be 
mediated through subsequent alterations in many genes that each confer a small to moderate breast 
cancer risk. A number of such genes have been identified including CHEK2, ATM, BRIP1, and PALB2 
(Nevanlinna and Bartek et al. 2006; Rahman, Seal et al. 2007; Renwick; Thompson et al. 2006; Seal, 
Thompson et al. 2006).
Acquired somatic mutations are responsible for the other 90% of breast cancer cases. A 
number of gene profiling studies have been undertaken to identify clinically relevant mutations (Chin, 
Teschendorff et al. 2007; Chin, DeVries et al. 2006). These studies have highlighted the genetic 
complexity of the disease and demonstrated that a relatively large number of somatic mutations drive 
each breast tum our. One key somatic aberration is amplification of the ERBB2 locus which occurs in 
approximately 20% of all human breast cancers and leads to a clinically aggressive subtype of the disease 
(Paik, Hazan et al. 1990). Further sequencing studies have identified a large number of point mutations 
that are present in breast tumours (Greenman, Stephens et al. 2007; Wood, Parsons et al 2007). These 
include high-frequency mutations in TP53 (53%), PIK3CA (26%) and CDH1 (21%) and less common 
mutations in genes such as IKBKB, IKBKA, CHD5, STK11, STK6 and BRAF. Interestingly, multiple somatic 
mutations have now been found to be enriched in signalling pathways that have previously been 
identified as being pathogenic in breast cancer (Lin, Gan et al. 2007; Chittenden, Howe et al. 2008). Thus, 
the overall genetic complexity of breast cancer is only just beginning to emerge, and elucidation of the  
growing number of disease-causing mutations will aid in the discovery o f improved treatm ents and 
eventual cures for the disease.
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1.2.4 Gene expression profiling of breast cancer subtypes
Gene expression profiling of breast cancer has recently identified the presence of multiple 
molecular subtypes of the disease. Microarrays were performed to characterise gene expression 
patterns in a set of 65 specimens of human breast tumours from 42 different individuals (Perou, Sorlie et 
al. 2000). This revealed that the phenotypic diversity of breast tumours was associated with 
corresponding diversity in gene expression. These gene expression profiles were subsequently used to 
subdivide breast cancers into five different molecular groups: the oestrogen receptor (ER)-positive 
luminal A and luminal B tumours and the ER-negative basal-like, ERBB2-positive and normal breast 
tumours (Perou, Sorlie et al. 2000; Sorlie, Perou et al. 2001). The luminal A and luminal B cancers over­
express ER, oestrogen-responsive genes and genes that are characteristically expressed in luminal 
epithelial cells (Perou, Sorlie et al. 2000). The luminal A cancers often express the transcription factors, 
GATA-3 and FOXA1, and the progesterone receptor (PR) (Sorlie, Tibshirani et al. 2003; Badve, Turbin et 
al. 2007), whereas luminal B cancers have a less well understood molecular phenotype, but are known to 
be PR-negative and express higher levels of the proliferation marker Ki67 and possibly the tyrosine 
kinase receptor ERBB2 (Cheang, Chia et al. 2009). The ERBB2-positive tumours over-express ERBB2 and 
neighbouring genes such as growth factor receptor-bound protein-7 (GRB7); they lack ER expression and 
generally have high levels o f NF-kB activation (Sorlie, Perou et al. 2001; Bertucci, Borie et al. 2004; Biswas 
and Iglehart 2006). Basal-like tumours over-express a range of genes that characterise basal epithelial 
cells (Perou, Sorlie et al. 2000). These tumours are often also denoted as 'triple negative' due to their 
general lack of ER, PR and ERBB2 (Perou, Sorlie et al. 2000). However, although the majority of basal-like 
tumours are also 'triple negative', this is not always the case as some basal-like tumours can express 
ERBB2 (Rouzier, Perou et al. 2005) and conversely some 'triple negative' tumours do not express basal 
markers (Tischkowitz, Brunet et al. 2007; Tan, Marchio et al. 2008). The normal breast-like tumours 
resemble normal breast tissue samples and over-express many genes that characterise non-epithelial 
mammary cells and lack luminal epithelial cell markers, but have strong expression of basal epithelial 
genes (Perou, Sorlie et al. 2000; Sorlie, Perou et al. 2001). Notably, these different subtypes can be used 
to predict clinical outcome, with luminal A cancers having the best prognosis and ERBB2-positive and 
basal-like tumours being more aggressive with a worse prognosis (Sorlie, Tibshirani et al. 2003; Sotiriou, 
Neo et al. 2003).
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1.2.5 Mouse models of breast cancer
Transgenic mouse models of human breast cancer are an im portant research tool for 
understanding the basic biology of the disease and for pre-clinical testing of novel therapeutic targets 
and treatm ents. Their value, however, is dictated by how accurately they recapitulate the circumstances 
that lead to the initiation and progression of the human disease. Furthermore, as breast cancer is such a 
heterogeneous disease, it is essential to use a model that most accurately represents the disease 
subtype that the investigation is aiming to target.
A number of promoters have been used to drive the expression of known oncogenes to 
mammary epithelium (Table 1.1). Many recognised oncogenes, including ERBB2/Neu, Ha-Ras, Polyoma 
middle T antigen, TGF-a, Wnt-1 and c-Myc have been expressed under the control of these promoters to 
initiate or modulate breast carcinogenesis in mice.
Promoter Origin Expression Activation Strengths Weak­
nesses
Reference
MMTV Mouse
Mammary
Tumour
Virus
Mammary 
epithelial 
cells, several 
other tissues
Steroid
hormones
Strong
promoter
Requires 
pregnancy 
for strong 
expression, 
expressed in 
other tissues
(Muller, Sinn et 
al. 1988)
WAP Whey acidic 
protein
Secretory 
mammary 
epithelial cells
Lactogenic
hormones
Mammary
gland
specific
Requires
pregnancy
(Schoenenberger, 
Andres et al. 
1988; Lipnik, 
Petznek et al. 
2005)
BLG Bovine 0- 
lactoglobulin
Mammary 
epithelial cells 
-  mostly 
luminal, 
salivary gland
Pregnancy
and
lactation
Mammary
gland
specific
Requires
pregnancy
(Ali and Clark 
1988; Bortner and 
Rosenberg 1997; 
Molyneux, Geyer 
et al. 2010)
K14 Cytokeratin
14
Basal 
mammary 
epithelial 
cells, skin, 
salivary gland, 
thymus
N/A Does not 
require 
pregnancy
Expressed in 
other tissues
(Turksen, Kupper 
et al. 1992; 
Molyneux, Geyer 
et al. 2010)
Table 1.1: Promoters used to drive oncogenes to the mammary epithelium
(Table adapted from Jonkers and Derksen 2007)
The vast majority of this thesis focuses on understanding the role of the NF-kB transcriptional 
co-factor, BCL3, in breast cancer initiation and progression (for a detailed description of NF-kB and BCL3, 
see sections 1.3 and 1.4 respectively). NF-kB activation has been shown to be strongly associated with 
ERBB2 signalling in breast cancer (Biswas, Cruz et al. 2000; Biswas, Shi et al. 2004; Biswas and Iglehart 
2006; further highlighted in section 1.3.4.2). It was therefore appropriate to use a model driven by this 
oncogene in this study. A number of transgenic mouse models that recapitulate the initiation and
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progression of ERBB2-positive disease have been generated to provide insight into the molecular 
mechanisms behind the potent transforming ability of this oncogene in breast cancer (for review, see 
Ursini-Siegel, Schade et al. 2007). A detailed description of the two ERBB2-driven models utilised in this 
thesis is presented below.
1.2.5.1 M M TV /N K  and M M T V /N 2 mouse models
In 1988, the first ERBB2 transgenic mouse model expressing an activated form of Neu, the rat 
homologue of ErbB2, under the transcriptional control of the mammary-specific mouse mammary 
tum our virus long terminal repeat (MMTV-LTR) promoter was generated (M uller, Sinn et al. 1988).
These transgenic mice (herein referred to as M M TV/N K ) were derived by the microinjection of 
a recombinant plasmid composed of the entire MMTV-LTR  and a cDNA encoding the activated NEU 
protein into one-cell mouse embryos. Five founder lines containing the activated Neu transgene were  
generated. The best characterised line was shown to uniformly express the Neu transgene in all 
mammary epithelial cells. These mice presented with numerous hyperplastic lesions early in mammary 
epithelial developm ent, leading to multifocal tumours covering the entire mammary gland with an 
average latency of 3 months. Other lines expressing the transgene in a less uniform manner developed 
more sparsely distributed tumours that correlated with the expression pattern of the transgene. These 
tumours were also infrequently shown to metastasize to the lungs. Given that tumours arose 
comparatively rapidly, and no morphologically normal mammary epithelium was present in lines where  
the transgene was uniformly expressed, it was suggested that over-expression of an activated variant of 
the NEU protein requires few, if any, further genetic events for transformation of the primary mammary 
epithelium to occur (Muller, Sinn et al. 1988).
This pioneering model of ERBB2-driven breast cancer effectively demonstrated that over­
expression of activated Neu alone is sufficient to transform mammary epithelial cells in vivo. However, 
this model is limited with respect to recapitulating the human disease as there is no evidence for 
comparable £/?BB2-activating mutations in primary human ERBB2-positive cancers (Lemoine, Staddon et 
al. 1990). Furthermore, clinical studies have demonstrated that over-expression of wild-type ERBB2 in 
human breast cancers is primarily due to gene amplification (Slamon, Clark et al. 1987).
To overcome this limitation, a second transgenic model was generated that over-expressed 
unactivated Neu in the mammary epithelium (Guy, Webster et al. 1992), also under the control of the  
M M T V  prom oter (herein referred to as M M T V /N 2). These mice were shown to develop focal mammary 
tumours that often metastasized to the lungs with a much longer latency period of approximately 7 
months. Tumours were surrounded by A/ei/-over-expressing hyperplastic mammary epithelium, 
indicating that, unlike the M M T V /N K  model, expression of the unactivated Neu alone is not sufficient for 
mammary tumourigenesis (Guy, Webster et al. 1992). This model is now often used to explore the
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potential effects of genetic alteration of other potential oncogenes or tum our suppressors in ERBB2- 
positive breast cancer (Cao, Luo et al. 2007; Ju, Katiyar et al. 2007).
Both the M M TV /N K  and M M T V /N 2 transgenic mouse models have been used extensively in this 
thesis to gain a greater understanding of the role of the NF-kB co-factor, BCL3, in breast cancer initiation 
and progression.
1.2.6 Breast cancer stem cells
The classic models of carcinogenesis propose that cancer arises via a series of stochastic events 
whereby, given the right combination of mutations, any cell within an organ is able to be transformed 
and produce tumours containing cells that are all equally malignant (Nowell 1976). Recently, however, a 
fundamentally different model for describing the initiation and maintenance of cancers has been 
proposed. The 'cancer stem cell hypothesis' states that cancers originate from only stem or progenitor 
cells (reviewed in Reya, Morrison et al. 2001). Stem cells are characterised by their ability to undergo 
both self-renewal and multi-lineage cell differentiation. The process of self-renewal can be either 
symmetrical, whereby the cell produces two daughter stem cells, or asymmetrical, whereby the cell 
produces one daughter stem cell and one cell that is able to differentiate along one of a variety of 
lineages. The cancer stem cell hypothesis proposes that de-regulation of these normally tightly 
controlled processes of self-renewal gives rise to heterogeneous tumours that are driven by a small 
subset of cells referred to as cancer stem cells or tum our-initiating cells (reviewed in Wicha, Liu et al. 
2006).
Evidence for the existence of cancer stem cells was first found in acute myelogenous leukaemia 
(Bonnet and Dick 1997). Here, leukaemic stem cells were identified on the basis of their ability to initiate 
human Acute Myeloid Leukaemia (AML) when transplanted into immunocompromised mice. A similar 
approach has now been utilised to demonstrate the existence of breast cancer stem cells. Al-Hajj et al. 
(2003) demonstrated that, when grown in immunocompromised mice, only a small minority of human 
breast cancer cells were able to grow tumours. Furthermore, they showed that human breast cancers 
contain a small cellular population characterised by the expression of certain cell surface markers, which 
display stem cell-like properties. When as few as 100 of these cells were transplanted into 
immunocompromised mice, they were able to form tumours. In accordance with the cancer stem cell 
hypothesis, the tumours formed in these mice had the same phenotypic heterogeneity as the initial 
tumour, suggesting that they were driven by multipotent cells. Furthermore, cells from these tumours 
were able to generate new tumours after transplantation into new recipient mice, demonstrating the 
self-renewal ability of the cells. In contrast, transplantation of up to 20,000 cells not expressing these 
surface markers failed to form tumours at all (Al-Hajj, Wicha et al. 2003).
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Elucidation of signalling pathways that regulate self-renewal has become of prime importance 
for gaining further understanding of how de-regulation of this process can lead to carcinogenesis. Recent 
evidence suggests that key oncogenic pathways such as those mediated by ERBB2, NOTCH and NF-kB 
signalling regulate breast stem cell behaviour (Dontu, Jackson et al. 2004; Korkaya, Paulson et al. 2008; 
Liu, Sakamaki et al. 2010; Wang, Kao et al. 2010) and as such may provide excellent targets for breast 
cancer therapy.
1.2.6.1 Functional Identification o f breast cancer stem cells
Advances in cell culture techniques have been im portant in the identification and study of both 
normal mammary and breast cancer stem cells. The in vitro study of mammary stem cells has been based 
on work from the neuronal field in which a cell culture assay, known as the neurosphere assay, was 
developed to identify neural stem cells (Reynolds and Weiss 1992; Rietze and Reynolds 2006). Similar cell 
culture conditions have since been adopted to aid in the identification of both normal mammary and 
breast cancer stem cells (Dontu, Abdallah et al. 2003; Ponti, Costa et al. 2005). Initially Dontu et al. 
(2003) demonstrated that when normal human mammary epithelial cells are plated on non-adherent 
surfaces and grown in serum-free medium containing a specific set of growth factors, they form spherical 
colonies term ed mammospheres. These mammosphere colonies were shown to be enriched for cells 
that exhibit functional characteristics of stem/progenitor cells such as multipotency and self-renewal 
(Dontu, Abdallah et al. 2003). The mammosphere-forming assay is now routinely used to identify key 
mediators of stem cell behaviour in both human and rodent cell populations (Dontu, Jackson et al. 2004; 
Fillmore and Kuperwasser 2008; Bhat-Nakshatri, Appaiah et al. 2010; Tao, Roberts et al. 2011).
The use of flow cytometry for isolating breast cancer stem cells on the basis of cell surface 
markers has also been crucial in studying these populations. Both limiting dilution transplant 
experiments and analysis of cell surface markers in mammosphere cultures identified human breast 
cancer stem cells as being CD44+/CD24- (Al-Hajj, Wicha et al. 2003;Ponti, Costa et al. 2005). More  
recently, aldehyde dehydrogenase 1 (ALDH1), an enzyme responsible for the oxidation of aldehydes to 
carboxylic acids, has been shown to be over-expressed in human breast cancer stem cells (Ginestier, Hur 
et al. 2007) and is now routinely used in the identification of this cell population (Korkaya, Paulson et al. 
2008; Aktas, Tewes et al. 2009; M orim oto, Kim et al. 2009; Tanei, Morim oto et al. 2009; Charafe-Jauffret, 
Ginestier et al. 2010).
In murine breast tumours, the appropriate cell surface marker to use depends heavily on the 
model of breast cancer that is being evaluated. For example, the mammary luminal progenitor marker, 
integrin p-3 (CD61), has been shown to define an enriched breast cancer stem cell population in M M TV- 
Wnt-1 and p53+/' tum our models (Vaillant, Asselin-Labat et al. 2008), whereas, in accordance with human 
breast cancers, breast cancer stem cells in Brcal-deficient mouse mammary tumours are enriched in the
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CD44+/CD24- population (Wright, Calcagno et al. 2008). In the M M T V /N eu  models of breast cancer, 
Stem cell antigen 1 (Sca-1) and CD24-positive populations have been shown to enrich for breast cancer 
stem cells in tumours driven by the activated and unactivated forms of the Neu transgene, respectively 
(Liu, Deng et al. 2007; Grange, Lanzardo et al. 2008). In addition to cell surface markers, ALDH1 activity, 
as detected by an enzymatic 'Aldefluor' assay or immunohistochemistry, has also been used as a marker 
of breast cancer stem cells in murine tumours (Luo, Fan et al. 2009).
1.2.7 Treatment of breast cancer
The treatm ent of newly diagnosed breast cancer generally depends on the extent of the 
disease and usually involves surgery combined with post-operative radiotherapy. Adjuvant treatm ent 
with combination chemotherapy regimens such as CMF (Cyclophosphamide, M ethotrexate, Fluorouracil) 
or FEC (Fluorouracil, Epirubicin, Cyclophosphamide) to reduce the risk o f recurrence after surgery is also 
commonplace (reviewed in Lopez-Tarruella and Martin 2009). In spite of the advances in the treatm ent 
of newly diagnosed breast cancers, still about 30% of patients eventually develop metastatic disease that 
is generally incurable (reviewed in O'Shaughnessy 2005). The recent molecular characterisation and 
identification of distinct breast cancer subtypes has allowed the developm ent of targeted therapies that 
are directed specifically towards certain biological features of individual tumours.
1.2.7.1 EGFR fam ily  receptor signalling: molecular targets fo r  breast cancer treatm ent
Currently, there are several fundamental molecular signalling pathways against which targeted 
therapies are being directed in breast cancer. Among these is the Epidermal Growth Factor Receptor 
(EGFR) family of tyrosine kinase receptors (for review, see Normanno, Bianco et al. 2003). The EGFR 
family consists of four different receptor tyrosine kinases: EGFR (ERBB1), ERBB2 (HER2), ERBB3 and 
ERBB4 (Ullrich, Coussens et al. 1984; Coussens, Yang-Feng et al. 1985; Kraus, Issing et al. 1989; Plowman, 
Culouscou et al. 1993). These receptors are composed of an extracellular ligand-binding domain, a 
transmembrane domain and a cytoplasmic tyrosine kinase-containing domain. The EGFR family of 
receptors are activated following ligand binding and subsequent homo- or hetero- dimerisation. Dimer 
formation results in kinase activation, which leads to auto- and trans-phosphorylation of tyrosine 
residues (King, Borrello et al. 1988; Stern and Kamps 1988; Carraway and Cantley 1994; Zhang, Gureasko 
et al. 2006; reviewed in Schlessinger 2000).
EGFR family receptors and their ligands are often over-expressed in breast cancer and 
frequently play an important role in the pathology of the disease. In particular, EGFR expression has been 
reported in 14-91% of human breast cancers and has been associated with an aggressive tum our 
phenotype and poor patient prognosis (Walker and Dearing 1999; Prenzel, Fischer et al. 2001). M ore  
recently, EGFR over-expression has been linked to the basal or triple-negative subtype of the disease
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(Nielsen, Hsu et al. 2004; Reis-Filho and Tutt 2008). ERBB2 over-expression occurs in approxim ately 20%  
of human breast cancers and generally correlates with poor prognosis (Paik, Hazan et al. 1990). 
Furtherm ore, ERBB3 and ERBB4 over-expression have also been reported (Lemoine, Barnes et al. 1992; 
Srinivasan, Gillett et al. 2000; Suo, Risberg et al. 2002).
Following ligand binding, the EGFR family receptors undergo tyrosine phosphorylation, which 
enables them  to interact w ith adapter proteins linking them  to intracellular signalling pathways that are 
implicated in cancer initiation and progression (reviewed in Norm anno 2009). The primary intercellular 
signalling cascades activated by the EGFR family receptors are the phosphatidylinositol 3-kinase/v-akt 
murine thym om a viral oncogene homologue 1 (PI3K/AKT) pathway, o f which mTOR (mamm alian target 
of rapamycin) and NF-kB are key targets, and the Ras/Raf/m itogen-activated protein kinase kinase 
(M EK)/m itogen-activated protein kinase (MAPK) pathway. M any drugs that specifically target different 
elem ents o f these signalling pathways are under developm ent or currently being used in the clinic 
(Figure 1.5).
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Figure 1 .5: EGFR and  ERBB2-driven signalling pathw ays and  target-based  agents in developm ent fo r  
breast cancer trea tm en t
Growth factors produced either by tum our cells or by surrounding stromal cells bind to and activate 
growth factor receptors, including EGFR and ERBB2, that are over-expressed on tum our cells. The 
growth factor receptors activate downstream  signalling pathways that regulate different processes 
involved in the pathogenesis of breast cancer including cell proliferation, survival and invasion. Many  
agents that specifically target different aspects o f these signalling pathways are in clinical 
developm ent. TKI, Tyrosine kinase inhibitor (figure adapted from Norm anno, M orabito  et al. 2009).
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1.2.7.2 Target-based agents in breast cancer
Target-based therapies can be divided into three broad categories: agents directed against 
specific subtypes of the disease, inhibitors of specific signalling pathways, and drugs targeted towards 
aspects of the tum our microenvironment such as angiogenesis. The first target-based therapeutic 
strategy for breast cancer came in the form of endocrine treatm ent for ER+ subtypes of the disease, 
firstly with tamoxifen (reviewed in Jordan 2006) and later on with the aromatase inhibitors (Nabholtz, 
Buzdar et al. 2000) and fulvestrant (Howell, Osborne et al. 2000). Since then, many agents that are active 
against the EGFR family receptors have been developed (for review, see Normanno, Morabito et al. 
2009; Figure 1.5). These include monoclonal antibodies such as trastuzumab, which bind the extracellular 
domain of the receptor (Carter, Presta et al. 1992) and small-molecule tyrosine kinase inhibitors, such as 
lapatinib, which directly inhibit tyrosine kinase phosphorylation o f the receptor (Rusnak, Affleck et al.
2001). When used in combination with chemotherapy, these agents have been shown to have 
considerable efficacy in treating subtypes of the disease that over-express certain EGFR family receptors 
(Geyer, Forster et al. 2006; Slamon, Layland-Jones et al. 2001; Gasparini, Gion et al. 2007; von Minckwitz, 
du Bois et al. 2009). M ore recently, numerous agents directed against downstream signalling pathways 
of the EGFR family receptors have been developed. These drugs include mTOR, Src and MEK inhibitors 
(Yu, Toral-Barza et al. 2001; Lombardo, Lee et al. 2004; Yeh, Marsh et al. 2007). Most of these agents 
have only been tested in unselected patients with breast cancer, and, as a result, have shown little 
efficacy. However, pre-clinical findings do suggest that they may be useful in specific subtypes of the 
disease (for review, see Normanno, Morabito et al. 2009).
W hile responses to many of these targeted treatm ents have been encouraging, resistance is 
still prevalent, and disease improvement can be short-lived. Moreover, owing to their lack of molecular 
targets, triple-negative cancers are completely resistant to targeted therapies that are currently 
approved in the clinic. Therefore, there is still a need to identify new or synergistic targets to treat 
various subtypes of the disease.
One such molecular target may be the NF-kB family of transcription factors which have been 
shown to be activated downstream of EGFR family receptors. NF-kB plays a key role in many 
physiological processes, such as innate and adaptive immune responses, inflammation and cell 
proliferation, death and motility. The potential of NF-kB as a therapeutic target in breast cancer has 
already been highlighted in a number of reports in the literature (Helbig, Christopherson et al. 2003; 
Aggarwal, Shishodia et al. 2005; Cao, Luo et al. 2007; Park, Zhang et al. 2007; Connelly, Barham et al. 
2010; Liu, Sakamaki et al. 2010). This has led to a great deal o f interest in the development of inhibitors 
of NF-kB signalling.
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1.3 NF-kB
1 .3 .1  NF-k B fam ily  o f transcrip tion  factors
Nuclear factor binding to the intronic kappa-light-chain enhancer elem ent in B cells (NF-kB) was 
first identified in 1986 (Sen and Baltimore 1986). NF-kB is a family of transcription factors that can both 
induce and repress gene expression through binding to DNA sequences, known as kB motifs, in 
promoters. The family is made up of five subunits — p65 (RelA), c-Rel, RelB, NF-kB1 (p l05 /p 50 ) and NF- 
kB2 (p l00 /p 52 ) — which all share a conserved REL Homology Domain (RHD) within their N-terminus 
that is required for dimerisation, DNA binding and interaction with inhibitors of NF-kB (IkB) (reviewed in 
Perkins 2007) (Figure 1.6).
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Figure 1.6: Structural domains o f the NF-kB and IkB fam ily  o f proteins
All NF-kB family members contain an N-terminal Rel-homology domain (RHD, red) that contains a 
nuclear localization domain and mediates DNA binding and dimerisation. The Rel sub-family contains 
transactivation domains (TAD, purple; TA1 and TA2 are sub-domains of the TAD). The inhibitor of kB 
family consists of IkBo , IkB(3, kBy, IkBc, IkB*; and BCL3. Like plOO and p l0 5 , they all contain ankyrin 
repeat domains (ARD, blue). DD, region with homology to a death domain; LZ, Leucine zipper-like 
motif; PEST, domain rich in proline (P), glutamate (E), serine (S) and threonine (T), (figure adapted 
from Perkins 2007).
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The subunits can be split into two broad groups depending on their requirem ent for proteolytic 
cleavage. The first group consists of the REL subunits, p65 (RelA), c-Rel and RelB, which are synthesised 
in their mature forms. They contain a transactivation domain (TAD) within their C-terminus which is 
necessary for transcriptional activation (Kamens, Richardson et al. 1990; Ryseck, Bull et al. 1992; Schmitz 
and Baeuerle 1991) and has also been shown to interact with some transcription components such as 
the p300/cyclic-AMP-response element-binding protein (CBP) (Zhong, Voll et al. 1998), the TATA-binding 
protein (TBP) and the transcription factor MB (TFIIB) (Xu, Prorock et al. 1993). The second group consists 
of NF-kB1 (p l0 5 ) and NF-kB2 (plOO), which are synthesised as large precursors to the mature DNA- 
binding proteins, p50 and p52. These active NF-kB subunits are produced upon proteolytic cleavage of 
the C-terminus (Palombella, Rando et al. 1994; Heusch, Lin et al. 1999). p50 and p52 subunits do not 
have a TAD and are therefore only able to activate transcription when bound to either other 
transcriptionally active NF-kB subunits or co-activating proteins (reviewed in Beinke and Ley 2004), such 
as BCL3 (see section 1.4).
1.3.2 NF-kB regulation and signalling pathways
In most unstimulated mammalian cells, the REL subunits, p65, c-Rel and RelB, are retained in 
an inactive state within the cytoplasm through interactions with IkB proteins. There are five principle IkB 
proteins, kB a, IkBP, IkBe, kBy and IkB  ^(Figure 1.6). These proteins are characterised by the presence of 
multiple ankyrin repeats in their C-terminus and function predominantly by masking a conserved nuclear 
localisation sequence that is found in the RHD of NF-kB subunits (reviewed in Hayden and Ghosh 2004; 
Huxford, Huang et al. 1998; Jacobs and Harrison 1998; Malek, Chen et al. 2001; Malek, Huang et al. 
2003). p50 and p52 are also retained in an inactive state in the cytoplasm in the form of their larger 
precursors, p l0 5  and plOO. These kB-like proteins contain ankyrin repeat domains in their C-terminus, 
which are similar to those found in traditional IkB proteins and, as a result, are also able to inhibit the 
activity o f multiple NF-kB subunits by sequestering them to the cytoplasm (Mercurio, DiDonato et al. 
1993; Sun, Ganchi et al. 1994; Rice, MacKichan et al. 1992). The processing of p l0 5  and plOO is essential 
for p50 and p52 to function as nuclear transcription factors. Both p50 and p52 homodimers can interact 
with another IkB family member, BCL3 which contains the classical IkB ankyrin repeat m otif in its C- 
terminus but, in contrast with other IkB proteins, can function as either a transcriptional activator or 
repressor of NF-kB activity (see section 1.4).
NF-kB subunits form a variety of different hetero- or homo-dimers, which can be activated by 
over 150 stimuli such as pro-inflammatory cytokines, bacterial products, viruses and growth factors 
(reviewed in Pahl 1999). NF-kB activation occurs via a number of distinct activation pathways. The two  
most commonly observed are the canonical (classical) and non-canonical (non-classical) pathways (Figure 
1.7). Both of these key pathways are induced via activation of the IkB Kinase (IKK) complex, although IKK-
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independent signalling pathways have also been identified (Schoonbroodt, Ferreira et al. 2000; Romieu- 
Mourez, Landesman-Bollag et al. 2002; Kato, Delhase et al. 2003). The IKK complex consists of two  
catalytic subunits, IKKa and IKKp (also known as IKK1 and IKK2; Zandi, Rothwarf et al. 1997), and multiple 
copies of a regulatory subunit called the NF-kB essential m odifier (NEMO, also known as IKKy Rothwarf, 
Zandi et al. 1998). Upon activation, the IKK complex acts to phosphorylate NF-KB-bound IkB proteins, 
which target them  for ubiquitin-dependent degradation by the proteasome. This results in the release of 
NF-kB dimers, which are then free to translocate to the nucleus, where they can regulate transcription of 
a wide variety of genes.
The canonical pathway The non-canonical pathway
Ubiquitin-dependent
Degradation
Cytoplasm
Nucleus
Figure 1.7: Canonical and non-canonical NF-kB signalling pathw ays
The inhibitor of kB kinase (IKK) complex is composed of IKKa, IKKP and IKKy. The IKKP subunit of the 
canonical pathway is activated in response to a range of stimuli such as tumour-necrosis factor-a (TNF-a), 
interleukin (IL-1) or lipopolysaccharide (LPS) and phosphorylates the NF-kB bound IkB proteins targeting  
them  for ubiquitin-dependent degradation. This allows translocation of p65:p50 (or c-REL:p50) 
heterodimers to the nucleus where they can transcriptionally activate target genes. The IKKa subunit of 
the non-canonical pathway is activated by the NF-kB inducing kinase (NIK) in response to other stimuli 
such as the TNF family members, lymphotoxin p (LTp) and BAFF, resulting in the phosphorylation of plOO 
This triggers the ubiquitin- dependent degradation of the C- term inal half of plOO, releasing the N- 
term inal half, p52. Dimers composed of p52 and another subunit (most commonly RELB) translocate to 
the nucleus and activate transcription (figure adapted from Cao and Karin 2003)
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1.3.2.1 The canonical signalling pathway
The canonical signalling pathway is activated by a variety of stimuli including viral infections 
(Hammarskjold and Simurda 1992; Mastronarde, He et al. 1996), exposure to bacterial products such as 
lipopolysaccharide (LPS) (Souvannavong, Saidji et al. 2007) and cytokines, such as tum our necrosis factor- 
a  (TNF-a) and interleukin-1 (IL-1) (Osborn, Kunkel et al. 1989). The predominant IKK subunit involved in 
canonical signalling is IKKP (Li, Van Antwerp et al. 1999), although some IKKp-independent mechanisms 
have also been reported (Cao, Bonizzi et al. 2001; Merkhofer, Cogswell et al. 2010). Upon activation of 
this pathway, IxBa is rapidly phosphorylated on serines 32 and 36 by IKKp (Woronicz, Gao et al. 1997). In 
some cell types, IxBp and IkBe are also phosphorylated but with slower kinetics (reviewed in Fischer, 
Page et al. 1999; Perkins 2006; Wu and Ghosh 2003). Phosphorylation results in proteasomal 
degradation o f IkB proteins and the release of NF-kB dimers, predominantly composed of p50 and p65 
subunits. These dimers are then free to translocate to the nucleus, where they regulate gene 
transcription (Figure 1.7).
1.3.2.2 The non-canonical signalling pathway
The non-canonical signalling pathway is activated by a subset of NF-kB induction stimuli 
including LPS (Souvannavong, Saidji et al. 2007) latent membrane protein-1 (LMP1) of Epstein-Barr virus 
(Luftig, Yasui et al. 2004), stimulation of the CD40 (Coope, Atkinson et al. 2002) and lymphotoxin-p 
receptors (Dejardin, Droin et al. 2002; M uller and Siebenlist 2003), and B-cell-activating factor of the TNF 
family (BAFF, Claudio, Brown et al. 2002). Induction of the non-canonical pathway leads to activation of 
IKKa by the NF-kB inducing kinase (NIK) which results in the phosphorylation and subsequent processing 
of plOO to p52 by the proteasome in a ubiquitin-dependent manner (Senftleben, Cao et al. 2001; Xiao, 
Harhaj et al. 2001; Fong, Zhang et al. 2002). This releases the resulting p52 containing hetero- or 
homodimers, consisting predominantly o f RelB:p52 complexes, to translocate to the nucleus where they 
can regulate gene transcription by targeting distinct kB DNA elements.
1.3.2.3 Atypical NF-kB signalling pathway: processing o f p l0 5  to p50
As well as the canonical and non-canonical signalling pathways, NF-kB activation can occur via a 
number of other IKK-dependent or independent mechanisms (reviewed in Perkins and Gilmore 2006; 
Schoonbroodt, Ferreira et al. 2000; Romieu-Mourez, Landesman-Bollag et al. 2002; Huang, Wuerzberger- 
Davis et al. 2003; Kato, Delhase et al. 2003). An important alternative signalling pathway results in the  
generation of p50 subunits from p l0 5 . Once generated, p50 can produce either hetero- or homo-dimers, 
which can translocate to the nucleus and modulate transcription.
In many cell types, high levels of p50 can be generated in the absence of a stimulus via either 
post-translational or co-translational mechanisms (reviewed in Beinke and Ley 2004; Pereira and Oakley
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2008). Post-translational processing involves the constitutive proteolytic removal of the c-terminal half 
of p l0 5  by the proteasome. p l0 5  contains a glycine-rich region (GRR) between the RHD and ankyrin 
repeats, which is essential to this process (Lin and Ghosh 1996). The GRR functions as a processing stop 
signal, which prevents the RHD from entering into the proteasome (Orian, Schwartz et al. 1999). This 
ensures that only the C-terminus of p l0 5  is degraded and p50 is released. In co-translational processing, 
p50 and p l0 5  are generated from a single mRNA as a result of the proteolysis of incompletely 
synthesised p l0 5  polypeptides by the 26S proteasome (Lin, DeM artino et al. 1998). In addition to these 
tw o constitutive mechanisms, some reports have demonstrated that p l0 5  can also undergo inducible 
IKK|3-dependent processing, which results in either complete degradation or the production of p50 
(reviewed in Orian, Gonen et al. 2000; Beinke and Ley 2004; Cohen, Achbert-W einer et al. 2004).
1.3.2.4 Modulators o f NF-kB activity
There are a number of proteins and stimuli that do not directly induce the activation and 
nuclear translocation o f NF-kB subunits, but are known to alter NF-kB in alternative ways. Modulators of 
NF-kB activity can mediate a number of post-translational modifications or can form co-operative 
interactions that result in the targeting of NF-kB subunits to specific promoters. Post-translational 
modifications can either promote or inactivate the transcriptional activity of NF-kB and in some cases can 
cause NF-kB subunits to become transcriptionally repressive (reviewed in Chen and Greene 2004).
A key post-translational modification is nuclear phosphorylation of NF-kB subunits by nuclear 
kinases. Phosphorylation of p65 has been particularly well studied and can result in either transcriptional 
activation or repression (reviewed in Viatour, Merville et al. 2005). For example, protein kinase A can 
phosphorylate p65 at Ser-276 (Zhong, SuYang et al. 1997). Phosphorylations at this site have been shown 
to stimulate p65 transcriptional activity by promoting its interaction with the cAMP response element- 
binding (CREB)-binding protein (CBP) and p300 co-activators (Zhong, Voll et al. 1998) and to displace 
p50-histone deacetylase (HDAC)-l repressive complexes from DNA (Zhong, May et al. 2002). In contrast, 
p65 transactivation can be inhibited by the ARF tum our suppressor via the chkl-dependent 
phosphorylation of p65 at Thr-505 (Rocha, Garrett et al. 2005). p65 transcriptional activity can also be 
stimulated or inhibited by acetylation at lysine residues (reviewed in Campbell and Perkins 2004). 
Acetylation is induced, at least in part, by Histone acetyl transferases (HATs), such as p300 and PCAF, 
while HDACs such as HDAC3 and SIRT1 can promote their removal (Chen, Fischle et al. 2001; reviewed in 
Chen and Greene 2004).
The numerous post-translational modifications and protein interactions that can occur, allow  
tight control over the transcriptional activity and function of NF-kB subunits at specific promoters. They 
also highlight the complexity and context-specific differences of this signalling pathway, all of which must 
be considered when investigating NF-xB-mediated events.
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1.3.3 Biological roles of NF-kB proteins
Once in the nucleus, NF-kB dimers can regulate gene transcription by binding to kB sites 
consisting of 5'-GGGRNWYYCC-3' sequences (R=purine, W=adenine or thymine, Y=pyrimidine and N=any 
nucleic acid). Almost all combinations of NF-kB hetero- and homodimers can be formed. The 
composition of the dimer can vary dramatically depending on cell type and the nature of the stimulus. 
Furthermore, different NF-kB complexes bind to kB sites with varying preferences and form different 
protein— protein interactions at promoter sites, resulting in the transcription of distinct gene subsets. 
Consequently, NF-kB transcription factors are able to tightly regulate a wide range of genes in a manner 
that is suitable for the context in which they are set (reviewed in Hoffmann, Natoli et al. 2006).
Genetically engineered NF-kB knock-out models of both individual and multiple NF-kB subunits 
have been generated in order to gain a greater understanding of their specific biological roles (Weih, 
Carrasco et al. 1995; Beg, Sha et al. 1995; Sha, Liou et al. 1995; Caamano, Rizzo et al. 1998; Franzoso, 
Carlson et al. 1998; Grumont, Rourke et al. 1998). These studies indicate that NF-kB subunits have 
distinct functions in innate and adaptive immune responses and also reveal an essential role for NF-kB in 
regulating apoptosis, particularly in the nervous and immune systems and liver (for review, see 
Gerondakis, Grumont et al. 2006).
NF-kB mediates the expression of over 150 genes, many of which are known to be involved in 
immunity and homeostasis, such as cytokines, immunoreceptors, acute phase proteins, enzymes, 
adhesion molecules and transcription factors (reviewed in Pahl 1999). In addition, NF-kB signalling can 
promote cell survival through the induction of either anti-apoptotic genes, such as c-IAPl and 2 (Wang, 
Mayo et al. 1998) and BCL-XL (Chen, Edelstein et al. 2000), or growth-promoting genes such as CYCLIN D1 
(Guttridge, Albanese et al. 1999) and IGFBP2 (Cazals, Nabeyrat et al. 1999). Conversely, in certain 
circumstances it can induce cell death through the regulation of pro-apoptotic genes such as the death 
receptors, DR4-DR6 (Ravi, Bedi et al. 2001; Kasof, Lu et al. 2001), and the BCL2 family member, BCL-XS 
(Chen, Kandasamy et al. 2003; reviewed in Kucharczak, Simmons et al. 2003). The multitude of NF-kB 
gene targets renders this family o f transcription factors essential mediators of normal tissue 
development and homeostasis within the body.
1.3.4 NF-kB in mammary gland development and breast cancer
1.3.4.1 Norm al mam m ary gland development
Although there is little evidence to suggest that NF-kB is involved in the early embryonic 
development of the mammary gland, this family of transcription factors have been shown to exhibit 
dynamic and tightly regulated expression patterns during the post-natal stages of development. p65, p50 
and IkBq are expressed in the mammary epithelial cells of virgin, pregnant, lactating and involuting mice.
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NF-kB DNA-binding activity peaks at day 16 of gestation in mice and decreases to undetectable levels 
during lactation before being re-activated during involution (Brantley, Yuli et al. 2000). This well- 
regulated expression of NF-kB activity is essential for mammary gland development, as demonstrated by 
the fact that genetically modified mice harbouring altered NF-kB proteins show substantial defects at 
multiple stages of mammary gland development (Baxter, Came et al. 2006; Brantley, Chen et al. 2001; 
Cao, Bonizzi et al. 2001). For example, mammary epithelia with elevated NF-kB activity as a consequence 
of IkB<x deficiency showed increased lateral ductal branching and hyperplasia when transplanted into 
wild-type mammary fat pads, indicating that it has an important role in maintaining normal epithelial 
architecture (Brantley, Chen et al. 2001). Moreover, during pregnancy, NF-kB activation has been shown 
to be essential for lobuloalveolar development. This was demonstrated by the use of IKKa knock-in mice, 
which display no IKKa kinase activity and, as a result, have severely impaired pregnancy-induced NF-kB 
activation. Knock-in IKKa mice showed reduced epithelial cell proliferation during pregnancy to such an 
extent that alveolar developm ent at the end of gestation in mutant mice was comparable to that of mid­
pregnant wild-type glands (Cao, Bonizzi et al. 2001). Furthermore, during involution, suppressed NF-kB 
activity brought about by the conditional deletion of the IKKP gene was shown to result in delayed 
apoptosis and mammary gland remodelling (Baxter, Came et al. 2006). Collectively, these data 
demonstrate that NF-kB signalling is essential in the development of the normal mammary gland.
1.3.4.2 NF-kB in breast cancer
As well as being an essential mediator of normal physiological processes, NF-kB signalling, 
when deregulated, has been implicated in the aetiology of a number of human autoimmune diseases 
such as multiple sclerosis, inflammatory bowel diseases, rheumatoid arthritis and psoriasis (reviewed in 
Kurylowicz and Nauman 2008). Furthermore, NF-kB transcription factors have been shown to regulate 
many genes implicated in malignant cell growth, such as those involved in cell proliferation and survival, 
angiogenesis, metastases and inflammation (Figure 1.8). There is now an increasing number of 
experimental and epidemiological studies to indicate that inappropriate activation of NF-kB by 
pathogens, carcinogens or inflammatory cytokines plays a direct or indirect role in the initiation and 
progression of many human cancers (reviewed in Baldwin 2001).
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Figure 1.8: NF-kB target genes involved in the pathogenesis o f cancer
De-regulated NF-kB signalling can promote carcinogenesis by regulating target genes involved in cell 
survival, proliferation, invasion, inflammation, epithelial-to-mesenchymal transition and angiogenesis.
The evidence to suggest that NF-kB signalling plays an important role in breast carcinogenesis is 
overwhelming. A number of studies have demonstrated elevated NF-kB activity in both breast cancer cell 
lines and tissues (Nakshatri, Bhat-Nakshatri et al. 1997; Sovak, Bellas et al. 1997; Cogswell, Guttridge et 
al. 2000; Biswas, Shi et al. 2004; Zhou, Eppenberger-Castori et al. 2005). Increased canonical signalling, as 
demonstrated by the presence of p50:p65 heterodimers, was reported in the majority of these studies. 
However, Cogswell et al. (2000) showed elevated DNA binding of the p50, p52 and c-Rel subunits in 
human tum our samples (Cogswell, Guttridge et al. 2000), suggesting that the non-canonical signalling 
pathway may also play a role in mammary tumourigenesis.
Mechanisms that lead to constitutive NF-kB activation are not absolutely clear. However, in 
vitro studies have demonstrated that NF-kB can be activated downstream of a number of known 
oncogenes such as EGFR (Biswas, Cruz et al. 2000) and Ha-Ras (Finco, Westwick et al. 1997). 
Interestingly, a positive correlation between over-expression of the ERBB2 oncogene and NF-kB 
activation has been observed in both human breast cancer cell lines and primary tum our samples 
(Biswas, Shi et al. 2004; Zhou, Eppenberger-Castori et al. 2005). Furthermore, in ERBB2-expressing cell 
lines, administration of the EGFR family ligand, heregulin, resulted in rapid activation of NF-kB, and,
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conversely, treatm ent with the ERBB2 monoclonal antibody, trastuzumab, inhibited NF-kB activation 
(Biswas, Shi et al. 2004). The pathway leading to NF-kB activation downstream of ERBB2 has not been 
well characterised. It has, however, been shown that ERBB2 can induce NF-kB signalling via a PI3K/AKT 
pathway (Pianetti, Arsura et al. 2001). Over-expression of ERBB2 in Ba/F3 haematopoietic cells resulted 
in IKK-independent activation of the classical NF-kB pathway as well as PI3K/AKT activities. Subsequent 
expression of dominant-negative PI3K and AKT plasmids blocked NF-kB DNA binding (Pianetti, Arsura et 
al. 2001). Furthermore, Biswas et al. (2000) demonstrated that EGF-induced NF-kB activation and 
subsequent breast cancer cell proliferation could be blocked by the addition of a PI3K inhibitor. Indeed, a 
number of other studies have suggested that NF-kB is activated downstream of PI3K signalling (Dan, 
Cooper et al. 2008; Makino, Day et al. 2004). In contrast, a more recent study by Merkhofer et al. (2010) 
demonstrated that, although both the NF-kB and PI3K/AKT pathways were induced downstream of 
ERBB2 signalling in an ERBB2-positive breast cancer cell line, IKKa-mediated NF-kB activation was 
independent o f PI3K signalling. Treatm ent of cells with the PI3K inhibitor, LY294002, blocked ERBB2- 
induced phosphorylation of AKT but had no effect on the phosphorylation status of p65. These results 
suggest that NF-kB can also be activated downstream of ERBB2 signalling via PI3K independent pathways 
that are yet to be elucidated.
Although one study showed that high NF-kB activity was able to identify a subset of aggressive 
hormone-dependent breast cancers (Zhou, Eppenberger-Castori et al. 2005), it appears that NF-kB over­
expression or activation is predominantly found in ER-negative breast cancer cells and tissues (Nakshatri, 
Bhat-Nakshatri et al. 1997; Biswas, Shi et al. 2004). In addition, the correlation between ERBB2 and NF-kB 
signalling was also primarily found in ER-negative tumours (Biswas, Shi et al. 2004). It has been suggested 
that this effect may be due to the ability of the ER to exert a general inhibition of NF-kB transcriptional 
activity (Nakshatri, Bhat-Nakshatri et al. 1997). The constitutive activity of an NF-KB-dependent promoter 
was shown to be efficiently inhibited when ER-negative cells were transfected with ER. Alternatively, the 
effect may be due to the developm ent of oestrogen independence as a result of NF-kB activation, as 
suggested by Pratt et al. (2003).
Many genes im portant for the metastatic process have been shown to be regulated by NF-kB. 
These include MMPs (which facilitate tissue penetration), chemokines (which induce cell migration) and 
vascular endothelial growth factor (VEGF) (which is essential for tum our angiogenesis; reviewed in 
Basseres and Baldwin 2006). Furthermore, a number of experimental studies have demonstrated a role 
for NF-kB in promoting metastases. For example, reduced lung metastases and suppression of M M P-9  
was observed in a mouse xenograph model following the pharmacological inhibition of NF-kB in human 
breast cancer cells with curcumin (Aggarwal, Shishodia et al. 2005). Administration of a different 
pharmacological inhibitor of NF-kB, parthenolide, in combination with docetaxel also resulted in reduced
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metastases in another breast cancer xenograph model (Sweeney, M ehrotra et al. 2005). Furthermore, 
inhibition of NF-kB in the Ha-Ras-transformed mammary epithelial cell line, EpRas, resulted in reduced 
lung lesions in an experimental tail vein metastases model (Huber, Azoitei et al. 2004). This was due to its 
effect on epithelial-to-mesenchymal transition. More recently, Connelly et al. (2010) demonstrated that 
conditional inhibition of NF-kB in the aggressive polyoma middle T oncogene (PyVT) breast cancer model 
resulted in a reduction in tum our burden and metastases in comparison with controls. Another recent 
study showed that inhibition of NF-kB, as a consequence of the stable expression of IkBcx resulted in 
reduced tum our angiogenesis via the down-regulation of VEGF in an ERBB2-positive murine allograft 
breast cancer model (Liu, Ju et al. 2009).
1.3.4.3 Inhibition o f NF-kB: a potential therapeutic target in breast cancer?
It is clear from the extensive literature on the role of NF-kB in breast cancer that this pathway 
has great therapeutic potential as a target for inhibition in the disease. The obvious association between  
ERBB2 expression and NF-kB activation strongly suggests that ERBB2-positve tumours may preferentially 
benefit from NF-kB blockade. Furthermore, the identification of an inverse correlation between NF-kB 
activity and ER status may also be exploited in the therapy of human breast cancers. For example, 
combination treatm ent of ER-positive tumours with both an anti-oestrogen and an NF-kB inhibitor may 
prevent the developm ent of resistance to hormonal therapy in some patients.
M ore than 750 compounds have been shown to have inhibitory effects on NF-kB signalling 
(reviewed in Gilmore and Herscovitch 2006). These agents can generally be classified into those that 
block activation of the IKK complex, those that prevent the phosphorylation or proteasomal degradation 
of IkB and those that inhibit the nuclear translocation and function of NF-kB subunits (Figure 1.9). A few  
of these agents, such as the proteasome inhibitor, bortezomib, have undergone clinical trials in breast 
cancer patients with some success (Orlowski and Dees 2003; Awada, Albanell et al. 2008; Schmid, 
Kuhnhardt et al. 2008; Irvin, Orlowski et al. 2010). However, a major caveat to global sustained inhibition 
of NF-kB signalling is that many of the functions regulated by this transcription factor that make it such a 
desirable drug target also play a major role in homeostasis within the body. Unselective disruption to this 
pathway during development or in adulthood will potentially lead to adverse effects such as immune 
suppression, which could be particularly harmful in cancer patients, who are likely to already be 
immunocompromised from other drug treatments. Moreover, as NF-kB has been shown to play an 
integral role in normal murine mammary gland development, therapeutic inhibition of this signalling 
pathway in breast cancer may have particularly pronounced and detrim ental effects on the normal cells 
within the gland. Establishing a balance between treating the disease and unwanted side effects is the  
challenge faced when designing suitable therapeutics to target this pathway. An alternative approach to 
global inhibition of NF-kB is to target modifying co-factors such as the kB-like protein, BCL3, which could
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potentially provide a more selective inhibitory effect on cancer cells while having minimal effects on the 
normal surrounding tissue.
genistein
dhmecT
emodin, apigenin 
9-aminocridine
bortezomib, cyclosporine, 
vincristine, vinblastine, 
saquinavir
curcumin,thalidomide, trans-resveratrol, 
parthenolide, CHS828, BAY 11-7082,
BAY 11-7085, aspirin, sulindac, methotrexate
Figure 1.9: Targets o f NF-kB inhibitors
AKT which links ERBB2 to NF-kB signalling, can be blocked by genistein. IKK and proteosomal inhibitors 
prevent the degradation of IkB that is required for the nuclear translocation of NF-kB dimers, emodin, 
apigenin and 9-aminocridine inhibit the phosphorylation of p65. DHMEQ 
(dehydroxymethylepoxyquinomicin) acts to block the nuclear translocation of the p50/p65 complex 
(figure adapted from Haffner, Berlato et al. 2006).
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1.4 B-Cell Lymphoma 3
1.4.1 Introduction
B-Cell Lymphoma 3 (BCL3) was originally discovered through its involvement in the  
t(14;19)(q32.3;q l3.2 ) chromosomal translocation found in a subset of patients with B-cell chronic 
lymphocytic leukaemia (Ohno, Takimoto et al. 1990). Subsequent analysis revealed it to be a m em ber of 
the IkB family of proteins on the basis of its structure (Ohno, Takimoto et al. 1990; Hatada, Nieters et al. 
1992; Wulczyn, Naumann et al. 1992). However, unlike classical IkB proteins which act to sequester NF- 
kB subunits to the cytoplasm, BCL3 is predominantly a nuclear protein (Bours, Franzoso et al. 1993; 
Nolan, Fujita et al. 1993; Zhang, Didonato et al. 1994) which is involved in regulating NF-KB-mediated 
gene transcription in a cell-type and stimulus-specific manner.
1.4.2 BCL3 structure
The human BCL3 gene, located on chromosome 19, is approximately 11.5kb in length, contains 
nine exons and encodes a 446-residue protein (Figure 1.10) (McKeithan, Ohno et al. 1994). The gene 
encodes seven copies of a 33-37-amino acid element called the ankyrin repeat domain (ARD), which is 
common to all IkB proteins. The first two exons encode a proline rich N-terminus which contains a 
nuclear localisation sequence (NLS) within the first 30 amino acids (Keutgens, Zhang et al. 2010). Exons 3- 
8 encode the seven ankyrin repeats that are essential for the interaction of BCL3 with p50 and p52 
(Bours, Franzoso et al. 1993). The serine- and proline-rich C-terminus is encoded by exon 9 (McKeithan, 
Ohno et al. 1994). Both the C-terminus and N-terminus of the BCL3 protein contain transactivation 
domains, which are essential for it to function as a transcriptional co-activator (Bours, Franzoso et al. 
1993). The mouse Bcl3 gene, located on chromosome 7, is homologous to the human gene.
1.4.3 Regulation of BCL3
BCL3 is a key m odulator of NF-kB transcriptional activity and as such it can cause the aberrant 
expression of NF-kB gene targets. BCL3 expression therefore has to be tightly controlled at both the  
transcriptional and protein level.
1.4.3.1 Transcriptional regulation
BCL3 gene expression has been shown to be induced by a number of different factors including 
cytokines, hormones, endotoxins and viral oncogenic proteins (Table 1.2). The function of the resulting 
BCL3 protein can vary dramatically according to the stimulus that induced it and the cell type in which it 
was induced.
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Figure 1.10: Structure o f  the BCL3 protein
BCL3 is a 446-residue protein consisting of a proline-rich N-term inal domain (first 120 amino acids), an 
ankyrin repeat domain (betw een amino acids 120 and 355) and a proline/serine-rich C-terminus 
(between amino acids 355 and 446). A nuclear localisation sequence (NLS, black) is contained within the  
first 30 amino acids of the N-terminus. Both the N- and C-termini contain transcriptional activation 
domains (TAD, purple; figure adapted from Michel, Soler-Lopez et al. 2001; Perkins 2007).
Inducer Cell Type Reference
G ranulocyte-m acrophage colony- 
stim ulating factor (GM-CSF) 
Erythropoietin (Epo)
Human Erythroleukaemia Cells, 
Haematopoietic Progenitor Cells
(Zhang, Harhaj et al. 1998), 
(Croker, M ielke et al. 2008)
Granulocyte colony-stim ulating  
factor (G-CSF)
Mouse Myeloid Progenitors (Kreisel, Sugimoto et al. 
2011)
ln te leukin-4  (IL-4) M urine T-Helper Cells (Rebollo, Dumoutier et al. 
2000).
ln terleukin-9  (IL-9) Mouse T-Lymphocytes, 
Mast Cells
(Richard, Louahed et al. 
1999)
ln terleukin-6  (IL-6) Human Multiple Myelom a Cells, 
Haematopoietic Progenitor Cells
(Brocke-Heidrich, Ge et al. 
2006)
(Brenne, Fagerli et al. 2009) 
(Croker, Mielke et al. 2008)
In terleukin -10 (IL-10) Mouse Macrophages (Kuwata, W atanabe et al. 
2003)
Interleukin (IL)-15,21, TN Fa and 
Insulin-Like G row th Factor-1 (IGF-1)
Human Myeloma Cells (Brenne, Fagerli et al. 2009)
Interleukin (IL)-4 and-13 Normal human primary 
epiderm al keratinocytes
(Buchau, MacLeod et al. 
2009)
TNF-a Human Hepatocellular 
Carcinoma Cells
(Brasier, Lu et al. 2001).
Adiponectin Human Macrophages (Folco, Rocha et al. 2009)
Epstein-Barr virus (EBV) la tent 
m em brane protein 1 (LMP1)
Cervical carcinoma cells (Kung and Raab-Traub 2008)
Lipopolysaccharide (LPS) Mouse primary T Cells (Bassetti, W hite et al. 2009)
Table 1.2: Examples o f  inducers o f  BCL3 expression
Using various model systems it has been dem onstrated that BCL3 expression is regulated at the  
transcriptional level by the inducible transcription factors, Activator Protein 1 (A P I), STAT3 and NF-kB 
itself. Analysis of the murine Bcl3 prom oter revealed two API-binding sites (Rebollo, Dum outier et al. 
2000). The same study showed that the induction of Bcl3 expression by IL-4 in a m urine T helper cell line
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was controlled by the binding of constituents of the A P I transcription factor at API-binding sites in the  
Bcl3 promoter.
Further analysis of the Bcl3 promoter identified one STAT3-binding site (Kung and Raab-Traub
2008), and two high-affinity NF-KB-binding sites (Brasier, Lu et al. 2001). In addition, two highly 
conserved enhancers for BCL3 transcription, HS3 and HS4, have been described (Ge, Li et al. 2003). The 
HS3 enhancer contains binding sites for NF-kB, STAT3, A P I, CRE and Ets, as well as two potential AP4- 
binding sites (Ge, Li et al. 2003). The HS4 enhancer contains three STAT3 binding sites (Brocke-Heidrich, 
Ge et al. 2006). The importance of STAT3 in the regulation of BCL3 expression was demonstrated in a 
study investigating the effects of LMP1 on BCL3 expression and EGFR induction. The results showed that, 
in LMPl-expressing cells, increased levels of phosphorylated STAT3 were detected at binding sites not 
only on the BCL3 prom oter but also on the HS3 and HS4 intronic enhancers (Kung and Raab-Traub 2008), 
resulting in induced BCL3 expression.
The transcriptional regulation of BCL3 is a tightly controlled process that is cell and stimulus 
specific. This is illustrated by the regulation of BCL3 in response to IL-6. BCL3 expression was shown to be 
induced by IL-6 in multiple myeloma cell lines via STAT3 binding to the HS4 intronic enhancer, resulting in 
BCL3 negatively regulating its own transcription at NF-kB sites within its own promoter (Brocke-Heidrich, 
Ge et al. 2006). However, in the hepatocellular carcinoma cell line, HepG2, IL-6 was incapable of inducing 
BCL3 expression even though STAT3 was also found to be bound to, and to activate, an HS4 reporter 
construct in response to the cytokine (Brocke-Heidrich, Ge et al. 2006). Interestingly, an earlier study 
showed that BCL3 could be induced in this HepG2 cell line in response to a different stimulus, TNF-a, in 
an NF-xB-dependent rather than STAT3-dependent manner (Brasier, Lu et al. 2001). The authors 
suggested that BCL3 transcription can be initiated by both NF-kB and STAT3, but only NF-kB can 
additionally stabilise the BCL3 mRNA. Thus, in multiple myeloma cells that are known to have a sustained 
low level of NF-kB activation (Feinman, Koury et al. 1999), IL-6-induced BCL3 mRNA may be stabilised by 
NF-kB. However, in HepG2 cells that lack background NF-kB activation, IL-6-induced BCL3 mRNA is not 
stabilised and protein expression is not observed. This suggests that NF-kB is essential for BCL3 
expression. The exact mechanisms behind the co-ordinated actions of A P I, STAT3 and NF-kB on BCL3 
expression remain to be identified.
1.4.3.2 Post-transcriptional regulation
After DNA is transcribed and mRNA is formed, the translation of transcripts is regulated by 
Micro-RNAs (MiRNAs) or RNA-binding proteins. There is evidence to suggest that BCL3 is regulated at the  
post-transcriptional level. For example, a recent study demonstrated that MiRNA-125 targets and down- 
regulates BCL3 at the translational level in human ovarian cancer cells (Guan, Yao et al. 2010). In 
addition, it has been shown that, although BCL3 mRNA is highly expressed in mouse splenocytes, it is not
32
Chapter 1: General Introduction
detected at the protein level unless mice are treated with oestrogen, which induces strong nuclear BCL3 
protein expression (Dai, Phillips et al. 2007). The mechanism behind this post-transcriptional 
modification was not explored, but the authors again suggest that MiRNAs may be involved.
1.4.3.3 Degradation
Mechanisms underlying BCL3 degradation are generally still poorly defined. However, a few  
recent studies have given some insight into this process. An early study demonstrated that glycogen 
synthase kinase (GSK)-mediated phosphorylation of BCL3 resulted in its ubiquitination and degradation 
(Viatour, Dejardin et al. 2004). It has subsequently been shown that an interaction between the N- 
terminal domain of BCL3 and the proteasome subunit p type-1 (PSMB1), is essential for this degradation 
to occur (Keutgens, Zhang et al. 2010). BCL3 has also been shown to interact with the E3-ligase, 
transducin 0-like lX -related protein 1 (TBLR1), which promoted its polyubiqutination and subsequent 
degradation in a GSK3-independent manner (Keutgens, Shostak et al. 2010).
1.4.4 Molecular functions of BCL3
Unlike other IkB proteins, which act primarily to sequester NF-kB subunits in an inactive state in 
the cytoplasm, BCL3 most often binds to p50 and p52 NF-kB subunits, where it has been shown to 
modulate their cellular localisation and transcriptional activity in a variety of contrasting ways.
1.4.4.1 Modulation o f NF-kB p50 and p52 transcriptional activity
The very first reports on the function of BCL3 showed that its central ARD preferentially 
interacts with p50 and p52 homodimers to inhibit their binding to DNA (Hatada, Nieters et al. 1992; Kerr, 
Duckett et al. 1992; Wulczyn, Naumann et al. 1992; Franzoso, Bours et al. 1992; Franzoso, Bours et al. 
1993; Inoue, Takahara et al. 1993; Naumann, Wulczyn et al. 1993; Nolan, Fujita et al. 1993). Some of 
these studies proposed that BCL3 could prevent both p50:p65 heterodimers and p50 homodimers from  
binding to kB sites (Kerr, Duckett et al. 1992; Wulczyn, Naumann et al. 1992; Naumann, Wulczyn et al.
1993). This was subsequently disputed by other reports demonstrating that BCL3 could only inhibit the  
binding of p50 and p52 homodimers. The discrepancy between these observations was suggested to be 
due to the model systems used (Nolan, Fujita et al. 1993). Wulczyn et al. (1992) used a bacterially 
derived, truncated version of BCL3 that was unlikely to have undergone sufficient post-translational 
modifications. BCL3 phosphorylation was subsequently shown to be essential for the efficient inhibition 
of p50 and p52 DNA binding (Nolan, Fujita et al. 1993). Truncation and the resulting loss of 
phosphorylation may well have reduced BCL3 specificity towards p50 and p52 homodimers. In the case 
of Kerr et al. (1992), inhibition of p50:p65 only occurred at very high BCL3 concentrations, which may not 
have been physiologically relevant. Despite these discrepancies, all of the initial reports supported the  
proposal suggested by Franzoso et al. (1992 & 1993) that BCL3 can facilitate NF-kB transactivation of
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target genes by binding to, and removing inhibitory p50 and p52 dimers from NF-kB DNA-binding sites, 
and thereby enhancing the binding of active NF-kB subunits.
In contrast with these early studies that were predominantly carried out using BCL3 derived 
from bacteria or insect cells, it was subsequently shown that, in mammalian-derived models, BCL3 does 
not necessarily inhibit the binding of NF-kB subunits to DNA, but it can instead function as a co-activator 
that can promote transcription in association with p50 and p52 homodimers (Fujita, Nolan et al. 1993; 
Bours, Franzoso et al. 1993). Analysis of the N-terminus and C-terminus of the BCL3 protein revealed that 
they both contain essential and co-operative transactivation domains (Fujita, Nolan et al. 1993), further 
supporting the notion that BCL3 can behave as a co-activator of transcription. Numerous subsequent 
studies have demonstrated the co-activating function of BCL3 (Hirano, Tanaka et al. 1998; Pan and 
McEver 1995; Na, Choi et al. 1999; Zhang, Warren et al. 2007).
M ore recent reports have shown that BCL3 can also indirectly repress NF-kB activation by 
facilitating the binding o f inactive p50 homodimers to NF-KB-binding sites, thereby preventing the 
association of other transactivating dimers (Muhlbauer, Chilton et al. 2008; Kuwata, W atanabe et al. 
2003; Caamano, Perez et al. 1996; Carmody, Ruan et al. 2007; Wessells, Baer et al. 2004). For example, 
Kuwata et al. (2003) demonstrated that BCL3 was able to suppress TNF-a expression in macrophages by 
driving inhibitory p50 homodimers onto the TNF-a promoter. It is possible that the BCL3-dependent 
increase in p50 homodimer binding is not due to an increase in the DNA-binding affinity of p50 
homodimers, but is instead due to altered turnover of p50, resulting in an increase in the number of 
homodimers present in the nucleus. Indeed, it has been shown that BCL3 can delay the K48- 
ubiquitination and subsequent degradation of DNA-bound p50 homodimers, thereby promoting p50 
DNA occupancy (Carmody, Ruan et al. 2007).
Overall, the literature suggests that BCL3 has two contrasting functions in the regulation of NF- 
xB-mediated transcription which are context and stimulus specific. In one role, it binds to p50 and p52 
homodimers and acts as a co-activator of NF-kB target gene transcription. In the other role, it can delay 
the turnover of p50 and promote the stable occupancy of repressive p50 homodimers to DNA, thereby  
indirectly inhibiting the transcription of NF-kB target genes.
The precise mechanisms underlying these dual functions remain unclear. However, it is highly 
likely that post-translational modifications may be essential in determining the functional outcome of 
BCL3 expression. A number of reports have shown BCL3 to be heavily phosphorylated in its C-terminal 
domain in a variety of different cell types (reviewed in Viatour, Merville et al. 2004; Fujita, Nolan et al. 
1993; Viatour, Dejardin et al. 2004; Bundy and McKeithan 1997; Nolan, Fujita et al. 1993; Caamano, 
Perez et al. 1996). The phosphorylation status of BCL3 has been found to have a pronounced effect on its 
interaction with p50 and p52 NF-kB subunits (Nolan, Fujita et al. 1993; Caamano, Perez et al. 1996;
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Bundy and McKeithan 1997). Bundy et al. (1997) proposed that the ability of BCL3 to enhance or inhibit 
p52 DNA binding is heavily dependent on its concentration and phosphorylation status, which, as a 
result, is likely to affect NF-KB-dependent gene transcription. Later work by Viatour et al. (2004) 
demonstrated that GSK3 can mediate BCL3 phosphorylation at two C-terminal serine residues (Viatour, 
Dejardin et al. 2004). BCL3 phosphorylation at these sites modulated its association with HDACs-1, -3 and 
-6 and limited the expression of target genes such as SLP1 and CXCL1. Interestingly, the binding of BCL3 
to p50 and p52 NF-kB subunits was later shown to be required for its GSK3-dependent constitutive 
phosphorylation (Keutgens, Zhang et al. 2010). C-terminal phosphorylation of BCL3 also resulted in the 
ubiquitination of two lysine residues in the N-terminus of the protein, which lead to its subsequent 
degradation (Viatour, Dejardin et al. 2004). Interestingly, these N-terminal lysine residues are located in 
one of the transactivation domains of BCL3 (Bours, Franzoso et al. 1993). Previous studies have 
demonstrated that ubiquitination of DNA bound transcription factors within their transactivation domain 
is essential for their transcriptional activity (reviewed in Freiman and Tjian 2003; Conaway, Brower et al.
2002). This raises the possibility that the ubiquitination status of BCL3 may be important in determining 
its transcriptional activity. In addition, Lys63-polyubiquitination of BCL3 has been shown to be necessary 
for its nuclear translocation in keratinocytes and B-cells (Massoumi, Chmielarska et al. 2006; 
Hovelmeyer, Wunderlich et al. 2007). Deubiquitination of BCL3 was found to prevent its nuclear 
translocation and, as a result, inhibited p50:BCL3- or p52:BCL3-dependent transcription (Massoumi, 
Chmielarska et al. 2006; Hovelmeyer, Wunderlich et al. 2007; Massoumi, Kuphal et al. 2009). It is also 
possible that other post-translational modifications such as acetylation are responsible for regulating the 
transcriptional function of BCL3, although this is yet to be proven experimentally.
1.4.4.2 Subcellular localisation o f NF-kB subunits
BCL3 has also been shown to regulate NF-kB signalling by influencing the subcellular 
localisation of NF-kB transcription factors in a variety of contrasting ways (Naumann, Wulczyn et al. 
1993; Zhang, Didonato et al. 1994; W atanabe, Iwamura et al. 1997). An early study demonstrated that 
BCL3 was generally confined to the cytoplasm in Cos7 cells and that it was able to promote the  
translocation of p50 from the nucleus into the cytoplasm (Naumann, Wulczyn et al. 1993). The BCL3 
protein has subsequently been shown to contain a nuclear localisation sequence in its N-terminal 
domain (Keutgens, Zhang et al. 2010) and to predominantly reside in the nucleus (Bours, Franzoso et al. 
1993; Nolan, Fujita et al. 1993; Zhang, Didonato et al. 1994; Keutgens, Zhang et al. 2010). Furthermore, 
BCL3 has now been demonstrated to successfully translocate p50 from the cytoplasm into the nucleus 
(Zhang, Didonato et al. 1994) and in another study, enhance the number of p50 homodimers in the  
nucleus by the apparent liberation of p50 from cytoplasmic p l05:p50  complexes (W atanabe, Iwamura et 
al. 1997).
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1.4.4.3 Regulation o f alternative transcription factor path ways
Although BCL3 primarily acts as a mediator of NF-kB transcription via interactions with p50 and 
p52 homodimers, it has also been shown to function independently o f NF-kB subunits and regulate the  
transcriptional ability of other transcription factors (Na, Choi et al. 1998; Na, Choi et al. 1999; 
Jamaluddin, Choudhary et al. 2005). For example, specific associations between BCL3 and the general 
transcription factors, TFIIB, TBP, and TFIIA, have been demonstrated (Na, Choi et al. 1998). In addition, 
BCL3 has been shown to co-activate both the Retinoid X receptor (RXR) and the A P I transcription factors 
(Na, Choi et al. 1998; Na, Choi et al. 1999) and in contrast, repress STAT1 transcriptional activity 
(Jamaluddin, Choudhary et al. 2005). These effects on other transcriptional pathways give increased 
insight into the functional diversity of BCL3.
1.4.4.4 Formation o f co-activating or co-repressing complexes
Co-activator and co-repressor complexes are composed of multiple proteins that bind to 
transcription factors and control chromatin modifications, thereby aiding in the regulation of 
transcription. BCL3 has been shown to form both co-activator and co-repressor complexes to facilitate 
transcriptional regulation (Na, Choi et al. 1998; Dechend, Hirano et al. 1999; Na, Choi et al. 1999; Kim, 
Kim et al. 2005; Zhao, Ramakrishnan et al. 2005; Kabuta, Hakuno et al. 2010; Hishiki, Ohshima et al. 
2007; Jamaluddin, Choudhary et al. 2005; Yang, Williams et al. 2009; Keutgens, Shostak et al. 2010; 
Wessells, Baer et al. 2004). Dechend et al. (1999) demonstrated that the ankyrin repeat domain of BCL3 
can physically interact with the nuclear proteins TIP60, BARD1, JAB1 and Pirin. TIP60 or BARD1 were able 
to form quaternary complexes with BCL3:p50 homodimers, JAB1 increased the DNA-binding ability of 
BCL3:p50 and Pririn had both of the above effects. The TIP60:BCL3:p50 interaction led to super­
activation of an NF-kB target gene in Drosophila SL2 cells. Interestingly, all of these BCL3-interacting 
proteins are able to bind other transcription factors, suggesting that BCL3 can act to mediate cross talk 
between NF-kB and a variety of other transcriptional regulators (Dechend, Hirano et al. 1999). 
Additionally, BCL3 has been shown to interact with other co-activators of transcription such as SRC-1, 
CBP/300 and PPARy co-activator l a  (Na, Choi et al. 1999; Na, Choi et al. 1998; Yang, Williams et al.
2009). In contrast, it has also been shown that BCL3 can form complexes with transcriptional co­
repressors such as HDACs to inhibit transcription (Wessells, Baer et al. 2004; Jamaluddin, Choudhary et 
al. 2005). A study by Wessells et al. (2004) demonstrated that LPS induced TNF-a production in 
macrophages could be attenuated by BCL3, p50 and HDAC1 complexes. In addition, BCL3 has been 
shown to recruit HDAC1 to the IL-8 promoter and repress NF-kB- and STAT1- mediated transcription 
(Jamaluddin, Choudhary et al. 2005). Interestingly, another report suggested that, rather than forming a 
co-repressor complex with HDACs, BCL3 could bind to, and remove, repressive HDACs from DNA in order 
to promote transcription (Viatour, Dejardin et al. 2004). M ore recently, interactions between BCL3 and
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the co-repressor, CtBP, have been observed (Keutgens, Shostak et al. 2010). This association was 
identified to be crucial for both stabilising BCL3 and for its ability to repress gene transcription. The 
underlying mechanisms that determ ine how these complexes interact with BCL3 remain unclear. 
However, there is evidence to suggest that the specific sequence of the kB DNA-binding site may dictate 
which co-regulatory complex is formed (Leung, Hoffmann et al. 2004).
1.4.5 Physiological functions of BCL3
As a modifier of the NF-kB signalling pathway, BCL3 is involved in the regulation of a number of 
cellular processes. BCL3 knock-out mice have been generated in order to gain an understanding of the  
basic physiological roles of the gene (Franzoso, Carlson et al. 1997; Schwarz, Krimpenfort et al. 1997). 
These mice develop apparently normally, in that they display no alterations in their gross anatomy or 
behaviour. However, they have disorganised B and T cells in germinal centres and severe defects in the  
microarchitecture o f the spleen and lymph nodes. This is accompanied by an inability to produce 
antigen-specific antibodies and a failure to resist infection by certain microbial pathogens such as 
Toxoplasma, gondii, Listeria monocytogenes, and Streptococcus pneumoniae (Franzoso, Carlson et al. 
1997; Schwarz, Krimpenfort et al. 1997; Riemann, Endres et al. 2005).
Bcl3- deficient and nf-xbl (p l05 /p 50 )-  or nf-xb2 (pl00/p52)~  deficient mice share similar 
phenotypes in many respects. For example, both Bcl3-deficient and /?/-/rb2-deficienct mice have similar 
defects in lymphoid organogenesis (Caamano, Rizzo et al. 1998; Franzoso, Carlson et al. 1998). Moreover, 
the response to pathogenic challenge is remarkably similar in nf-xb l-  and Bcl3- deficient mice (Sha, Liou 
et al. 1995). These similarities serve to confirm the biochemical co-operation between BCL3 and the p50 
and p52 subunits for transcriptional regulation in vivo. However, although there is clear overlap in the  
phenotypes of these knock-out mice, several differences also exist, indicating that BCL3 is capable of 
functioning independently of p50 and p52 NF-kB subunits. Interestingly, mice lacking both BCL3 and p52 
fail to survive beyond 4 weeks of age because of severe multi-organ inflammation, attributed to an 
enrichment of autoreactive T-cells (Zhang, Wang et al. 2007). This indicates that BCL3 has additional 
redundant roles in preventing the immune system from attacking its host that only become apparent in 
the absence of p52.
1.4.5.1 BCL3 and immune responses
The immunological defects observed in Bcl3- deficient mice indicate a central role for BCL3 in 
the immune system. Subsequent studies have investigated this further and highlighted BCL3 to be 
essential for appropriate T-cell survival and immune responses. The inability o f Bc/37' mice to resist 
certain microbial challenges was found to be due to an impaired protective T helper 1-like response 
(Franzoso, Carlson et al. 1997). Further analysis of T-cells from Bcl3-deficient mice revealed that they
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displayed defects in T helper 2 (Th2) cell differentiation with impaired IL-4, IL-5 and IL-13 cytokine 
production (Corn, Hunter et al. 2005). This was attributed to a BCL3-dependent decrease in the 
expression of GATA-3, a transcription factor known to activate IL-4 expression, which in turn induces the  
differentiation of naive helper T-cells to Th2 cells (Zhu, Yamane et al. 2006). A number of studies have 
demonstrated that BCL3 is also able to prolong the survival of T-cells a fter activation with an 
immunological adjuvant, a material that improves the immune response of vaccines (Rebollo, Dumoutier 
et al. 2000; Mitchell, Hildeman et al. 2001; Mitchell, Teague et al. 2002; Mitchell, Thompson et al. 2002; 
Bauer, Villunger et al. 2006; Li, Eppolito et al. 2006; Rangelova, Kirschnek et al. 2008; Valenzuela, 
Hammerbeck et al. 2005; Bassetti, W hite et al. 2009). For example, BCL3 expression was shown to be up- 
regulated in T-cells in response to IL-12 (Valenzuela, Hammerbeck et al. 2005; Li, Eppolito et al. 2006), a 
cytokine produced in antigen-presenting cells which are the direct targets of adjuvants (Trinchieri 2003). 
The downstream consequences of BCL3 induction in T-cells has been shown to involve the blockade of 
BIM activation to inhibit apoptosis (Bauer, Villunger et al. 2006). Interestingly, later studies suggest that, 
although BCL3 over-expression is able to mimic the effect of adjuvants, it is not absolutely essential for 
their action on T-cell survival (Bassetti, W hite et al. 2009; Chilton and Mitchell 2006). This was 
demonstrated by the fact that T-cells from Bd3'h mice exhibited long-term survival in response to 
adjuvants that was comparable to that in wild-type mice. The authors presented data to suggest that 
other IkB proteins, such as IkB(3 or IkBe, could act in the absence of BCL3 to promote a survival advantage 
to T-cells activated in response to adjuvant stimulation (Chilton and Mitchell 2006). This study also 
proposed an essential role for BCL3 in the production of gamma interferon (INFy) upon secondary 
stimulation of T-cells with antigens (Chilton and Mitchell 2006). INFy is a cytokine that is critical for 
immunity against viral and intracellular bacterial infections. The link between INFy and BCL3 provides 
further insight into how BCL3 functions as a mediator of microbial resistance. Evidence to support this 
association was provided in another study in which BCL3-deficient mice were shown to be highly 
susceptible to L monocytogenes infection, in part due to diminished INFy brought about by the 
increased expression of IL-10 in Bc/37' macrophages (Riemann, Endres et al. 2005). In addition, this 
increase in IL-10 and loss of INFy was recapitulated in BCL3-deficient mice after lung challenge with  
Klebsiella pneumoniae, rendering them more susceptible to this pathogen than wild-type mice (Pene, 
Paun et al. 2011).
As well as playing an important role in supporting T-cell responses, BCL3 can also regulate the 
immunological functions of other cells. BCL3-deficient mice have been shown to be incapable of 
developing tolerance to repeated toll-like receptor (TLR) stimulation, which is im portant in preventing 
deleterious inflammatory responses (Carmody, Ruan et al. 2007). This defect was attributed to the 
hyper-responsiveness of BCL3-deficient macrophages, dendritic cells and B-cells to TLR signalling,
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resulting in aberrant cytokine production. Another report showed that BCL3 can act as a transcriptional 
modulator of the cutaneous innate host immune response by regulating the expression of antimicrobrial 
peptides and cytokines in keratinocytes (Buchau, MacLeod et al. 2009). Furthermore, BCL3 has been 
shown to play a critical role in limiting granulocyte proliferation and differentiation under emergency 
inflammatory conditions in the lung, resulting in the prevention of acute inflammatory tissue injury 
(Kreisel, Sugimoto et al. 2011).
Overall, BCL3 clearly plays a subtle but important role in the regulation and function of cells of 
the immune system. Consequently, when deregulated it has been shown to be implicated in the 
pathology of a number o f human diseases of the immune system, such as autoimmune type 1 diabetes 
(Ruan, Zheng et al. 2010), atopic dermatitis (Massoumi 2009), crohn's disease (Fransen, Visschedijk et al.
2010) and lymphoid malignancies (see section 1.4.6).
1.4.5.2 BCL3 and cell survival, proliferation and apoptosis
A number of reports have shown that BCL3 expression can enhance the survival of a variety of 
different cell types by either promoting proliferation or preventing apoptosis. Studies relating to the role 
of BCL3 in the immune response clearly demonstrated that BCL3 can prolong the survival of T-cells by 
delaying their apoptosis (see section 1.4.5.1 above). To study this further, mice over-expressing BCL3 in 
T-and B-cells were generated. These transgenic animals developed a lymphoproliferative disorder 
involving splenomegaly and an accumulation of mature B-cells in the bone marrow, lymph nodes and 
peritoneal cavity (Ong, Hackbarth et al. 1998). B-cell expansion was found to be due to increased 
proliferation of the cells rather than as a result of a defect in apoptosis. Subsequently to this, numerous 
studies have demonstrated the ability of BCL3 to promote the proliferation of a variety of cell types 
(Zhang, Harhaj et al. 1998; Na, Choi et al. 1999; Viatour, Dejardin et al. 2004; Park, Chung et al. 2006; 
Zhang, W arren et al. 2007; Brenne, Fagerli et al. 2009; Zamora, Espinosa et al. 2010). For example, the  
expression of BCL3 in response to GM-CSF and Epo in an erythroleukaemia cell line was associated with  
increased proliferation, suggesting that BCL3 may participate in the regulation of NF-kB target genes 
involved in erythropoiesis (Zhang, Harhaj et al. 1998). Na et al. (1999) showed that microinjection of a 
BCL3 expression vector into Rat-1 fibroblast cells stimulated A P I transactivation and enhanced the  
proliferation potential of the cells. This pro-proliferative effect has also been demonstrated in murine 
xenograft and allograft transplant models (Pratt, Bishop et al. 2003; Viatour, Dejardin et al. 2004). For 
example, over-expression of BCL3 in NIH3T3 fibroblast cells resulted in the form ation of tumours when 
injected into the flanks of nude mice whereas injection of wild-type NIH3T3 cells did not. Interestingly, 
GSK-mediated phosphorylation of BCL3 attenuated this effect (Viatour, Dejardin et al. 2004).
Numerous studies have now demonstrated that BCL3-mediated increases in cell proliferation 
involve the transcriptional upregulation of CYCLIN D l, an im portant regulator of G l-  to S-phase
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transition (Westerheide, Mayo et al. 2001; Massoumi, Chmielarska et al. 2006; Park, Chung et al. 2006; 
Zhang, W arren et al. 2007; Wang, Shi et al. 2010). Over-expression of BCL3 in immortalized human breast 
epithelial cells resulted in a shortened G1 phase of the cell cycle and an increase in CYCLIN D1 mRNA and 
protein expression. BCL3, in co-operation with p52 homodimers was found to directly transactivate the 
CYCLIN D1 promoter via NF-xB-binding sites (Westerheide, Mayo et al. 2001). Subsequently, BCL3 has 
been shown to upregulate CYCLIN D1 expression in a number of different cell types, such as mouse 
primary keratinocytes (Massoumi, Chmielarska et al. 2006), human bronchial epithelial cells (Wang, Shi 
et al. 2010) and human hepatocytes (Park, Chung et al. 2006).
Inhibition of BCL3 expression by the tumour suppressor, p53, can also alter cell survival. Over­
expression of p53 in H1299 human non-small-cell-lung carcinoma cells reduced the levels of 
transcriptionally active BCL3:p52 complexes and concomitantly increased the levels of repressive 
HDACl:p52 complexes, resulting in active repression of the CYCLIN D1 prom oter and subsequent cell 
cycle arrest (Rocha, M artin et al. 2003). Interestingly, BCL3 has also been shown to be capable of 
suppressing DNA damage-induced p53 activity by transcriptionally up-regulating its inhibitor, HDM2 
(Kashatus, Cogswell et al. 2006). This suppression inhibited p53-induced apoptosis via reduced 
transcription of the pro-apoptotic genes, p21 and NOXA. A num ber of other studies have also 
demonstrated that BCL3 is able to provide an overall survival advantage by inhibiting apoptosis rather 
than driving proliferation (Ahmed and Milner 2009; Kabuta, Hakuno et al. 2010).
A few  studies have demonstrated that instead of promoting cell survival, BCL3 can have a pro- 
apoptotic effect in some contexts (Nishikori, Ohno et al. 2005; Brocke-Heidrich, Ge et al. 2006). Ectopic 
expression of BCL3 resulted in increased apoptosis in a myeloma cell line (Brocke-Heidrich, Ge et al. 
2006) and induction of a hyperphosphorylated form of BCL3 by CD30 in anaplastic large cell lymphoma 
cell lines was associated with a concomitant increase in pro-apoptotic genes and subsequent cell death 
(Nishikori, Ohno et al. 2005). In spite of this, the overwhelming evidence suggests that a primary role of 
BCL3 is to enhance the overall survival of cells by either promoting cell proliferation or inhibiting 
apoptosis in response to a variety o f stimuli. These functions provide insight into how de-regulated 
expression of BCL3 could potentially fulfil an oncogenic role.
1.4.6 BCL3 and cancer
BCL3 was originally identified through its involvement in a recurring chromosomal 
translocation t(14;19)(q32;q l3) found in some cases of B-cell chronic lymphocytic leukaemia (Ohno, 
Takimoto et al. 1990; Ueshima, Bird et al. 1985; McKeithan, Ohno et al. 1990; Yabumoto, Ohno et al.
1994). As a result of this translocation, BCL3 becomes juxtaposed to the immunoglobulin heavy chain 
gene locus, leading to the high expression of BCL3 mRNA and protein (reviewed in Willis and Dyer 2000). 
Over-expression of BCL3 has now also often been observed in a number of other B-and T-cell
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malignancies (Canoz, Rassidakis et al. 2004; Martin-Subero, Wlodarska et al. 2006; Martin-Subero, 
Ibbotson et al. 2007; Mathas, Johrens et al. 2005; Au, Horsman et al. 2002; McKeithan, Takimoto et al. 
1997; Rassidakis, Oyarzo et al. 2003; Ohno, Nishikori et al. 2005; Soma, Gollin et al. 2006; Szymanowska, 
Klapper et al. 2008). The expression of BCL3 has been assessed in a large panel of lymphoid neoplasms 
by immunohistochemistry (Canoz, Rassidakis et al. 2004). This study revealed that BCL3 was over­
expressed in 6% of B-cell malignancies, 23% of T-cell malignancies, and 41% of Hodgkin lymphomas. A 
subsequent study assessed BCL3 expression in 72 cases of chronic lymphocytic leukaemia and observed 
that 17% were positive for BCL3 expression (Schlette, Rassidakis e t al. 2005). Interestingly, high 
expression of BCL3 correlated with trisomy 12 and genetic abnormalities on chromosome 19, but was 
not limited to cases with the t(14;19)(q32;q l3) translocation, implying that these other chromosomal 
alterations may also lead to BCL3 expression. As well as B- and T-cell malignancies, BCL3 expression has 
recently been observed in myeloma cells from patients with multiple myeloma and was shown to be 
induced by a number of cytokines in myeloma cell lines, resulting in increased cell proliferation (Brenne, 
Fagerli et al. 2009). Notably, some studies suggest that high expression of BCL3 correlates with 
aggressive disease and poor patient outcome (Chapiro, Radford-Weiss et al. 2008; Martin-Subero, 
Ibbotson et al. 2007; Kelly, Wright et al. 2008; Brenne, Fagerli et al. 2009). Chapiro et al. (2008) proposed 
that chronic lymphocytic leukaemias with the t(14;19)(q32;q l3) translocation and high BCL3 expression 
define a particularly aggressive subtype of the disease. In addition, high BCL3 expression in patients with 
multiple myeloma correlated with a shorter 5-year survival (Brenne, Fagerli e t al. 2009). These studies 
indicate a potential role for BCL3 in promoting the progression of haematological malignancies.
Although BCL3 has primarily been investigated in lymphomas, it has also been shown to be 
highly expressed in a number of solid epithelial cell cancers (Thornburg, Pathmanathan et al. 2003; 
Cogswell, Guttridge et al. 2000; Mishra, Bharti et al. 2006; Pallares, M artinez-Guitarte et al. 2004; O'Neil, 
Buzkova et al. 2007). In nasopharyngeal cancers, BCL3:p50 homodimer complexes were shown to be 
specifically activated (Thornburg, Pathmanathan et al. 2003). Chromatin immunoprecipitation (ChIP) 
assays demonstrated that this complex was bound to kB consensus sequences within the EGFR 
promoter. Similarly, in oral carcinoma, p50 was shown to be up-regulated and bound to DNA in 
conjunction with BCL3 (Mishra, Bharti et al. 2006). Interestingly, expression of p50 and BCL3 was shown 
to be higher in Human Papillomavirus (HPV)-positive oral cancers that have a good prognosis in 
comparison with those that were HPV-negative and generally have a worse prognosis. The authors 
suggested that HPV-driven NF-kB activation could promote the differentiation of oral carcinoma cells, 
leading to better patient prognosis (Mishra, Bharti et al. 2006).
Studies evaluating the expression of NF-kB subunits in hepatocellular and endometrial cancers 
revealed a very high percentage of BCL3-positive cells within tumours (Pallares, Martinez-Guitarte et al.
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2004; O'Neil, Buzkova et al. 2007). In a study of 30 patients with hepatocellular carcinoma, BCL3 was 
found to be over-expressed in 90% of all hepatocellular tum our cell nuclei in comparison with 26% of 
adjacent non-neoplastic cells (O'Neil, Buzkova et al. 2007). p50 and p52, but not p65, were also 
commonly observed in the nuclei of tum our cells, suggesting that BCL3:p52 and BCL3:p50 interactions 
may be important in the pathogenesis of this disease. Likewise, evaluation o f 84 cases of endometrial 
cancer revealed that all tumours displayed BCL3 positivity, with 60.7%  of them  showing nuclear 
immunostaining (Pallares, Martinez-Guitarte et al. 2004). BCL3 nuclear positivity correlated with p52 
nuclear positivity, suggesting an involvement of BCL3:p52 complexes in this cancer type. Interestingly, in 
colon cancer, BCL3 expression was found to be the same in primary tum ours and normal tissues in a 
study of 23 patients with metastatic disease (Puwada, Funkhouser et al. 2010). However, nuclear BCL3 
expression in primary tumours correlated negatively with patient survival, implying that BCL3 may play a 
role in, and be a good prognostic marker for, metastatic disease.
Cylindromas have also been shown to be associated with BCL3 (Ikeda and Dikic 2006; 
Massoumi, Chmielarska et al. 2006). Cylindromas are generally benign skin tumours caused by loss of 
function mutations in the tum our suppressor gene, CYLD (for review, see Massoumi and Paus 2007). 
CYLD can bind to and deubiquitinate BCL3 to prevent its nuclear translocation in some cell types 
(Massoumi, Chmielarska et al. 2006; Hovelmeyer, Wunderlich et al. 2007; Massoumi, Kuphal et al. 2009). 
Mice lacking CYLD are highly susceptible to chemically induced skin tumours because of the 
accumulation of nuclear BCL3 resulting in up-regulated CYCLIN D1 expression (Massoumi, Chmielarska et 
al. 2006). A similar mechanistic observation has been made in melanoma cells. The transcription factor, 
SNAIL, was shown to inhibit CYLD expression, resulting in the nuclear translocation of BCL3. In these 
cells, nuclear BCL3 was shown to activate both the CYCLIN D1 and N-cadherin promoters leading to 
increased proliferation and invasion, implicating it in the poor prognosis observed in patients with CYLD- 
negative myeloma (Massoumi, Kuphal et al. 2009).
1.4.6.1 BCL3 and breast cancer
The role of BCL3 in breast cancer developm ent has not been extensively investigated. There 
are, however, a small number of studies describing BCL3 expression and function in human breast 
tum our samples, normal mammary epithelial cells and breast cancer cell lines. Cogswell et al. (2000) was 
the first to analyse BCL3 expression in primary human breast tumours and human breast cancer cell 
lines. Although the nuclear extracts from the majority of breast cancer cell lines analysed expressed NF- 
kB subunits, BCL3 was found not to be expressed in any of them . However, analysis of samples from four 
breast cancer patients revealed that the protein levels of BCL3, along with p50, p52 and c-Rel, were 
increased in all tum our samples in comparison with normal adjacent tissue. This was found to be 
regulated at the RNA level in two further samples, which also showed increases in CYCLIN D1 expression.
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In support of these data, a more recent report found that 9 out of 12 human breast cancer tumours had 
higher BCL3 protein levels than their corresponding adjacent tissue (Choi, Lee et al. 2010). In contrast 
with the study by Cogswell et al. (2000), this report also showed that BCL3 protein levels were elevated  
in breast cancer cell lines in comparison with a normal breast cell line. The discrepancies are likely to be 
due either to the use of different cell lines (work from Cogswell and co-workers does not clearly state 
which cells were analysed) or the fact that the latter study did not specifically assess nuclear extracts. In 
addition to demonstrating BCL3 over-expression in breast tumours, the work by Choi et al. (2010) also 
established a mechanism underlying the potential pro-oncogenic function o f BCL3 in breast cancer. BCL3 
was shown to bind to and stabilize the transcriptional repressor, CtBP, by inhibiting its ubiquitination. 
This BCL3-mediated stabilisation resulted in the repression of CtBP-dependent pro-apoptotic genes, such 
as p21 and NOXA, and consequently inhibited apoptosis. The interaction between BCL3 and CtBP was 
subsequently shown to be clinically relevant, as the over-expression of BCL3 protein levels in breast 
tum our samples correlated with the over-expression of CtBP in the same samples. In addition to this 
anti-apoptotic function, the well-established mechanism behind BCL3-induced proliferation involving 
transactivation of the CYCLIN D1 promoter has also been demonstrated in mammary epithelial cells of 
human and rat origin (Westerheide, Mayo et al. 2001; Zhang, W arren et al. 2007).
As NF-kB activity has been associated with ER-negative breast cancer, the effect of NF-kB and 
BCL3 on the transition of breast cancer cells from oestrogen dependence to independence has also been 
investigated (Pratt, Bishop et al. 2003). It was established that the withdrawal of oestrogen from the  
oestrogen-dependent MCF7 breast cancer cell line resulted in up-regulated BCL3 expression, suggesting 
that it had a role to play in promoting the transition to oestrogen independence. Interestingly, 
transplantation of MCF7 cells ectopically expressing BCL3 into ovariectomised nude mice resulted in 
substantially augmented tum our establishment and growth but it was insufficient to maintain tum our 
growth, upon removal of an oestrogen pellet. Although these results demonstrate that BCL3 expression 
alone is unable to confer oestrogen independence, they do clearly demonstrate its oncogenic potential 
in breast cancer cells.
Collectively, the limited evidence in the literature would suggest that BCL3 can potentially fulfil 
an oncogenic function in the mammary gland. Further investigation into the role of BCL3 in specific 
subtypes of the disease and elucidation of the precise mechanisms determining its effects will help to  
establish its potential as a new therapeutic target in breast cancer.
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1.5 Aims of this study
As described in the introduction, both STAT3 and NF-kB transcription factors play an important 
role in regulating mammary gland involution. As BCL3 is a known STAT3 transcriptional target and NF-kB 
co-factor that is up-regulated at the onset of involution, it is possible that it may also play a role in the 
regulation of involution. The first aim of this study was therefore to:
•  Determine the effect of BCL3 deficiency on normal m am m ary gland development and 
progression through the pregnancy cycle with particular reference to involution.
NF-kB is known to be heavily involved in the pathogenesis of ERBB2-positive breast cancer 
which has resulted in much interest in the development o f NF-kB inhibitors for treating the disease. 
However, as NF-kB is essential for a variety of normal physiological functions, sustained global inhibition 
of this transcription factor is likely to have many detrim ental side effects. It was hypothesised that as a 
modulator of NF-kB activity, BCL3 may contribute to the initiation or progression of breast cancer, but 
that therapeutic inhibition of this co-factor may be less likely to have unfavourable side effects than 
universal inhibition of NF-kB. The rest of the thesis therefore aimed to:
•  Establish the effect of BCL3 deficiency on ERBB2-driven breast cancer development and 
progression in mice.
•  Investigate mechanisms behind BCL3-mediated effects on murine ERBB2-driven breast cancer 
in vitro.
•  Determine w hether any BCL3-mediated effects on murine ERBB2-positive breast carcinogenesis 
are also observed in human breast cancer cell lines representing both ERBB2-positive and 
negative sub-types of the disease.
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2.1 Animal experiments
All procedures involving the use of animals were carried out in accordance with the 
institutional guidelines complying with the U.K. Home Office Regulations (Animals [Scientific Procedures] 
Act 1986).
2.1.1 Animals
The generation of Bc/i7', M M T V /N 2 and M M TV/NK  mice has been described previously (Muller, 
Sinn et al. 1988; Guy, Webster et al. 1992; Schwarz, Krimpenfort et al. 1997). These animals were all 
obtained from Jax Mice and Services (Bar Harbor, Main, US) and in-bred on an FVB background. 
M M T V /N 2 or M M TV/N K  mice were crossed with Bc/3_/' mice to create three further cohorts of transgenic 
mice, Bcl3 h/M M T V /N 2 (or NK), BcI3+//M M T V /N 2 (or NK) and BcI3+/V M M T V /N 2 (or NK).
The generation of mice with the mammary specific deletion o f Stat3 (Blg/Cre/Stat3^ox/ ) has 
been described previously (Chapman, Lourenco et al. 1999). Briefly, mice with one null Stat3  allele and 
one floxed Stat3  allele were crossed with mice expressing Cre under the control of the P-lactoglobulin 
milk gene {Big) prom oter (Seibert, Bentley et al. 1998). These animals were a gift from Professor Alan 
Clarke and maintained on a Black-6 background.
The above experimental mice received an RM3(E) expanded diet (Special Diets Service, UK) and 
tap w ater ad Libitum and were housed in colony specific cages (max 5/cage) with a 12hr day/night cycle. 
Animals were weaned and ear marked at approximately 4 weeks of age.
Six to eight week old Balbc/scid mice were obtained from Charles River Laboratories 
(Wilmington, US) and were housed in individually ventilated cages (Allentown Inc. New Jersey, US) with a 
12hr day/night cycle. Mice received a Teklad global 19% protein extruded rodent diet (Harlan 
Laboratories, Indianapolis, US) and w ater ad Libitum. All food, w ater, saw dust and water bottles were  
autoclaved before use. All procedures were performed under a laminar flow hood (Allentown).
2.1.2 Genotyping
All mice were genotyped by polymerase chain reaction (PCR) at 6-8 weeks of age. DNA was 
extracted from tail or ear biopsies after weaning at 4 weeks of age.
2.1.2.1 DNA extraction
A small section o f the tail or ear was taken, placed in a 1.5ml eppendorf tube and stored at - 
20°C. DNA was then isolated by adding 500m l lysis buffer (lOOmM Tris-Hcl; pH8.5 [Sigma], 5m M  EDTA 
[Fisher Scientific], 0.2% w /v  sodium dodecyl sulphate [SDS; Sigma], 200m M  sodium chloride [Fisher 
Scientific]) and 5pl o f proteinase K [Roche]) to the sample and incubated overnight at 55°C. Samples 
were mixed thoroughly and centrifuged at 13,000rpm for 10 minutes. The supernatant was transferred 
to a clean eppendorf tube and 500pl of isopropanol (Fisher Scientific) was added and left for 5 minutes
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to precipitate out the DNA. Samples were centrifuged for 5 minutes to pellet the DNA. The pellet was 
washed in 70% ethanol (Fisher Scientific) and dried at 55°C before being dissolved in lOOpI RNAse and 
DNAse free H20  at 55°C for 1 hour. This DNA solution was used for the PCR protocols outlined in Table 
2.1-2.4.
2.1.2.2 Generic PCR protocol
Primers were purchased from Sigma-Genosys and were either designed using primer 3 
software (h ttp ://frodo .w i.m it.edu /prim er3/) or using previously published sequences (Table 2.2). To 
check for mis-priming, all sequences were verified by performing in silico PCR 
http://genome.csdb.cn/cgi-bin/hgPcr.
Appropriate volumes (Table 2.3& 2.4) of DNA extract or DNase and RNase free w ater (Sigma) 
control were loaded into separate wells of 0.2ml strip tubes (StarLabs). A PCR mastermix containing all 
other reaction components was then prepared according to Table 2.3 or 2.4. Appropriate volumes of 
mastermix was added to each well and gently pipetted to ensure homogeneous mixing of DNA and 
reaction mix. Strip tubes were sealed with appropriate caps (StarLabs) and were then briefly spun in a 
Technico Mini Centrifuge (Technico). Reactions were then run on a iCycler PCR machine (BioRad) 
according to the cycling conditions detailed in Table 2.1.
2.1.2.3 Gel electrophoresis
After the completion of PCR reactions, products were visualised by gel electrophoresis. An 
appropriate marker (e.g. Easyladder 1 [Bioline]) and all samples were loaded onto 3% agarose gels (made 
by dissolving twelve 0.5g agarose tablets [Bioline] in 1 x Tris-Borate-EDTA [TBE] Buffer [Sigma] containing 
0.006% [v/v] SafeView Nucleic Acid Stain [NBS Biologicals]). Gels were run in 1 x TBE buffer at 150V for 
20-30minutes and products were visualised under UV light on a GelDoc (BioRad).
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PCR Step Bcl3 N2/NK Stat3 WT/Flox Stat3 Null Blg/Cre
No.
Cycles
Temp
(°C)
Time No.
Cycles
Temp
(°C)
Time No.
Cycles
Temp
(#C)
Time No.
Cycles
Temp
(°C)
Time No.
Cycles
Temp
(°C)
Time
Initial Denaturation 1 94 3 min 1 94 2 min 1 95 3 min 1 95 3 min 1 94 3
Denature
35
94 30 sec
35
94 30 sec
35
95 30 sec
38
95 30 sec
30
95 30
Anneal 66 1 min 60 30 sec 67 1 min 55 1 min 55 30
Extension 72 1 min 72 1 min 72 1 min 72 1 min 72 1
Final Extension 1 72 2 min 1 72 5 min 1 72 5 min 1 72 10 1 72 5
Hold 1 4 oo 1 4 OO 1 4 oo 1 4 OO 1 4 OO
Table 2.1: PCR cycling conditions
Target Forward Primer Sequence (5' to 3')
Reverse Primer Sequence 
(3' to 5’) Product Size
Bcl3WT AGG TGG CAG AAA TGT TCA C CAC CAT GTT CAG GCT GTT GT 598bp
Bcl3 null AAA AGT TCG ACA GCG TCT CCG ACC TTG GCG ACC TCG TCT TGG GAA TCC 209bp
N2/NK TTT CCT GCA GCA GCC TAC GC CCG GAC TAC ACC CAA GGC 600bp
5tat3
WT/Floxed CCT GAA GAC CAA GTT CAT CTG TGT GAC CAC ACA AGC CAT CAA ACT CTG GTC TCC
W T 230bp 
Floxed 320bp
Stat3 null AGC AGC TGA CAA CGC TGG CTG AGA AGC T ATC GCC TTC TAT CGC CTT CTT GAC GAG lOOObp
Blg/Cre TGA CCG TAC ACC AAA ATT TG CTA TCA CTT TG T CCC CGT TA lOOObp
Table 2.2: Genotyping primers and product sizes
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PCR Reaction Component Nz/NK Stat3 WT/Flox Stat3 Null Blg/Cre
Crude DNA 1.5pl 2 pl 2.4|il 2 pl
PCR-grade Water (Sigma) 15.5pl 32.2pl 22pl 32.2pl
Go Taq PCR Buffer (Promega) 5pl 10|il N/A lOpI
Magnesium Chloride (25mM; Promega) 2.5|il 5(il N/A 5pl
Failsafe Buffer E (Epicentre Technologies) N/A N /A 25pl N/A
dNTPs (25mM; dATP, dCTP, dGTP, dTTP; Promega) 0.2pl 0.4pl N/A 0.4pl
Forward Primer (Sigma Genosys, lOOpM) O.lpl O .lp l O.lpl O.lpl
Reverse Primer (Sigma Genosys, lOOpM) O.lpl O .lp l O.lpl O.lpl
Go Taq DNA Polymerase (Promega) O.lpl 0.2|il N /A 0.2pl
Failsafe Taq (Epicentre Technologies) N/A N/A 0.4pl N/A
Total Reaction Volume 25pl 50|il 50pl 50pl
Table 2.3: PCR reaction components (N2/ NK, Stat3, Blg/Cre)
PCR Reaction Component Bcl3
Crude DNA 1.2pl
PCR-grade Water (Sigma) 15.25|il
10xNH4 Reaction Buffer (Bioline) 3 pi
Magnesium Chloride (50mM; Bioline) 1.2pl
dNTPs (lOmM; dATP, dCTP, dGTP, dTTP; romega) 0.6pl
Null Primer Mix (Sigma Genosys, 20pM) 20pM) 1.5pl
WT Primer Mix (Sigma Genosys, 20pM) 1.5pl
BIOTAQ Red DNA Polymerase (Bioline) 0.75pl
Total Reaction Volume 25pl
Table 2.4: PCR reaction 
components (Bcl3)
2.1.3 Experimental procedures
2.1.3.1 Tumour checking
Twice weekly, BCI3'1'/M M T V /N 2 (or NK), Bcl3+//M M T V /N 2 (or NK) and BcI3+/+ /M M T V /N 2 (or NK) 
mice were inspected for tumours by palpation and existing tumours were measured with callipers. When 
tumours reached their size limit (either 500m m 3 or 4000m m 3), animals were killed by cervical dislocation 
and tissues were either snap frozen in liquid nitrogen for protein or RNA analysis or fixed in formalin for 
histological analysis. Tumour volume was calculated using the following formula:
(tumour w idth2) x tum our length /  2.
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2.1.3.2 Tail vein injections
Cells were transfected for 48 hours (see section 2.5.5). Cells were harvested using 
Tryspin/EDTA (0.25% w /v  [Invitrogen]), washed, disaggregated into single cell suspensions and 
resuspended at 4 x l0 6 cells/ml in serum free L-15 media (Invitrogen), maintained on ice and taken to the 
surgical room. Six-eight week old female virgin Balbc/scid mice were used for tail vein injections. When 
removed from their individually ventilated cages, animals were continually kept under a laminar flow  
hood and all procedures were carried out aseptically. The oxygen flow m eter for the induction chamber 
was set to 0.8L/m in and animals were placed into the induction chamber, ensuring the lid was closed 
tightly. Anaesthesia was induced by turning the vaporiser to deliver 5% isoflurane (Abbot). When the 
animal was fully anaesthetised, as determined by a lack of m ovem ent and slow but steady breathing, it 
was transferred from the induction chamber to the maintenance anaesthetic mask and the vaporiser for 
the induction chamber was turned to 0. The oxygen flow m eter for the mask was set to 0.8L/min and the 
anaesthetic vaporiser was set to 2.5% to adequately maintain anaesthesia. The animal was placed on its 
side and its tail was gently warmed by placing a bag of warm  w ater over it. W hen the tail was warm  
enough for the tail vein to become clearly visible, 200pl of suspended cells were drawn into a 29G needle 
(BD Micro-Fine), ensuring all bubbles were removed. The tail was held straight and horizontally in the left 
hand and the needle was carefully inserted into the lateral tail vein with the right hand. The solution was 
injected slowly into the tail vein. A successful injection was characterised by the immediate clearing of 
the solution down the vein. The animal was then removed from the anaesthesia, placed into a recovery 
cage, kept warm and monitored frequently. Animals were left for 21 days before being culled by cervical 
dislocation. Lungs were dissected and fixed in 4% formalin before being processed for H&E staining (see 
sections 2.2.2-2.3.1). Metastases were measured and counted as outlined in section 2.3.2.2.
2.2 Tissue sampling and processing
2.2.1 Removal and fixation of tissues
All animals were culled by cervical dislocation prior to dissection.
2.2.1.1 Tissues fo r involution studies
Mam m ary tissue was collected from animals at 10 days lactation and at 12, 18 and 24 hours 
after forced involution, initiated by the removal of pups. Fourth abdominal mammary glands were fixed 
in 4% formalin in Phosphate buffered saline (PBS, Gibco) at 4°C overnight after which they were 
transferred to 70% ethanol (in distilled H2O[dH20]) and stored at 4°C until processed for histology. For 
protein or RNA extraction, lymph nodes were excised from whole mammary glands which were then 
removed and immediately snap frozen in liquid nitrogen before being stored at -80°C until required.
50
Chapter 2: Materials and Methods
2.2.1.2 Wholemounting
Fourth abdominal mammary glands were carefully dissected. The gland was spread across a 
microscope slide (R.A. Lamb) ensuring that the structure and shape of the gland were preserved. The 
spread tissue was placed into a 50ml tube containing Carnoy's solution (60% v/v  ethanol, 30% v/v  
chloroform [Fisher Scientific], 10% acetic acid [Fisher Scientific]) for 2-4 hours. The tissue was transferred 
into 70% ethanol for 15 minutes and washed under a slow running tap for 5 minutes before being 
transferred into a 50ml tube containing Carmine solution for staining (Carmine solution was prepared by 
mixing lg  Carmine (Sigma) with 2.5g aluminium potassium sulphate (Sigma) in 500ml dH20. This was 
then boiled for 20 minutes and adjusted to a final volume of 500ml with dH20. The solution was filter 
sterilised and a crystal of thymol [Alfa Aesar] was added as a preservative before it was stored at 4°C). 
The tissue was incubated in Carmine solution overnight at room tem perature. The next day, the tissue 
was transferred into a coplin jar (R.A. Lamb) and rinsed with tap w ater until the w ater ran clear. The 
tissue was dehydrated by incubation in increasing concentrations of ethanol (10%, 50%, 70%, 90% and 
100% ethanol for 10 minutes each). The tissue was then transferred to xylene (Fisher Scientific) for at 
least an hour. Slides were mounted for visualisation using DPX (R.A. Lamb).
2.2.1.3 Tissues fo r  tum our studies
All mammary tumours were excised when they reached their size limit (either 500m m 3 or 
4000m m 3). Half of each tum our was fixed in 4% formalin for histology and the other half was 
immediately snap frozen in liquid nitrogen and stored at -80°C for future RNA or protein extraction. Any 
available tissue from either pre-neoplastic, non-tumour bearing mammary glands or from mammary 
tissue adjacent to tumours was also fixed and frozen in the same way. Lungs were also dissected and 
fixed in 4% formalin for histology.
2.2.2 Tissue processing and sectioning for histology
2.2.2.1 Dehydration o f tissue
Tissue processing was performed by the Cardiff Biosciences Histology Unit using an automatic 
processor (Leica TP1050). Tissues were first dehydrated in increasing concentrations of ethanol followed 
by xylene and finally paraffin (70% ethanol for 1 hour, 95% ethanol for 1 hour, 2 x 100% ethanol for 1 
hour 30 minutes, 100% ethanol for 2 hours, 2 x xylene for 1 hour, 2 x paraffin for 2 hours). Tissues were 
then embedded in paraffin wax. Paraffin tissue blocks were cut at a thickness of 5pm on a microtome 
cutter (Leica RM2135) Sections were then placed on poly-L-lysine (PLL) coated slides (polysine, Thermo 
Fisher) and heated at 58°C for 24 hours before being stained for histology or for use in 
immunohistochemistry.
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2.3 Histological analysis of tissue sections
2.3.1 Haematoxylin and eosin (H&E) staining
H&E staining was performed by the Cardiff Biosciences Histology Unit. Tissue sections were  
firstly de-waxed and rehydrated (see section 2.4.1.1) before being incubated in Meyer's Haemalum (R.A. 
Lamb) for 5minutes to stain all nuclei. The sections were then washed for 5 minutes in running tap  
water, counterstained in 1% aqueous Eosin (R.A. Lamb) for 5 minutes and then washed again (2x15 
seconds) in tap water. Sections were then dehydrated, cleared and mounted as described in section 
2.4.1.5.
2.3.2 Visualisation and quantification of H&E stained sections
Visualisation and quantification of all histological sections was carried out on an Olympus BX41 
Light Microscope (Olympus). All digital photos of sections were taken on a Colorview III (5 megapixel, 
soft imaging systems) camera with aid of the Analysis Software Package (Version 3.2, Build 831, Soft 
Imaging Systems).
2.3.2.1 Analysis o f apoptotic bodies in mammary involution samples
Apoptotic bodies were identified on mammary involution H&E sections by their distinctive 
appearance and location within the secretary alveoli lumens. Two random 4 x magnification pictures 
were taken and apoptotic bodies were counted with the aid of Image J software 
(http ://rsbw eb.n ih .gov/ij/). The average (mean) number of apoptotic bodies within these tw o fields was 
calculated and then the mean across all sections of the same genotypes was taken to generate an overall 
mean value. The standard error of the mean was calculated by standard methods and statistical analysis 
to identify any significant differences between genotypes was carried out using the M ann-W hitney U- 
test.
2.3.2.2 Analysis o f lung metastases
Photos of all visible lung metastases on H&E sections were taken and the area of each 
metastasis was measured using Image J software. The average (mean) area of an individual metastasis 
within each genotype was calculated and statistical analysis to identify significant differences between 
groups was carried out using the M ann-W hitney U-test.
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2.4 Immunohistochemistry (IHC)
2.4.1 Generic IHC protocol
All IHC was carried out using the following generic protocol. Any modifications used for a 
specific a target are outlined inTable 2.5.
2.4.1.1 De-waxing and rehydration
Tissues were de-waxed by soaking slides in xylene (2x5 minutes) and then rehydrated by 
soaking in decreasing concentrations of ethanol (100% ethanol for 2x2 minutes, 95% ethanol for 2 
minutes, 70% ethanol for 2 minutes) followed by a wash in dH20 .
2.4.1.2 Antigen retrieval and prevention o f endogenous staining
Antigen retrieval was performed either by heat treatm ent or by pressure treatm ent (seeTable 
2.5). For heat treatm ent, a 1 x citrate buffer solution (Thermo Scientific) was pre-heated to 99.9°C in a 
glass coplin jar (R.A.Lamb) in a waterbath after which slides were immersed into the solution and 
allowed to boil for 20 minutes. For pressure treatm ent, adequate citrate buffer was added to a pressure 
cooker and heated to boiling. Slides were then immersed in the solution and pressure cooked for 8 
minutes. Following either treatm ent, slides were left to cool in the solution at room tem perature for at 
least 30 minutes and then rinsed once in dH20 . To prevent endogenous peroxidise activity, the slides 
were treated with a 3% Hydrogen Peroxide solution (30% aqueous solution diluted 1:10 in dH20; Sigma) 
for 20 minutes and then washed twice in dH20  for 5 minutes and once in PBS/T (PBS plus 0.1% TWEEN- 
20 [Sigma]) for 5 minutes. Non-specific binding of antibodies was blocked by the addition of serum from  
the host species of the secondary antibody (Vector Laboratories) or Bovine Serum Albumin (BSA; Sigma) 
diluted in PBS/T in a humidified chamber at room tem perature for 20 minutes.
2.4.1.3 Incubation with primary and secondary antibodies
Primary antibody was diluted according to Table 2.5in 5% BSA in PBS/T and applied to the  
slides which were then incubated overnight at 4°C in a humidified chamber. The next morning primary 
antibody was removed and the slides were washed in PBS/T (3x5 minutes). Biotinylated secondary 
antibody (DAKO) was diluted 1:200 in 5% BSA in PBS/T and applied to the slides for 30 minutes at room  
tem perature in a humidified chamber.
2.4.1.4 Signal amplification and visualisation o f positivity using 3,3'-diaminobenzidine (DAB)
Signal amplification was achieved by the formation of an Avidin-Biotin Complex (ABC) using the 
Vectastain ABC kit (Vector Labs). The ABC reagents were prepared 30 minutes before required by adding 
1 drop of A and then 1 drop of B to 5mls of PBS/T and mixing well. Slides were washed in PBS/T (3x5 
minutes) and the ABC mix was applied and left at room tem perature for 30 minutes. After this, the slides
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were washed in PBS/T (3x5 minutes). The colorimetric detection of signal was achieved by the DAB 
method. Immediately before use, the DAB reagents from the DAB+ kit (DAKO) were prepared by mixing 1 
drop of chromagen per 1 ml of substrate buffer. This DAB solution was then applied to slides at room 
tem perature and the development of colour was monitored for 5-10 minutes until brown staining was 
visualised. The slides were then washed once for 5 minutes in PBS/T and then 2x5 minutes in dH20 .
2.4.1.5 Counterstaining, dehydration, clearing and mounting o f slides
Slides were counterstained by immersion in Meyer's Haematoxylin (R.A. Lamb) for 45 seconds. 
They were then thoroughly washed in tap water until it ran clear. The slides were dehydrated by soaking 
in increasing concentrations of ethanol (70% ethanol for 1x30 seconds, 95% ethanol for 1x30 seconds, 
100% ethanol 2x30 seconds) and cleared by soaking in xylene (2x2 minutes). Slides were then mounted 
and coversliped for viewing using DPX mounting solution.
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Antigen Ki67 Cleaved Caspase 3 p50 Phospho-p50
(Ser337)
p52 Phospho-p52
(Ser222)
Vimentin
Primary Antibody 
Source
Vector Labs Cell signalling Santa Cruz Santa Cruz Santa Cruz Gift from Prof. 
Neil Perkins
Santa Cruz
Catalogue
Number
VP-K452 9661 sc-114 sc-101744 sc-7386 N/A sc-7557
Primary Antibody 
raised in
Mouse (mAb) Rabbit (pAb) Rabbit (pAb) Rabbit (pAb) Mouse (mAb) Rabbit (mAb) Goat (pAb)
Antigen Retrieval Boiling w ater 
bath
Pressure Cooker Boiling w ater 
bath
Pressure Cooker Pressure Cooker Pressure Cooker Pressure Cooker
Serum Block 20% Normal 
Rabbit Serum
5% BSA 5% Normal Goat 
Serum
5% Normal Goat 
Serum
5% Normal 
Rabbit Serum
5% Normal Goat 
Serum
5% Normal 
Rabbit Serum
Primary Antibody 
Dilutions
1:20 1:200 1:5000 1:50 1:200 1:100 1:100
Secondary
Antibody
Biotinylated 
Rabbit anti- 
Mouse (Dako)
Biotinylated 
Goat anti- Rabbit 
(Dako)
Biotinylated 
Goat anti-Rabbit 
(Dako)
Biotinylated 
Goat anti-Rabbit 
(Dako)
Biotinylated 
Rabbit anti- 
Mouse (Dako)
Biotinylated 
Goat anti-Rabbit 
(Dako)
Biotinylated 
Rabbit anti-Goat 
(Dako)
Secondary
Antibody
Dilutions
1:200 1:200 1:200 1:200 1:200 1:200 1:200
Table 2.5: Immunohistochemistry antibodies and conditions
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2.5 Cell culture maintenance and procedures
2.5.1 Experimental cell lines
The human breast cancer cell lines, M DA-M B-231 and SKBR3, used in this investigation were a 
gift from  Dr. Julia Gee (D epartm ent o f Pharmacy, Cardiff University). The HCC1954 human breast cancer 
cell line was a gift from  Dr. M oham ed Bentires-Alj (Friedrich M iescher Institute for Biomedical Research, 
Switzerland) and the ZR-75-1 human breast cancer cell line was a gift from  Prof. W en Jiang (Wales 
College o f M edicine, Cardiff University). The M G 1361 murine m am m ary tum our cell line and the EPH4 
normal m urine m am m ary epithelial cell line were gifts from  Dr. Christine W atson (Departm ent of 
Pathology, Cambridge University). The N202A and N202E murine m am m ary tum our cell lines were gifts 
from  Dr. Pier-Luigi Lollini (Sezione di Cancerologia, Italy) and the 4T1 m urine m am m ary tum our cell line 
was a gift from  Dr. Robin Anderson (Departm ent o f Pathology, University o f M elbourne). Descriptions of 
the main cell lines used in this thesis are outlined below:
2.5.1.1  M DA -M B -231
M D A -M B -231 is a highly m etastatic human basal epithelial cell line isolated from  the pleural 
effusion o f an adenocarcinom a. The cells are 'triple negative' as they lack oestrogen, progesterone and 
ERBB2 receptors (Neve, Chin et al. 2006; Chapter 6, section 6.2.1). They strongly over-express EGFR (see 
Chapter 6, section 6.2 .1).
2 .5 .1 .2  ZR-75-1
The ZR-75-1 cell line is a m oderately metastatic human luminal epithelial cell line derived from  
a malignant ascitic effusion w ith  infiltrating ductal carcinoma. ZR-75-1 cells are oestrogen receptor 
positive and progesterone receptor negative (Neve, Chin et al. 2006). They express very low levels o f the  
ERBB2 receptor and over-express EGFR (see Chapter 6, section 6.2.1).
2 .5 .1 .3  HCC1954
HCC1954 is a m oderately  metastatic human basal epithelial cell line derived from  a primary 
grade 3 invasive ductal carcinoma. HCC1954 cells are oestrogen and progesterone receptor negative 
(Neve, Chin et al. 2006). They over-express both the ERBB2 receptor and EGFR (see Chapter 6, section 
6 .2.1).
2 .5.1 .4  SKBR3
The SKBR3 cell line is a poorly metastatic human luminal epithelial cell line derived from  a 
pleural effusion. SKBR3 cells are oestrogen and progesterone receptor negative (Neve, Chin et al. 2006). 
They over-express the ERBB2 receptor and have very low levels o f the EGFR receptor (see Chapter 6, 
section 6.2.1).
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2 .5 .1 .5  M G 1361
The M G 1361 cell line was established from a m am m ary adenocarcinoma that had arisen in a 
M M T V /N K  (activated Neu) transgenic C D -I mouse (Sacco, Gribaldo et al. 1998). This cell line shows an 
epithelial-like morphology and maintains a high level o f NEU expression in vitro. The cells are oestrogen 
and progesterone receptor positive (Sacco, Gribaldo et al. 1998).
2.5.2 Maintenance of cell lines
All human cell lines and m urine Eph4 cells were maintained in Dulbecco's modified Eagle's 
medium (D M E M ) supplem ented w ith 10% v /v  foetal bovine serum (FBS, Sigma), penicillin (50units/m l 
Invitrogen) streptom ycin (50units /m l, Invitrogen) and L-glutamine (2m M , Invitrogen). The N202A and 
N202E cell lines w ere  m aintained in the same media as above but supplem ented w ith  15% v /v  FBS. The 
M G 1361 cell line was m aintained in W illiams M edia E (Invitrogen) supplem ented w ith L-glutamine 
(2m M ), penicillin (50units /m l), streptomycin (50pg/m l), 15% v /v  FBS and 5ml non-essential amino acids 
(Sigma). The 4T1 cell line was m aintained in RPMI (Invitrogen) supplem ented w ith 10% v /v  FBS, penicillin 
(50units /m l Invitrogen) streptomycin (50units/m l, Invitrogen) and L-glutamine (2m M , Invitrogen).
All cell lines w ere  incubated at 37°C and 5% C 0 2 in T25 tissue culture flasks (Nunc) and were  
routinely passaged every 3 - 8  days at a split ratio o f 1:4 -1:12, when they became 80-90%  confluent. 
Growth m edia was com pletely aspirated and the cells w ere washed w ith PBS to remove any remaining 
serum. The wash was rem oved and 2mls o f 0.25%  Trypsin/EDTA was added to the flask followed by 
incubation at 37°C. W hen the cells were detached, a known volum e o f growth m edium  was added to the  
cells which w ere then split at an appropriate ratio by the removal excess cell suspension into waste. The 
remaining volum e o f cell suspension was m ade up to 6mls w ith com plete growth media.
2.5.3 Cell counting
Cells w ere trypsinised using 0 .25%  Trypsin/EDTA. Once detached, cells w ere resuspended in 
lOmls o f growth m edium , transferred to a 15ml falcon tube (BD Biosciences) and centrifuged at llO O rpm  
for 5 minutes at room tem perature . The supernatant was removed and the cells w ere resuspended in a 
known volum e o f growth m edia. Cells w ere counted in four 1m m 2 fields using an Improved Neubauer 
Counting Cham ber (Hawksley, Lancing, UK). The num ber of cells per ml o f suspension was determ ined by 
calculating the average count per square and multiplying it by 1 x 104.
2.5.4 Frozen storage of cells
A confluent T75 flask o f cells w ere trypsinised, resuspended in lOm ls o f growth medium, 
transferred to a 15ml falcon tube and centrifuged at llO O rpm  for 5 minutes at room tem perature. The 
supernatant was rem oved and cells w ere resuspended in 6mls o f com plete media containing 10% (v/v) 
dim ethyl sulfoxide (DMSO, Sigma) before being aliquoted into 1ml cryo tube vials (Nunc) and stored in
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liquid nitrogen. W hen necessary, frozen stocks were retrieved from  the liquid nitrogen stores and 
defrosted quickly to 37°C in a w aterbath  before being transferred to lOm ls o f com plete medium in a 15 
ml falcon tube. Cells w ere centrifuged at llO O rpm  at room tem perature  for 5 minutes, and the pellet 
was resuspended in 7mls o f com plete grow th media and transferred to a T25 flask.
2.5.5 Transient SiRNA transfection
ON-TARGET plus SMARTpool small interfering RNA (SiRNA) targeting an irrelevant control RNA, 
mouse Bcl3 or human BCL3 w ere  purchased from  Dharmacon (Table 2.6). The SMARTpool SiRNA 
contains a m ixture o f four SiRNAs tha t target the same gene to increase the efficiency o f gene silencing. 
The negative control SiRNA was designed to have minimal targeting o f known genes in human or mouse. 
Cells w ere transfected w ith  SiRNA using lipofectamine RNAiMAX (Invitrogen) according to the 
m anufacturers protocols to give a final SiRNA concentration of lO n M . Volum es and concentrations of 
reagents used in d ifferent tissue culture plates are outlined in Table 2.7. The appropriate volume of 
SiRNA was diluted in serum -free O pti-M E M  1 (Invitrogen) in the well o f a tissue culture plate and mixed 
gently. Lipofectamine RNAiMAX was mixed before use and the appropriate volum e was added to each 
well containing the SiRNA. This was mixed and incubated for 20 minutes at room tem perature to allow  
the SiRNA-Lipofectamine com plexes to form . M eanw hile, cells w ere diluted in com plete growth medium  
w ithout antibiotics to a concentration that would give 30-50%  confluency 24 hours after seeding (see 
Table 2.8). Cells w ere  then carefully and evenly added to each well containing SiRNA-lipofectamine 
complexes to give a final concentration of lO nM . Cells were incubated at 37°C in 5% C 0 2. Transfection 
times for each cell line w ere  optim ised (see Chapter 5 and Chapter 6).
SiRNA Target Sequences 
(5 '-3 ')
Final SiRNA 
Concentration
Source Catalogue
Number
Human Bcl3 
ON-TARGETplus 
SMART pool
AGACACGCCUCUCCAUAUU
GGCCGGAGGCGCUUUACUA
GCGCAAAUGUACUCCGGCA
GCCGGGAGCUCGACAUCUA
lOnM Dharmacon 
(Thermo Scientific)
L-003874-00-
0005
Mouse Bcl3 
ON-TARGETplus 
SMART pool
GCUUGGGAGCCGCGAAGUA
GCGCCAAACGUGAACGCUCA
GCGCGGACAUCGAUGCAGU
CCUGGAGGUUCGCAAUUAU
lOnM Dharmacon 
(Thermo Scientific)
L-045102-01- 
0005
Human/Mouse 
Control 
ON-TARGETplus 
SMART pool
UGGUUUACAUGUCGACUAA
UGGUUUACAUGUUGUGUGA
UGGUUUACAUGUUUUCUGA
UGGUUUACAUGUUUUCCUA
lOnM Dharmacon 
(Thermo Scientific)
D-001810-10
Table 2.6: SiRNA reagents and concentrations
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Tissue
Culture
Vessel
Relative
Surface
Area
Volume of cell 
plating 
medium
Volume of 
OptiMEM 1 
dilution medium
SiRNA
(pmol)
Final SiRNA 
concentration 
(nM)
Lipofectamine
RNAiMAX
96-well 0.2 lOOpI 20pl 1.2 10 0.2
48-well 0.4 200pl 40pl 2.4 10 0.4
24-well 1 500pl lOOpI 6 10 1
6-well 5 2.5ml 500pl 30 10 5
Table 2.7: Volumes and concentrations used for SiRNA transfections
Tissue Culture Vessel No. cells plated for SiRNA transfection or CellTitre Blue Assays (96-well plate only)
MDA-MB-231 ZR-75-1 HCC1954 SKBR3 MG1361
96-well 6x10s 6xl03 8x l03 8x l0 3 8xl03
48-well 1.2xl04 1.2xl04 1.6xl04 1.6xl04 1.6xl04
24-well 3xl04 3xl04 4xl04 4 x l04 4xl04
6-well 1.5x10s 1.5x10s 2xl05 2xlOS 2xl05
Table 2.8: Seeding densities for SiRNA transfections and CellTitre Blue assays
2.5.6 CeilTitre-blue cell viability assays
The CellTitre-Blue assay (Promega) provides a homogeneous, fluorom etric method for 
estim ating the  num ber o f viable cells present. It measures the m etabolic capacity o f the cells using an 
indicator dye, resazurin. Viable cells are able to reduce resazurin to the highly fluorescent product, 
resorufin. Any non-viable cells present lose their m etabolic capacity, fail to  convert the resazurin and do 
not produce a fluorescent signal.
The CellTitre-Blue reagent was thaw ed to room tem perature . Cells were plated at low  
confluency (see Table 2.8) into 96 well plates in lOOpI com plete growth m edium  to allow exponential 
growth. Triplicate control wells, containing only media w ere  also plated. Cells w ere incubated at 37°C in 
5% C 0 2 for the desired test exposure period (see individual experim ents). Assay plates were removed 
from  the incubator and 20pl CellTitre-Blue reagent was added to each well. The cells were incubated for 
a further hour at 37°C in 5% C 0 2. Fluorescence was then recorded at 560 /590n m  on a FLUOstar Optima 
plate reader (BMG Labtech, Offenburg, Germ any).
2.5.7 Trypan blue dye exclusion cell viability counts
The num ber o f viable cells present in a culture was also determ ined using Trypan Blue dye 
exclusion cell viability counts. Cells w ere removed from  the plate using 0 .25%  w /v  Trypsin/EDTA and 
resuspended in a known volum e o f media. lOpI of the cell suspension was mixed w ith lOpI Trypan Blue 
(Sigma) and placed on an Im proved Neubauer Counting Chamber and only viable cells excluding the blue
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dye w ere counted. The average num ber o f cells per 1m m 2 was m ultiplied by 2 x l0 4 to determ ine the 
num ber o f viable cells per ml o f suspension.
2.5.8 Boyden chamber assays
The Boyden cham ber assay is a m ethod used to analyse the m igratory or invasive capacity of 
cells. This assay utilises a Boyden cham ber containing tw o m edium filled com partm ents separated by a 
porous m em brane for m otility assays or a porous membrane coated w ith  M atrigel basem ent m em brane  
m atrix for invasion assays. Cells are placed into the upper cham ber containing a low concentration of 
serum and allowed m igrate or invade through the m em brane into the lower com partm ent containing 
media w ith  a high serum concentration. The membranes can then be fixed and stained and the num ber 
of cells that have m igrated or invaded to the lower side of the m em brane can be counted.
Transfected cells w ere rem oved from  tissue culture plates using 0.25%  w /v  Trypsin/EDTA and 
centrifuged at llO O rpm  fo r 5 minutes. Cells w ere washed twice in serum free media by resuspension and 
centrifugation. The appropriate num ber o f cells (2 x l0 5 cells/m l for ZR-75-1 and M D A -M B -231 cells, and 
4 x l0 5 cells/m l for HCC1954, SKBR3 and M G 1361 cells) w ere resuspended in the ir normal growth media 
containing only 0.2%  FBS. Com plete growth media (750pl containing a standard am ount of BSA [10-15%  - 
see section 2.5.2) was place into each well of a 24 well cell culture insert companion plate (BD 
Biosciences) to be used. A cell culture insert (BD Biosciences) was then carefully placed into each well of 
the insert companion plate using tweezers. For motility assays, a cell culture insert composed o f an 8pm  
pore, transparent polyethylene terephthalate (PET) m em brane (BD Biosciences) was used and for 
invasion assays, BD BioCoat™ G row th Factor Reduced M atrigel Invasion cham ber (BD Biosciences) was 
used. 350pl o f the cell suspension was added to the appropriate upper chambers and plates were  
incubated for 24-48  hours at 37°C and 5% C 0 2 (see individual results for incubation periods).
2.5.8.1  Cell fixing and staining
A fter incubation, all m edia was carefully aspirated from  top and bottom  wells and replaced 
w ith 70% ice cold ethanol to fix the  cells. Plates were incubated at -20°C for at least 1 hour. A fter this 
tim e, ethanol was aspirated from  the inserts and replaced with tap w ater. Each insert was picked up 
individually using tweezers and im m ersed in a beaker o f tap w ater to ensure all ethanol was removed. A 
moisten cotton wool bud was then used to  mechanically remove all cells fixed on the upper side of the  
m em branes. Following this, cells w ere  stained by individually immersing the inserts into filtered Harris' 
Haematoxylin (Sigma) for 1 m inute. Inserts were then washed in a beaker o f tap w ater to remove the  
dye before being immersed in 0.5%  filtered Eosin (Sigma) for 2 minutes. The inserts were washed in a 
beaker o f tap w ater and placed back into the companion plates to aw ait m ounting.
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2 .5 .8 .2  M ounting o f membranes
Glycerol Gelatin (Sigma) was heated in a beaker o f boiling w ater and once liquefied, a drop was 
placed onto an appropriately labelled microscope slide (R.A.Lamb). Using a sharp blade, the m em brane  
was cut out o f the insert and placed onto the corresponding slide w ith  tweezers. Another drop of 
Glycerol Gelatin was added to the top o f the membrane and a coverslip was placed on the slide under 
firm  pressure. M ounted slides w ere left to  air dry before being counted as described in individual results 
sections.
2.5.9 Flow cytometry
Transfected cells w ere  removed from tissue culture plates using Im M  EDTA (Sigma) and 
centrifuged at llO O rpm  for 5 minutes. The pellet was washed tw ice in Fluorescence activated cell sorting 
(FACS) buffer (PBS supplem ented w ith 2% v /v  FBS). Cells w ere  resuspended at a density o f 4 x l0 6 cells /m l 
and lOOpI o f this suspension was aliquoted into the appropriate wells o f a 96 well plate before being 
centrifuged on a plate spinner at llO O rpm  for 5 minutes. The supernatant was removed and the pellet 
was resuspended in lOOpI o f the appropriate fluorescently conjugated primary antibody (FITC- 
conjugated anti-CD24 [BD Pharmingen, Cat no. 553261], PE-conjugated anti-Scal [BD Pharmingen, Cat 
no. 553336]) and left on ice for 30 minutes in the dark. Cells w ere  then centrifuged on a plate spinner 
and the antibody was rem oved. The pellet was washed tw ice in FACS buffer before being filtered  
through a 40pm  cell strainer (BD Biosciences) into a FACS collection tube (BD Biosciences) to ensure a 
single cell suspension. FACS was perform ed on a FACSAria Flow Cytom eter (BD Biosciences) and analysis 
o f results was undertaken using a FlowJo software package. Gates were set to exclude >99% of cells 
labelled w ith isoform -m atched control antibodies conjugated w ith the corresponding fluorochromes. If 
sorting was perform ed, cells w ere  collected in an appropriate volum e o f FACS buffer.
2.5.9.1  A ldefluor assay
The aldefluor assay (Stemcell Technologies, Grenoble, France) is a m ethod to identify stem cells 
on the basis of the ir high aldehyde dehydrogenase (ALDH) activity. A fluorescent aldefluor reagent 
diffuses into cells and is a substrate for ALDH. The am ount o f fluorescent ALDH reaction product is 
directly proportional to the ALDH activity in cells. Cells w ith high expression o f ALDH are recognised by 
comparing the fluorescence o f test cells with that o f a control sample containing the specific ALDH 
inhibitor, diethylam inobenzaldehyde (DEAB).
Aldefluor reagents w ere  prepared according to m anufacturer's instructions. Transfected cells 
w ere removed from  tissue culture plates using Im M  EDTA and centrifuged at llO O rpm  for 5 minutes. 
The cells w ere washed tw ice in FACS buffer by resuspension and centrifugation. Cells were suspended in 
lm l o f aldefluor assay buffer and counted. The samples w ere adjusted to a concentration o f lx lO 6
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cells/m l w ith  aldefluor assay buffer. A 'control' and a 'test' tube w ere prepared for each sample to be 
tested and 1ml o f the adjusted cell suspension was placed into each 'test' tube. 5|al o f DEAB reagent was 
added to the control tube and recapped im m ediately before 5pl o f activated aldefluor substrate was 
added per ml o f test suspension in the 'test' tube. The suspension was mixed and 0.5m l was im m ediately  
transferred to the 'control' tube containing the DEAB substrate. The 'test' and 'control' tubes were  
incubated for 45  minutes at 37°C. The tubes were then centrifuged at llO O rp m  for 5 minutes and the  
pellets w ere resuspended in aldefluor buffer. Samples w ere placed on ice. The fluorescence of cells was 
measured in the green fluorescence channel o f a FACSAria flow  cytom eter (BD Biosciences). Analysis was 
perform ed using FlowJo software. Gates were set to exclude >99% o f control cells incubated with DEAB.
2.5.10 Mammosphere assays
M am m osphere assays can be used for the in vitro propagation o f m am m ary epithelial cells in 
an undifferentiated state in non-adherent cell culture conditions. The resulting m am m osphere colonies 
are enriched for m am m ary stem /early  progenitor cells that are able to undergo self-renewal and form  
new colonies upon disaggregation and re-seeding (see Chapter 1: General Introduction, section 1.2.6). 
This assay is therefore  suitable for the functional identification o f this cell population.
Cells w ere rem oved from  tissue culture plates using 0.25%  w /v  Trypsin/EDTA and centrifuged 
at llO O rpm  for 5 m inutes. Cells were then resuspended in m am m osphere culture m edium (serum-free  
epithelial grow th m edium  [M EBM , Lonza], supplemented w ith  B27 [invitrogen], 20ng/m l Epidermal 
Growth Factor [EGF, Sigma], 5m g/m l Insulin [Sigma], 0 .0008%  v /v  p-m ercaptoethanol [Sigma] and 
lm g /m l hydrocortisone [Sigma]) and disaggregated into single cell suspensions by mechanical agitation. 
Cells w ere counted and seeded into ultra-low attachm ent plates (Corning) at density o f 4000 cells/ml 
(unless otherwise stated) before being incubated for 7 days at 37°C and 5% C 0 2 to allow the form ation of 
m am m osphere colonies. A fter this incubation period, the num ber o f m am m osphere per well were  
counted. In order to determ ine the self-renewal capacity o f cells, m am m ospheres w ere collected by 
gentle centrifugation at llO O rp m  and mechanically and enzym atically dissociated into single cells in 
0.25%  w /v  Trypsin/EDTA at 37°C. Cells w ere centrifuged at llO O rpm  before being counted and re-seeded 
into ultra-low  attachm ent plates at a density of 4000 cells/ml. Cells w ere  then incubated for 7 days at 
37°C and 5% C 0 2 a fter which tim e the num ber of mammospheres per well was counted.
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2.6 Protein analysis by western blotting
2.6.1 Protein extraction from cells
2.6.1.1  Preparation o f whole cell protein extracts
M edia was com pletely aspirated from  cell culture flasks and the cells w ere  washed twice in ice 
cold PBS. A further 12ml o f PBS was added to the flask and cells w ere scraped using a cell scraper (Nunc) 
and transferred into 15ml falcon tubes. The cells w ere centrifuged at llO O rp m  for 5 minutes and the  
supernatant was rem oved. Cell pellets w ere e ither stored at -80°C until required or im m ediately lysed by 
the addition o f 100-300pl o f RIPA buffer (150m M  sodium chloride [Fisher Scientific], 1% v /v  Nonidet-P40  
[Roche], 0.5%  w /v  sodium deoxycholate [Sigma], 0.1% w /v  sodium dodecyl sulphate [SDS; Sigma], 50m M  
Tris [Sigma], pH8) containing protease (Complete mini protease inhibitor tablets [Roche]) and 
phosphatase inhibitors ( Im M  sodium orthovanadate [Sigma], lO m M  sodium fluoride [Fluka Biochemika], 
lO m M  sodium pyrophosphate [Sigma]). The cell pellet was passed through a 23G needle 10 times to 
ensure com plete cell lysis and incubated on ice for 30 minutes. Lysates w ere  centrifuged at 10,000rpm  
for 15 minutes at 4°C to pellet cell debris and the supernatant was aliquoted into to fresh tubes and snap 
frozen in liquid nitrogen before being stored at -80°C until required.
2.6.2 Protein extraction from tissues
2.6.2.1  Preparation o f whole tissues
W hole tissue samples were removed from  the -80  freezer and lOOmg was cut on dry ice and 
placed into a spinLyse tube (Lysing M atrix  D; MP Biomedicals) containing 500pl o f RIPA buffer (for 
composition o f RIPA buffer see section 2 .6 .1 .1 ) and homogenized tw ice at 6500rpm  for 45 seconds on 
Precellys 24 lysis and homogenization machine (Bertin Technologies). Samples w ere transferred to a 
fresh tube and passed through a 23G needle 8 tim es before being placed on ice for 30 minutes. Samples 
w ere then centrifuged at 10,000rpm  for 10 minutes at 4°C. The supernatant was carefully transferred to 
a fresh tube using a 23G needle and 1ml syringe to avoid the top layer o f milk. This was then centrifuged 
at 10,000rpm  for 10 minutes at 4°C and the supernatant was removed, aliquoted and snap frozen in 
liquid nitrogen before being stored at -80°C until required.
2 .6.2.2  Preparation o f cytoplasmic and nuclear protein fractions fro m  tissues
W hole tissue samples w ere removed from  the -80 freezer and 50m g was cut on dry ice and 
placed into a spinLyse tube containing 1ml o f filtered NEBA+ (filtered NEBA [lO m M  Hepes pH7.9, lO m M  
potassium chloride, O .lm M  EDTA pH8.0, O .lm M  EGTA pH8], Im M  1,4 D ithiothreitol [Fluka Biochemika], 
50m M  sodium chloride, Im M  sodium orthovanadate, Im M  sodium pyrophosphate and one com plete 
mini protease inhibitor tab let) and homogenized twice at 6500rpm  for 45 seconds on Precellys 24 lysis
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and homogenization machine. Samples w ere centrifuged at 3000rpm  for 2 minutes at 4°C and the  
supernatant was transferred to a new tube, and placed on ice for 10 minutes. 50pl o f 10% NP40- 
alternative (Calbiochem) was added to each sample and homogenised tw ice at 6500rpm  for 45 seconds 
before being transferred to  a new tube and centrifuged at 13,000rpm  for 30 seconds at 4°C. The 
supernatant (cytoplasmic fraction) was rem oved, aliquoted and flash frozen in liquid nitrogen before  
being stored at -80 for later use. The pellet was resuspended in lOOpI NEBC+ (filtered NEBC [10% v /v  
glycerol, 20m M  Hepes pH7.0, 0 .4M  sodium chloride, Im M  EDTA pH8.0, Im M  EGTA pH8.0] Im M  1,4 
Dithiothreitol, 50m M  sodium fluoride, Im M  sodium orthovanadate, Im M  sodium pyrophosphate and 
one com plete mini protease inhibitor tab let) and placed on ice for 30 m inutes before being centrifuged 
for 10 m inutes at 4°C. The supernatant (nuclear fraction) was removed, aliquoted and snap frozen in 
liquid nitrogen before being stored at -80°C until required.
2.6.3 Determination of protein concentrations
Protein concentrations w ere analysed using the BCA protein Assay kit (Pierce) according to 
m anufacturer's instructions. Protein samples were first diluted by 1:5 and 1:10 in RIPA Buffer (see 
section 2 .6 .1 .1  for com position) and 12.5pl o f each diluted sample was added to a 96 well round 
bottom ed plate (Nunc) in duplicate. BCA protein assay reagent A was added to BCA protein assay 
reagent B in a ratio o f 50:1 and lOOpI o f this mix was added to each sample. A standard curve was also 
generated by diluting 2m g/m l BSA in PBS to produce 4 known protein concentrations (2m g/m l, lm g /m l, 
0 .5m g/m l, 0 .25m g /m l) to  which lOOpI o f BCA reagent mix was added. Samples w ere mixed well and 
incubated at 37°C for 30 minutes to allow the purple colour to develop. Colour intensity o f each sample 
was measured on a nanodrop spectrophotom eter (ND-1000; Labtech International) at 562nm . The 
relative concentration o f protein in each sample was extrapolated from  the standard curve.
2.6.4 Western analysis
2.6.4.1  Preparation o f protein samples
A fter protein concentrations w ere  determ ined, 20pg (tissue samples) or 70pg (cell samples) of 
protein w ere diluted in RIPA buffer (see section 2.6.1.1 for composition) to produce a final volume of 
lOpI and 2.5pl o f 5X laemm li buffer (0 .125M  Tris-HCL pH6.8, 4% w /v  SDS, 40%  v /v  glycerol, 0.1% w /v  
brom ophenol blue [Sigma], 6% v /v  beta-m ercaptoethanol [Sigma] in ddH20) was added to each sample. 
Just before loading, the samples w ere heated to 95°C for 5 minutes to denature the proteins.
2 .6.4.2 Casting o f polyacrylam ide gels
All M ini western SDS-PAGE gels w ere set in M ini-Protean III (Bio-Rad) gel casting apparatus. 
Resolving gel mixtures composed o f varying concentrations o f Acrylamide/Bis (depending on target
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protein size) w ere prepared (Table 2.9), poured and left to set for 30 minutes. Once set, the 4% stacking 
gel mixture was prepared and poured over the resolving gel (Table 2.9). A clean 10 or 15-well comb was 
inserted im m ediately into the apparatus and the gel was left to set for 30 m inutes. Once set, the combs 
w ere removed and the wells w ere rinsed w ith ddH20.
Component
Molecular Weight of 
Protein
ddHzO
8% Resolving 
Gel (x2)
40-150kDa
4.7m l
10% Resolving 
Gel (x2)
25-100kDa
4.1m l
12% Resolving 
Gel (x2)
15-75kDa
3.4m l
4% Stacking 
Gel (x2)
6.1m l
30% Acrylamide/Bis 
(Sigma)
10% w /v SDS
2.7m l 3.3ml
lOOpI lOOpI
4.0m l
lOOpI
1.3ml
1.5M Tris-HCI, pH8.8 2.5ml 2.5ml 2.5m l
0.5M Tris-HCI, pH6.8 2.5ml
lOOpI
10% Ammonium 
Persulphate (Sigma) 
TEMED
50pl
5pl
50pl
5pl
50pl
5pl
50pl
lOpI
Table 2.9: Composition of polyacrylamide gels
2 .6 .4 .3  Gel electrophoresis
Gels w ere  placed in the M ini-Protean III (Bio-Rad) electrophoresis tank and immersed in 1 x 
Tris-Glycine running buffer (Table 2.10). Protein molecular w eight m arker (PageRuler Plus; Fermentas) 
was loaded into the first lane o f each gel and prepared protein samples w ere loaded into the appropriate  
remaining wells. The samples w ere resolved down SDS-PAGE gels for approxim ately 45-60 minutes at 
150V until the dye front reached the bottom  o f the gel.
2 .6.4.4  Transfer o f proteins to PVDF mem branes
A fter separation o f protein, gels w ere  carefully removed from  glass plates and soaked in 1 x 
Tris-Glycine transfer buffer (Table 2 .10) fo r 10 minutes. Immobilon-P, Polyvinylidene difluoride (PVDF; 
M illipore) m em brane was cut to size, pre-soaked in m ethanol (Fisher Scientific) for 10 seconds and 
washed in ddH20. The stacking gel was then cut away and discarded and the resolving gel was placed 
onto the m em brane in a standard w e t electroblotting system (BioRad). Air bubbles were carefully rolled 
out a fter the addition o f each layer. An ice block was inserted into the transfer apparatus and proteins 
w ere transferred by electroblotting in 1 x Tris-Glycine transfer buffer (Table 2 .10) at 100V for 1 hour. 
Blotting apparatus was then dismantled and membranes were washed for 5 minutes in PBS/T.
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2 .6 .4 .5  Probing o f membranes
Following transfer, m em branes w ere blocked in milk blocking solution (Table 2.10) under 
agitation for 1 hour at room tem perature  and then incubated in 5mls o f primary antibody (Table 2.11 &  
2.12) at 4°C on a roller m ixer (Stuart, M erton , UK) overnight. The following morning the m em brane was 
washed (3x5 minutes) in PBS/T before being incubated in 5mls o f the appropriate horseradish- 
peroxidase (HRP)-conjugated secondary antibody (Table 2.11 & 2.12) for 1 hour at room tem perature on 
a roller mixer. Following this incubation, membranes were washed 3x5 m inutes in PBS/T prior to protein 
detection by enhanced chemiluminesence.
2 .6 .4 .6  Visualisation o f protein bands
The appropriate ECL reagent kit (GE Healthcare; Table 2.11 & 2.12) was used to visualise the  
immobilised protein bands conjugated to HRP-labelled secondary antibodies according to manufacturer's  
instructions. ECL solutions w ere mixed well and 2mls were im m ediately distributed evenly across the  
m em brane and incubated in the dark for 1 m inute (ECL) or 5 minutes (ECL plus). A fter removal of excess 
reagent, the m em brane was placed in a light-proof cassette and exposed to light sensitive films 
(Amersham Hyperfilm  ECL; GE Healthcare) under safelight conditions for varying lengths of tim e to give a 
range o f exposure intensities. All films w ere developed on an autom atic film processor (Xograph 
Compact X4 autom atic X-ray film processor). Processed films w ere then realigned w ith the original 
m em brane and the target protein was identified by comparison to the molecular weight marker.
2 .6 .4 .7  Stripping and re-probing o f membranes
In order to study more than one protein band from  the same set o f samples, membranes were  
stripped o f the ir original antibodies and re-probed with a new one. The m em brane was washed in PBS/T 
(3 x 5m inutes) and incubated in stripping buffer (Table 2.10) at 55°C for 30 minutes w ith gentle agitation. 
The stripping buffer was removed and the m em brane was rinsed 5 times in dH20 before being incubated 
in PBS/T for 30 minutes at room tem perature . A fter incubation for a further hour in milk blocking 
solution, the m em brane was re-probed w ith  the appropriate primary and secondary antibodies and 
protein bands w ere visualised using ECL or ECL plus reagents as described in section 2 .6.4.6.
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Solution Com position
10 x Electrophoresis Buffer 30.3g Tris base (Sigma), 144.4g Glycine (Sigma), Upto 1L dH20
1 x Tris-Glycine SDS-PAGE Running 
Buffer (1L)
890m l dH20 ,1 0 0 m l 10 x Electrophoresis Buffer, 10ml 10% w /v
SDS
1 xTris-Glycine Transfer Buffer 700m l dH20, 100ml 10 x Electrophoresis Buffer, 200m l 
M ethanol
M ilk Blocking Solution 5% w /v  non-fat milk powder (M arvel) in PBS/T
Stripping Buffer 62.5m M  Tris-Hcl (pH6.8), 2% w /v  SDS, lOOmM 2-beta- 
m ercaptoethanol
Table 2.10: Composition of solutions used in western analysis
2 .6 .4 .8  Quan tification o f protein bands
In some cases protein bands w ere semi-quantified. The intensity o f protein bands was 
measured using a GelDoc (BioRad) and normalised to the band intensity o f the ir corresponding loading 
control. The average normalised intensity o f all samples from  one genotype was calculated to allow  
comparisons betw een genotypes to be made.
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Target EGFR(Total) ERBB2(NEU) 
(Total)
p50 P52 AKT(Total) Phospho-AKT
(Ser473)
ERK (Total) Phospho-ERK
(Thr202/Tyr204)
Caveolin-1
Primary
Antibody
Source
CST Abeam Santa Cruz Santa Cruz CST CST BD
Transduction
Laboratories
CST CST
Catalogue
Number
2232 Ab2428 sc-114 sc-7386 9272 9271 610123 20G11 3238
Primary 
Antibody 
Raised in
Rabbit (pAb) Rabbit (pAb) Rabbit (pAb) Mouse (mAb) Rabbit (pAb) Rabbit (pAb) Mouse (mAb) Rabbit (mAb) Rabbit (pAb)
Primary
Antibody
Dilution
1:1000 in 5% 
w/v BSA*
1:200 in 5% 
w/v BSA*
1:200 in 5% 
w/v BSA*
1:500 in 5% 
w/v BSA*
1:500 in 5% 
w/v BSA*
1:1000 in 5% 
w/v BSA*
1:5000 in 5% 
w/v BSA*
1:1000 in 5% w/v 
BSA*
1:1000 in 5% 
w/v BSA*
Secondary
Antibody
HRP-
conjugated
anti-Rabbit
(Dako)
HRP-
conjugated
anti-Rabbit
(Dako)
HRP-
conjugated
anti-Rabbit
(Dako)
HRP-
cojugated
anti-Mouse
(Dako)
HRP-
conjugated
anti-Rabbit
(Dako)
HRP-conjugated
anti-Rabbit
(Dako)
HRP-
conjugated
anti-Mouse
(Dako)
HRP-conjugated 
anti-Rabbit (Dako)
HRP-
conjugated
anti-Rabbit
(Dako)
Secondary
Antibody
Conditions
1:2000 in 5% 
w/v BSA*
1:2000 in 5% 
w/v BSA*
1:2000 in 5% 
w/v BSA*
1:2000 in 5% 
w/v BSA*
1:2000 in 5% 
w/v BSA*
1:2000 in 5% 
w/v BSA*
1:2000 in 5% 
w/v BSA*
1:2000 in 5% w/v 
BSA*
1:2000 in 5% 
w/v BSA*
Detection
Reagents
ECL ECL ECL ECL ECL ECL+ ECL ECL ECL
Target 
Protein Size
175kda 185kda 50/105kda 52/100kda 60kda 60kda 42-85kda 42,44 kda 21kda
Table 2.11: Western antibodies and conditions
CST = Cell Signalling Technologies; pAb = polyclonal antibody; mAb monoclonal antibody; *BSA or milk diluted in PBS/T
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Target STAT3
(Total)
Phospho-STAT3
(Tyr705)
E-Cadherin Vimentin Snail BCL3 Tubulin 0-Act in Lamin A/C
Primary
Antibody
Source
CST CST Upstate Santa Cruz Santa Cruz Santa Cruz Abeam Abeam CST
Catalogue
Number
9132 9131 07-697 sc-7557 sc-10433 sc-185x Ab6160 Ab8227 2032
Primary 
Antibody 
Raised in
Rabbit (pAb) Rabbit (pAb) Rabbit (pAb) Goat (pAb) Goat (pAb) Rabbit (pAb) Rat (mAb) Rabbit (pAb) Rabbit (pAb)
Primary
Antibody
Dilution
1:1000 in 5% 
w/v BSA*
1:1000 in 5% w/v 
BSA*
1:500 in 5% 
w/v milk*
1:200 in 5% 
w/v BSA*
1:500 in 5% 
w/v milk*
1:200 in 5% 
w/v milk*
1:10000 in 5% 
w/v BSA*
1:5000 in 5% 
w/v BSA*
1:1000 in 5% 
w/v BSA*
Secondary
Antibody
HRP-
conjugated
anti-Rabbit
(Dako)
HRP-conjugated 
anti-Rabbit (Dako)
HRP-
conjugated
anti-Rabbit
(Dako)
HRP-
conjugated
anti-Goat
(Dako)
HRP-
conjugated
anti-Goat
(Dako)
HRP-
conjugated
anti-Rabbit
(Dako)
HRP-
conjugated
anti-Rat
(Dako)
HRP-
conjugated
anti-Rabbit
(Dako)
HRP-
conjugated
anti-Rabbit
(Dako)
Secondary
Antibody
Conditions
1:2000 in 5% 
w/v BSA*
1:2000 in 5% w/v 
BSA*
1:2000 in 5% 
w/v BSA*
1:2000 in 5% 
w/v BSA*
1:2000 in 5% 
w/v BSA*
1:2000 in 5% 
w/v BSA*
1:2000 in 5% 
w/v BSA*
1:2000 in 5% 
w/v BSA*
1:2000 in 5% 
w/v BSA*
Detection
Reagents
ECL ECL ECL ECL+ ECL ECL+ ECL ECL ECL
Target Protein 
Size
86kda 86kda 106kda 57kda 29kda 60kda 50kda 48kda 70kda
Table 2.12: Western antibodies and conditions continued
CST = Cell Signalling Technologies; pAb = polyclonal antibody; mAb monoclonal antibody; *BSA or milk diluted in PBS/T
CT>
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2.7 Caspase assays
Caspase-Glo 3 /7 , 8 and 9 assays (Promega) are luminescent assays tha t measure the activity of 
individual caspases. The assays provide luminogenic substrates for individual caspases. Addition of the  
Caspase-Glo reagent to the sample results in cell lysis followed by caspase cleavage o f the substrate and 
a resulting luminescent signal which is proportional to the am ount o f caspase activity present in the  
sample.
2.7.1 Determination of caspase activity in mammary tissues
W hole m am m ary tissue samples were removed from  the -80  freezer and approxim ately lOOmg 
was cut on dry ice and placed in spinLyse tubes containing 1ml o f lysis buffer (Promega) and 2pg/m l of 
aprotinin (Sigma). Samples w ere spin lysed twice for 45 seconds on Precellys 24 lysis and homogenization
machine. The supernatant was transferred to a fresh tube and passed through a blue 23G needle seven
tim es before being rested on ice for 10 minutes. Samples w ere centrifuged at 13,000rpm  at 4°C for 15 
minutes. Protein concentrations were determ ined as per section 2.6.3. Samples w ere normalised and 
stored at -80°C until required for the Caspase-Glo assay.
Caspase-Glo 3 /7 , 8 or 9 reagents w ere prepared according to  m anufacturer's instructions and 
50pl o f each normalised protein sample was pipetted into a w ell o f a 96 well plate black walled plate 
(Corning). An equal am ount o f Caspase-Glo reagent was added to  each sample and to one em pty well to 
serve as a 'blank' control. The plate was placed on a plate shaker and agitated at 300-500rpm  for 30  
seconds before being incubated at room tem perature  for 1 hour. The luminescence o f each sample was 
read on a FLUOstar Optim a plate reader and the 'blank' control value was subtracted from all other 
values.
2.7.2 Determination of caspase activity in cells
Transfected cells w ere rem oved from  tissue culture plates using 0.25%  w /v  Trypsin/EDTA and 
centrifuged at llO O rpm  for 5 minutes before being resuspended in com plete growth m edium. Cells were  
counted and resuspended at a density o f 2 x l0 5 cells/m l and lOOpI o f this suspension was plated into 
appropriate wells o f a black-walled 96-w ell plate. At the same tim e, lOOpI o f com plete media alone was 
plated into trip licate wells to  serve as a 'blank' control. The plate was incubated at 37°C and 5% C 02 for 
an appropriate am ount of tim e (as indicated in the results sections). A fter incubation, Caspase-Glo 
reagents w ere  prepared according to m anufacturer's instructions, and plates w ere removed from the  
incubator and allowed to equilibrate to room tem perature. To each w ell containing cells or 'blank' 
controls, lOOpI o f Caspase-Glo reagent was added. The plate was then gently agitated on a plate shaker 
at 300-500rpm  for 30 seconds before being incubated at room tem perature  1 hour. The luminescence of
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each sample was then measured on a FLUOstar Optima plate reader and the 'blank' control value was 
subtracted from  all o ther values.
2.8 RNA analysis
2.8.1 Isolation of RNA
All bench work surfaces and equipm ent were treated w ith RNAseZAP (Am bion) before use and 
RNAse free H20 (Sigma) was used throughout.
2.8.1.1  Extraction and purification o f RNA fro m  tissues
Frozen tissue (50mg) was cut on a petri dish on dry ice and placed in a spinLyse tube containing 
lm l o f Trizol (Invitrogen) reagent. Tissues w ere spinLysed twice at 6500rpm  for 45 seconds on Precellys 
24 lysis and homogenization machine and w ere then centrifuged at 8000  x g for 10 minutes at 4°C. The 
supernatant was transferred to a new RNAse free tube and 200pl o f chloroform  was added to each 
sample and shaken vigorously by hand for 30 seconds. Samples w ere  left for 3 minutes at room  
tem perature  and then centrifuged again at 8000 x g for 15 m inutes at 4°C. The aqueous phase was 
removed and placed into a fresh RNAse free tube containing 400p l o f isopropanol and mixed gently to 
precipitate out the RNA before being purified using an RNeasy M ini Kit (Qiagen) according to 
m anufacturer's instructions. Concentration and quality o f RNA was quantified on a NanoDrop 
spectrophotom eter (ND-1000; Labtech International).
2 .8 .1 .2  Purification o f RNA fro m  cells
Purification o f RNA from cells was achieved using the RNeasy M ini Kit according to 
m anufacturer's instructions. Concentration and quality o f RNA was quantified on a NanoDrop 
spectrophotom eter.
2.8.2 Reverse transcription
Reverse transcription was perform ed using RevertAID Premium Reverse Transcriptase 
(Fermentas). cDNA was synthesised from  500 -  lOOOng RNA samples diluted in 12.5pl o f RNase free H20. 
A m aster reaction mix containing Random Primers and dNTPs (Table 2.13) was prepared in a nuclease 
free tube on ice and 2pl was added to each sample to make a total volum e o f 14.5pl. Samples were then  
mixed gently, centrifuged and heated to  65°C for 5 minutes before being returned im m ediately to ice. A 
second reaction mix containing the reverse transcriptase (Table 2.13) was prepared and 5.5pl was added 
to each sample to m ake a final volum e o f 20pl. Samples w ere then incubated for 10 minutes at 25°C, 30 
minutes at 50°C and 5 m inutes at 85°C before being returned to ice. For each experim ent, controls were  
prepared in exactly the same way but w ith reaction mixes lacking the reverse transcriptase enzyme. 
Samples w ere e ither used im m ediately or stored -70°C until required.
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Reaction Mix 1 Component Volume Per Reaction
dNTPs (lOmM; dATP, dCTP, dGTP, dTTP; Promega) lp l
Random Primers (500ug/ml [Promega]) lu l
Reaction Mix 2 Component Volume Per Reaction
5xRT Buffer (Fermentas) 4pl
RNasin Plus (40u/pl; Promega) 0.5pl
RevertAID Premium Reverse Transcriptase (200u/pl; Fermentas) in i
Table 2.13: Reaction mix components fo r reverse transcription
2.8.3 Quantitative real-time polymerase chain reaction (QRT-PCR) & semi-quantitative PCR
2.8.3.1  Prim er design
All prim er sets w ere designed across exon boundaries using the Prim er3 web-based program  
h ttp ://fro d o .w i.m it.e d u /p rim e r3 /. To check for mis-priming, all sequences w ere  verified by performing in 
silico PCR (http://genom e.csdb.cn/cgi-bin/hgPcr). All primers w ere  purchased from  Sigma-Genosys and 
sequences can be found inTable 2.15.
2 .8 3 .2  QRT-PCR
QRT-PCR was perform ed using Step One Plus Realtime PCR System (Applied Biosystems), in 
conjunction w ith  StepOne (v2.1; Applied Biosystems) software. Each reaction was perform ed in triplicate  
and a m inim um  o f 3 separate biological samples w ere analysed. One housekeeping gene (Cyclophilin B or 
Beta-Actin) was always run as a reference.
An arbitrary standard curve was generated by pooling 5pl o f cDNA from  each sample to make a 
neat cDNA control which was then diluted 1:5 and 1:25 w ith  PCR-grade w ater to make three cDNA 
standards. Appropriate volumes (Table 2 .14) o f cDNA test samples, cDNA standards or PCR-grade H20 
(Sigma) control w ere loaded into separate wells o f a 96 well reaction plate (MicroAm p Fast Optical 
0.1m l; Applied Biosystems).
A PCR m asterm ix containing all o ther reaction com ponents was then prepared according to 
Table 2.14. M asterm ix (22.5pl) was added to each well and gently pipetted to ensure homogeneous 
mixing o f cDNA and reaction mix. The PCR plate was then sealed w ith appropriate caps (MicroAmp  
Optical 8-capstrip; Applied Biosystems) before being loaded into the Realtime PCR machine.
All reactions w ere run under the  same cycling conditions o f initial denaturation at 95°C for 10 
minutes followed by 45 cycles o f 95°C for 15 seconds and 60°C for 1 m inute (with a plate read after each 
cycle). A m elting curve (95°C for 15 seconds, 60°C for 1 m inute [optics off], 60°C to 95°C at 0.2°C  
increments every 15 seconds [optics on]) was constructed at the end o f the experim ent and data was 
collected w ith  Step one plus software.
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2 .8 .3 .3  Analysis o f QRT-PCR data
Data was initially examined using Step One Plus software. M elting curves were analysed to 
ensure that only one peak at the expected melting tem perature was observed and that the H20 control 
samples produced no product.
Ct values for standards w ere plotted against relative amounts (neat cDNA = 1, 1:5 dilution = 
0.2, 1:25 dilution = 0 .04) to generate a standard curve for each prim er set. Relative mRNA expression in 
each sample was extrapolated by plotting Ct values on the standard curve. The differences between the  
amounts am plified in samples for a target gene and corresponding samples am plifying a reference gene 
was then calculated to get a normalised relative expression value. Generally, an average expression value 
across all biological replicates was taken and values were normalised back to  the control samples.
2 .8 .3 A  Sem i-quantitative PCR
W hen only sem i-quantitative PCR analysis was required, PCR reactions w ere set up, run and 
visualised as described in sections 2.1.2.2 and 2.1.2.3, using m aster mixes detailed in Table 2 .14 and 
cycling conditions detailed in section 2.8.3.2.
Reaction Component QRT-PCR Semi-quantitative PCR
cDNA Template 2.5|il 2.5pl
PCR grade Water 12.65|il 13.9|il
Go Taq PCR Buffer 5 pl 5pl
Magnesium Chloride (25mM) 2.5pl 2.5|il
dNTPs (lOmM; dATP, dCTP, dGTP, dTTP) 0.5|il 0.5|il
Forward Primer (lOpM) 0.25pl 0.25|il
Reverse Primer (10pM) 0.25|il 0.25pl
Go Taq DNA Polymerase O.lpl O.lpl
Sybr Green (Invitrogen) 1.25|il N/A
Total Reaction Volume 25pl 25|il
Table 2.14: QRT-PCR and semi-quantitative PCR reaction components
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Target Species Forward Primer Sequence 
(5' to 3')
Reverse Primer Sequence 
(5' to 3')
Product
Size
Bcl3 Mouse AGC CTG AAC ATG GTG CAA CT CCA CCA TGA GAG GTG TGT CA 184bp
FasR Mouse TCG GAG ATG CTA TTA GTA CCT TG GAT CTG GGC TGT CCT GCC T 78bp
FasL Mouse TTC ATG GTT CTG GTG GCT CTG GT CTG GGG TTG GCT ATT TGC TTT TCA 143bp
DR 5 Mouse ATA AAA AGA GGC TGT GAA CGG G GGT CCA AGA GAG ACG A 64bp
TNFR1 Mouse GAC CGG GAG AAG AGG GAT AG GTT CCT TTG TGG CAC TTG GT 92bp
TNFR2 Mouse GAC CTG AGT TGG ATC CCT GA TGT GCA CAT ATG CAG AAG CA 98bp
Trail Mouse ATA AAA AGA GGC TGT GAA CGG G GGT CCA AGA GAG ACG A 64bp
Faim Mouse CGG GCG AGT TTG TCG ATG AT AGC TCT GGG ATT TCC CTG TT 142bp
c-flip Mouse TGC TGA TGG AGA TTG GTG AG CCT TGG CTA TCT TGC CTC TG 96bp
Cyclin D1 Mouse AGT GCG TGC AGA AGG AGA TT CTC TTC GCA CTT CTG CTC CT 89bp
Cyclophilin B Mouse CCA TCG TGT CAT CAA GGA CTT CAT TTG CCA TCC AGC CAG GAG GTC T 216bp
Nm el Mouse AGA TCA TCA AGC GGT TCG AG CAC CAG GCC AGT AAA GAA GG 128bp
Nme2 Mouse GCG AGA TCA TCA AAC GGT TC CGA TGT AAT GCT GCT TCA GG 96bp
Nme3 Mouse CGC GAG AAA CCC TTC TAC AG AAG CAT GCA CGA CAT CCA G 94bp
Nme4 Mouse TAC ATG AGC TCT GGG CCT GT TCT GTT GAG TCG GTG TGT CC 95bp
Timpl Mouse ATC AGT GCC TGC AGC TTC TT TCA CTC TCC AGT TTG CAA GG 140bp
Timp2 Mouse AAG CAG TGA GCG AGA AGG AG GGG GGC CGT GTA GAT AAA CT 137bp
TgfB Mouse TGC GCT TGC AGA GAT TAA AA CGT CAA AAG ACA GCC ACT CA 135bp
Cavl Mouse GCA CAC CAA GGA GAT TGA CC TCC CTT CTG GTT CTG CAA TC lOlbp
ig fir Mouse CCT CGG TGA TGA AGG AGT TC TCA CCG CGT GTC ATT AGT TC 106bp
R a b ll Mouse GGT GGA AAA AGA GTA AAC CTT GC CTC CGT TCG AAT CTC GGT AG 94bp
Gabl Mouse GGA CCT TTC CGA GCG ATA G CTC TTC ACC CGA GAC ACC TC 98bp
Sphk2 Mouse GGC ATT GTC ACT GTG TCT GG GAT CCA CAG GGG AGG ACA C 116bp
Tcfap2c Mouse GAC CTG CTG CTG CCT CAC TGC GAA TGA CAG TCT GAT CG 142bp
Arhgdib Mouse ATC TCG AGG CCC TCA AAA AG CCA GTC CGG TAT GTG TGT TG 130bp
BCL3 Human TAT TGC TGT GGT GCA GGG TA GGT GTC TGC CGT AGG TTG TT 105bp
B-ACTIN Human ACA TCT GCT GGA AGG TGG AC CCC AGC ACA ATG AAG ATC AA 103bp
CYCLIN D1 Human CAA ATG TGT GCA GAA GGA GGT CTC CTC GCA CTT CTG TTC CT 91bp
NME1 Human ACC TTC ATT GCG ATC AAA CC AAC AAG GCG GAA TCC TTT CT 90bp
NME2 Human GCT TCG AGC AGA AGG GAT TC ATG GTC GGT CTT TCA GGT CA 99bp
NME4 Human GTG ATC CAG CGC TTT GAG AG AGC TCA TGT AGC GGA TGA GG 139bp
TIMP1 Human GGG CTT CAC CAA GAC CTA CA GAC TGG AAG CCC TTT TCA GA 141bp
TIMP2 Human AAG CGG TCA GTG AGA AGG AA GGG GGC CGT GTA GAT AAA CT 137bp
CAV1 Human GAG CTG AGC GAG AAG CAA GT TCC CTT CTG GTT CTG CAA TC 130bp
RAB21 Human TGC ATT GGG TCC AAT TTA CT CAT TTC CCA ACA TTT TCC GTA 125bp
GAB1 Human ATT CCA CGA GCA TTT CCA AG GGT GAA TTG GGA TTC ATT GG 143bp
5PHK2 Human GAG CCT GAG TGA GTG GGA TG CAG TCA GGG CGA TCT AGG AG 90bp
ARHGDIB Human GCC CTC AAA AAG GAA ACC AT TCC TGT AGG TGT GCT GAA CG 118bp
Table 2.15: QRT-PCR primer sequences
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2.9 Microarray analysis
RNA was extracted according to section 2.8.1 and in order to rem ove any contaminating
genomic DNA, RNA samples w ere treated with Deoxyribonuclease I, Am plification Grade (Invitrogen)
according to m anufacturer's instructions. Quality control, RNA labelling, hybridisation and bioinformatics 
w ere all perform ed by the Cambridge Genomic Service (Departm ent o f Pathology, University of 
Cambridge, Tennis court Road, Cambridge [www.cgs.path.cam .ac.uk]). M icroarray analysis was 
perform ed using an lllumina MouseRef-8 version 2 BeadChip which targets >25000  transcripts and 
enables the evaluation o f eight samples in parallel. The content o f this BeadChip is derived from the  
National Centre for Biotechnology Inform ation Reference Sequence (NCBI RefSeq) database (Build 36, 
Release 22), supplem ented w ith probes derived from the Mouse Exonic Evidence Based Oligonucliotide 
(MEEBO) set. Comparisons between datasets were perform ed by the Cambridge Genomic Service using 
the R-package Limma (Smyth 2004). Samples were ranked according to adjusted p-values obtained from  
T-tests corrected for m ultiple testing. Normalised data was returned in Excel form at.
2.10 Statistical analysis
2.10 .1 .1  Kaplan-M eier survival analysis
All tum our-free  survival curves and statistical analysis o f tum our-free  survival times were performed  
using the Kaplan-M eier m ethod with the aid o f MedCalc statistical analysis software (Version 11.4.3.0, 
w w w .m edcalc.org /).
2 .10 .1 .2  Kolmogorov-Smirnov analysis
Differences in the distribution of data to determ ine w h eth er data was param etric or non-parametric  
w ere tested for using the Kolmogorov-Smirnov test. This test was perform ed using the M initab statistics 
package (Version 14.20).
2 .10 .1 .3  M ann-W hitney U-test
The M ann-W hitney U-test was used to determ ine statistical differences betw een non-param etric data 
sets. This was perform ed using the M in itab  statistics package (Version 14.20).
2 .10 .1 .4  Student's t-test
The Student's T-test was used to  determ ine statistical differences betw een normally distributed data sets 
and betw een data sets w ith sample sizes o f n=3. This test was perform ed using Excel 2007 software.
2 .10 .1 .5  Chi-Squared test
The Chi-Squared test was used to determ ine statistical differences between observed frequencies and 
expected frequencies o f data.
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Chapter 3: Introduction
3.1 Introduction
The m am m ary gland is a highly complex and specialised tissue which is able to undergo 
m ultiple cycles o f proliferation, d ifferentiation, secretion, and apoptosis. During pregnancy there is a 
huge expansion in the num ber o f luminal epithelial cells which, at birth, become the milk secreting cells 
of the gland. A fter weaning, these cells become obsolete and are rem oved in a well co-ordinated event 
called involution, which involves extensive apoptosis, collapse o f alveolar structures and tissue 
remodelling back to a pre-pregnant state. The process o f involution is an extraordinary example of 
developm ental apoptosis in mammals and can be studied not only to aid in the  understanding o f normal 
m am m ary gland developm ent but also to identify key mediators o f m am m ary epithelial cell death, 
which, when deregulated, could be involved in the pathology of diseases such as cancer.
Leukaemia inhibitory factor (LIF)-activated STAT3 has previously been identified as one o f the  
key initiators o f apoptosis in m am m ary gland involution (Chapman, Lourenco et al. 1999; Humphreys, 
Bierie e t al. 2002; Kritikou, Sharkey et al. 2003; Schere-Levy, Buggiano e t al. 2003). Although STAT3 
activation is essential, it alone is not sufficient to induce apoptosis as it can be suppressed in the  
presence o f constitutively active AKT (Schwertfeger, Richert et al. 2001), and as such, additional 
signalling pathways that synergise to m ediate efficient cell death during involution must be involved. 
One such pathway is m ediated by the NF-kB family o f transcription factors which have previously been 
shown to be up-regulated at the im m ediate onset o f involution (Clarkson, Heeley et al. 2000). Deletion of 
the NF-kB upstream regulator, IKKp, resulted in delayed involution via a reduction in the transcription of 
death receptors and ligands (Baxter, Came et al. 2006) suggesting that, in addition to STAT3, this 
signalling pathw ay is also vitally im portant in the initiation o f involution.
Currently there is little evidence for an interaction betw een the STATs and NF-kB in mammary 
epithelial cells. However, the tw o  transcription factors have been shown to form  a complex to activate 
the serum amyloid A gene (Hagihara, Nishikawa et al. 2005) which is upregulated during involution. A 
previous study of STAT3 and STAT5 transcriptional targets in m am m ary epithelial cells in vitro showed 
that while no NF-kB genes w ere  significantly regulated by STATs, the NF-kB co-factor gene, Bcl3, was 
found to be a principal transcriptional target o f STAT3 (Clarkson, Boland et al. 2006). This association has 
previously been observed in m yelom a cells (Brocke-Heidrich, Ge et al. 2006) and reflects a possible 
mechanism by which the tw o  pathways may undergo cross-talk to regulate involution.
The role o f BCL3 in regulating m am m ary epithelial cell fate in the pregnancy cycle has not 
previously been investigated. However, large scale microarray analysis o f the murine pregnan'cy cycle 
revealed tha t Bcl3, along w ith  a group o f other STAT3 or NF-kB transcriptional target genes, is up- 
regulated in the first 12 hours o f involution w ith a subsequent decline by 24 hours (Clarkson, Wayland et
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al. 2004). This is an indication that it might be involved in regulating the initial apoptotic signals that are 
transduced very early on in the involution process.
The overall aim o f this chapter was to investigate the effect o f BCL3 deletion on m ammary  
gland developm ent during the murine pregnancy cycle. Initially, the gross m orphology o f the mammary  
gland in the absence o f BCL3 was assessed. As Bcl3 has previously been shown to be a downstream  
target o f STAT3 and to be transiently up-regulated in early involution, the rest o f the  chapter focussed on 
determ ining w hether it contributes to the pro-apoptotic effects o f STAT3 specifically at this stage of the  
cycle.
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3.2 Results
3.2.1 Gross mammary epithelial morphology is unaffected by the absence of BCL3 in virgin 
glands and during pregnancy and lactation
As part o f a previously perform ed large scale microarray analysis o f transcriptional changes in 
the mouse pregnancy cycle, Bcl3 mRNA levels w ere assessed. This study revealed that Bcl3 expression 
rem ained at consistently low levels in the virgin gland and throughout the  gestation and lactation stages 
of the cycle (Clarkson, Wayland et al. 2004).
In order to determ ine w hether loss o f BCL3 affected the gross m am m ary epithelial morphology 
during these stages o f the pregnancy cycle, the fourth abdominal m am m ary glands from  3 BclJ1' and 3 
8c/3+/+ post-pubescent virgin, pregnant and lactating mice w ere  harvested before being fixed for 
subsequent H&E staining and analysis.
In virgin mice, the majority o f the m am m ary glands w ere  composed o f adipocytes, with  
infrequent epithelial ducts present. No phenotypic differences w ere  observed between the Bcl3+/+ and 
Bcl3'h m am m ary glands (Figure 3.1). At 15 days gestation, extensive expansion o f the epithelial 
com partm ent tha t is classically associated w ith this stage o f the  cycle was evident. However, loss of BCL3 
had no effect on the histology o f the gland in comparison to w ild-type controls at this tim e point (Figure
3.1). At 10 days lactation, glands w ere predom inantly composed o f alveoli lined by secretary epithelial 
cells. Again, loss o f BCL3 did not result in any phenotypic differences in comparison to controls (Figure
3.1). Furtherm ore, no differences w ere observed in the ability o f 8c/3'A m others to feed and maintain 
the ir litters in comparison to 8c/3+/+ m others.
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Figure 3 .1: Loss o f BCL3 has no effect on the gross morphology o f the m am m ary gland
Fourth abdominal mammary glands from 3 8c/3+/+ and 3 Sc/37' mice were harvested at different 
stages of the pregnancy cycle (virgin, 15 day gestation and 10 day lactation). No gross histological 
differences were observed at any time point analysed. Representative images are shown. Scale 
bars indicate 100pm.
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3.2.2 Bcl3 displays a transient increase in expression during early involution that is
dependent on STAT3
Previous microarray analysis revealed that Bcl3 expression transiently increases during early 
involution, indicating that it may be involved in mediating this stage o f the pregnancy cycle (Clarkson, 
Wayland et al. 2004).
In order to confirm this finding, RNA from the fourth abdominal m am m ary glands of four FVB 
mice was harvested at 10 days lactation and at 12, 18 and 24 hours involution. cDNA was prepared and 
QRT-PCR for Bcl3 expression was perform ed. The expression profile was com pared to an internal control, 
cyclophilin B.
Bcl3 mRNA expression increased significantly by 2.5 fold in samples taken at 12 hours 
involution in comparison to those taken from lactating glands (Figure 3.2A, T-Test, p=0.00028). Bcl3 
expression furth er increased dramatically over the next six hours and at 18 hours involution expression 
was 12.9 fold higher than in 10 day lactating controls (Figure 3.2A, T-Test, p=0.0001). At 24 hours 
involution Bcl3 expression showed a small but insignificant decrease in comparison to 18 hour samples 
(Figure 3.2A, T-Test, p>0.05). Although this is only partially consistent w ith  previous microarray data of 
transcriptional changes during m am m ary gland developm ent, whereby expression levels w ere highest at 
12 hours involution (Clarkson, Wayland et al. 2004), it does confirm a transient increase in Bcl3 
expression in the early stages of the process.
Several transcription factors, including LIF-activated STAT3 have been shown to play im portant 
roles in the regulation of apoptosis at the onset o f murine m am m ary involution (Chapman, Lourenco et 
al. 1999; Humphreys, Bierie e t al. 2002; Kritikou, Sharkey et al. 2003; Schere-Levy, Buggiano et al. 2003; 
Watson 2006). As Bcl3 has previously been shown to be a transcriptional target o f STAT3 (Brocke- 
Heidrich, Ge et al. 2006), the question o f w hether its expression is regulated by STAT3 during the early 
stages o f m am m ary gland involution was addressed.
For this study, m am m ary specific Stat3  knock-out mice, in which expression of Cre recombinase 
is directed specifically to m am m ary epithelial cells by the prom oter o f the beta-lactoglobulin {Big) gene 
w ere utilised (Seibert, Bentley et al. 1998; Chapman, Lourenco et al. 1999). Fourth abdominal m ammary  
glands o f mice expressing Blg/Cre and either one floxed Stat3  and one w ild-type Stat3  allele 
(iBlg/Cre/Stat3^ml+) or one floxed Stat3  and one null Stat3  allele (Blg/Cre/Sta t3flox/") w ere harvested at 18 
hours involution. RNA from  these frozen glands (n=3) was subsequently extracted and analysed for Bcl3 
expression by QRT-PCR.
Glands w ith the m am m ary epithelial specific loss o f Stat3  (B /g/Cre/Stot3flox/') had 77% less Bcl3 
mRNA expression at 18 hours involution in comparison to Stat3  expressing (Blg/Cre/Stat3nox/+) control
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glands (Figure 3.2B, T-Test, p=0.034). This indicated that elevated Bcl3 expression during early murine 
m am m ary involution is dependent on STAT3 signalling.
Taken together, these results suggest that Bcl3 expression is up-regulated between 12 and 24 
hours involution, in response to STAT3.
82
Chapter 3: Results
16
14
12
8
6
4
2
0
B
1.2 i
5'C5
I
Q.
UJ
<
Zoc
E
£2oco
Blg/Cre/Stat3flox/+ Blg/Cre/Stat3flox/-
Figure 3.2: Bcl3 expression transiently increases in response to 5TAT3 signalling a t 18 hours 
involution
RNA was harvested from the fourth abdominal mammary glands of FVB mice at 10 days lactation 
and at 12, 18 and 24 hours involution (n=4 at each time point). Subsequent QRT-PCR analysis 
revealed that Bcl3 expression transiently increased to a maximum at 18 hours involution with a 
subsequent small decline at 24 hours involution. Error bars represent ± standard error of the mean 
(SEM) (A). RNA was harvested from the fourth abdominal mammary glands of 3 Blg/Cre/Stat3*oxh 
and 3 Blg/Cre/Stat3nox/' mice. QRT-PCR analysis showed that Bcl3 expression was significantly lower 
in the absence of STAT3 at 18 hours involution (B, *=T-test, p=0.0304). Data is represented as Bcl3 
mRNA levels relative to cyclophilin B mRNA levels. Error bars represent ± SEM.
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3.2.3 Bcl3f/' glands exhibit increased numbers of apoptotic bodies in comparison to both
Bcl3+/+ and BCI3'1' glands at 18 hours involution
Previous work in this chapter dem onstrated that loss of BCL3 does not affect the gross 
morphology o f the virgin, pregnant or lactating m ammary gland. However, as Bcl3 showed a striking 
STAT3-dependent increase in expression during early involution, it was o f interest to closely examine 
w hether it contributes to the pro-apoptotic effects o f STAT3 during this stage o f the pregnancy cycle.
In order to achieve this, the num ber o f apoptotic bodies present in H&E stained fourth  
abdom inal m am m ary gland sections from Bcl3+/+, Bc/3+/' and flc/37' (n£4) mice harvested at 12, 18, 24 
and 48  hours involution was analysed.
Apoptotic bodies w ere clearly identifiable at all tim e-points by the ir distinctive appearance and 
location w ithin the secretary alveoli lumens (Figure 3.3 &  3.4). To quantify any changes between  
genotypes, the num ber o f shed apoptotic bodies across tw o random fields o f view  was counted and an 
average was taken.
At 12 hours involution, no differences in the average num ber o f shed apoptotic bodies were 
observed (Figure 3.3 &  3.5, M ann-W hitney U-test for all comparisons, p>0.05). Interestingly, at 18 hours 
involution, w hen Bcl3 expression was at its highest, Bcl3+/' glands displayed a marked increase in the  
appearance o f apoptotic bodies in comparison to both the flc/3+/+ or BcB'1' glands. This was found to be 
significant only when the Bcl3+/' glands w ere compared to the Bcl3A glands (Figure 3 .3-3.5), mean±SEM  
num ber o f shed apoptotic bodies per field o f view was: 1036±151 for Bcl3+I' glands and 586±93 for Bc/37' 
glands, M ann-W hitney U-test, p=0.0104). At 24 and 48 hours involution, no significant differences were  
observed betw een genotypes (Figure 3.3 &  3.5, M ann-W hitney U-test for all comparison, p>0.05).
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Figure 3.3: Histological analysis o fB cl3+/+, Bcl3+/' and Bcl3v glands a t 1 2 ,1 8 , 24 and 48 hours involution
H&E stained sections (n>4) of fourth abdominal mammary glands from Bc/3+/+, Bcl3+/' and Bc/3V" mice 
taken at 12 ,1 8 , 24 and 48 hours involution were analysed. No gross histological differences were observed 
at 12, 24 or 48 hours involution. At 18 hours involution increased numbers of apoptotic bodies were 
observed in Bcl3+/' glands in comparison to Bcl3+/+ and Bc/37' glands. Representative images are shown. 
Scale bars indicate 200pm . See figure 3.4 for higher magnification images and figure 3.5 for quantification 
of the number of shed apoptotic bodies present.
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Figure 3 .4: Bcl3*^' glands display increased apoptotic Bci3>/J Bcl3:
a t 18 hours involution
Representative images of H&E stained sections from fourth abdominal mammary glands from Bc/3+/+, 
Bc/3+/' and Bc/37' mice at 18 hours involution. Bc/3+/' glands display more apoptotic bodies than Bc/3+/+ or 
Bc/37' glands. Representative apoptotic bodies are highlighted with arrows. Scale bars indicate: Left 
panel 500pm , Right panel 100pm.
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Figure 3.5: Bc!3+/ glands exhibit significantly m ore apoptotic bodies a t 18 hours involution in 
comparison to Bcl3v glands
Fourth abdominal mammary glands from fic/3+/+, 8c/3+/‘ and 8c/37' mice (n £ 4) were harvested 
for H&E sectioning and subsequent histological analysis. The average number of shed apoptotic 
bodies across two fields of view were counted. No significant differences were observed 
between genotypes at 12, 24 or 48 hours involution (Mann-W hitney U-test for all comparisons, 
p>0.05). At 18 hours involution, 8c/3+/' glands displayed significantly more shed apoptotic 
bodies than 8c/37' glands (*=  Mann-W hitney U-test, p=0.0104). Error bars represent ± SEM.
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3.2.4 Selection of a cohort to analyse Bcl3*/m phenotype at the molecular level
Data in the previous section showed that Sc/37' glands had significantly less shed apoptotic  
bodies than Bcl3+/~ glands at 18 hours involution. However, no differences w ere observed between the  
Bcl3+/+ and the 8c/37' glands. This data suggests that there may be a complex BCL3 dosage-dependent 
phenotype occurring that results in a transient increase in apoptosis in the 8c/3+/" mice in comparison to 
the 8c/3+/+ and 8c/37" mice at 18 hours involution. To determ ine w hether this phenotypic difference 
corresponded w ith any changes at the molecular level, four 8c/3+/ and four 8c/37' glands at 1 2 ,1 8  and 24 
hours involution w ere selected to be further analysed.
In order to choose the cohorts to analyse, glands w ere visually graded according to the degree 
of milk stasis they displayed. Glands displaying high milk stasis, characterised by entirely milk-filled 
lumens w ere  graded 1 while glands that exhibited a high proportion of collapsed lumens with low milk 
stasis w ere graded 4. Glands displaying interm ediate phenotypes w ere designated a grade of either 2 or 
3 (Figure 3.6).
M ilk  accumulation and stasis has been shown to be one o f the m ajor mechanisms for the  
induction o f involution (Quarrie, Addey et al. 1996; Quaglino, Salierno et al. 2009). In order, therefore, to 
use this physiological process as a selection criterion for a cohort to  analyse, it was im portant to ensure 
that BCL3 had no effect on this param eter. To achieve this, the percentage o f glands displaying high 
stasis was analysed in Bcl3+/' and BclJ1' mice and revealed no statistical differences in this param eter 
between cohorts at any involution tim e point (Table 3.1, Chi-Squared test p>0.05). Therefore, four 
animals w ith glands exhibiting high milk stasis (grades 1 or 2) were randomly chosen for each cohort. 
This exclusion criterion not only allowed the selection of a reasonable size cohort to work with but also 
removed additional biological variation between glands. The chosen cohort displayed a similar 
distribution o f apoptotic bodies to the original full cohort w ith Bc/37' glands exhibiting significantly less 
apoptotic bodies than Bcl3+/~ glands at 18 hours involution (Figure 3.7, M ean lS E M  num ber o f shed 
apoptotic bodies per field o f view was: 11051173 for Bcl3+/' glands and 530191 for Bc/37' glands, M ann- 
W hitney U-test, p=0.0304) indicating that the selection criteria did not artificially skew the data. These 
cohorts w ere used in all subsequent experiments to determ ine w hether the observed change in 
apoptotic bodies also correlated with changes at the molecular level.
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Figure 3.6: M ilk  stasis grading scale
Involuting mammary glands were graded visually according to the degree of milk stasis they 
displayed. Representative images of H&E sections at 18 hours involution indicating the milk stasis 
grading scale are shown. Grade 1 glands display a very high degree of stasis with entirely milk- 
filled lumens. Grade 4 glands have a large number of collapsed lumens with low levels of milk 
stasis. Grade 2 and 3 glands have intermediate levels of milk stasis. Scale bars indicate 200pim.
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% Glands Displaying High Stasis
Genotype 12 Hrs Involution 18 Hrs Involution 24 Hrs Involution
8c/3v 80% 66.6% 62.5%
Bcl3' 71.4% 80% 71.4%
Table 3.1: The percentage o f  glands displaying a high degree o f stasis is the sam e in Bcl3+/ and  Bcl3 7 
mice
The percentage of glands displaying high stasis (grades 1 or 2) in Bcl3+/' and Bcl3'/' mice was calculated. 
No statistical differences in the frequency of high stasis glands was observed between genotypes at 12, 
18 or 24 hours involution (Chi-Squared test p>0.05).
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Figure 3.7: Bcl3m/' glands have significantly less shed apoptotic bodies a t 18 hours involution than 
Bcl3+/ glands from  the chosen cohort
H&E sections of mammary glands from  Bcl3+/' and B cU 1' mice (n=4) in the chosen cohort were analysed 
for the average number of shed apoptotic bodies across two fields of view at 12, 18 and 24 hours 
involution. No significant differences were observed at 12 or 24 hours involution (Mann-W hitney U-test 
for both comparisons, p>0.05). At 18 hours involution, Bcl3+/' glands had significantly more shed 
apoptotic bodies than Bcl3 f glands (*=M ann-W hitney U-test, p=0.0304). Error bars represent ± SEM.
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3.2.5 BCI3'1' glands display significantly less caspase 3 /7  activity at 18 hours involution than
Bc/3+/' glands
Having selected a final cohort and shown that Bc/37' mice had significantly less shed apoptotic  
bodies than Bc/3+/" mice at 18 hours involution, it of was interest to see if this difference corresponded to 
changes in caspase activity w ithin the gland. Caspase 3 /7 , 8 and 9 assays (see Chapter 2: M aterials and 
Methods, section 2.7) were perform ed on whole protein extracts from  the fourth  abdominal mammary 
glands o f the four Bc/3+/' and four Bc/37' mice at 1 2 ,1 8  and 24 hours involution.
At 12 and 24 hours involution, no significant differences in caspase 3 /7 , 8 or 9 activity were  
observed betw een the Bc/3+/' and Bc/37' m am m ary glands (Figure 3.8A-C, M ann-W hitney U-test for all 
comparisons, p>0.05). However, at 18 hours involution, the activity o f all th ree  caspases was lower in the 
Bc/37' glands in comparison to Bc/3+/' glands. This only reached significance in the measurement of 
caspase 3 /7  activity (Figure 3.8A, M ean caspase 3 /7  activity as measured by relative light units ± SEM 
was: 154158.75  ± 16035.787 for Bc/3+/' mice and 60588.33 ± 18350.63 for Bc/37' mice; M ann-W hitney U- 
test, p=0.034).
These data dem onstrate that in concordance w ith the previously observed decreased number 
of apoptotic bodies, Bc/37' m ammary glands also have significantly low er capsase 3 /7  activity than Bc/3+/' 
glands.
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Figure 3.8: Bcl3v m am m ary glands have significantly less caspase 3 /7  activity than Bcl3+/ glands 
Whole protein extracts from Bcl3+/' and BclJ1' fourth abdominal mammary glands at 1 2 ,1 8  and 24 hours 
involution (n=4) were prepared. Caspase 3 /7 , 8 and 9 assays were performed on all samples. No 
significant differences were observed in caspase 8 or 9 activity at any tim e point (Mann-W hitney U-test 
for all comparisons, p>0.05). Bcl3'/' mammary glands had significantly less caspase 3 /7  activity than 
Bcl3+/ mammary glands at 18 hours involution (*= M ann-W hitney U-test, p=0.034). No significant 
differences in caspase 3 /7  activity were observed at 12 or 24 hours involution (Mann-W hitney U-test for 
all comparisons, p>0.05). Error bars represent ± SEM.
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3.2.6 The percentage and distribution of NF-kB p50 and p52 subunits is unaltered in Bel3'1'
glands compared to Bcl3+/' glands at 18 hours involution
BCL3 has been reported to interact with and alter the location and function of the NF-kB p50 
and p52 sub-units in a variety o f different ways (see Chapter 1: General Introduction, section 1.4.4) that 
can be dependent on its concentration (Bundy and McKeithan 1997). As Bc/3+/' m am m ary glands were  
shown to have significantly more shed apoptotic bodies at 18 hours involution in comparison to both 
flc/3+/+ and Bc/37' m am m ary glands, it was o f interest to determ ine w heth er this was a BCL3-dose 
dependent effect on the distribution o f p50 and p52 subunits.
In order to achieve this, Immunohistochemistry (IHC) directed against the total or 
phosphorylated forms o f p50 and p52 was perform ed on fourth abdominal m am m ary glands taken from  
the four previously selected Bc/3+/' and four Bc/37' mice at 18 hours involution. Sections were examined 
microscopically for any apparent differences in staining pattern.
The NF-kB p50 antibody used was able to detect both p50 and p l0 5  proteins. The m ajority of 
staining was found to be in the nuclear com partm ent o f epithelial cells in both the Bc/3+/ and Bc/37' 
sections, although some diffuse cytoplasmic staining was also observed (Figure 3.9A). No obvious visual 
difference in the distribution of staining was noted between the Bc/3+/' and Bc/37' sections. To quantify 
this, 1000 cells from  each sample were assessed and counted on a scale o f 1-4 according to the intensity 
of their nuclear staining (l=negative, 2=weak staining, 3=m oderate staining, 4=intense staining). Scores 
of 1 and 2 w ere grouped together and counted as negative and scores o f 3 and 4 w ere grouped and 
counted as positive staining. No significant differences (M ann-W hitney U-test, p>0.05) were observed in 
the percentage o f positively stained cells in the Bc/3+/' sections in comparison to the Bc/37' sections 
(Figure 3.9A, mean±SEM percentage of positively stained nuclei was 56±8.9%  for Bc/3+/' mice and 
55±5.99%  for Bc/37' mice).
Phosphorylation o f p50 at serine 337 has been shown to be critical for the DNA binding of p50 
(Hou, Guan et al. 2003). To assess any differences in the phosphorylation and therefore DNA binding of 
p50, IHC was perform ed using an antibody specific to the phospho-ser337 form  of p50 (p-p50ser337). 
Staining was observed to be predom inantly nuclear w ith no obvious visual differences between the 
Bc/3+/' and Bc/37' sections (Figure 3.9B). This was quantified according to the above scoring system and 
from  this quantification no significant differences (M ann-W hitney U-test, p>0.05) in the percentage of 
positively stained cells between the Bc/3+/' and Bc/37' m ammary glands w ere found (Figure 3.9B, 
mean±SEM percentage o f positively stained nuclei was 65.6±7.699%  for Bc/3+/‘ mice and 59.2±19.9%  for 
Bc/37' mice).
The NF-kB p52 antibody used detected both p52 and plOO proteins. The vast majority of 
staining observed w ith this antibody was found in the nuclear com partm ent o f epithelial cells (Figure
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3.10A) and no visual differences were observed between the Bc/3+/' and Bc/37' sections. Nuclear staining 
was quantified and this confirmed that there was no significant difference (M ann-W hitney U-test, 
p>0.05) in the percentage of positively stained nuclei between the tw o  cohorts (Figure 3.10A), 
m eanlSEM  percentage o f positively stained nuclei was 72.1±15.7%  for Bcl3+I~ mice and 81.6±5.63%  for 
Bc/37 mice).
Phosphorylation o f p52 at serine 222 has been shown to disrupt transcriptionally active p52 
homodimer/BCL3 complexes and instead prom ote the form ation o f transcriptionally repressive p52/C- 
REL/HDAC1 complexes (Barre and Perkins 2010). IHC directed against serine 222 phosphorylated p52 
was perform ed to determ ine w hether there were any BCL3-dependent changes in this transcriptionally 
repressive form  of p52. As with the pan-p52 antibody, the m ajority o f staining was observed to be in the 
nucleus of the epithelial cells (Figure 3.10B) and no visual differences in the intensity or distribution of p- 
p52ser222 was observed between the Bc/3+/' and Bc/37' glands. Nuclear staining was quantified and this 
confirmed that there were no significant differences (M ann-W hitney U-test, p>0.05) in the percentage of 
positively stained nuclei between the tw o cohorts (Figure 3.10B, m eanlSEM  percentage of positively 
stained nuclei was 79.4±21.2%  for Bc/3+/‘ mice and 66.6113.95%  for Bc/3+/' mice).
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Figure 3.9: The distribution and percentage o f p50 and p -p 5 (fer337 positively stained epithelial cells is 
unchanged in Bcl3v glands compared to Bcl3+/ glands
Fourth abdominal mammary glands from the 4 previously chosen Bcl3+/' and Bcl3''' glands were
harvested and subjected to p50 and p-p50 er IHC. Representative images of p50 (A) and p-p50ser (B) 
stained glands are shown along with negative controls. Scale bars indicate 50pm. p50 (A) and p-p50ser337 
(B) staining was predominately located in the nuclei but some diffuse cytoplasmic staining was also 
observed. No significant differences in the percentage of p50 (A) or p-p50ser337 (B) positively stained 
nuclei were observed (Mann-W hitney U-test for both comparisons, p>0.05). Error bars represent ± SEM.
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Figure 3 .10  The distribution and percentage o f p52 and p-p52ser222 positively stained epithelial cells is 
unchanged in Bcl3v  glands compared to Bci3+/ glands
Fourth abdominal mammary glands from the 4 previously chosen Bcl3+/' and BclJ1' glands were 
harvested and subjected to p52 and p-p52Ser222 IHC. Representative images of p52 (A) and p-p52ser222 (B) 
stained glands along with negative controls are shown. Scale bars indicate 50pm. p52 (A) and p-p52ser222 
(B) staining was predominately located in the nuclei but some diffuse cytoplasmic staining was also 
observed. No significant differences in the percentage of p52 (A) or p-p52ser222 (B) positively stained 
nuclei were observed (Mann-W hitney U-test for both comparisons, p>0.05). Error bars represent ± SEM.
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3.2.7 BclB'1' glands have the same protein levels of key regulators of involution in
comparison to Bcl3+/' glands
Involution is initiated by changes in the expression o f key m olecular regulators of apoptosis and 
cell survival such as STAT3, ERK and AKT (Chapman, Lourenco et al. 1999; Kritikou, Sharkey et al. 2003; 
Abell, Bilancio et al. 2005). In order to determ ine w hether com plete loss o f BCL3 altered the expression 
of these proteins, western analysis was performed on involuting m am m ary glands from  Bc/3+/' and Bc/37' 
mice.
Total proteins w ere extracted from  the m am m ary glands o f the four Bc/3+/' and four Bc/37' mice 
at 12, 18 and 24 hours involution. The individual biological samples from  each tim e point were pooled 
and target proteins w ere analysed by western blotting. First, levels o f the key initiator o f early involution, 
STAT3, w ere  assessed. No differences in the protein expression of e ither total or activated STAT3, as 
measured by its phosphorylation on tyrosine 705, were observed between the Bc/3+/* and Bc/37' 
m am m ary glands (Figure 3.11A). Equal loading o f the proteins was confirmed by visualising levels of the  
housekeeping standard protein, Tubulin, which indicated no differences in the am ount of protein loaded 
between samples (Figure 3.11A).
W estern analysis was then directed against the ERK protiens. ERK survival signals are down- 
regulated at the onset o f involution to allow efficient apoptosis to occur (Kritikou, Sharkey et al. 2003). 
Both total and active ERK, as measured by its phosphorylation threonine 202/tyrosine 204 were down- 
regulated over the first 24 hours of involution (Figure 3.11B). However, Bc/3+/' and Bc/37' mice were  
found to have comparable levels at each tim e point (Figure 3.11B).
Finally, protein levels of the anti-apoptotic kinase, AKT, which has been shown to be down- 
regulated at the onset o f involution to allow pro-apoptotic signals from  STAT3 to take effect 
(Schwertfeger, Richert et al. 2001; Abell, Bilancio et al. 2005) w ere analysed. Both total and active AKT, 
as measured by its phosphorylation on serine 473, w ere assessed in pooled samples at 12, 18 and 24 
hours involution. Results show that Bc/37' glands have comparable AKT protein levels to Bc/3+/‘ glands at 
all tim e points analysed (Figure 3.11B). Equal loading o f proteins for all westerns was confirmed by 
Tubulin (Figure 3.11B). Overall, these data indicate that these key mediators of involution remain 
unaltered in Bc/37'glands in comparison to Bc/3+/'glands.
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Figure 3.11: Bcl3v' glands exhibit comparable protein levels o f key initiators o f involution to Bcl3+/ 
glands
Total protein extracts from four Bcl3+/~ and four Bd3'/' mammary glands at 12, 18 and 24 hours 
involution were pooled together and subjected to western analysis. No differences in total or 
phosphorylated STAT3 (A), ERK or AKT (B) protein levels were observed at any time-point analysed. 
Equal loading was confirmed by visualising levels of Tubulin.
98
Chapter 3: Results
3.2.8 Analysis of the expression of components of the extrinsic apoptosis pathway in Bcl3+/' 
and BCI3'1' mammary glands
It has previously be shown that the TNF family o f death receptors and ligands, which are 
responsible for activating the 5 principle mammalian extrinsic apoptosis pathways, are induced in the  
early stages o f involution (Clarkson, Wayland et al. 2004). Furthermore, some o f these receptors may be 
regulated by NF-kB as the absence of its up-stream regulator, IKK(3, was shown to result in delayed 
involution via reduced expression of death ligands (Baxter, Came et al. 2006).
In order to establish w hether differences in the levels o f apoptosis observed between Bc/3+/' 
and Bc/37 glands was due to BCL3-mediated changes in extrinsic apoptosis pathways, the expression of 
death receptors and ligands was analysed. cDNA was generated from  the m am m ary glands of mice taken 
from  the previously chosen cohorts (n=4) at 18 hours involution and QRT-PCR was performed. Gene 
expression was normalised to an internal control, cyclophilin B. In no instance was a significant difference 
in the expression of any o f the death receptors (T nfrl, Tnfr2, Fasr, DR5) or e ither o f the death receptor 
ligands {Fasl, Trail) detected between the Bc/3+/' and Bc/37' glands at 18 hours involution (Figure 3.12, 
M ann-W hitney U-test for all comparisons, p>0.05).
O ther components of the extrinsic pathway w ere also investigated. Fas apoptotic inhibitory 
molecule (FAIM) is a highly conserved antagonist o f the FAS death receptor and has previously been 
shown to be dependent on NF-kB signalling (Sole, Dolcet et al. 2004). QRT-PCR analysis showed that 
Bc/37' glands had a very small but significant increase in the expression of Faim  at 18 hours involution in 
comparison to Bc/3+/' glands (Figure 3.12, M ann-W hitney U-test, p= 0 .0304). This may indicate that in 
Bc/3+/' glands, Faim  is down-regulated which allows for increased FAS signalling resulting in amplified cell 
death at 18 hours involution.
It has previously been shown that FAIM modulates FAS m ediated apoptosis by influencing the  
expression of another antagonist of FAS signalling, C-FLIP, and in turn regulating the binding of caspase 8 
to FAS (Huo, Xu et al. 2009). The expression o f c-flip was therefore investigated in the presence or 
absence of BCL3 at 18 hours involution. No changes, however, were observed between the genotypes 
(Figure 3.12, M ann-W hitney U-test, p>0.05).
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Figure 3.12: Bcl3v m am m ary glands have significantly increased Faim expression in comparison 
to Bcl3+/ glands
RNA was harvested from four Bcl3+/' and four B cU 1' mammary glands at 18 hours involution and 
subjected to QRT-PCR analysis directed against different components of the extrinsic apoptosis 
pathway. No significant differences were observed in any of the death receptors or ligands 
analysed (M ann-W hitney U-test for all comparisons, p>0.05). c-flip expression also remained 
unaltered (M ann-W hitney U-test, p>0.05). Bc/37" glands had significantly more Faim mRNA than 
Bcl3+/' glands (* = M ann-W hitney U-test, p=0.0304). Data is represented as target gene mRNA 
expression relative to cyclophilin B mRNA expression. Error bars represent ± SEM.
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3.3 Discussion
Post-lactational m am m ary gland involution is a well orchestrated event involving the removal 
of redundant secretary epithelial cells and remodelling of the gland back to a pre-pregnant state. This 
process is tightly controlled by a num ber of key regulators of apoptosis, including the transcription 
factors, STAT3 and NF-kB (Chapman, Lourenco et al. 1999; Baxter, Came et al. 2006; Watson 2006). The 
role of the NF-kB co-factor and STAT3 transcriptional target, BCL3, has not previously been analysed at 
any stage o f the pregnancy cycle, including involution. The overall aim of this chapter, therefore, was to 
assess w hether loss o f BCL3 had any phenotypic consequences on the m am m ary gland during the  
pregnancy cycle and, in particular, w hether it contributed to the pro-apoptotic effects of STAT3 during 
early involution.
In order to address this, m ammary glands from  Bc/3+/+, Bcl3+/' and Bc/37' mice were examined 
for gross histological differences at various stages o f the pregnancy cycle. Although loss of BCL3 had no 
morphological effects on virgin, pregnant or lactating glands (Figure 3.1), an interesting phenotype in 
which Bcl3+/* glands exhibited increased shed apoptotic bodies in comparison to both Bc/37" and Bc/3+/+ 
glands at 18 hours involution was observed (Figure 3 .3-3.5). To see a phenotype at this stage o f the  
pregnancy cycle was not surprising as both this and a previous study have shown Bcl3 to be 
transcriptionally up-regulated in early involution (Figure 3.2; Clarkson, Wayland et al. 2004). W hat was 
surprising, however, was to observe no difference between the Bc/3+/+ and Bc/3'7' glands but to 
specifically identify a Bc/3+/' phenotype. One explanation for this could be that BCL3 is able to exert a 
very specific doseage-dependent effect on NF-kB subunit transcriptional activity. Indeed, previous 
studies have observed that BCL3 concentration can have a profound effect on the distribution and 
function o f certain NF-kB complexes. For example, Bundy et al. (1997) dem onstrated that the ratio of 
BCL3 to p52 was fundam ental in determ ining the binding of p52 homodimers to DNA. M ore recently, 
down-regulation o f BCL3 in H1299 human lung carcinoma cells was shown to result in a shift from p52 
homodimer/BCL3 transactivating complexes to p52 hom odim er/H DA C l repressive complexes (Rocha, 
M artin  et al. 2003). It is possible, therefore, that interm ediate concentrations of BCL3, as a result of 
heterozygosity, could subtly alter the ratio o f transactivating to inhibitory NF-kB complexes in such a way 
as to transiently prom ote apoptosis to an extent that isn't observed in glands that are either completely 
devoid o f BCL3 or w ild-type for BCL3.
Having identified this phenotype, it was of interest to establish w hether it correlated with any 
BCL3-dependent changes at the molecular level. Firstly, in order to identify any changes in the  
distribution or phosphorylation of p50 and p52, IHC using antibodies directed against these NF-kB 
subunits was perform ed in Bc/3+A and Bc/37' glands at 18 hours involution. No differences in the cellular 
distribution or phosphorylation status o f either subunit were observed (Figure 3.9-10). IHC is, at best,
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only a sem i-quantitative method to analyse protein expression and so very subtle changes in the  
quantity o f protein present are unlikely to be identified. Furtherm ore, BCL3 primarily acts to alter the  
transcriptional function of p50 and p52 homodimers. W hile the use of antibodies targeting 
phosphorylated forms o f proteins can potentially identify the DNA binding ability o f the subunits, they 
cannot determ ine which complexes are being formed and w hether they are transactivating or inhibitory. 
To address this in the future, more precise experiments such as Co-IP and ChIP would need to be 
perform ed.
The increase in apoptotic bodies observed in Bcl3+/' glands at 18 hours involution correlated 
with a significant increase in caspase 3 /7  activity and a trend towards an increase in caspase 8 and 
caspase 9 activity (Figure 3.8). Caspases have previously been shown to be involved in mediating 
epithelial cell apoptosis during mammary gland involution (M arti, R itter et al. 2001) although a recent 
study suggests that this may be a redundant mechanism (Kreuzaler, Staniszewska et al. 2011). Activation 
of the caspase cascade occurs via either the intrinsic or extrinsic pathway. Caspase 3 /7  is an effector 
caspase tha t conducts the overall execution of apoptosis via cleavage o f a wide range of substrates, 
whereas caspase 8 and caspase 9 are upstream mediators of the extrinsic or intrinsic pathway  
respectively (reviewed in Jin and El-Deiry 2005). The observed increase in caspase 3 /7  activity in the  
Bcl3+/' glands is not surprising as an increase in apoptotic bodies had already been identified in glands 
from  the same mice. Therefore, rather than identifying a direct mechanism by which Bcl3+/' glands 
displayed enhanced apoptosis, the correlation in these results serves to confirm that the shed epithelial 
cells are, in fact, apoptotic.
Both the intrinsic and extrinsic apoptosis pathways have been implicated in mammary  
involution (Schorr, Li et al. 1999; W alton, W agner et al. 2001; Baxter, Came et al. 2006). As NF-kB has 
specifically been shown to prom ote m am m ary epithelial cell apoptosis via death receptor signalling 
involving the extrinsic pathway (Baxter, Came et al. 2006), it was of interest to determ ine w hether the 
increased apoptosis observed in Bcl3+/~ glands, was also due to alterations in this pathway. However, as 
results from  caspase 8 and 9 assays did not reach significance (Figure 3.8B8iC), it is difficult to determine  
which apoptosis pathway was being up-regulated. Nevertheless, an insignificant trend towards an 
increase in the activity o f both caspases was observed, suggesting that both pathways are up-regulated 
to  induce apoptosis in the Bcl3+/~ glands. Larger cohorts would be required to make a more definite 
conclusion on this.
Bcl3+/' and Bc/3'A glands had similar total and phosphorylated protein levels of the key 
regulators of m am m ary gland involution, AKT, STAT3 and ERK, suggesting that these pathways are 
unaffected by the different concentrations of BCL3. Furthermore, even though NF-kB has previously 
been shown to prom ote apoptosis via increased death receptor signalling (Baxter, Came et al. 2006), no
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differences in the expression of these receptors or their ligands were identified. However, Bcl3+/' glands 
did express significantly lower levels of Faim  mRNA than Bc/37' glands at 18 hours involution (Figure 
3.12). FAIM is known to antagonise FAS signalling in a variety of tissues (Sole, Dolcet et al. 2004; Choi, 
Reimers et al. 2007) and has been implicated in mediating resistance to FAS-induced cell death (reviewed 
in Rothstein 2000). Previous studies have shown that FAS signalling is fundam ental in early involution as 
mice lacking FAS or FAS ligand display delayed involution (Song, Sapi et al. 2000). Increased FAS signalling 
m ediated by the down-regulation o f Faim  may reflect a mechanism by which Bcl3+/' glands display a 
transient increase in apoptosis at 18 hours involution. This conclusion, however, must be viewed with 
some caution as the observed increase in Faim  expression was very subtle.
3.3.1 Summary
Overall, the data from this chapter identified a heterozygous phenotype whereby Bcl3+I' glands 
display a transient increase in apoptotic bodies at 18 hours involution in comparison to both Bc/3+/+ and 
Bc/37' glands. However, this did not correlate with any outstanding differences at the molecular level 
which may indicate that the molecular mechanism responsible fo r this phenotype has not been 
identified. However, it could also bring into question w hether the observed phenotype is real or in fact 
due to small cohort numbers and large biological variation. This may need to be addressed in the future  
with larger cohorts of animals.
BCL3 was originally identified as a proto-oncogene in B-cell chronic lymphocytic leukaemia 
(Ohno, Takim oto et al. 1990) and has since been implicated in a num ber o f o ther malignancies including 
breast cancer (Cogswell, Guttridge et al. 2000; Thornburg, Pathm anathan et al. 2003; Mathas, Johrens et 
al. 2005; Mishra, Bharti et al. 2006). The observation that loss o f BCL3 had no gross effects at any stage 
of the pregnancy cycle is on one level disappointing. Nevertheless, it does indicate that it may potentially 
be an excellent therapeutic target in breast cancer as inhibition should have no detrim ental side-effects 
on normal m am m ary tissue, which is a primary aim in cancer therapy. However, in order to establish 
w hether this NF-kB co-factor is a bone fid e  therapeutic target in breast cancer, its function and 
mechanism of action in the disease must be investigated to beyond w hat is already known in the 
literature. This will therefore be the primary focus of the following three chapters o f this thesis.
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4.1 Introduction
The NF-kB family o f transcription factors has previously been shown to be elevated in many 
malignant diseases including breast cancer (Bargou, Emmerich et al. 1997; Cogswell, Guttridge et al. 
2000; Sovak, Bellas et al. 1997; Suh, Payvandi et al. 2002; Nair, Venkatram an et al. 2003; Abdel-Latif, 
O'Riordan et al. 2004; Kojima, Morisaki et al. 2004). NF-kB activation is strongly associated with signalling 
downstream  o f the EGF family of receptors (EGFR), in both aggressive EGFR-positive, ER-negative 
(Biswas, Cruz e t al. 2000) and ERBB2-positive, ER-negative breast cancer subtypes (Biswas, Shi et al. 
2004).
ERBB2 is over-expressed in approximately 20% of breast cancers (Paik, Hazan et al. 1990). 
These tum ours are a clinically aggressive subtype o f breast cancer resulting in poor prognosis and an 
increased incidence of metastases. Current therapy for ERBB2-positive breast cancer involves the use of 
receptor-targeted drugs such as the humanised monoclonal antibody, trastuzum ab (Herceptin), which, in 
com bination w ith chem otherapy, can delay disease progression in patients w ith metastatic disease 
(Slamon, Leyland-Jones et al. 2001; Viani, Afonso et al. 2007). However, owing to prevalent de novo and 
acquired resistance mechanisms, relapse is common (Cobleigh, Vogel et al. 1999; Vogel, Cobleigh et al. 
2002; reviewed in Nahta and Esteva 2006). Therefore, there is still a clinical need to identify new or 
synergistic therapeutic m olecular targets for ERBB2-positive breast cancer and to identify mechanisms 
for suppressing disease progression in this patient group with poor prognosis.
The potential for NF-kB as a new therapeutic target in these aggressive forms of breast cancer 
has been highlighted by a num ber o f studies in the literature (Helbig, Christopherson et al. 2003; 
Aggarwal, Shishodia e t al. 2005; Cao, Luo et al. 2007; Park, Zhang et al. 2007). For example, inhibition of 
NF-kB by genetic m odification of IKKa, a common upstream regulator o f NF-kB activity, resulted in 
reduced tum ourigenesis in an in vivo mouse model o f ERBB2-positive breast cancer (Cao, Luo et al. 
2007). Furtherm ore, numerous reports implicating NF-kB in the aetiology of metastasis in a variety of 
cancer cell types have been published (Rehman and Wang 2009; Fritz and Radziwill 2010; Gavert, Ben- 
Shmuel et al. 2010; Hernandez, Hsu et al. 2010; Yan, Xu et al. 2010; Li, Li e t al. 2009). In breast cancer, 
NF-kB regulates pro-m etastatic genes (Helbig, Christopherson et al. 2003; Park, Zhang et al. 2007), and it 
has also been shown to have a direct effect on metastasis in in vivo mouse models (Aggarwal, Shishodia 
et al. 2005; Aggarwal, Ichikawa et al. 2006; Park, Zhang et al. 2 0 0 7 ).
Although this has led to much interest in the use of NF-kB inhibitors to suppress tum our 
progression in cancer patients (reviewed in Haffner, Berlato et al. 2006; Shen and Tergaonkar 2009) 
there are significant risks associated w ith sustained global inhibition of NF-kB signalling, as this would 
have profound effects on normal tissues, particularly on cells o f the im m une system. An alternative
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strategy might therefore be to target modifying NF-kB co-factors, such as BCL3 that could potentially be 
more selective in their inhibitory actions.
BCL3 has previously been shown to be a proto-oncogene, originally identified on the basis of its 
high transcript expression in some patients with B-cell chronic lymphocytic leukaemia (Ohno, Takimoto 
et al. 1990). It has since been implicated in a number of other human malignancies including breast 
cancer (Cogswell, Guttridge et al. 2000; Thornburg, Pathmanathan et al. 2003; Mathas, Johrens et al. 
2005; M ishra, Bharti et al. 2006). Interestingly, results from chapter 3 dem onstrated that loss of BCL3 has 
no marked physiological effects on murine mammary gland developm ent or progression through the 
pregnancy cycle, even in the early stages of involution when it is highly expressed; suggesting that 
therapeutic modulation o f this NF-kB co-factor would not be detrim ental to  normal m am m ary tissues.
To date, no in vivo studies aimed at specifically assessing the effects of BCL3 modulation on 
ERBB2-driven tumourigenesis exist. In view of this, the overall aim of this chapter was to assess the 
potential role o f BCL3 in tw o  transgenic ERBB2-positive mouse models o f breast cancer. The effects of 
BCL3 deletion on both tum our initiation and progression will be characterised.
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4.2 Results
4.2.1 BCL3 deficiency significantly delays the onset of M M T V /N 2 but not M M TV/NK
mammary adenocarcinomas
In order to establish the effects of BCL3 deficiency in the context o f susceptibility to ERBB2- 
positive m am m ary tumours, BCL3-deficient mice (Schwarz, Krimpenfort e t al. 1997) were crossed with
mice over-expressing either the w ild-type (M M T V /N 2) (Guy, W ebster e t al. 1992) or the activated
(M M TV /N K )  (M uller, Sinn et al. 1988) rat Neu transgene to generate cohorts o f fem ale litterm ates of all 
genotype combinations. Mice were routinely taken through one pregnancy at 6-8  weeks of age to ensure 
high expression of the M M T V  prom oter. Cohorts were monitored for changes in m am m ary epithelial 
morphology and w ere inspected for the occurrence of palpable m am m ary tum ours twice weekly. 
Kaplan-M eier analysis was performed to determ ine tum our-free survival times.
Initially, the effect of BCL3 deficiency on the form ation o f M M T V /N K  adenocarcinomas was 
assessed. M ice from  all three cohorts developed multifocal solid adenocarcinomas involving the majority 
of the m am m ary gland that were histologically identical to each o ther (Figure 3.4B). Analysis o f tum our- 
free survival tim es showed that BCL3 deficiency had no significant effect on tum our latency in this mouse 
model (Figure 4.1A). Bcl3+h/M M T V /N K  and Bcl3+//M M T V /N K  mice acquired m am m ary tumours with  
mean onset ages (T50) o f 165 and 163 days, respectively, while B c U 1'/M M T V /N K  mice had a small but 
insignificantly reduced rate of tumourigenesis (T50=179 days, Kaplan-M eier analysis, Bcl3+/+/M M T V /N K  
vs Bcl3'h/M M T V /N K :  p=0.3453, x2=0.8905, DF=1). As expected, Bcl3'h mice lacking the M M T V /N K  
transgene did not acquire tumours.
It is well established that the activated NEU protein can act as an extrem ely potent oncogene in 
the m am m ary gland. However, no equivalent activating mutations in primary human ERBB2-positive 
breast cancer have been discovered (Lemoine, Staddon et al. 1990). It was therefore of interest to 
analyse BCL3 deficiency in the more clinically relevant, w ild-type Neu over-expressing, M M T V /N 2 model. 
Results show that BcI3'//M M T V /N 2 mice developed unifocal, solid adenocarcinomas that were 
histologically identical to those form ed in BcI3+/'/M M T V /N 2 and BcI3+/+/M M T V /N 2 mice (Figure 4.2B). 
However, unlike in the M M T V /N K  model, analysis of tum our-free survival times revealed that deletion of 
each Bcl3 allele caused incremental delays in the form ation of spontaneous tum ours (Figure 4.2A). Mice 
expressing both alleles of Bcl3 on the M M T V /N 2 background (BcI3+/+/M M T V /N 2) acquired mammary  
tum ours w ith a mean onset age (T50) o f 176 days. Deletion of a single Bcl3 allele (BcI3+/'M M T V /N 2) 
significantly reduced the rate of tumourigenesis to T50=214 days (Kaplan-M eier analysis, p=0.033, 
X2=4.53, DF=1), while deletion o f both alleles (Bcl3'hM M T V /N 2) further delayed the formation of 
neoplasias to T50=255 days (Kaplan-M eier analysis, p=0.0001, x2=15.22, DF=1).
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These data indicate that depletion of BCL3 is able to suppress tumourigenesis in the clinically 
relevant w ild-type Neu over-expressing (M M T V /N 2) model, whereas it has no effect on the latency of 
tum ours driven by the activated Neu (M M T V /N K ) transgene.
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Figure 4.1: Loss o f BCL3 has no effect on the latency or histology o f M M T V /N K  induced mammary  
adenocarcinomas
Mice from all cohorts were inspected twice weekly for the formation of mammary 
adenocarcinomas. No statistically significant differences were observed between any cohorts 
bearing the M M TV/N K  transgene (A, Kaplan-Meier analysis for all comparisons, p>0.05). H&E 
sections revealed that mice from all three cohorts developed solid adenocarcinomas that were 
histologically similar to each other (B). Scale bars: top row=500pm, bottom row=50pm.
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Figure 4.2: Loss o f BCL3 results in the delayed onset o f M M T V /N 2 m am m ary adenocarcinomas
Mice from all cohorts were inspected twice weekly for the formation of mammary 
adenocarcinomas. Deletion of each Bcl3 allele resulted in incremental delays in tumour formation 
(A, Kaplan-Meier analysis BcI3+/M M T V /N 2 vs BcI3+/+/M M T V /N 2, p=0.033 and Bci3'/'M M T V /N 1 vs 
BcI3+/+/M M T V /N 2, p=0.0001). H&E sections revealed that mice from all three cohorts developed 
solid adenocarcinomas that were histologically similar to each other (B). Scale bars: top 
row=500pm, bottom row=50pm .
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4 .2 .2  BCL3 defic iency does no t reduce NEU (ERBB2) or EGFR p ro te in  levels
In order to determine whether changes in tumour latency were due to alterations in transgene 
levels, western blots for NEU protein expression on tumours were performed. NEU (ERBB2) levels were 
unchanged or slightly higher in the BcI3','/M M TV/N 2  tumours (Figure 4.3), indicating that delays in 
tum our formation were not due to BCL3-dependent effects on the Neu transgene. Furthermore, EGFR 
protein expression also remained unchanged or slightly raised in the Bcl3'l'/M M T V /N 1 mice (Figure 4.3). 
Equal loading of protein between samples was confirmed by visualising levels of the housekeeping 
protein, Tubulin.
Figure 4.3: Loss o f BCL3 does not reduce NEU or EGFR protein levels
Protein from BcI3+/+/M M T V /N 2 and Bcl3','/M M T V /N 1 tumours was extracted and subjected 
to western analysis. NEU and EGFR protein expression was variable between tumours but 
loss of BCL3 did not correlate with a reduction in the levels of either of these proteins. 
Equal loading was confirmed by Tubulin.
BcI3+/7MMTV/N2 Bcl3‘/ ' /MMTV/N2
NEU (ERBB2)
Tubulin 50kda
185kda
175kda
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4.2.3 BCL3 depletion has no effect on tumour growth rates in M M T V /N 2 or M M TV/N K  mice
To directly assess the effects o f BCL3 deletion on the growth rates o f m ammary tumours in 
M M T V /N 2 and M M T V /N K  mice, tum ours w ere measured twice weekly as described in Materials and 
Methods. M ean primary tum our volumes within each cohort were plotted against tim e to generate 
growth curves representing the mean primary tum our growth rate. Graphs represent growth curves up 
to the point when the first animals within any cohort had to be culled because o f licensing tum our size 
restrictions.
In the M M T V /N K  mice, no significant differences in primary tum our growth rates were 
detected betw een genotypes at any tim e-point (Figure 4.4A). At 4 weeks a fter initial detection, primary 
tum ours from  Bc/37 /M M T V /N K  (n=13) mice reached a mean±SEM tum our volum e of 390±133 m m 3, 
while tum ours from  Bcl3+/'/M M T V /N K  (n=10) and Bcl3+/+/M M T V /N K  (n=8) mice reached mean±SEM  
volumes o f 398±159m m 3 and 347±110m m 3 respectively (M ann-W hitney U-test for all comparisons, 
p>0.05).
Despite the striking effect on tum our latency in the M M T V /N 2 mice, BCL3 deficiency did not 
significantly reduce primary tum our growth rates in this model (Figure 4.4B). However, a clear trend was 
observed, and the lack o f significance was due to large biological variation. At 6 weeks after initial 
detection, prim ary tum ours from  Bcl3'/'/M M T V /N 2 (n=20) mice reached a mean±SEM volume of 
266±100m m 3, while tum ours from  Bcl3+/'/M M T V /N 2 (n=21) and Bcl3+/+/M M T V /N 2 (n=16) mice reached 
mean±SEM volumes o f 479±110m m 3 and 454±116m m 3, respectively (M ann-W hitney U-test for all 
comparisons, p>0.05).
Taken together w ith  previous results, these data suggest that BCL3 deficiency primarily affects 
tum our initiation rather than growth rates of established lesions.
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Figure 4.4: Loss o f BCL3 has no effect on the growth rates o f M M TV/N2 or MMTV/NK  
mammary adenocarcinomas
Tum our growth was assessed by measuring tumours twice weekly. No significant differences 
in tum our volum e w ere observed between cohorts carrying the M M T V /N K  (A) or M M T V /N 2 
(B) transgene at any tim e point (M ann-W hitney U-test for all comparisons, p>0.05). Error 
bars represent ± SEM.
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4.2.4 BCL3 deficiency does not reduce tumour burden in M M T V /N 2 or M M TV/N K  mice
At dissection (perform ed when primary tumours reached a size of 500±13 .5m m 3) all mammary  
glands from  all experim ental and control mice were carefully inspected macroscopically for the presence 
of tum ours, and the mean num ber of tum ours per mouse was calculated. Tumours were defined as any 
lesion greater than 13.5m m 3.
As expected, the tum our burden of mice expressing the M M T V /N K  transgene was higher than 
those expressing the M M T V /N 2 transgene (Figure 4.5A compared to Figure 4.5C). In the M M TV /N K  
model, no significant differences in tum our burden were identified between cohorts (Figure 4.5A, 
m eaniSEM  num ber of tum ours per animal was 3.5±0.6 for Bcl3+/+/M M T V /N K  animals (n=12), 4 .6±1.3 for 
Bcl3+/'/M M T V /N K  animals (n=5), and 4.5±2.5  for BC13'1'/M M T V /N K  animals (n=8); M ann-W hitney U-test 
for all comparison, p>0.05). BCL3 deficiency also did not result in a reduction in the percentage of mice 
with unifocal tum ours (Figure 4.5B, percentage of mice w ith unifocal tum ours was 12.5% for 
Bcl3+/V M M T V /N K  animals [n=12], 20% for Bcl3+//M M T V /N K  animals [n=5], and 21.43% for Bcl3'h 
/M M T V /N K  animals [n=8]).
Similarly, despite the previously observed effect on primary tum our initiation in the M M T V /N 2 
mice, BCL3 deficiency had no significant effect on overall tum our burden in this model (Figure 4.5C, 
m eaniSEM  num ber of tum ours per animal was 2 .2±0.65 for Bcl3*/+/M M T V /N 2 animals [n=5], 1.8±0.37  
for Bcl3+//M M T V /N 2 animals [n=13], and 1.78±0.24 for Bcl3'/'/M M T V /N 2 animals [n=9]; Mann-W hitney  
U-test for all comparisons, p>0.05). As expected, the percentage o f mice with unifocal tumours was 
higher in the /W/W7V//V2-expressing animals than those expressing the M M T V /N K  transgene (Figure 4.5D  
compared w ith Figure 4.5B). However, BCL3 deficiency did not affect this, w ith Bcl3+/+/M M T V /N 2 animals 
having 40% unifocal tum ours and Bcl3+/'/M M T V /N 2 and Bcl3'/'/M M T V /N 2 having 53.8% and 33.33%, 
respectively (Figure 4.5D).
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Figure 4 .5: BCL3 deficiency has no effect on the tum our burden o f M M T V /N K  or M M T V /N 2 mice
The average number of tumours per mouse at sacrifice was assessed. BCL3 deficiency had no 
effect on the overall tum our burden in either the M M TV/N K  (A) or M M T V /N 2 (C) mice (Mann- 
W hitney U-test for all comparisons, p>0.05). M M T V /N 2 mice had a higher proportion of unifocal 
tumours than M M T V /N K  mice (B vs D). BCL3 deficiency had no clear effects on the percentage of 
animals with unifocal tumours in either the M M TV/N K  (B) or M M T V /N 2 (D) models. Error bars 
represent ± SEM.
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4.2.5 Proliferation and apoptosis in M M TV /N Z tumours is unaffected by BCL3 deficiency
To analyse proliferation and apoptosis rates at the cellular level, primary tumours, dissected at 
a size of approximately 500 m m 3, from six BcI3+/* /M M T V /N 2 and six BcI3'/'/M M T V /N 2 mice were analysed 
by immunohistochemistry (IHC). Proliferating cells at any active phase of the cell cycle (G l, S, G2 or M) 
were visualised by performing anti-Ki67 IHC. This revealed that, similarly to the BcI3+i+/M M T V /N 2 
controls, BcI3'/'/M M T V /N 2 tumours had a high proportion o f proliferating cells that were distributed 
evenly across the tum our (Figure 4.6A). To quantify this, the num ber of Ki67-positive cells per 1000 cells 
(across three fields of view) was scored to calculate the percentage positivity. In BcI3'/'/M M T V /N 2 
tum ours (n=6), the m eaniSEM  percentage of Ki67-positive cells was found to be 55.5±6.7% , and in the 
BcI3*/+/M M T V /N 2 control mice (n=6) it was 62.6±5.7%  (Figure 4.6A). This observed decrease in positively 
stained cells in BcI3'/'/M M T V /N 2 tumours compared to BcI3+/+/M M T V /N 2 tum ours was not significantly 
different (M ann-W hitney U-test, p>0.05), indicating that BCL3 deficiency does not reduce the number of 
proliferative cells in M M T V /N 2 tumours. To further confirm this, mRNA expression of Cyclin D l,  a 
principle NF-kB target gene that is essential for m am m ary epithelial cell growth (Cao, Bonizzi et al. 2001), 
was analysed in tum ours from BcI3+/+/M M T V /N 2 (n=6) and BcI3'/'/M M T V /N 2 (n=6) animals (Figure 4.6B). 
Any changes in Cyclin D l  mRNA expression between cohorts was found to be statistically insignificant 
(M ann-W hitney U-test, p>0.05), reflecting the large biological variation between samples.
In order to establish w hether BCL3 deficiency had an effect on apoptosis rates, anti-Cleaved 
Caspase 3 (CC3) IHC was perform ed, and results were quantified by counting the number of CC3-positive 
cells per field o f view. Levels o f apoptosis in tumours from  both cohorts were very low. No significant 
differences (M ann-W hitney U-test, p>0.05) in CC3-positive cells were observed (Figure 4.6C, m eaniSEM  
num ber o f CC3-positive cells per field o f view was 13.8±5.18  for BcI3+/+/M M T V /N 2 mice [n=6] and
13.612.7 for Bcl3'h/M M T V /N 2 mice [n=6]).
Taken together, these data indicate that BCL3 deficiency does not affect proliferation or 
apoptosis rates in M M T V /N 2-d riven m am m ary tumours.
116
Chapter 4: Results
B
Bcl3+/*
MMTV/Nj
Bcl3/-
MMTV/N2
Ki67
100  -  
90 - 
80 - 
70 - 
60 - 
50 
40 - 
30 H 
20 - 
10 -  
0
Bcl3+/* Bcl3-'-
MMTV/N2 m m t v / n2
1.4
§ 12
g 0.8 
oeI 0.6
|  0.4  
ce
0.2
0
Bcl3+/+ Bcl3-/‘
MMTV/N2 m m t v / n 2
Cleaved Caspase 3
Bcl3+/+
MMTV/N2
Bel 3-/ 
MM7V/N2
V  :• r V T
100
90
80
70
60
50
40
30
20
10
0
M M TV/Nj M M TV/N,
Figure 4.6: Proliferation and apoptosis is unaffected by BCL3 deficiency in M M T V /N 2 tumours
Sections from BcI3+/+/M M T V /N 2 and Bcl3'l'/M M T V /N 1 tumours were generated and subjected to IHC 
analysis to assess levels of proliferation and apoptosis. No significant differences were observed in 
either Ki67 (A) or Cleaved Caspase-3 (C) staining (Mann-W hitney U-test for all comparisons, p>0.05). 
mRNA expression of Cyclin D l  in the same cohorts was also assessed and revealed no significant 
differences (B, M ann-W hitney U-test, p>0.05). Scale bars indicate 100pm. Error bars represent ± 
SEM.
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4.2.6 BCI3'1'/M M T V /N 2 mice develop pre-neoplastic hyperplasias that are histologically
comparable to those formed in BcI3+/* /M M T V /N 2 mice
M M TV-induced m am m ary carcinomas are often preceded by alterations in pre-neoplastic 
tissue such as hyperplastic epithelial ducts (Cardiff 1984). Furthermore, selective suppression of the  
alternative NF-kB pathway by genetic deletion of IKKa in mouse m am m ary glands was shown to result in 
the delayed onset and growth o f ERBB2-positive tumours, which was in part due to inhibition of pre­
neoplastic hyperplasias (Cao, Luo et al. 2007). In order to establish w hether the delay in tum our 
form ation observed in the M M T V /N 2 mouse model was due to BCL3-dependent differences in pre­
neoplastic tissue, m am m ary glands from  150-day-old nulliparous M M T V /N 2 mice w ithout detectable 
tum ours w ere  analysed for alterations in m am m ary epithelial morphology.
W holem ount analysis and H8iE-stained sections showed that, compared with oncogene-devoid 
wild-type FVB mice, both BcI3'/'/M M T V /N 2 and BcI3+/* /M M T V /N 2 m am m ary glands exhibited pronounced 
epithelial hyperplasias w ith marked increases in alveolar numbers (Figure 4.7). However, there were no 
observable differences in pre-neoplastic epithelial cell morphology between the tw o M M T V /N 2- 
expressing cohorts. In order to analyse proliferation rates at the cellular level, anti-Ki67 IHC was 
perform ed on pre-neoplastic tissues from  BcI3'/'/M M T V /N 2 and BcI3+i+/M M T V /N 2 mice. Ki67-positive 
cells w ere observed in hyperplastic ducts in tissues from both cohorts (Figure 4.8A). This was quantified 
by scoring the percentage o f Ki67-positive cells within the luminal and myoepithelial compartment. 
Results showed that BCL3 deficiency had no effect on the percentage o f Ki67-positive cells within pre­
neoplastic M M T V /N 2 hyperplasias (Figure 4.8A, m eaniSEM  percentage o f Ki67-positive cells was 
14.4±2.4  for BcI3+/+/M M T V /N 2 mice (n=6) and 17.2±4.5 for BcI3'/'/M M T V /N 2 mice (n=6); M ann-W hitney  
U-test, p>0.05).
To further confirm  that BCL3 did not affect pre-neoplastic cellular proliferation, QRT-PCR 
analysis of Cyclin D l  mRNA expression was performed on cDNA generated from  pre-neoplastic tissues 
(Figure 4.8B). Surprisingly, the results showed that Cyclin D l  mRNA expression was approximately 2.5- 
fold higher in BcI3'/' /M M T V /N 2 tissues than in BcI3+/+/M M T V /N 2 controls. However, this change was 
found to be statistically insignificant (M ann-W hitney U-test, p>0.05).
These data indicate that the BCL3-mediated delay in tum our latency is not due to reduced 
proliferation and delayed form ation o f hyperplastic ducts in pre-neoplastic tissues.
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Figure 4 .7: Loss o f  BCL3 does not affect the form ation o f  pre-neoplastic hyperplasias
Wholemounts and H&E sections from pre-neoplastic tissues of FVB/WT, BcI3+,+/M M T V /N 2 and 
BcI3'/'/M M T V /N 2 animals (n>3) were analysed. BcI3*/+/M M T V /N 2 (middle row) and Bcl3h/M M T V /N 2 
(bottom row) tissues exhibited pronounced hyperplasias in comparison to FVB/WT (top row) glands 
(hyperplasias are highlighted by red arrows in BcI3+/+/M M T V /N 2 and BcI3'/'/M M T V /N 2 H&E sections 
whereas a normal epithelial duct is highlighted by a black arrow in the FVB/WT H&E section). Loss of 
BCL3 did not affect the formation of hyperplasias in M M T V /N 2 expressing glands (middle row vs 
bottom row). Scale bars on H&E sections: middle panel=500pm, right panel=100pm. Representative 
images are shown.
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Figure 4.8: Loss o f BCL3 does not affect the proliferation o f pre-neoplastic tissues
Pre-neoplastic tissues from BcI3*/+/M M T V /N 2 and BcI3'/'/M M T V /N 2 animals were subjected to anti- 
Ki67 IHC. No differences in the percentage of Ki67 positive cells were observed (A, Mann-Whitney U- 
test, p=0.05). QRT-PCR analysis in the same cohorts revealed no significant differences in Cyclin D l 
mRNA expression (B, M ann-W hitney U-test, p>0.05). Scale bars indicate 50pm. Error bars represent ± 
SEM.
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4.2.7 BCL3 deficiency has no effect on NF-kB p50 and p52 protein levels
One o f the m ajor functions of BCL3 is to act as a co-activator o f transcriptionally inactive p50 
and p52 NF-kB homodimers (see Chapter 1: General Introduction, section 1.4.4.1). It has also been 
shown to act as a chaperone to shuttle p50 and p52 homodimers to and from  the nucleus (Zhang, 
Didonato et al. 1994). In order to determ ine whether BCL3 alters nuclear or cytoplasmic p50 or p52 
protein levels in the M M T V /N 2 model, western blot analysis was perform ed on BcI3+/+/M M T V /N 2 and 
BcI3'/'/M M T V /N 2 adenocarcinomas.
Tumours (at approximately 500 m m 3) were dissected, and both nuclear and cytoplasmic 
protein fractions were prepared for western blot analysis. Three separate tum ours from each genotype 
were analysed. Beta-Actin and Lamin A/C were used as cytoplasmic and nuclear loading controls, 
respectively.
Firstly the cytoplasmic fraction was analysed. These samples were shown to be completely free 
of nuclear contam ination as dem onstrated by the lack of Lamin A/C (Figure 4.9A, Lamin A/C lane). 
W estern analysis directed against p50 and p52 revealed that, although there was variable protein 
expression w ithin each genotype, no consistent BCL3-dependent loss or gain o f these NF-kB subunits was 
observed in the cytoplasmic fraction. In order to semi-quantify this visual observation, the band intensity 
of each sample was measured and normalised to the corresponding Beta-Actin band intensity and an 
average normalised intensity was taken for each genotype. These results confirmed that BCL3 did not 
significantly affect p52 (Figure 4.9B) or p50 (Figure 4.9C) cytoplasmic protein expression (m eaniSEM  
cytoplasmic p52 band intensity was 1.1510.28 for BcI3+/+/M M T V /N 2 tum ours and 0.9910.407 for Bc/37' 
/M M T V /N 2 tum ours, M ann-W hitney U-test, p>0.05. M ean iSE M  cytoplasmic p50 band intensity was 
1.3510.415 fo r BcI3+/+/M M T V /N 2 tum ours and 0.9810.12 for BcI3'/ '/M M T V /N 2 tumours, M ann-W hitney  
U-test, p>0.05).
The nuclear fraction was then analysed. Although these samples were clearly enriched in 
nuclear protein as dem onstrated by the expression of Lamin A/C, the crude nature of this extraction 
resulted in a high degree o f cytoplasimc contam ination, as indicated by the protein expression of Beta- 
Actin in these samples (Figure 4.9A). However, taking into account the fact that BCL3 did not affect the 
protein expression o f p50 or p52 in the cytoplasmic fraction, it was concluded that any changes observed 
in these samples was likely to have occurred in the nuclear fraction. No obvious visual BCL3-dependent 
changes in p50 or p52 were observed in the nuclear fraction (Figure 4.9A). However, Lamin A/C protein 
expression showed that nuclear loading was not even. Therefore, in order to take this into account and 
to sem i-quantify the results, the band intensity o f each sample was normalised to the average band 
intensity o f the corresponding tw o Lamin A/C bands and an average for each genotype was taken. This 
confirmed visual observations and showed that BCL3 did not significantly alter the expression o f p52
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(Figure 4.9D) or p50 (Figure 4.9E) in the nuclear fraction (m eaniSEM  nuclear p52 band intensity was 
1.1210.29 for BcI3+/+/M M T V /N 2 tum ours and 0.9110.15 for BcI3'/'/M M T V /N 2 tumours, M ann-W hitney U- 
test, p>0.05. M ean iSE M  nuclear p50 band intensity was 0.418+0.09 for BcI3*/+/M M T V /N 2 tumours and 
0.3410.06  for BcI3'/~ /M M T V /N 2 tum ours, M ann-W hitney U-test, p>0.05).
A clear lim itation in these results is that only a sem i-quantitative analysis could be employed 
and that the nuclear fraction was not clear o f cytoplasmic contam ination. However, it can be cautiously 
concluded tha t depletion of BCL3 does not directly affect cytoplasmic or nuclear levels of p50 or p52 
within tum ours.
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Figure 4.9: Loss o f BCL3 does not affect the expression o f p50 or p52 in the nuclear or cytoplasmic 
fractions o f M M T V /N 2 tumours
Nuclear and cytoplasmic protein fractions were extracted from three BcI3+/+/M M T V /N 2 and three Bcl3' 
/'/M M T V /N 2 tumours and subjected to western analysis (A). Average p50 and p52 protein expression 
was normalised to Beta-Actin (cytoplasmic fraction, B&C) or Lamin A/C (nuclear fraction, D&E). No 
significant differences in p52 or p50 protein expression was observed in either the nuclear or 
cytoplasmic fractions (M ann-W hitney U-test for all comparisons, p>0.05). Error bars represent ± SEM 
across the three samples from each genotype.
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4.2.8 BCL3 deficiency reduces the size and occurrence of lung metastases in ERBB2-driven
tumours
The role of NF-kB in the metastatic progression of ERBB2 tum ours in vivo has not been 
previously reported, yet there is a body of both in vitro and in vivo evidence that suggests that NF-kB 
signalling might contribute directly to this process (Helbig, Christopherson et al. 2003; Aggarwal, 
Shishodia e t al. 2005; Park, Zhang et al. 2007; Connelly, Barham et al. 2010). It has previously been 
shown that M M T V /N 2 and, to a lesser extent, M M T V /N K  mice develop metastases to the lungs (Muller, 
Sinn et al. 1988; Guy, W ebster et al. 1992). To establish w hether BCL3 has an effect on the invasion of 
ERBB2-driven tum ours to secondary sites, experimental and control mice on both M M T V /N 2 and 
M M T V /N K  backgrounds w ere examined for the presence of lung metastases. M ice were dissected when 
primary tum ours reached a size o f approximately 4000m m 3 and lungs were removed and visualised 
macroscopically before being fixed for subsequent H&E staining and analysis.
In the  M M T V /N 2 model, BCL3 deficiency reduced not only the percentage of mice with 
metastatic lung lesions, but also the tum our mass in those lungs that exhibited metastases (Figure 
4.10A&C). Only 50% of BcI3'/'/M M T V /N 2 (n=8) mice had developed lung lesions at the experimental end­
point com pared w ith  82% of the BcI3+/+/M M T V /N 2 (n = l l )  mice (Figure 4.10A). Interestingly, 100% of 
BcI3*i ' /M M T V /N 2 (n=8) mice presented w ith lung lesions (n=8), indicating that Bcl3 heterozygosity was 
not sufficient to delay the m etastatic progression. M easurem ent o f lung lesions revealed that complete 
loss of BCL3 resulted in a significant decrease in the area o f lung metastases present (Figure 4.10C, 
m eaniSEM  area o f lung lesions, was 195077162344pm 2 for Bc!3*h/M M T V /N 2 animals, 
135067136772pm 2 for BcI3+/'M M T V /N 2 animals, and 48555110083pm 2 for BcI3'/'/M M T V /N 2 animals; 
M an n -W h itn ey  U-test BcI3+/+/M M T V /N 2 vs BcI3~/'/M M T V /N 2 p=0.0051). Although BCL3 depletion 
reduced the size o f lung lesions and the percentage of mice w ith them , it had no effect on the mean 
num ber of lung lesions developed per metastases-positive mouse (Figure 4.10B, M ann-W hitney U-test 
for all comparisons, p>0.05). H&E-stained sections of lung lesions revealed that, as previously described 
(Guy, W ebster e t al. 1992), the cellular morphology o f lung metastases present in BcI3+/+/M M T V /N 2 mice 
was identical to the prim ary tum our (Figure 4.11). This was also true of lesions arising in Bci3+/~ 
/M M T V /N 2 and BcI3'/ '/M M T V /N 2 mice, and no histological differences were observed between 
genotypes (Figure 4 .11).
The frequency and size o f metastatic lung lesions in the M M T V /N K  model was also assessed. At 
the outset o f this analysis, it should be noted that some cohort numbers for this experiment were low 
(Bcl3+/+/M M T V /N K , n=10; Bcl3+/'/M M T V /N K , n=5; Bcl3'h/M M T V /N K , n=5). Complete loss of BCL3 resulted 
in a 20% reduction in the num ber o f animals w ith evidence o f lung metastases (Figure 4.12A, 60% 
Bcl3+/+/M M T V /N K  metastases-positive animals in comparison with 40% Bcl3'h/M M T V /N K  metastases-
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positive animals). As observed in the M M T V /N 2 model, 100% of Bcl3+/'/M M T V /N K  mice developed 
metastatic lung lesions, again suggesting that Bcl3 heterozygosity has no effect on the onset of 
metastatic lesions. Unlike in the M M T V /N 2 model, BCL3 deficiency did not result in a reduction in the 
area of lung metastases present (Figure 4.12C, m eaniSEM  area of lung lesions was 6823618277pm 2 for 
Bc!3*h/M M T V /N K  animals, 174269160695pm 2 for B c t f ' /M  M T V /N  K ari\ma\s and 1941941169210pm 2 for 
Bc/37 /M M T V /N K ;  M an n -W h itn ey  U-test for all comparisons p>0.05). However, a decrease in the mean 
num ber o f lung lesions present per metastases-positive mouse was observed (Figure 4.12B, from
13.818.7 in the Bcl3+,+/M M T V /N K  controls to 8.0±2.82 and 2.011.4 in the Bcl3+//M M T V /N K  and Bc/37' 
/M M T V /N K  animals, respectively). This was found to be insignificant because of very small cohort sizes 
(Figure 4.12B, M an n -W h itn ey  U-test for all comparisons, p>0.05). All lung metastases were histologically 
identical to  the prim ary tum ours from  which they originated, and, similarly to the M M T V /N 2 model, no 
morphological differences w ere  observed between cohorts (Figure 4.13).
Overall, these data indicate that BCL3 delays the metastatic progression o f mammary tumours 
driven by the M M T V /N 2 transgene. However, in the M M T V /N K  model, BCL3-deficiency is unable to 
suppress the pro-m etastatic effects o f the highly aggressive, activated NEU protein.
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Figure 4.10: BCL3 deficiency reduces the size and occurrence o f lung metastases
The percentage of mice harbouring lung metastases was reduced from 82% in BcI3*/* /M M T V /N 2 
mice (n = l l )  to only 50% in B c& ’ /M M T V /N -, mice (n=8). 100% Bcl3+/'/M M T V /N 2 (n=8) mice 
exhibited lung metastases (A). The number of lung metastases per metastases positive mouse was 
unaffected by the absence of BCL3 (B, M ann-W hitney U-test, p>0.05). The average area of 
metastases in B c l3 '/M M T V /N 2 mice was significantly smaller than in BcI3+/+/M M T V /N 2 mice (C, 
**M an n -W h itn ey  U-test, p=0.0051). Error bars represent ± SEM.
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Figure 4 .11: BCL3 deficiency does no t a lte r  the gross histology o f  M M T V /N 2 driven lung 
m etastases
H&E stained lung sections from  BcI3+i +/M M T V /N 2, Bcl3+I/M M T V /N 2 and Bcl37 /M M T V /N 2 mice 
were analysed for histological changes. M ice from all three cohorts developed lung metastases that 
were histologically identical to the primary tum ours from which they arose (middle panel vs right 
panel). No histological differences were observed in lung metastases between cohorts (middle 
panel). However, loss o f BCL3 did result in an overall reduction in the size of lung metastases (left 
panel). Scale bars: Left panel=500pm , right and middle panels=50pm.
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Figure 4 .12: BCL3 deficiency does not significantly reduce the size or num ber o f M M T V /N K  driven 
lung metastases
The percentage of animals harbouring lung metastases was reduced from 60% in Bcl3+/*/M M TV/N K  
mice (n=10) to 40% in Bcl3h/M M T V /N K  mice (n=5). 100% of Bcl3+//M M T V /N K  mice (n=5) exhibited 
lung metastases (A). Loss BCL3 resulted in an insignificant decrease in the average number of lung 
lesions per metastases positive mouse (B, M ann-W hitney U-test, p>0.05). No significant differences 
were observed in the average area of metastases (C, Mann-W hitney U-test, p>0.05). Error bars 
represent ± SEM.
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Figure 4 .13: BCL3 deficiency does not affect the gross histology o f M M T V /N K  driven lung 
metastases
H&E stained lung sections from Bcl3+/+/M M T V /N K , Bcl3+//M M T V /N K  and Bcl3h/M M T V /N K  mice 
were analysed for histological changes. Mice from all three cohorts developed lung metastases that 
were histologically identical to the primary tumours from which they arose (middle panel vs right 
panel). No histological differences were observed in lung metastases between cohorts (middle 
panel). Scale bars: Left panel=500pm, right and middle panels=50pm.
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4.2.9 BCL3 deficiency has a small but significant effect on the proliferation and apoptosis of
M M T V /N i metastatic lesions
The reduced size and occurrence of metastatic lesions within the lungs of BcI3'/'/M M T V /N 2 
mice suggested that BCL3 deficiency was able to delay the metastatic progression of ERBB2 tumours. 
This delayed progression could have been due either to later dissemination and seeding of primary 
tum our cells at secondary sites, or reduced tum our growth kinetics of the metastatic lesions. In order to 
determ ine w hether the latter hypothesis could explain the observed phenotype, anti-Ki67 and anti-CC3 
IHC was perform ed on 6 BcI3*/* /M M T V /N 2 and 6 BcI3~i '/M M T V /N 2 lung sections to visualise the  
proliferative and apoptotic nature of these secondary tumours. Ki67 staining revealed that there was a 
high proportion of actively proliferating cells distributed evenly across metastatic lesions in sections from  
both cohorts of mice (Figure 4.14A). Quantitative analysis of Ki67 staining (calculated as in section 4.2.5) 
showed a small but significant decrease in the percentage of Ki67-positive cells from 52.414.12%  in the 
BcI3+/+/M M T V /N 2 controls to 37.95±4.19%  in the BcI3'/'/M M T V /N 2 animals (Figure 4.14A, M ann-W hitney  
U-test, p=0.0294). IHC directed against CC3 revealed very low levels o f apoptosis within the secondary 
lesions o f all mice. Q uantitative analysis o f this staining (calculated as in section 4.2.5) showed that loss 
of BCL3 resulted in a significant increase in the percentage o f CC3-positive cells present (Figure 4.14B, % 
CC3-positive cells ± SEM were: 0 .3567±0.11  for BcI3 ^ /M M T V /N 2 mice and 0.929±0.239 for Bd3'h 
/M M T V /N 2, M ann W hitney-U -test, p=0.0225).
These data show that loss of BCL3 results in a small but significant reduction in the 
proliferation, and an increase in the apoptosis of cells seeded at secondary sites, indicating that the  
reduced size o f m etastatic lesions could be due BCL3 dependent effects on tum our growth kinetics.
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Figure 4 .14: Loss o f BCL3 reduces the rates o f proliferation and apoptosis in M M T V /N 2 metastatic 
lesions
Sections from BcI3+/+/M M T V /N 2 and BcI3 / /M M T V /N 2 lung lesions (n=6) were subjected to Ki67 and 
CC3 IHC. Depletion of BCL3 resulted in a significant decrease in the percentage of Ki67-positive cells 
(A, * = Mann-W hitney U-test, p=0.0294) and a significant increase in the percentage of CC3 positive 
cells (B, * = M ann-W hitney U-test, p=0.0255, CC3 positive cells highlighted by black arrows). Scale bar 
indicates 50pm . Error bars represent ± SEM.
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4.3 Discussion
A num ber of previous studies have observed the activation of NF-kB in both mammary 
carcinoma cell lines and prim ary breast cancer samples of both human and rodent origin (Dejardin, 
Bonizzi et al. 1995; Nakshatri, Bhat-Nakshatri et al. 1997; Sovak, Bellas et al. 1997; Cogswell, Guttridge et 
al. 2000). This has been found to be predom inantly associated with EGFR-family signalling (Biswas, Cruz 
et al. 2000; Biswas, Shi e t al. 2004), indicating that NF-kB may have a primary function in this subtype of 
breast cancer. To date, however, only a few  studies into the potential role o f BCL3 in breast cancer exist 
(Cogswell, Guttridge et al. 2000; Pratt, Bishop et al. 2003; Choi, Lee et al. 2010), and none have focused 
specifically on the effects of this NF-kB co-factor in ERBB2-positive m ammary carcinogenesis.
W ith  this in mind, the aim o f this chapter was to analyse the effect o f BCL3 depletion on the 
initiation and progression o f m am m ary carcinomas in tw o ERBB2-driven murine models o f breast cancer. 
It was hypothesised that depletion of BCL3 in this aggressive subtype of the disease may modulate NF-kB 
activity in such a way as to selectively reduce mammary tumourigenesis w ithout causing the detrim ental 
side effects on m am m ary tissues that global inhibition of NF-kB has previously been shown to incur (Cao, 
Bonizzi e t al. 2001; Baxter, Came et al. 2006). The key findings from  this chapter were that loss of BCL3 
resulted in a profound delay in both the initiation and progression of M M T V /N 2 tumours.
4.3.1 BCL3 promotes the initiation of M M TV /N 2 tumours
Data presented here dem onstrate that deletion o f either one or both Bcl3 alleles from  
M M T V /N 2 mice dram atically delays the onset o f ERBB2-driven murine m am m ary tumours (Figure 4.2). 
Similar results have been observed previously, following the selective suppression of the non-canonical 
NF-kB pathway by genetic deletion o f IKKa in a comparable model o f m am m ary tumourigenesis (Cao, 
Luo et al. 2007). In this case, delayed tum our initiation, tum our growth and pre-neoplastic cellular 
proliferation w ere observed and attributed to suppressed Cyclin D l  expression in the absence of IKKa. 
M ore recently, Connelly e t al. (2010) also dem onstrated a CYCLIN D l-dependent delay in tum our 
form ation and growth a fter conditional global inhibition of NF-kB signalling in the PyVT murine model of 
breast cancer. A similar mechanism, however, was not shown to be responsible for the BCL3-dependent 
delays in tum our initiation observed in the present study, as Cyclin D l  expression in both pre-neoplastic 
tissues and tum ours was found to be unaltered in the absence of BCL3, and, furtherm ore, no effect on 
tum our growth (Figure 4 .4  &  4 .6) or pre-neoplastic cellular proliferation (Figure 4.8) was observed. 
Interestingly, in the less clinically relevant M M T V /N K  model, tum our initiation was unaffected by BCL3 
depletion (Figure 4 .1). It is possible that the highly aggressive nature of the product of the activated Neu 
transgene may act to override any inhibitory effects that loss of BCL3 could incur. Alternatively, BCL3 
inhibition may delay the kinase activation o f the wild-type M M T V /N 2 transgene resulting in prolonged 
tum our latency in this m odel w ithout having an effect on the latency of tumours driven by the already
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kinase active M M T V /N K  transgene (see Chapter 7: General Discussion, section 7.3.1, for further 
discussion on this).
4.3.2 BCL3 promotes the metastatic progression of M M TV /N 2 tumours
M orta lity  in breast cancer is generally attributed to organ-specific metastasis rather than to the 
primary tum our. Therefore, one of the most interesting observations from this chapter was that BCL3- 
deficient M M T V /N 2 tum ours exhibited an impaired capacity to metastasize to the lungs (Figure 4.10). 
Both the percentage of mice w ith lung lesions and the average tum our mass in those lungs that did 
exhibit metastases w ere reduced in Bcl3'/m,/M M T V /N 2 mice. A similar result was not observed in the 
M M T V /N K  model (Figure 4 .12) which again may suggest that the potent oncogenic signal from the 
activated Neu  transgene overrides any BCL3-mediated effects.
NF-xB-dependent changes in the metastatic potential of tum ours driven by the PyVT oncogene 
have previously been observed (Connelly, Barham et al. 2010). However, a significant decrease in 
primary tum our burden was also detected in this model, and therefore w hether the putative NF-xB- 
m ediated effects w ere  directly on metastases or as a result o f reduced seeding from smaller primary 
tum ours rem ained undeterm ined. Im portantly, in the present study, loss o f BCL3 resulted in no changes 
in overall tum our burden (Figure 4 .5), and so it is highly unlikely that the observed reduction in lung 
metastases stems from  anything but a direct BCL3-dependent metastatic phenotype.
A significant reduction in proliferation and increase in apoptosis, as measured by Ki67 and CC3 
IHC, w ere observed in the m etastatic lesions that form ed in BcI3'/ '/M M T V /N 2 mice (Figure 4.14) in 
comparison to controls. On first consideration, this would suggest that loss of BCL3 reduces the capacity 
of cells to survive and proliferate at secondary sites. However, it must be noted that, because loss of 
BCL3 delayed the m etastatic progression of M M T V /N 2 tumours, all o f the BcI3'//M M T V /N 2 lung lesions 
analysed w ere consistently smaller in size than controls. Therefore, the observed changes in growth 
kinetics could simply be due to  the fact that smaller metastases at an earlier stage of seeding proliferate 
more slowly than well-established ones, regardless o f BCL3 status. This hypothesis is somewhat 
supported by results from  earlier experiments demonstrating that loss of BCL3 had no effect on the 
proliferation or apoptosis rates o f comparably sized primary tum ours (Figure 4.6). Therefore, whether 
this result reflects a genuine BCL3-mediated change in the growth kinetics of M M T V /N 2 lung metastases, 
or w hether it is an experim ental artefact remains unknown. Either way, the effect of BCL3 on the 
m etastatic potential o f M M T V /N 2 tum ours is likely to extend further than simply affecting established 
secondary tum our grow th. This is evident in the fact that a much higher percentage of B c & '/M M T V /N 2 
mice displayed absolutely no evidence o f lung metastases than controls, suggesting that there must be 
an additional anti-m etastatic effect at an earlier stage of the process. This hypothesis will be explored 
further in the next chapter.
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4.3.3 Summary
In summary, work from  this chapter has demonstrated for the first tim e that the NF-kB co­
factor, BCL3, can have a profound effect on the initiation and metastatic progression of ERBB2-driven 
murine m am m ary tum ours. Taken together w ith data from chapter 3 showing that loss of BCL3 has no 
detrim ental effects on normal m am m ary tissues, these results indicate that BCL3 may represent an 
attractive new therapeutic target for this subtype of human breast cancer. Mechanisms involved in 
driving this BCL3-mediated oncogenic effect will be investigated further in chapter 5.
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Chapter 5: Introduction
5.1 Introduction
W ork in chapter 4 dem onstrated that BCL3 deficiency delayed both the onset and progression 
of m am m ary carcinogenesis in a clinically relevant ERBB2-driven transgenic mouse model. This is the first 
tim e that BCL3 has been shown to have such an effect, although the NF-kB family of transcription factors 
have previously been implicated in this subtype o f the disease.
Breast cancer developm ent and progression is a multi-step process that involves primary 
tum our growth and local tissue invasion followed by dissemination and re-establishment at secondary 
sites. M ultip le  mechanisms, including individual cell autonomous alterations or more global changes in 
the tum our m icroenvironm ent, and large cell populations can influence this process. In order to further 
evaluate the potential o f BCL3 as a new therapeutic target, it will be essential to elucidate the molecular 
mechanisms by which it exerts pro-oncogenic effects on breast cancer cells.
NF-kB has previously been implicated in a num ber o f processes that contribute to mammary 
tumourigenesis. Firstly, it has been shown to directly regulate the transcription of cancer-related genes 
associated w ith  proliferation, angiogenesis, metastases, inflam mation and apoptosis suppression 
(reviewed in Basseres and Baldwin 2006). In addition to this, previous reports have also demonstrated its 
ability to influence genes that regulate the process of epithelial-to-mesenchymal transition (EMT) (Chua, 
Bhat-Nakshatri e t al. 2007; Criswell and Arteaga 2007; Liu, Sakamaki et al. 2010), a type of cell plasticity 
whereby epithelial cells lose some of their epithelial characteristics and acquire properties that are 
typically associated w ith  mesenchymal cells.
M ore  recently, the incidence and metastatic properties o f ERBB2-positive tumours have been 
attributed to the expansion o f a tum our-initiating or cancer stem /progenitor cell population (Korkaya, 
Paulson et al. 2008). Canonical NF-kB signalling has been implicated in this process, as demonstrated by 
its elevation in luminal progenitor cell populations in a dimethylbenzanthracene (DMBA) murine 
m am m ary tum our model (Pratt, Tibbo et al. 2009) and more recently by loss of stem cell markers 
following its inhibition in a m urine ERBB2 driven-tum our model (Liu, Sakamaki et al. 2010). Furthermore, 
NF-kB has been shown to prom ote the classic in vitro functional features of breast cancer stem cells, 
which include the capacity to  invade the extracellular matrix and to grow as multicellular, spheroids, 
term ed mam m ospheres (Zhou, Zhang et al. 2008; W u, Deng et al. 2009; Storci, Sansone et al. 2010).
W hile the m olecular mechanisms underlying the effect o f NF-kB in cancer have been the 
subject o f intensive study, the means by which BCL3 may prom ote carcinogenesis remain largely 
undeterm ined. Previous studies have, nevertheless, dem onstrated it to be involved in the transcriptional 
regulation o f cancer-related genes including those involved in proliferation (Westerheide, Mayo et al. 
2001; Massoumi, Chmielarska et al. 2006; Park, Chung et al. 2006), apoptosis evasion (Kashatus,
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Cogswell et al. 2006) and, more recently, cell motility and invasion (Massoumi, Kuphal et al. 2009; 
Miyazaki, Simizu et al. 2010) in a variety o f cancer types.
The overall aim o f this chapter was to more closely dissect mechanisms behind the BCL3- 
m ediated effects on ERBB2-driven tumourigenesis identified in chapter 4. Firstly, in order to build upon 
previous in vivo results and to establish w hether BCL3 deficiency directly influences tum our cell 
behaviour, a range of in vitro  experim ents utilising the M M TV/N K  tum our-derived, MG1361 murine 
m am m ary cancer cell line w ere perform ed. Secondly, based on the previously identified involvement of 
NF-kB in the regulation o f EMT and cancer stem /progenitor cell populations, the effect of BCL3 
suppression on these cancer-associated processes was also evaluated. Finally, in an attem pt to identify 
BCL3-regulated, cancer-associated genes, global gene expression analysis was performed on MG1361  
cells subjected to  BCL3 suppression.
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5.2 Results
5.2.1 Bcl3 is highly expressed in ERBB2-positive murine mammary cancer cell lines
Previous reports have demonstrated a strong association betw een ERBB2 receptor signalling 
and NF-kB activity in breast cancer (Biswas, Shi et al. 2004; Zhou, Eppenberger-Castori et al. 2005). In 
order to determ ine w hether elevated Bcl3 expression also correlates w ith ERBB2 status, Bcl3 mRNA 
levels were analysed by QRT-PCR in two ERBB2-positive and three ERBB2-negative murine mammary cell 
lines (Figure 5.1). Four separate wells of each cell line were grown to 70% confluency and harvested for 
RNA isolation and subsequent cDNA preparation and QRT-PCR analysis. Gene expression was normalised 
to an internal control, cyclophilin B. Results show that the ERBB2-positive M G 1361 and N202A cells, 
previously derived from  M M T V /N K  and M M T V /N 2 mammary tum our respectively (Sacco, Gribaldo et al. 
1998; Nanni, Pupa et al. 2000), had significantly higher Bcl3 expression than the N202E (ERBB2-negative) 
controls (N202E vs N202A, M an n -W h itney  U-test, p=0.0304; N202E vs M G 1361, M ann-W hitney U-test, 
p=0.0304). The o ther tw o ERBB2-negative cell lines (4T1 and Eph4) had comparable Bcl3 mRNA 
expression to the N202E cells. These data suggest that, as with NF-kB subunits, high Bcl3 expression 
correlates w ith ERBB2 positivity in murine mammary tum our cells.
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Figure 5 .1: Bcl3 expression is highest in ERBB2-positive m urine m am m ary cancer cell line. 
QRT-PCR analysis o f Bcl3 mRNA expression in two ERBB2-positve and three ERBB2-negative 
murine cancer cell lines. Bcl3 mRNA expression was significantly higher in the ERBB2-positive 
N202A and M G 1361 cells in comparison to the ERBB2-negative N202E cells ^ M a n n -  
W hitney U-test, p=0.0304). Four independent wells for each cell line were analysed. Error 
bars represent ± SEM.
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5.2.2 Optimisation of Bcl3 SiRNA in MG1361 cells
Having established that Bcl3 expression was high in the ERBB2-positive M G1361 and N202A  
cells, a num ber o f in vitro experiments aimed at determining the direct mechanisms involved in the 
contribution of BCL3 to tumourigenesis in ERBB2-positive breast cancer cells were performed. In these 
experiments, an SiRNA approach was adopted to efficiently suppress Bcl3.
Initially, the Bcl3 SiRNA technique was optimised on the basis of the manufacturer's protocol. 
The cells w ere plated in transfection medium containing either lO nM  Bcl3 SiRNA or lO nM  control SiRNA 
and incubated for 4 8 -1 2 0  hours (M G1361 cells) or 2 4 -7 2  hours (N202A cells). Triplicate wells of cells 
w ere harvested at appropriate time points, and cDNA was prepared for QRT-PCR analysis. All results 
were normalised to an internal control housekeeping gene, cyclophilin B.
In the M G 1361 cells, the optimal transfection tim e period was shown to be 48 hours, during 
which tim e Bcl3 transcript levels were reduced by greater than 80% of constitutive levels (Figure 5.2A). 
Loss of Bcl3 at 48 hours was confirmed by semi-quantitative PCR (Figure 5.2B). Transfection for longer 
periods of tim e also resulted in considerable suppression o f Bcl3 mRNA, but this was never equivalent to 
the 48 hour tim e period (72 hours = 60% reduction, 96 hours = 52% reduction, and 120 hours = 47%  
reduction). M G 1361 cells were therefore transfected for 48 hours before all subsequent SiRNA 
experiments, and Bcl3 expression was routinely checked to ensure that a 70% or greater suppression of 
transcript levels was achieved.
Optimisation of Bcl3 knock-down was also attem pted in N202A cells. However, these cells 
proved difficult to  transfect, and at no tim e point were Bcl3 transcript levels suppressed to below 50% of 
controls (Figure 5.2C, 24 hours = 44% reduction, 48 hours = 37% reduction, and 72 hours = 30% 
reduction). These cells were therefore not used for subsequent SiRNA experiments.
Three different BCL3 antibodies were used in an a ttem pt to analyse BCL3 protein levels after 
transfection. However, a fter numerous attem pts, none of the antibodies gave a clear band at the 
appropriate size for BCL3 and therefore knock-down at the protein level could not be confirmed in these 
murine cells.
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Figure 5.2: Bcl3 SiRNA efficiently suppresses Bcl3 mRNA expression in MG1361 cells
MG1361 cells were transfected for 48-120 hours with lOnM Bcl3 or control SiRNA before being 
harvested for QRT-PCR analysis. Bcl3 mRNA expression was most efficiently suppressed at 48 hours 
(A). Semi-quantitative PCR showing loss of Bcl3 expression after SiRNA transfection for 48 hours (B). 
N202A cells were incubated for 24-72 hours with lOnM Bcl3 or control SiRNA before being 
harvested for QRT-PCR analysis. Bcl3 SiRNA did not suppress Bcl3 mRNA expression to below 50% of 
constitutive levels at any time point analysed (C). Error bars represent ± SEM.
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5.2.3 Suppression of Bcl3 does not affect the proliferation or apoptosis of MG1361 cells in 
adherent conditions
Previous reports have demonstrated that BCL3 can prom ote the proliferation and survival of a 
variety of different cell lines (Ong, Hackbarth et al. 1998; Rebollo, Dum outier et al. 2000; Westerheide, 
Mayo et al. 2001; Dolgachev, Thomas et al. 2007). In order to establish w hether BCL3 could have this 
effect on ERBB2-positive murine mammary tum our cells, viability and apoptosis assays were performed  
on M G 1361 cells after Bcl3 SiRNA transfection.
M G 1361 cells were transfected with lO nM  control SiRNA or Bcl3 SiRNA for 48 hours. RNA was 
harvested to ensure that Bcl3 expression was suppressed to less than 30% of constitutive levels and all 
other cells were reseeded into 96-well plates. Live cell counts and CellTiter-Blue assays were performed 
at 24, 48 and 72 hours and a caspase 3 /7  assay was performed at 24 hours as described in materials and 
methods.
Trypan blue exclusion counts showed that suppression o f Bcl3 expression had no effect on the 
number of live cells present in normal adherent growth conditions at any of the tim e points tested 
(Figure 5.3A, M ann-W hitney  U-test for all comparisons, p>0.05). These data w ere confirmed in CellTiter- 
Blue viability assays, which showed no significant changes in the overall num ber of viable cells present 
after Bcl3 suppression at any tim e point (Figure 5.3B, M an n -W h itney  U-test for all comparisons, p>0.05). 
Furthermore, the expression o f Cyclin D l,  a principle NF-kB target involved in cell cycle regulation, 
remained unchanged imm ediately following the 48 hour Bcl3 SiRNA incubation period (Figure 5.3C, T- 
Test p>0.05).
The ability of BCL3 to alter apoptosis rates in this cell line was also analysed. Bcl3 suppression 
resulted in no significant differences in basal caspase 3 /7  activity a fter 24 hours in normal adherent 
growth conditions (Figure 5.3D, M an n -W h itney  U-test, p>0.05).
These data suggest that BCL3 deficiency has no effect on overall basal proliferation or 
apoptosis rates in M G 1361 ERBB2-positive tum our cells in vitro. This is consistent with the previous in 
vivo data from chapter 4 dem onstrating that loss of BCL3 did not affect the proliferation or apoptosis of 
ERBB2-positive murine tumours.
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Figure 5 .3: Suppression o f Bcl3 does not affect the proliferation or apoptosis o f murine 
M G 1361 cancer cell lines in adherent growth conditions
M G1361 cells were transfected with Bcl3 or control SiRNA for 48 hours before being re-seeded 
into normal adherent growth conditions. Trypan blue exclusion counts (A) and CellTiter-Blue 
viability assays (B) were performed 24; 48 and 72 hours later. Bcl3 suppression had no 
significant effects on the number of live cells per well (A) or on cell viability (B) at any time point 
tested (M ann-W hitney U-test for all comparisons, p>0.05). Error bars represent ± SEM of 6 
technical replicates. Bcl3 suppression resulted in no significant differences in Cyclin D1 mRNA 
expression (C, T-Test, p>0.05) or in basal caspase 3 /7  activity after 24 hours in normal adherent 
growth conditions (D, M ann-W hitney U-test, p>0.05). Error bars represent ± SEM of 3 technical 
replicates.
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5.2.4 Bcl3 suppression reduces the ability of MG1361 cells to metastasize to the lungs in a 
cell autonomous manner
Having previously established that BCL3 suppression can delay the metastatic progression of 
ERBB2-positive tum ours in vivo, the ability o f BCL3 to directly affect tum our cell motility in a cell 
autonomous m anner was assessed.
In order to achieve this, M G 1361 cells w ere transfected for 48 hours with lO nM  Bcl3 or control 
SiRNA before being directly transplanted into the tail vein o f imm unodeficient recipient mice with 
normal levels o f BCL3. M ice w ere culled three weeks later and lungs were harvested and fixed for H8iE 
staining. Sections w ere analysed for both the num ber and size of lung lesions present.
Examination o f H8iE stained lung sections revealed that introduction of cells with less than 20% 
of constitutive Bcl3 expression into the bloodstream of recipient mice resulted in a significant reduction 
in the frequency of lung metastases in comparison to controls (Figure 5.4A8iC, mean±SEM number of 
metastases per mouse was: 297 .2±140.3  for control SiRNA cells and 55±29.3  for Bcl3 SiRNA cells, Mann- 
W hitney U-test, p=0.0081). This dem onstrated that suppression of Bcl3 could reduce the ability of 
tum our cells to metastasize to secondary sites in a cell autonomous m anner that was independent of 
effects on the tum our m icroenvironm ent. Interestingly, the Bcl3 suppressed cells that did seed in the 
lungs form ed significantly larger lung lesions than controls (Figure 5.4B8iC, m eaniSEM  area of lung 
metastases was: 406 15 11 96 72 p m 2 for control SiRNA cells and 77233±26538 |im 2 for Bcl3 SiRNA cells, 
M ann-W hitney U-test, p=0.000). This may be due to the transient nature of SiRNA gene silencing and 
release o f Bcl3 inhibition during colonization and secondary tum our growth (see discussion section 
5.3.1).
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Figure 5.4: Bcl3 deficient cells are less able to seed in the lungs in an experim ental metastases model
MG1361 cells were transfected with lO nM  Bcl3 or control SiRNA for 48 hours before being injected into 
the blood stream of immunodeficient mice (n=5) with normal BCL3 levels. Mice were culled three weeks 
later and lungs were harvested and fixed for H&E staining and analysis. Bcl3 suppression significantly 
reduced the average number of metastases per mouse in comparison to controls (A, *=Mann-Whitney  
U-test, p=0.0081). Lung metastases that did form from Bcl3 suppressed cells were on average larger 
than controls (B, M ann-W hitney U-test, p=0.00). Error bars represent ± SEM. Representative images of 
H&E stained lungs (C). Scale bars indicate: left panel 1000pm, right panel 200pm. Representative 
photographs of whole lungs immediately after dissection (D). Black arrows indicate visible lung 
metastases.
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5.2.5 Bcl3 suppression reduces both the migratory and invasive capacity of MG1361 cells in
vitro
In order to address the underlying mechanisms for the observed cell autonomous effect on 
metastasis, Bcl3 was suppressed in the M G 1361 cells and metastatic cell properties were assessed in 
vitro.
Cells w ere transfected with lO nM  control SiRNA or Bcl3 SiRNA for 48 hours, and RNA was 
harvested to ensure sufficient Bcl3 suppression. Cells were then re-seeded onto Boyden motility or 
invasion chambers (as described in Materials and Methods, section 2.5.8) in low-serum medium and 
incubated fo r 24 or 48 hours, respectively, to allow the m ovem ent o f cells across the membranes down a 
serum concentration gradient.
Suppression of Bcl3 resulted in a significant 61% reduction (M ann-W hitney  U-test, p=0.0404) in 
the m igratory capacity (Figure 5.5A&B, first set of bars) and a 51% reduction (M ann-W hitney  U-test, 
p=0.0205) in the invasive capacity (Figure 5.5C&D, first set o f bars) o f M G 1361 cells through Boyden 
chamber m em branes. In order to ensure that any changes in cell numbers crossing the membranes was 
not due to reduced proliferation o f the cells, parallel wells were plated in normal adherent tissue culture 
plates in low serum media for the duration of the experiments and counted at the same tim e as the 
Boyden chambers w ere fixed. Cell counts revealed that, as previously observed, depletion of Bcl3 in the 
M G 1361 cells did not significantly alter their proliferative capacity in the 24 hour or 48 hour 
experim ental period (Figure 5.5B8iD, second panel of bars). These results confirm previous in vivo data 
indicating that suppression of BCL3 reduces both the migratory and invasive capacity of ERBB2-positive 
murine tum our cells.
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Figure 5.5: Bcl3 suppression reduces the m igratory and invasive capacity o f MG1361 murine 
m am m ary cancer cells
MG1361 cells were transfected with Bcl3 or control SiRNA for 48 hours before being plated onto 
Boyden motility or invasion chambers. Cells were left for 24 hours (for motility experiments) or 48 
hours (for invasion experiments) before being fixed and stained on Boyden chamber membranes. 
Representative images of migrated cells (A) and invaded cells (C) fixed on Boyden chamber 
membranes are shown. Scale bars indicate 200|im. Migrated cells (B, first set of bars) or invaded cells 
(D, first set of bars) were counted from three fields of view of each of three replicate Boyden 
chambers and graphically represented as a percentage of the number of control cells counted (error 
bars represent ± SEM of triplicate Boydens). Three parallel wells were plated for the duration of the 
experiments in normal adherent growth conditions in low serum media. Live cell counts were 
performed at the end of each experiment and represented as a percentage of the number of live 
control cells present (B8tD, second set of bars, error bars represent ± SEM of triplicate wells). Bcl3 
suppression resulted in a significant reduction in both the migratory capacity (B, *=Mann-Whitney U- 
test, p=0.0404) and the invasive capacity (D, *=Mann-Whitney U-test, p=0.0205) of MG1361 cells 
through Boyden chamber membranes. Bcl3 suppression had no affect on the proliferation of cells in 
low serum media throughout the duration of the experiments (B8iD, Mann-W hitney U-test, p>0.05). 147
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5.2.6 Loss of Bcl3 does not affect the anchorage-independent survival of MG1361 ceils
One of the m ajor obstacles that tum our cells have to overcome in order to metastasise is 
anchorage-independent cell death (anoikis) induced by detachment from the bulk tum our into the 
bloodstream. In order to determ ine w hether this form of apoptosis contributes to the reduced ability of 
BCL3-deprived cells to metastasise, in vitro anchorage-independent survival assays were performed.
M G 1361 cells w ere transfected for 48 hours with lO nM  Bcl3 SiRNA or a control SiRNA, and RNA 
was harvested to ensure sufficient Bcl3 suppression. Cells were then re-seeded into ultra-low- 
attachm ent plates and incubated for 24, 48 or 72 hours at which time-points live cell counts and 
CellTiter-Blue assays w ere perform ed.
No significant differences w ere observed in either live cell numbers (Figure 5.6A, M a n n -  
W hitney U-test fo r all comparisons, p>0.05) or cell viability, as determ ined by the CellTiter-Blue assay; 
(Figure 5.6B, M an n -W h itn e y  U-test for all comparisons, p>0.05) between control and Bc/3-depleted cells 
at any of the assessed tim e-points.
In order to directly assess apoptosis of the M G 1361 cells in these conditions, a caspase 3 /7  
assay was perform ed 24 hours after seeding into low-attachm ent conditions. Consistent with the above 
cell viability results, Bcl3 suppression did not significantly alter levels o f apoptosis in these conditions 
(Figure 5.6C, M an n -W h itn e y  U-test p>0.05).
These results indicate that suppression o f BCL3 does not alter the metastatic potential of cells 
by directly decreasing their ability to survive in anchorage-independent conditions.
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Figure 5.6: Bcl3 suppression does not affect the anchorage-independent survival o f M G  1361 
m urine m am m ary cancer cells
MG1361 cells were transfected with Bcl3 or control SiRNA for 48 hours before being re-plated 
into ultra-low attachm ent plates. Trypan blue exclusion counts (A) and CellTiter-Blue viability 
assays (B) were performed 24, 48 and 72 hours later. Bcl3 suppression had no significant effect 
on the number of live cells per well (A) or on cell viability (B) at any time point tested (Mann- 
W hitney U-test for all comparisons, p>0.05). Bcl3 suppression resulted in no significant 
differences in basal caspase 3 /7  activity after 24 hours in anchorage-independent growth 
conditions (C, M ann-W hitney U-test, p>0.05). Error bars represent ± SEM of 6 technical 
replicates.
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5.2.7 Suppression of Bcl3 does not alter epithelial-to-mesenchymal transition markers in
vitro or in vivo
Recent papers have dem onstrated that the process of epithelial-to-mesenchymal transition 
(EMT) is implicated in cancer cell invasion and metastases (Mani, Yang et al. 2007; Sarrio, Rodriguez- 
Pinilla e t al. 2008; W endt, Smith et al; 2010 Usami, Satake et al. 2008; Cano, Perez-Moreno et al. 2000). 
Essential to the EMT process is the repression of E-cadherin by transcription factors such as Snail and 
Slug resulting in the loss of epithelial cell-cell adhesion and the upregulation of Vimentin, an 
interm ediate filam ent expressed in mesenchymal cells (Battle, Sancho et al. 2000; Cano, Perez-Moreno et 
al. 2000; Bolos, Peinado et al. 2003).
NF-kB has previously been shown to be involved in promoting EMT in mammary cells (Huber, 
Azoitei et al. 2004; Chua, Bhat-Nakshatri et al. 2007; Criswell and Arteaga 2007). It was therefore  
proposed that BCL3 may also regulate EMT to enhance cell motility and invasion. This hypothesis was 
tested by analysing protein levels o f the key molecular EMT markers, E-cadherin, Vimentin and Snail, in 
both the BCL3-depleted M M T V /N 2 mouse mammary tumours and Bcl3 SiRNA-treated mammary tum our 
cells.
M G 1361 cells w ere treated with lO nM  Bcl3 or control SiRNA for 48 hours and RNA was 
harvested to confirm Bcl3 suppression. At the same tim e-point, whole cell lysates were extracted on ice 
for subsequent western analysis of target proteins. Results revealed that Bcl3 suppression had no effect 
on E-cadherin, Vim entin or Snail protein expression (Figure 5.7A). Equal loading of protein between 
samples was confirmed by visualising levels o f the housekeeping protein, Tubulin.
In order to confirm these results in vivo, total proteins were extracted from three 
BcI3+/+/M M T V /N 2 and three BcI3'/'/M M T V /N 2 late-stage (4000±50m m 3) mouse mammary tumours. 
W estern analysis was again used to detect protein levels of EMT markers. This demonstrated that E- 
cadherin protein expression rem ained unaltered in the absence of BCL3 (Figure 5.7B). Vimentin and Snail 
were undetectable in these tum ours by western blotting. In order to partially overcome this, sections 
from  three BcI3+i+/M M T V /N 2 and three BcI3'/'/M M T V /N 2 late-stage tumours were subjected to anti- 
Vim entin IHC. Results revealed a highly variable degree of cytoplasmic staining between samples within 
genotypes regardless of BCL3 status (Figure 5.7C), indicating that, within the samples analysed, BCL3 
depletion did not correlate w ith loss o f Vim entin in late-stage tumours.
Taken together these results suggest that BCL3 does not m ediate a pro-metastatic phenotype 
by inducing EMT, as defined by these molecular markers of the process, in ERBB2-positive tum our cells 
either in vitro or in vivo.
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Figure 5.7: Loss o f Bcl3 does not a lte r markers o f EMT
MG1361 cells were transfected with Bcl3 or control SiRNA for 48 hours and protein was 
extracted and subjected to western analysis. Suppression of Bcl3 had no effect on the protein 
expression of E-cadherin, Vimentin or Snail. Equal loading was confirmed by Tubulin (A). Protein 
from BcI3+/+/M M T V /N 2 and BclJ1'/M M T V /N 2 tumours was extracted and subjected to western 
analysis. Loss of BCL3 had no effect on the expression of E-cadherin in M M TV /N 2 tumours. Equal 
loading was confirmed by Tubulin (B). Three BcI3*/+/M M T V /N 2 and three Bcl3'/'/M M T V /N 1 
tumours were subjected to anti-Vimentin IHC. Highly variable cytoplasmic staining was observed. 
This did not correlate with BCL3 status (C). Scale bars indicate 50pm.
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5.2.8 Suppression of Bcl3 does not alter the self-renewing tumour cell population in 
MG1361 cells
Tumour incidence and metastatic properties of ERBB2-positive tumours have been ascribed to 
the expansion of a tum our-initiating or stem /progenitor cell population mediated by ERBB2 signalling 
(Korkaya, Paulson et al. 2008). Korkaya et al (2008) showed that over-expression of ERBB2 in a panel of 
breast cancer cell lines not only increased the proportion of cells positive for the stem /progenitor cell 
marker, aldehyde dehydrogenase 1 (ALDH1), but also increased the tumourigenicity and invasive 
capacity o f the this cell population.
Previous data in chapter 4 showed a striking effect of BCL3 on both the initiation and 
metastatic progression of ERBB2-positive tumours, both o f which could be due to alterations in the 
stem /progenitor cell population. It was therefore of interest to analyse the effects o f BCL3 suppression 
on this population in an ERBB2-positive mammary cell line.
Methods to identify stem /progenitor cell populations include culture o f cells in non-adherent, 
non-differentiating conditions to form mammospheres and the use of specific markers that are highly 
expressed in cells within this population (see Chapter 1: General Introduction, section 1.2.4). In order to 
determ ine w hether loss of BCL3 results in a reduction in the stem /progenitor cell pool, M G1361 cells 
were subjected to Bcl3 SiRNA and analysed for a variety of stem cell markers and for their ability to form  
mammospheres in non-adherent cell culture conditions.
5.2.8.1 Analysing the effect o f Bcl3 depletion on mammosphere form ation
On the basis o f established cell culture conditions for tum our-initiating m ammary cells, the  
ability of parental M G1361 cells to form mammospheres was assessed. Single cells were plated at 
various low densities (50 0 -80 00  cells/ml) in mammosphere culture medium as described in materials 
and methods. After incubation for 7 days, M G1361 cells generated clearly defined spherical 
mammosphere colonies at all seeding densities (Figure 5.8A). The num ber of mammospheres formed  
increased proportionally to the seeding density, with a mammosphere-forming frequency of 
approximately 1 in 100 (Figure 5.8B, light grey line), demonstrating that, at all seeding densities, 
mammospheres and not aggregates of bulk tum our cells were formed.
In order to show that the mammosphere structures form ed contain cells that are capable of 
self-renewal, the sphere-initiating ability of passaged primary M G1361 mammospheres was analysed. 
Primary mammospheres were dissociated into single cells, re-plated at low densities (500-8000  cells/ml) 
and incubated for a further 7 days. The mammosphere-forming frequency increased from approximately 
1 in 100 to between 2 and 5 in 100 (Figure 5.8B, passage 1 vs passage 2), demonstrating that the  
MG1361 mammospheres contain cells capable of self-renewal and secondary mammosphere formation.
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Having established that M G 1361 cells are able to form mammospheres containing cells with  
self-renewal capacity, the effect of Bc/3 suppression on mammosphere form ation was analysed. Cells 
were treated with lO nM  Bcl3 or control SiRNA for 48 hours and RNA was harvested for subsequent QRT- 
PCR analysis to confirm Bcl3 suppression. Single cells (4000 cells/ml) w ere re-seeded into ultra-low- 
attachm ent plates in mammosphere medium and incubated for 7 days. Figure 5.8C shows that initial 
Bcl3 suppression did not result in a reduction in the percentage o f mammosphere-forming units within  
the cell population (mean±SEM % mammosphere-forming units was 2.32±0.68%  for control cells and 
1.87±0.53%  for flc/3-suppressed cells; T-test, p>0.05). This indicates that BCL3 does not affect the size of 
the original stem /progenitor cell population in this cell line.
It has previously been reported that the number of mammospheres generated upon serial 
passage indirectly reflects the ability of the stem cells within them  to self-renew and the size of the 
passaged mammospheres reflects progenitor cell proliferation capacity (Dontu, Abdallah et al. 2003). 
Also, primary mammary cells isolated from murine ERBB2-positive m am m ary tumours, harbouring a 
genetic alteration of IKKa to globally inhibit NF-kB signalling, were capable of forming primary 
mammospheres but could not form secondary mammospheres upon serial passage (Cao, Luo et al. 
2007), indicating that inhibition of NF-kB impairs stem cell self-renewal ability. It was therefore of 
interest to passage on primary mammospheres into secondary culture to analyse the effect o f BCL3 
deficiency on their initial self-renewal capacity.
M G 1361 cells were transfected with lO nM  Bcl3 or control SiRNA for 48 hours. RNA was 
harvested to ensure sufficient Bcl3 suppression and 4000 cells/ml were seeded into ultra-low- 
attachm ent plates in mammosphere medium and incubated for 7 days. Primary mammospheres were  
then enzymatically dissociated into single cells, re-plated at 4000 cells/ml into ultra-low-attachm ent 
plates, and incubated for a further 7 days to allow the form ation of secondary mammospheres.
As previously demonstrated, Bcl3 suppression did not significantly decrease the size or number 
of primary mammospheres (Figure 5.8D). Secondary passage of cells resulted in an increase in the 
percentage of mammosphere-forming units in both the control and Bc/3-suppressed cells (from 2.32% to 
5.48% in control cells and from  1.87% to 4.72%  in Bc/3-suppressed cells, Figure 5.8D), suggesting that 
both cell populations contain cells w ith self-renewal capacity. However, there was no significant 
difference in the size or num ber of secondary mammospheres form ed between the Bc/3-suppressed and 
control cells (Figure 5.8D8iE, m eaniSEM  % secondary passage mammosphere-forming units was 
5.48±2%  for control cells and 4.72±1.57%  for Bc/3-suppressed cells; T-test, p>0.05).
These data suggest that early suppression of Bc/3 does not alter the size or the self-renewal 
ability o f the stem /progenitor cell populations within the M G1361 cell line. Clearly, a major limitation to 
this experim ent is that suppression of Bc/3 with SiRNA is tem porary. The assay therefore only evaluates
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the effects of BCL3 on the initial anoikis-resistant cell population and the subsequent consequences that 
this early inhibition has on their self-renewal ability.
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Figure 5.8: Bcl3 suppression has no effect on the form ation o f prim ary or secondary 
mammospheres
MG1361 cells form spherical mammospheres in low attachment conditions (A). Mammospheres 
form at a range of seeding densities and are composed of cells that are able to self-renew as 
demonstrated by increased mammosphere numbers in secondary passages (B). MG1361 cells were 
transfected with Bcl3 or control SiRNA for 48 hours and plated in mammosphere culture conditions 
for 7 days. Bcl3 suppression had no significant effect on the formation of primary mammospheres (C, 
T-test, p>0.05). The percentage of mammosphere forming units increased upon secondary passaging 
but this was unaffected by Bcl3 suppression (D, T-test, p>0.05). Bcl3 suppression had no effect on 
the size of primary or secondary mammospheres (E). All data represent the mean of three 
independent transfection experiments and error bars represent ± SEM.
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5.2.8.2  Analysing the effect o f Bcl3 deficiency on stem cell markers
ALDH1 is a detoxifying enzyme responsible for the oxidation of intracellular aldehydes and has 
been shown to be highly active in the stem /progenitor cell population in both the normal human 
m ammary gland and m ammary carcinomas (Ginestier, Hur et al. 2007). This m arker was used to establish 
w hether the effect o f BCL3 inhibition on tum our development and metastases correlated with changes 
in stem /progenitor cell populations.
M G 1361 cells were treated with lO nM  Bcl3 or control SiRNA for 48 hours, and Bcl3 suppression 
was confirmed by QRT-PCR. The proportion of cells with high ALDH1 activity was then measured using 
the Aldefluor assay as described in materials and methods. This assay works by assessing the ability of 
cells to convert the ALDH1 substrate, BAAA, into a brightly fluorescent reaction product, BAA-, which is 
retained in cells expressing high levels of ALDH1 and can be detected in the green fluorescent channel of 
a flow cytom eter.
Bcl3 suppression resulted in a small but insignificant reduction in the proportion of cells with 
high ALDH activity (Figure 5.9, percentage of ALDHl-positive cells ± SEM was 8.01±1.24%  for control cells 
and 6.83±1.98%  for Bcl3 SiRNA treated cells, T-test, p>0.05), indicating that it has little or no effect on 
the population o f cells marked by this enzyme.
In order to confirm this result, the expression o f CD24 and SCA1 which have independently 
been shown to enrich for stem /progenitor cells in M M T V /N 2 and M M T V /N K  tum our cell populations, 
respectively (Liu, Deng et al. 2007; Grange, Lanzardo et al. 2008), were also assessed in Bcl3 suppressed 
M G 1361 cells.
Firstly, it was necessary to identify which of these markers enriched for tum our initiating cells 
in the M G 1361 cell line. This was achieved by sorting the parental cells for CD24 and SCA1 expression 
and then plating cells from  each quadrant under mammosphere growth conditions. When cells were 
plated at 2000 cells/ml, both of the CD24+ populations had a higher percentage of mammosphere 
forming units than the CD24- populations. This was significant in the CD24+/SCA1- population in 
comparison to all o ther quadrants and unsorted control cells (Figure 5.10, mean±SEM percentage of 
mammosphere forming units was 3.2±0.52%  for CD24+/SCA1- cells in comparison to 1.8±0.23% in 
unsorted controls, 0 .75±0.27%  in SCA+/CD24- cells, 1.16±0.23%  in SCA1-CD24- cells and 1.75±0.37%  in 
SCA1+/CD24+ cells, T-test for percent o f CD24+/SCA1- mammosphere forming units compared to cells 
from  any o ther quadrant or unsorted controls, p<0.05). This indicated that in concordance with Liu et al. 
(2007), M G 1361 tum our initiating cells, as defined by the mammosphere functional assay, were enriched 
in the CD24-positive population.
To assess w hether loss of BCL3 resulted in a reduction in this CD24-positive population, 
M G 1361 cells w ere treated w ith lO nM  Bcl3 or control SiRNA for 48 hours and analysed on the basis of
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CD24 or SCA1 expression. Interestingly, Bcl3 depletion actually resulted in an increase in both of the  
CD24-positive populations (Figure 5 .11). Loss of Bcl3 significantly increased the percentage of 
CD24+/SCA1- cells from 19.8% to 26.9%  (Figure 5.11B, far left graph, T-test, p=0.000023) and the  
percentage o f CD24+/SCA1+ cells from 13.72%  to 16.8% (Figure 5.11B, far right graph, T-test, p=0.0048) 
in comparison to controls.
These data show that, although the CD24-positive population enriches for mammospheres in 
the M G 1361 cells, loss o f BCL3 surprisingly does not deplete, but instead increases this population.
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Figure 5.9: Loss o f Bel3 results in an insignificant reduction in the ALDHl-positive population in 
MG1361 murine m am m ary cancer cells
MG 1361 cells were transfected with Bcl3 or control SiRNA for 48 hours before being subjected to 
the Aldeflour assay. Representative FACS plots of MG1361 cells (A). Cells incubated with the 
Aldeflour substrate (BAAA) and the specific inhibitor of ALDH, DEAB, were used as a control to 
establish the base-line fluorescence of the cells and to define the ALDH1 -positive region (Rl) 
(top row, A). Incubation of cells with the Aldeflour substrate in the absence of DEAB induced a 
shift in BAAA fluorescence into the ALDHl-positive (R l) region in both control and Bcl3 SiRNA 
treated cells (bottom row, A). Suppression of Bcl3 resulted in an insignificant reduction in the 
percentage of ALDHl-positve cells (B, T-Test, p>0.05). Results are representative of three 
independent experiments and error bars represent ± SEM.
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Figure 5 .10: The CD24+/5CA1-population enriches fo r  mammospheres in M G  1361 cells 
M G 1361 parental cells were FACS sorted for CD24 and SCA1 expression. Cells from each 
quadrant were plated under mammosphere growth conditions and counted after 7 days. 
Both CD24+ populations had a higher percentage of mammospheres in comparison to 
CD24- populations. The SCA1-/CD24+ population had a significantly higher percentage of 
mammosphere forming units than cells from any other quadrant (T-test,* = p<0.05, * *  = 
p<0.01). As this experim ent confirmed previously published data, technical replicates only 
were performed (6 separate wells, error bars represent ± SEM).
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Figure 5 .11: Bcl3 suppression increases the CD24+ population in M G  1361 cells
M G 1361 cells were transfected with Bcl3 or control SiRNA for 48 hours before being analysed on the 
basis of CD24 and SCA1 expression. Representative FACS plots of M G 1361 control (A, left panel) and Bcl3 
(A, right panel) SiRNA treated  cells using CD24 and SCA1 cell surface markers are shown. Relevant 
isotype controls were used to establish the base-line fluorescence of the cells and to enable gates to be 
set (A, top row). The average percentage of cells in each quadrant was calculated and represented 
graphically (B). Suppression of Bcl3 resulted in a significant increase in the percentage of CD24+/SCA1+ 
and CD24+/SCA1- cells and a significant decrease in the percentage of CD24-/SCA1+ and CD24-/SCA1- 
cells (B, T -test,**= p< 0 .01 ). Data is representative of three independent Bcl3 SiRNA experiments 
performed on the same day and error bars represent ± SEM. The experim ent was also repeated on a 
different day and similar results were obtained (data not shown).
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5.2.9 Identification of BCL3 gene targets potentially involved in the metastatic process
As previously described, BCL3 is known to both negatively and positively modulate the 
transcriptional activity of p50 and p52 homodimers (see Chapter 1: General Introduction, section 1.4.4). 
In order to better understand the role of BCL3 in the identified cell autonomous metastatic phenotype, 
microarray analysis using an lllumina MouseRef-8 version 2 BeadChip (see Chapter 2: Materials and 
Methods, section 2.9) was performed on M G 1361 cells subjected to Bcl3 SiRNA.
MG 1361 cells w ere treated with lO nM  Bcl3 or control SiRNA in six separate experiments. RNA 
was harvested, and QRT-PCR analysis for Bcl3 expression was performed to identify samples with the 
largest degree o f Bcl3 suppression (Figure 5.12). Microarray analysis was performed on the four samples 
displaying the lowest Bcl3 expression, all of which had less than 30% of constitutive Bcl3 transcript levels.
M icroarray analysis identified a large number of genes that were regulated upon Bcl3 
suppression (see appendix 1 and 2 for lists of genes that showed the largest significant fold increases and 
decreases in expression). Ingenuity com puter software (http ://w w w .ingenuity.com ) was used to identify 
BCL3-regulated genes that are known to be involved in cell motility and invasion. Table 5.1 lists the 
m otility- and invasion-related genes that were regulated by BCL3 and predicted to have an NF-kB binding 
site w ithin the ir prom oter by PROMO 3.0 com puter software (http://alggen.lsi.upc.es/cgibin- 
/prom o_v3/prom o/prom oinit.cgi?dirDB=TF_8.3).
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Figure 5 .12: Selection o f M G  1361 RNA samples fo r  microarray analysis
MG1361 cells w ere independently transfected with Bcl3 or control SiRNA 6 times. RNA was harvested, 
cDNA was prepared and QRT-PCR analysis for Bcl3 expression was performed to identify samples with 
the greatest Bcl3 suppression. As a result of this analysis, samples 2, 3, 4 and 5 were sent for microarray 
analysis. Error bars represent ± SEM of 3 technical replicates.
Accession
Num ber
Definition P-Value
N M _008704.2 Non-metastatic cells 1 (NM23A; (Nmel), 0.00092
N M _008705.4 Non-metastatic cells 2 (NM23B; Nme2) 0.00062
N M _019730.1 Non-metastatic cells3(Nme3) 0.00332
N M _019731.1 Non-metastatic cells4(Nme4) 0.000006
N M _011593.2 Tissue inhibitor of metalloproteinase 1 (Timpl) 0.00395
N M _011594.3 Tissue inhibitor of metalloproteinase 2 (Timp2) 0.00633
N M _011595.2 Tissue inhibitor of metalloproteinase 3 (Timp3) 0.00490
N M _007616.3 Caveolin 1 (Cavl) 0.00086
N M _007486.1 Rho, GDP dissociation inhibitor (GDI) beta (Arhgdib) 0.00121
N M _010288.2 Gap junction membrane channel protein alpha 1 (Gjal) 0.00412
N M _010688.2 LIMand SH3 protein 1 (Laspi) 0.000979
N M _024454.1 Member RAS oncogene family (Rab21), 0.00081
N M _021356.2 Growth factor receptor bound protein 2-associated protein 1 (Gabl) 0.00980
N M _010513.2 Insulin-like growth factor 1 receptor (Ig flr) 0.001812
N M _020011.4 Sphingosine kinase 2 (Sphk2) 0.000183
N M _009335.1 Transcription factor AP-2, gamma (Tcfap2c) 0.002948
N M _011577.1 Transforming growth factor, beta 1 (Tgfbl) 0.003077
Table 5.1: M o tility  and invasion re lated  genes regulated by BCL3
M G1361 cells w ere transfected with Bcl3 or control SiRNA for 48 hours. Four independently transfected 
samples were analysed by microarray. BCL3-regulated invasion- and motility-related genes with putative 
NF-kB binding sites are listed.
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5.2.10 QRT-PCR validation of microarray targets in MG1361 cells
In order to validate the microarray-based results, QRT-PCR analysis was performed on 
candidate genes with putative NF-kB binding sites within their promoters. The expression of all genes 
was normalised to a cyclophilin B internal control. Firstly, the expression o f the first four members of the 
Nme  (N M 23) fam ily of nucleoside diphosphate kinase encoding genes, of which N m el in particular has 
been shown to be involved in the inhibition of cell m otility and metastases (Boissan, W endum et al. 
2005; Horak, Lee et al. 2007; M cDerm ott, Boissan et al. 2008) were verified. As observed in the 
microarray, the first three Nm e  anti-m otility genes were significantly up-regulated in response to Bcl3 
SiRNA in comparison to controls (Figure 5.13A, relative percentage mRNA increase in comparison to 
controls was 57% for N m e l,  T-test, p=0.0076; 56% for Nme2, T-test, p=0.044 and 36% for Nme3, T-test, 
p=0.038). Nm e4  was also up-regulated but this was not found to be significant (54% upregulation, T-test, 
p>0.05).
The microarray also identified that three of the tissue inhibitors o f metalloproteinases (Timps) 
were regulated by BCL3. The products of these genes act to inhibit matrix metalloproteinases that can 
prom ote breast cancer invasion and metastases by breaking down the extracellular matrix of 
surrounding stromal tissue (Zhang, Cao et al. 2008; reviewed in Duffy, Maguire et al. 2000; Chakraborti, 
Mandal et al. 2003). The expression of Tim pl and Timp2 was verified by QRT-PCR, and, as observed in 
the microarray, mRNA expression o f both genes was significantly up-regulated in response to Bcl3 
suppression (Figure 5.13B, relative percentage mRNA increase in comparison to controls was 36% for 
Tim pl, T-test, p=0.00098 and 50% for Timp2, T-test, p=0.029).
The mRNA expression o f several other putative NF-kB m otility-related gene targets identified in 
the microarray was analysed. O f these targets, only three were confirmed to be significantly regulated by 
BCL3 when mRNA expression was assessed by QRT-PCR. Caveolin-1 (Cav-1) is a structural component of 
caveolae m em brane domains in a variety of cells including m am m ary epithelia and has been shown to be 
a potent suppressor o f m am m ary tum our growth and metastases in vivo (Williams, Medina et al. 2004). 
QRT-PCR analysis revealed tha t Bcl3 suppression resulted in an 80% increase in the mRNA expression of 
this anti-invasive gene in comparison to controls (Figure 5.13C, T-test, p=0.00069). Furthermore, 
Arhgdib, a Rho GDP dissociation inhibitor that has been shown to behave as a metastases suppressor 
(Gildea, Seraj e t al. 2002), was significantly increased by 130% in response to Bcl3 suppression (Figure 
5.13C, T-test, p=0.00065), and Rab21, a small GTPase that has been shown to enhance cell adhesion and 
migration o f breast and prostate cells (Pellinen, Arjonen et al. 2006), was significantly decreased by 24% 
in Bc/3-depleted cells (Figure 5.13C, T-test, p=0.038).
These data indicate that BCL3 regulates the transcription o f a variety of motility- and invasion- 
related genes to m ediate a pro-m igratory and pro-invasive phenotype.
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Figure 5.13: BCL3 regulates the transcription o f a variety o f m otility- and invasion-related genes
M G1361 cells were transfected with Bcl3 or control SiRNA. QRT-PCR directed against targets 
identified by microarray analysis was performed. Bcl3 suppression resulted in a significant up- 
regulation of N m el, Nme2, and Nme3 (A, T-test, **=p<0.01 , *=p<0.05) and of Tim pl and Timp2 
(B, T-test, **=p< 0.01 , *=p<0.05). Of the other targets analysed, only Cavl and Arhgdib were 
significantly up-regulated and Rab21 was significantly down-regulated in response to Bcl3 
suppression (C, T-test, **= p<0.01 , *=p<0.05). Data are representative of three independent Bcl3 
transfection experiments. Error bars represent ± SEM.
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5.2.11 QRT-PCR analysis of gene targets potentially regulated by BCL3 in M M TV /N 2 tumours
Having identified a num ber of genes involved in cancer cell motility and invasion in vitro, it was 
of interest to analyse these same targets in vivo by harvesting RNA from BcI3+i+/M M T V /N 2 and 8c/3v" 
/M M T V /N 2 tumours.
RNA was isolated from three BcI3+/+/M M T V /N 2 and three BcI3'/'/M M T V /N 2 tumours that were 
dissected at 500±13.5  m m 3. cDNA was prepared, and QRT-PCR for a number of the previously identified 
targets was perform ed. The expression profile of genes was normalised to cyclophilin B.
Figure 5.14A shows that there were no significant changes in any of the Nme family of genes. 
Tim pl and Timp2 expression were also found to be unchanged in the absence of Bcl3, although Tim pl 
showed an insignificant trend towards an increase in the BcI3'/'/M M T V /N 2 tumours (Figure 5.14B, T-test, 
p>0.05). The only target that was significantly affected by the loss o f Bcl3 was Ig f lr  which showed a 37% 
decrease in comparison w ith controls (Figure 5.14C, T-test, p=0.018). None of the other targets were 
significantly changed, although similarly to Tim pl, Cavl showed an insignificant increase in the 8c/3v 
/M M T V /N 2 tum ours in comparison with controls (Figure 5.14C, T-test, p>0.05).
Large biological variation between samples was observed in the expression of Tim pl and Cavl. 
Therefore, in order to validate the above results, a further three 500 m m 3 tumours were analysed to 
increase the num ber in each cohort to six. Although a trend towards an increase in the expression of 
both genes was again observed in the BcI3'/'/M M T V /N 2 tumours compared with controls, still no 
significance was detected (Figure 5.14D, T-test for both comparisons, p>0.05).
As Arhgdib  was shown to be the most highly up-regulated m otility-related gene in the MG1361  
cells, it was im m ediately analysed in the larger cohort of six samples. Figure 5.14D shows, however, that 
there was no statistically significant difference in its expression between the BcI3'/'/M M T V /N 2 and 
BcI3+/+/M M T V /N 2 tum ours (T-test, p>0.05).
These results indicate that BCL3 deficiency does not alter the same set of motility-related genes 
in whole tum our samples. However, trends were observed which could indicate that BCL3 may have an 
effect on a smaller sub-population of cells within the tum our that have high metastatic potential.
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Figure 5.14: QRT-PCR analysis o f  m otility- and invasion- related genes in M M T V /N 2 tumours
RNA was extracted from BcI3+/+/M M T V /N 2 and B c lj '/M M T V /N i  tumours and QRT-PCR directed against a 
number of previously identified motility- and invasion-related genes was performed. No significant 
differences were identified in the Nme family of genes (A, T-test, p>0.05). In a cohort of three, loss of Bcl3 
resulted in an insignificant increase in the expression of Tim pl (B, T-test, p>0.05). Ig f lr  mRNA expression 
was significantly reduced in the absence of Bcl3 (C, T-test, *=p<0.05). The expression of Cavl, Timpl and 
Arhgdib was analysed in a larger cohort of six tumours. Trends, but no significant differences in the 
expression of these genes were observed (D, T-test, p>0.05). Error bars represent ± SEM.
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5.2.12 Loss of BCL3 does not alter the mRNA or protein expression of Caveolin 1 in
M M TV /N 2 tumours
M icroarray and QRT-PCR data from both the M G 1361 cell lines and the M M T V /N 2 tumours 
consistently showed Cavl to be up-regulated upon Bcl3 depletion, although this change was insignificant 
in early-stage (approximately 500 m m 3) tumours. It was hypothesised that there may be a greater 
regulation of this metastases-related gene in later-stage tumours. In order to establish this, RNA and 
protein w ere harvested from late-stage (approximately 4000m m 3) BcI3+i+/M M T V /N 2 and Bcl3'h 
/M M T V /N 2 tum ours and subjected to QRT-PCR and western analysis directed against Cavl.
Figure 5.15A shows Cavl mRNA expression to be increased in BcI3'i '/M M T V /N 2 tumours 
compared w ith  BcI3+/+/M M T V /N 2 tumours. This difference, however, was found to be statistically 
insignificant (T-test, p>0.05), again due to a high degree of biological variation and low sample sizes 
(n=3). W estern analysis of late-stage tumours revealed varying degrees o f CAV1 protein expression 
within cohorts (Figure 5.15B), but this did not correlate with BCL3 status, indicating that BCL3 does not 
directly regulate CAN/l to alter the metastatic potential of M M T V /N 2 tumours.
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Figure 5 .15: BCL3 does not regulate Caveolin 1 in late  stage M M T V /N 2 tumours
RNA and protein was extracted from BcI3+/+/M M T V /N 2 and BcI3'/~ /M M TV/N 2 tumours and QRT-PCR and 
western analysis directed against Caveolin 1 was performed. No significant differences in Cavl mRNA 
expression were observed (A, n=3, error bars represent ± SEM, T-test, p>0.05). High variation in the 
protein expression of Caveolin 1 was observed but this did not correlate with BCL3 status (B). Equal 
loading was confirmed by Tubulin.
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5.3 Discussion
Previous studies have identified a number of possible mechanisms by which NF-kB exerts its 
pro-oncogenic effect. These mechanisms include direct transcriptional regulation of cancer-related genes 
(reviewed in Basseres and Baldwin 2006) and more recently an involvement in regulating both EMT 
(Chua, Bhat-Nakshatri e t al. 2007; Criswell and Arteaga 2007; Liu, Sakamaki et al. 2010) and breast cancer 
stem /progenitor cell populations (Pratt, Tibbo et al. 2009; Liu, Sakamaki et al. 2010). Data presented in 
chapter 4 dem onstrated that BCL3 is able to exert similar pro-oncogenic effects. Although BCL3 has 
previously been implicated in the transcription of cancer-related genes (W esterheide, Mayo et al. 2001; 
Kashatus, Cogswell et al. 2006; Massoumi, Chmielarska et al. 2006; Park, Chung et al. 2006; Massoumi, 
Kuphal e t al. 2009; Miyazaki, Simizu et al. 2010), in depth investigation into the exact mechanism behind 
this has not been as well studied. The aim of this chapter was to elucidate some of the mechanisms by 
which BCL3 promotes ERBB2-driven tumourigenesis and, in particular, metastases.
5.3.1 The metastatic defect in BCL3 deficient tumour cells is due to a cell autonomous
effect involving motility rather than changes in EMT or the stem/progenitor cell
population
Initially, the question of w hether BCL3, like NF-kB, was over-expressed in ERBB2-positive cells 
was analysed. This was found to be the case (Figure 5.1) and lead to the use of the ERBB2-positve, 
M M T V /N K  tum our derived, M G 1361 cells in this study. The key findings from M G1361 Bcl3 SiRNA 
experiments w ere  that while suppression of BCL3 had no effect on the proliferation of cells in normal 
growth conditions (Figure 5.3), it did have a profound effect on the metastatic properties of cells as 
dem onstrated by both in vivo and in vitro experimental metastases models (Figure 5.4&5.5).
In order for cancer cells to successfully colonize a secondary site, they must detach from the  
primary tum our using extracellular matrix-degrading proteases, intravasate and survive in the blood 
stream, and then extravasate out o f the vasculature to seed and grow in the target tissue. In an attem pt 
to understand which of these stages are regulated by BCL3, intravenous tail vein experiments were  
perform ed. In this experim ental metastases model, the anoikis resistance and invasive properties of 
tum our cells are critical for the ir survival and extravasation out of the blood stream, primarily during the  
first few  hours after injection into the circulation. Based on the kinetics of SiRNA gene knock-down, 
transfected cells w ere likely to have maximal Bcl3 silencing imm ediately after injection into the blood 
stream. Therefore, the use o f transient SiRNA restricted the suppression of BCL3 activity to the crucial 
w indow of survival in the blood stream and extravasation out of it, w ith a release of this inhibition during 
the later stages of colonization and secondary tum our growth in the lungs. Thus, the role o f BCL3
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specifically in anoikis resistance and extravasation, rather than the subsequent steps was primarily 
addressed in this experiment.
Results revealed that Bc/3-suppressed cells produced less metastatic lung lesions than controls 
(Figure 5.4A) which indicated a requirem ent for BCL3 in either the anoikis resistance or extravasation 
stages o f the m etastatic process. Subsequent in vitro experiments dem onstrated that BCL3 had no effect 
on the ability o f cells to avoid anoikis (Figure 5.6), suggesting that it has a more crucial role to play in 
promoting the extravasation of cells out of blood vessels and into secondary tissue sites. Interestingly, 
when Bcl3 suppressed cells did form metastases, they were larger in size than controls (Figure 5.4B). It is 
possible that the Bc/3-depleted cells that were actually able to extravasate from the blood stream were 
highly aggressive w ith up-regulated alternative survival pathways. In comparison to controls, these cells 
may be m ore readily able to colonise and grow at secondary sites, particularly following the release of 
Bcl3 inhibition. Subsequent in vitro Boyden chamber experiments demonstrated that Bcl3 suppression 
reduced both the migratory and invasive capacity of M G1361 cells (Figure 5.5), which taken together 
with results from  tail vein and anoikis resistance experiments suggests that BCL3 promotes the 
extravasation o f cells by enhancing their intrinsic migratory and invasive capacity.
Collectively, these data imply that the reduced ability of BCL3-deficient cells to metastasise to 
the lungs is, at least in part, due to a cell autonomous effect that is independent of the tum our 
m icroenvironm ent. W hether BCL3 also regulates broader processes such as angiogenesis and 
inflam m ation to m ediate disease progression remains inconclusive. Intriguingly, however, loss of STAT3 
has previously been shown to delay the metastatic progression of ERBB2-positive tumours via both 
direct cell autonomous mechanisms and through effects on the tum our microenvironment (Ranger, Levy 
et al. 2009). Like NF-kB, STAT3 is pro-apoptotic during mammary involution (Chapman, Lourenco et al.
1999) but is paradoxically up-regulated in many malignancies including breast cancer (Hsieh, Cheng et al. 
2005; reviewed in Yu and Jove 2004). As Bcl3 is a downstream transcriptional target of STAT3, it is 
possible that the tw o co-operate to promote a metastatic phenotype and that BCL3 may also influence 
the tum our m icroenvironm ent to m ediate disease progression. It would be interesting to investigate this 
further in the future.
As NF-kB has previously been implicated in promoting the process of EMT (Chua, Bhat- 
Nakshatri e t al. 2007; Criswell and Arteaga 2007), the question of whether BCL3 may also exert some of 
its pro-m etastatic effects via regulating this process was investigated. To this end, the protein levels of 
some key markers o f EMT w ere assessed. No BCL3-dependent differences in the protein expression of E- 
cadherin, Snail or Vim entin were identified in the MG1361 cells and furtherm ore, Vim entin and E- 
cadherin w ere not found to be regulated by BCL3 in M M T V /N 2 tumours. NF-kB has been shown to 
regulate a num ber o f other genes involved in the EMT process such as the transcriptions factors SLUG,
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TWIST, SIP, ZEB1 and ZEB2 (Chua, Bhat-Nakshatri et al. 2007; Criswell and Arteaga 2007). However, 
microarray analysis of M G 1361 cells subjected to Bcl3 suppression did not reveal differential expression 
of any o f these genes (data not shown) .Taken together these data suggest that BCL3 does not exert any 
of its pro-m etastatic effect by mediating an EMT switch in this cell type.
Recently, a great deal of interest has surrounded the study of cancer stem cells and their role in 
tumourigenesis and metastases. The cancer stem cell hypothesis proposes that cancer originates from  
stem or progenitor cells through de-regulation of their normally tightly controlled self-renewal pathways, 
generating tum ours that are driven by a small subset of tum our initiating cells (TICs). Researchers have 
recently shown that these cells also display increased invasion and migration (Hammond, Helbig et al. 
2003; Helbig, Valmaggia et al. 2003). Both ERBB2 and NF-kB signalling have been implicated in promoting 
cancer stem cell properties (Korkaya, Paulson et al. 2008; Pratt, Tibbo et al. 2009; Liu, Sakamaki et al. 
2010; Storci, Sansone et al. 2010) and so the effect of BCL3 on this population of cells was analysed using 
the functional mammosphere assay and known TIC markers. Transient suppression of Bcl3 did not 
significantly reduce the percentage of either primary or secondary mammosphere forming units present 
in M G 1361 cells (Figure 5.8). A major caveat to this work, however, is that, as mentioned above, 
suppression o f Bcl3 by SiRNA is only temporary. In fact, transcript levels w ere shown to return to 50% of 
controls as early as day 5 (Figure 5.2) indicating that by the end of this 14 day experim ent both control 
and Bcl3 SiRNA treated cells were likely to have equivalent Bcl3 expression. Data from this experim ent 
can therefore only serve to evaluate the effects of BCL3 on the initial anoikis-resistant cell population 
and the subsequent consequences that this early inhibition has on their self-renewal ability. This makes it 
only possible to conclude that suppression of Bcl3 does not affect the size of the initial anoikis-resistant, 
TIC population or the early ability of these cells to self-renew. In contrast, perm anent global inhibition of 
NF-kB has previously been shown to reduce the capacity of primary ERBB2-positive murine tum our cells 
to undergo self-renewal and form  secondary mammospheres (Cao, Luo et al. 2007). It is possible that 
perm anent suppression o f BCL3 may lead to a similar phenotype. A comparable experim ent whereby  
BcI3+/+/M M T V /N 2 and BcB'1 /M M T V /N 2 primary tum our and pre-neoplastic cells were analysed for their 
m am m osphere-form ing abilities was in fact, attem pted. Unfortunately however, neither cell type form ed  
mammospheres on any occasion, preventing any conclusions from being drawn. Further evaluation using 
a technique to perm anently suppress BCL3 in cell lines should be performed in the future.
Surprisingly, Bcl3 suppression resulted in a significant increase in cells displaying the stem/TIC  
m arker CD24. Both this study and previous reports have demonstrated that selection o f cells expressing 
CD24 enriches for TICs as dem onstrated by increased mammosphere form ation (Figure 5.10; Liu, Deng et 
al. 2007). However, CD24-positivity is clearly not the exclusive factor that defines w hether a cell becomes 
a TIC. This is dem onstrated by the fact that selection of CD24-positive parental M G 1361 cells did not
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result in 100% mammosphere form ation, but instead it simply enriched for this phenotype (Figure 5.10). 
This implies that although the majority of TICs may be CD24-positive, all CD24-positive cells are not 
necessarily TICs. It is therefore possible that as observed, Bcl3 suppression does prom ote cells to become 
CD24-positive, but the percentage of TICs within this population remains unaltered. This hypothesis 
seems likely as Bcl3 suppression did not result in an increase in mammosphere form ation (Figure 5.8) or 
in the percentage of cells displaying another TIC marker, ALDH1 (Figure 5.9). Further analysis of the  
effect o f BCL3 on TIC populations is beyond the scope of this thesis, however, future experiments 
utilising a m ore comprehensive range of markers on both cell lines and primary tum our cells could be 
perform ed. The gold standard experiment to determine the effect of a particular variable on TICs 
involves assessing the ability of cells to re-establish an entire tum our cell population upon serial dilution 
when injected back into a mammary fat pad. It would be interesting to conduct this experiment with  
BCL3 depleted cell lines or primaries to gain a more conclusive insight into w hether it regulates the TIC 
population.
5.3.2 Gene expression profiling of Bcl3-deficient tumour cells reveals a combination of 
differentially expressed motility and invasion related genes
Gene expression profiling of MG1361 cells subjected to Bcl3 suppression revealed differential 
expression o f a variety o f genes involved in regulating motility and invasion (Table 5.1). QRT-PCR analysis 
confirmed a significant up-regulation in the expression of the first three members of the Nme family of 
anti-m otility genes. Although putative NF-kB DNA binding sites w ere found in the promoters of these 
genes, transcriptional modulation of Nme genes by NF-kB has not previously been reported and possibly 
reflects a novel NF-kB/BCL3 mediated pro-motility pathway in this cell type.
Tim pl and Timp2 were also significantly up-regulated in response to Bcl3 suppression. Indeed, 
inhibition of NF-kB has previously been shown to result in an up-regulation of Tim pl expression in 
human gastric cancer cell lines (Jin, Pan et al. 2007). TIMPs act to inhibit the activity of M MPs which 
break down extracellular membranes enabling cancer cells to intravasate into the blood circulation or to  
extravasate out o f it (reviewed in Kim, Yu et al. 1998; Deryugina and Quigley 2006; Zhang, Yang et al. 
2010). Analysis of microarray data revealed that the MMPs themselves were not regulated at the  
transcriptional level by BCL3 (data not shown). However, as TIMPs inhibit MMPs post-transcriptionally 
(Murphy, Houbrechts et al. 1991; Willenbrock and Murphy 1994; Huang, Meng et al. 1997) it is likely that 
changes in the ir activity would only be identified at the protein level. The functional output o f the BCL3- 
mediated regulation o f Timp genes could be studied in the future by utilising zymography techniques to 
analyse the activity o f M M Ps in response to BCL3 suppression. Overall, the regulation of Timp gene 
expression suggests that BCL3 promotes metastatic properties of cells by indirectly up-regulating MMPs.
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This further supports the previously proposed hypothesis that it plays a major role in mediating the  
extravasation stage of the metastatic process in which MMPs are so vital.
Disappointingly, none of the motility-related genes identified on the microarray were also 
significantly regulated by BCL3 in M M T V /N 2 tumours, although there was a trend towards an increase in 
Tim pl, C avl and Arhgdib in the BcI3'/'/M M T V /N 2 tumours. It is possible that larger changes in the  
expression of these genes may occur in small tum our cell populations, for example, in those invading 
cells at the edge of the tum our. This hypothesis is difficult to prove although possible future experiments 
could involve analysis of the protein expression of possible targets on whole tum our sections by IHC.
5.3.3 Summary
In summary, the data presented in this chapter has established that, in accordance with  
previous in vivo studies in chapter 4, suppression of BCL3 results in a reduction in the motility and 
invasive capacity o f murine ERBB2-positve tum our cells in vitro. The data suggests that in the M M T V /N 2 
model, BCL3 may directly mediate the ability of tum our cells to metastasize to the lung in a cell 
autonomous manner. Any additional effects that BCL3 has on the on tum our microenvironment, such as 
inflam m ation or angiogenesis remain to be elucidated and deserve further attention in the future.
All data up to this point has been collected from mouse models of ERBB2-positive breast 
cancer. To evaluate more effectively whether BCL3 is likely to have similar effects in humans, it is 
essential to  use models, such as human tum our-derived cell lines, that more closely recapitulate the  
genetic complexities of the human disease. This will therefore be the primary focus of chapter 6.
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Chapter 6: Introduction
6.1 Introduction
In the previous two chapters, BCL3 was shown to have a profound effect on ERBB2-driven 
m ammary carcinogenesis in both an in vivo mouse model of breast cancer and in a mouse mammary  
tum our cell line. W hile this provides substantial evidence that it has a pro-oncogenic role to play in the  
initiation and progression of breast cancer, there are several limitations in the use of any mouse model 
system to recapitulate the human disease. One such lim itation stems from the fact that mammary  
tumours arising in genetically engineered mouse models are, by definition, largely genetically 
homogeneous and fail to  adequately capture the substantial genetic heterogeneity of the human 
disease. Generally speaking, any given mouse model can mimic only one, or at best a small subset, o f the 
different types of breast cancer that have been found to occur in humans. This is certainly the case in the  
M M T V /N 2 model. M am m ary tumours driven by the M M T V /N 2 transgene are histologically comparable to 
human Ductal Carcinoma in situ (DCIS) (Cardiff and Wellings 1999), in which ERBB2 is over-expressed in 
40-60%  of high grade cases (Lodato, Maguire et al. 1990; Somerville, Clarke et al. 1992). W hile this 
observation indicates that it is a suitable model for studying the effects o f BCL3 on ERBB2-positive DCIS, 
it would be inappropriate to use data generated from M M T V /N 2 models to draw conclusions about its 
potential oncogenic role in any other subtype of the disease. A second lim itation in using the M M T V /N 2 
mouse model and tum our cell lines derived from it, is that expression o f the Neu transgene is driven by a 
strong viral prom oter which does not effectively im itate the endogenous human ERBB2 prom oter and 
has doubtful physiological relevance to the human disease. Furthermore, there are inherent interspecies 
differences between mice and humans that may or may not directly impact the disease. One such 
example is ER, which, in some subtypes of the human disease, is highly expressed (Perou, Sorlie et al.
2000) but, in contrast, is generally low or absent in tumours from most mouse models (Herschkowitz, 
Simin et al. 2007). M any of these limitations can be overcome by the use of human breast cancer cell 
lines.
Cultured human tum our-derived cell lines have previously been shown to have genetic 
alterations that reflect the primary tum our from which they came (Neve, Chin et al. 2006), rendering 
them  a useful tool to investigate the molecular mechanisms involved in d ifferent subtypes o f the human 
disease. Breast cancer is commonly sub-divided into five different types, namely normal-like, luminal A, 
luminal B, basal-like or ERBB2-positive, according to certain gene expression profiles assessed by 
microarrays (Sotiriou, Neo et al. 2003). These different subtypes can be used to predict clinical outcome, 
with luminal A cancers having the best prognosis and ERBB2-positive and basal-like tum ours being more 
aggressive w ith a worse prognosis (Sotiriou, Neo et al. 2003).
As previously discussed, NF-kB activation is associated with both EGFR and ERBB2 signalling 
(Biswas, Cruz et al. 2000; Biswas, Shi et al. 2004). M ore recently, it has been shown to be highly active in
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a large proportion o f basal breast cancer cell lines (Yamaguchi, Ito et al. 2009) and also in some human 
basal breast tumours (Biswas, Shi et al. 2004). Basal tumours often over-express EGFR (Nielsen, Hsu et al. 
2004; Livasy, Karaca et al. 2006) and are generally negative for ERBB2 and for the oestrogen and 
progesterone receptors, in which case they are designated 'triple negative' tum ours (reviewed in Chacon 
and Costanzo 2010). The shortage of molecular therapeutic targets makes basal-like, triple-negative  
tumours difficult to treat (reviewed in De Laurentiis, Cianniello et al. 2010), thus identification o f new  
therapeutic targets to treat patients with these aggressive tumours is highly desirable.
Having previously demonstrated that inhibition of BCL3 had anti-m etastatic effects in ERBB2- 
driven murine models of breast cancer, the overall aim of this chapter was to establish w hether these 
effects might also be observed in a panel of human breast cancer cell lines. The cell lines investigated 
w ere chosen to represent the ERBB2-positive and EGFR-positive, disease subtypes in which NF-kB 
activation has previously been found to be most prevalent. In particular, the M DA-M B-231 cells were  
chosen as a model o f the difficult to treat basal-like, and triple negative breast cancer subtype.
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6.2 Results
6.2.1 BCL3 is highly expressed in ERBB2-positive human breast cancer cell lines
As discussed previously, NF-kB activity has been shown to be strongly associated with EGFR 
receptor family signalling in breast cancer. Work from chapter 4 further dem onstrated that Bcl3 was 
highly expressed in ERBB2-positive murine mammary cells. In order to determ ine w hether this was also 
the case in human breast cancer cells, a panel of human cell lines displaying different ERBB2 and EGFR 
protein levels were analysed for BCL3 expression.
Firstly, to confirm the ERBB2 and EGFR status of each cell line, whole cell protein lysates were  
prepared for subsequent western analysis. This revealed that in accordance with previous reports 
(Clinchy, Gazdar e t al. 2000; Neve, Chin et al. 2006), high ERBB2 protein levels were detected in the
HCC1954 and SKBR3 cell lines, whereas very low levels were detected in the ZR-75-1 cells and it was
completely absent in the M DA-M B-231 cell line (Figure 6.1A). In contrast, the ZR-75-1 and M DA-M B-231  
cells expressed very high EGFR protein levels, whereas lower levels were present in the HCC1954 cells 
and it was undetectable in the SKBR3 cells. Equal loading of protein between samples was confirmed by 
visualising levels o f the housekeeping protein, Tubulin (Figure 6.1A). This analysis confirmed that the four 
cell lines have differing combinations of ERBB2 and EGFR receptor expression, representing different 
subclasses o f breast cancer.
In order to establish the relative BCL3 expression in these cell lines, QRT-PCR was performed. 
Four separate wells o f each cell line were grown to 70% confluency and RNA was isolated for subsequent 
cDNA preparation and BCL3 QRT-PCR analysis. Gene expression was normalised to the house keeping 
gene 6-ACTIN. Figure 6.1B shows that the ERBB2-positive, HCC1954 and SKBR3 cell lines, have almost 7 
fold higher BCL3 expression in comparison to the ERBB2-negative, M DA-M B-231 and ZR-75-1 cells. This 
indicates that high BCL3 expression correlates with ERBB2 but not EGFR positivity.
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Figure 6.1: BCL3 expression correlates with high ERBB2 rather than EGFR protein levels
Total protein was extracted from HCC1954, MDA-MB-231, ZR-75-1 and SKBR3 cells and subjected to  
western analysis (A). HCC1954 and SKBR3 cells had high ERBB2 protein levels whereas it was almost 
absent in the ZR-75-1 cells and completely absent in MDA-MB-231 cells. EGFR protein levels were highly 
expressed in M DA-MB-231 and ZR-75-1 cells whereas lower levels were found in the HCC1954 cells and 
it was completely absent in the SKBR3 cells. Equal loading was confirmed by Tubulin (A). RNA was 
harvested from the same cell lines for subsequent QRT-PCR analysis (B). The ERBB2-positive HCC1954 
and SKBR3 cells had almost 7 fold more BCL3 mRNA than the ERBB2-negative M DA-MB-231 and ZR-75-1 
cells. Data represent samples harvested from 4 separate wells and error bars represent ± SEM. BCL3 
mRNA expression was normalised to 6-ACTIN mRNA expression.
178
Chapter 6: Results
6.2.2 Optimisation of BCL3 SiRNA in human breast cancer cell lines
Having established the relative ERBB2, EGFR and BCL3 expression in these cell lines, a num ber 
of experiments aimed at determining w hether BCL3 suppression can have similar anti-m etastatic effects 
in human cells as it does in mouse models, were performed. These experiments adopted an SiRNA 
approach to efficiently suppress BCL3.
As with the mouse cell lines, the SiRNA technique was optimised on the M DA-M B-231 cell line 
according to the manufacturer's protocol. Cells were plated in transfection media containing either 
lO nM  of human BCL3 SiRNA or lO nM  of control, non-targeting SiRNA and incubated for 48 to 120 hours. 
RNA from triplicate wells was isolated at appropriate tim e points and cDNA was prepared before 
subsequent BCL3 QRT-PCR analysis. Gene expression was routinely normalised to 6-ACTIN. Results show 
that at all tim e points analysed, BCL3 transcript levels were reduced to less than 30% of constitutive 
levels (Figure 6.2A) in M DA-M B-231 cells. Semi-quantitative PCR confirmed this (Figure 6.2B). M DA-M B- 
231 cells w ere therefore transfected for 48 hours in all subsequent experiments.
HCC1954, ZR-75-1 and SKBR3 cells were also transfected with lO nM  BCL3 or control SiRNA for 
48 hours and QRT-PCR analysis was performed to confirm that BCL3 expression could be suppressed. 
BCL3 transcript levels were suppressed to less than 30% of constitutive levels in all cell lines (Figure 
6.3A). This was confirmed by semi-quantitative PCR (Figure 6.3B). On the basis of these results, all cells 
were transfected for 48 hours and QRT-PCR was routinely performed prior to every SiRNA experim ent to  
ensure that BCL3 expression was suppressed to less than 30% of constitutive levels.
In order to ensure that BCL3 was suppressed at the protein level, cell lines were transfected for 
48 hours and protein was harvested for subsequent western analysis. BCL3 protein expression was 
clearly lost in both the HCC1954 (Figure 6.3C) and SKBR3 (Figure 6.3D) cells. However, base-line BCL3 
protein expression was completely undetectable by western blotting with three separate antibodies in 
the ERBB2-negative M DA-M B-231 and ZR-75-1 cells (data not shown) and so the effect of BCL3 SiRNA at 
the protein level in these cell lines could not be established.
179
Chapter 6: Results
A
B
Bcl3
Beta-Actin
Time (Hr): 48 48 72 72 96 96 120 120
Control SiRNA: + - + - + - + -
Bcl3 SiRNA: - + . + . + . +
Figure 6.2: BCL3 SiRNA efficiently suppresses BCL3 mRNA expression in M DA-M B-231 cells
MDA-MB-231 cells were transfected for 48-120 hours with lO nM  BCL3 or control SiRNA before being 
harvested for QRT-PCR analysis. BCL3 mRNA expression was efficiently suppressed to less than 30% of 
constitutive levels at all time-points analysed (A, error bars represent ± SEM of triplicate wells, data is 
represented as BCL3 mRNA expression relative to 6-ACTIN mRNA expression). This was confirmed by 
semi-quantitative PCR (B).
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Figure 6.3: BCL3 SiRNA efficiently suppresses BCL3 expression in HCC1954, ZR-75-1 and SKBR3 
cells
HCC1954, ZR-75-1 and SKBR3 cells were transfected with lO nM  BCL3 or control SiRNA for 48 
hours before being harvested for QRT-PCR analysis. BCL3 mRNA expression was efficiently 
suppressed to less than 30% of constitutive levels in all three cell lines (A, error bars represent ± 
SEM of triplicate wells, data is represented as BCL3 mRNA expression relative to 6-ACTIN mRNA 
expression). This was confirmed by semi-quantitative PCR (B). Total proteins were also harvested 
from cell lines transfected with BCL3 SiRNA for 48 hours and subjected to western analysis. BCL3 
SiRNA efficiently suppressed BCL3 protein levels in HCC1954 (C) and SKBR3 (D) cells. Equal 
loading was confirmed by Tubulin.
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6.2.3 Suppression of BCL3 reduces the viability of human breast cancer cell lines in 
adherent growth conditions
Previous reports have demonstrated that BCL3 can promote cell survival in a variety of contexts 
(Ong, Hackbarth et al. 1998; Rebollo, Dumoutier et al. 2000; W esterheide, M ayo et al. 2001; Dolgachev, 
Thomas et al. 2007). W ork in chapter 5, however, showed that suppression o f BCL3 did not reduce the 
viability o f ERBB2-positive murine mammary cancer cells. In order to establish the effects of BCL3 on 
human ERBB2- or EGFR-positive breast cancer cells, viability assays w ere perform ed on HCC1954, MDA- 
M B-231, SKBR3 and ZR-75-1 cells subjected to BCL3 SiRNA.
All cell lines w ere transfected with lO nM  BCL3 or control SiRNA and incubated for 48 hours. 
RNA was harvested for subsequent QRT-PCR analysis to ensure that BCL3 expression was suppressed to 
less than 30% of constitutive levels. All other cells were counted and re-seeded into 96 -w e ll plates. Live 
cell counts and CellTiter-Blue assays were performed on all cell lines 24 hours later.
Trypan blue exclusion counts revealed that BCL3 inhibition resulted in a significant reduction in 
the num ber o f live cells present 24 hours after seeding in three out o f the four cell lines tested (Figure 
6.4A, mean+SEM num ber o f live cells per well was: 72350±4127 for M D A -M B -231 control SiRNA vs 
4164212414 for M D A -M B -231 BCL3 SiRNA, Mann-W hitney U-Test, p=0.000; 5035712150 for ZR-75-1 
control SiRNA vs 3528512376 for ZR-75-1 BCL3 SiRNA, M ann-W hitney U-Test, p=0.0002 and 25714+1711  
for SKBR3 control SiRNA vs 1842811461 for SKBR3 BCL3 SiRNA, M ann-W hitney U-Test, p=0.0298). In the  
EGFR and ERBB2-double positive HCC1954 cells, there was only an insignificant trend towards a 
reduction in the num ber of live cells present (Figure 6.4A, m eaniSEM  num ber o f live cells per well was 
4377712614 for HCC1954 control SiRNA vs 36111+2465 for HCC1954 BCL3 SiRNA, M ann-W hitney U-Test, 
p>0.05).
These results w ere confirmed in CellTiter-Blue assays which showed significant reductions in 
the overall num ber of viable cells present a fter BCL3 inhibition compared to controls in the M DA-MB-231  
(23% reduction, M ann-W hitney U-Test, p=0.0106), ZR-75-1 (42% reduction, M ann-W hitney U-Test, 
p=0.002) and SKBR3 cells (32% reduction, M ann-W hitney U-Test, p=0.0051) but not in the HCC1954 cells 
(2% increase, M ann-W hitney U-Test, p>0.05; Figure 6.4B).
CYCLIN D1 has previously been implicated in mediating NF-kB and BCL3-dependent changes in 
cell proliferation (W esterheide, M ayo et al. 2001). In order to establish w hether this was the mechanism 
responsible for the observed changes in cell viability, CYCLIN D1 QRT-PCR was performed on human cell 
lines subjected to BCL3 SiRNA. No significant changes in the expression o f this gene were observed in any 
of the cell lines tested (Figure 6.4C, T-test for all comparisons, p>0.05) indicating that CYCLIN D1 is not 
specifically responsible for BCL3 dependent changes in the viability of these cell lines.
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Figure 6.4: BCL3 suppression reduces the viability o f M DA -M B -231, ZR-75-1 and SKBR3 cells
MDA-MB-231, ZR-75-1, SKBR3 and HCC1954 cells were transfected with BCL3 or control SiRNA 
for 48 hours before either being harvested for RNA and subsequent QRT-PCR analysis or being 
subjected to viability assays. After 24 hours in normal adherent growth conditions, 
suppression of BCL3 resulted in significantly reduced viability of M DA-M B-231, ZR-75-1 and 
SKBR3 but not HCC1954 cells as determined by live cell counts (A) and CellTiter-Blue assays (B, 
Mann-W hitney U-test, *=p<0.05, **=p<0.01). Data represent 6 independent wells. CYCLIN D1 
mRNA expression was assessed by QRT-PCR and was found to be unchanged in all cell lines 
after BCL3 suppression (C, T-test for all comparisons, p>0.05). Data is represented as CYCLIN 
D1 mRNA levels relative to 6-ACTIN mRNA levels. Error bars represent ± SEM.
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6.2.4 BCL3 inhibition reduces the motility of human ERBB2-positive and negative breast
cancer cell lines
Having previously shown in chapters 4 and 5 that loss o f BCL3 has anti-m etastatic effects in 
mouse models o f breast cancer, it was o f interest to determ ine w hether these effects might also be 
observed in differing subtypes o f the human disease. This was achieved by subjecting ERBB2-positive and 
EGFR-positive hum an breast cancer cell lines to BCL3 SiRNA before perform ing Boyden cham ber motility  
assays.
Cells w ere  treated  w ith  lO nM  BCL3 or control SiRNA for 48 hours and RNA was harvested to 
ensure sufficient BCL3 suppression. Cells were re-seeded onto Boyden m otility  chambers in low serum  
media and incubated for 24 or 48  hours to allow the m ovem ent o f cells across m em branes down a 
serum concentration gradient.
Consistent w ith  the observations in mouse tum our cells, a significant decrease in cell motility  
was observed in th ree  o f the four human breast cancer cell lines tested. BCL3 suppression resulted in a 
56% reduction in the  m igratory capacity o f the highly motile ERBB2-negative, M D A -M B -231  cells (Figure 
6.5A&B, M an n -W h itn ey  U-test, p=0.0008). Similar results were observed in the ERBB2-low, ZR-75-1 cells, 
w ith BCL3 inhibition resulting in a 49% reduction in their migratory capacity (Figure 6.5C&D, M ann- 
W hitney U-test, p=0.0002). The ERBB2-positive, SKBR3 and HCC1954 cells w ere found to be far less 
motile than the  M D A -M B -231  and ZR-75-1 cells. These two cell lines w ere therefore  treated with  
hepatocyte g ro w th /scatter factor (HGF) whilst on Boyden chambers to increase their base-line m otility  
(Arihiro, Oda e t al. 2000). Suppression of BCL3 in the HGF treated-SKBR3 cells resulted in a 47%  reduction 
in cell m otility  through Boyden membranes (Figure 6.6C&D, M ann-W hitney U-test, p=0.0304). 
Interestingly, the  m igratory capacity o f the HGF-treated, ERBB2- and EGFR- double positive HCC1954 
cells was unaffected by BCL3 inhibition (Figure 6.6A&B, M ann-W hitney U-test, p>0.05).
Having previously shown that BCL3 suppression resulted in reduced viability o f some of the  
human cell lines, it was im portant to  ensure that changes in cell numbers crossing the membranes was 
not simply due decreased proliferation of the cells resulting in low er cell numbers. To achieve this, 
parallel wells w ere  plated in norm al adherent tissue culture plates in low serum media for the duration  
of the experim ents and counted at the same tim e as the Boyden chambers w ere fixed. In these low  
serum conditions there  w ere  only slight but insignificant decreases in cell numbers that were not big 
enough to account fo r the observed changes in motility (Figure 6.5B&D second set o f bars, Figure 
6.6B&D second set o f bars).
These results dem onstrate that in accordance with previous data from  mouse models, 
suppression o f BCL3 has pronounced anti-m otility effects on human cell lines and that these effects are 
not restricted to  ERBB2-positve cells only.
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Figure 6 .5  BCL3 suppression reduces the m igratory capacity o f  ERBB2-negative, EGFR-positive 
hum an breast cancer cell lines
M D A -M B -231 and ZR-75-1 cells w ere transfected with BCL3 or control SiRNA for 48 hours before 
being re-plated onto Boyden m otility chambers. Cells were left for 24 hours before being fixed and 
stained on Boyden cham ber membranes. Representative images of migrated M DA -M B -231 (A) and 
ZR-75-1 (C) cells on Boyden cham ber membranes are shown. Scale bars indicate 100pm . Migrated  
cells (B&D, first set o f bars) w ere counted from three fields of view o f each of three replicate Boyden 
chambers and graphically represented as a percentage of the num ber o f control cells counted. Three 
parallel wells w ere plated for the duration of the experiments in normal adherent growth conditions 
in low serum m edia. Live cell counts were performed at the end of each experim ent and 
represented as a percentage o f the num ber of live control cells present (B&D, second set of bars). 
Suppression o f BCL3 resulted in a significant reduction in the percentage o f cells migrating through 
Boyden chambers in both the M DA -M B -231 (B, *=M ann-W hitney U-test, p=0.0008) and ZR-75-1 (D, 
*=M an n -W h itn ey  U-test, p=0.0002) cells lines. The number o f live cells present in parallel wells at 
the end o f the experim ent was not significantly affected by BCL3 suppression in e ither cell line (B&D, 
M ann-W hitney U-test, p>0.05). Error bars represent ± SEM o f triplicate Boyden chamber 
experiments.
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Figure 6.6: BCL3 suppression reduces the m igratory  capacity o f  SKBR3 cells but not HCC1954 cells 
SKBR3 and HCC1954 cells were transfected w ith BCL3 or control SiRNA for 48 hours before being re­
plated onto Boyden motility chambers in the presence of HGF. Cells were left for 48 hours before 
being fixed and stained on Boyden cham ber membranes. Representative images of migrated 
HCC1954 (A) and SKBR3 (B) cells on Boyden chamber membranes are shown. Scale bars indicate 
100pm . M igrated cells (B&D, first set of bars) were counted from  three fields of view of each of 
three replicate Boyden chambers and graphically represented as percentage of the num ber of 
control cells counted. Three parallel wells were plated for the duration of the experiments in normal 
adherent growth conditions in low serum media. Live cell counts were perform ed at the end of each 
experim ent and represented as a percentage of the number of live control cells present (B&D, 
second set o f bars). BCL3 suppression did not significantly affect the m otility o f HCC1954 cells (B, 
M ann-W hitney U-test, p>0.05) but resulted in a significant reduction in the motility of SKBR3 cells 
(D, *=M ann-W hitney  U-test, p=0.0304). The number of viable cells present in low serum conditions 
at the end o f the experim ent was not significantly affected by BCL3 suppression in either cell line 
(B&D, M ann-W hitney U-test, p>0.05). Error bars represent ± SEM of triplicate Boyden chamber 
experiments. 186
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6.2.5 Suppression of BCL3 results in a reduction in the anchorage-independent survival of
ZR-75-1 cells
Having established that BCL3 has pro-proliferative and m otility  functions in human breast 
cancer cells, the affect o f BCL3 suppression on the ability o f cells to resist anoikis was investigated as this 
has previously been shown to prom ote breast cancer progression and metastasis by enabling survival in 
the vascular or lymphatic channels (Doum a, Van Laar e t al. 2004).
M D A -M B -231, ZR-75-1, SKBR3 and HCC1954 cells w ere transfected for 48  hours w ith  lO nM  
BCL3 or control SiRNA and RNA was harvested for subsequent QRT-PCR analysis to  ensure efficient BCL3 
suppression. Cells w ere then re-seeded into ultra-low -attachm ent plates in com plete growth m edium  
and incubated for 24 hours at which tim e-po in t CellTiter-Blue viability assays w ere perform ed.
Loss o f BCL3 did not affect the viability o f M DA -M B -231, SKBR3 or HCC1954 cells grown in 
anchorage-independent conditions (Figure 6.7, M ann-W hitney U-test for all comparisons, p>0.05). There  
was, however, a significant decrease in the viability o f the BCL3 suppressed ZR-75-1 cells com pared to  
controls (Figure 6.7, 33% decrease, M ann-W hitney U-test, p=0.0022), indicating that, in this cell line, loss 
of BCL3 resulted in increased anoikis.
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Figure 6.7: BCL3 suppression results in a significant reduction in the viability o f ZR-75-1 cells in 
anchorage-independent conditions
M DA-M B-231, ZR-75-1, SKBR3 and HCC1954 cell lines were transfected with BCL3 or control SiRNA for 
48 hours before being re-plated in anchorage independent conditions. CellTiter-Blue assays were 
performed 24 hours later. BCL3 suppression significantly reduced the viability of ZR-75-1 cells in non­
adherent conditions (*=M ann-W hitney U-test, p=0.0022) whereas it had no effect on the other cell 
lines tested (M ann-W hitney U-test for all comparisons, p>0.05). Data represent results from 6 wells of 
the same transfection experiment. Error bars represent ± SEM.
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6 .2 .6  BCL3 suppression does n o t a lte r  th e  expression o f e p ith e lia l-to -m es en c h ym a l 
tra n s itio n  m arkers  in M D A -M B -2 3 1  cells
In order to determ ine whether inhibition of BCL3 had anti-m otility effects due to suppression 
of the EMT process, the MDA-MB-231 cells were treated with lO nM  BCL3 or control SiRNA for 48 hours, 
and whole cell lysates were extracted on ice for subsequent western analysis of tw o key markers of EMT, 
E-cadherin and Vimentin.
W estern analysis revealed that there were no clear changes in the expression of E-cadherin or 
Vim entin in BCL3 suppressed cells suggesting that BCL3 did not mediate an EMT switch, as defined by 
these molecular markers, in this cell line. Equal loading of protein between samples was confirmed by 
visualising levels of the housekeeping protein, Tubulin (Figure 6.8).
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Figure 6.8: BCL3 suppression has no effect on the expression EM T markers in M DA -M B -231 cells
M DA-M B-231 cells w ere transfected with BCL3 or control SiRNA for 48 hours. Cells were then 
harvested for total proteins and subjected to western analysis. No changes were observed in the 
protein expression o f E-cadherin or Vimentin. Equal loading was confirmed by Tubulin.
189
Chapter 6: Results
6.2.7 Analysis of motility-related gene targets potentially regulated by BCL3
W ork in this chapter has so far shown that loss o f BCL3 inhibits the m otility of the EGFR- 
positive, ZR-75-1 and M D A -M B -231 cells, and the ERBB2-positive, SKBR3 cells. In order to determ ine  
w hether BCL3 regulated the same set o f m otility-related genes in these human breast cancer cell lines as 
it did in M G 1361  m urine tum our cells, the expression o f m otility-related gene targets identified from  the  
M G 1361 m icroarray analysis (see Chapter 5, sections 5 .2 .9& 5.2 .10) were assessed. As a comparison, the  
expression o f these genes was also assessed in the ERBB2- and EGFR-positive HCC1954 cells, the motility  
of which was unaffected by BCL3 suppression.
Hum an cell lines w ere transfected with lO n M  BCL3 or control SiRNA for 48  hours. The HCC1954 
and SKBR3 cells w ere treated w ith HGF during the last 24 hours o f transfection to increase the ir base-line 
m otility and to recapitulate the conditions in which Boyden cham ber m otility  experim ents were  
previously perform ed. Triplicate wells o f RNA w ere harvested for cDNA preparation and subsequent 
QRT-PCR analysis. Gene expression was normalised to the internal control, 6-ACTIN.
The first targets to be analysed w ere the four N M E  metastases suppressor genes that were  
identified to  be increased upon BCL3 suppression in M G 1361 cells. O f note, three d ifferent prim er sets 
w ere used in an a ttem p t to amplify N M E3. However, this gene could not be detected in any cell line by 
any set o f primers. QRT-PCR analysis directed against the o ther three N M E  genes showed that there  
w ere no outstanding changes in their expression in any of the cell lines analysed (Figure 6.9), although 
there was a very small but significant increase in N M E2  expression in the BCL3 suppressed HCC1954 cells 
com pared to controls (Figure 6.9D, 25% increase, T-test, p=0.0154).
Next, TIMP1  and TIMP2  were analysed. Interestingly, BCL3 suppression resulted in a significant 
up-regulation o f TIMP1 in comparison to control cells in three o f the four cell lines tested, including the  
HCC1954 cells whose m otility was unaffected by BCL3 suppression (Figure 6.10A,B&D, M DA -M B -231  
cells: 74%  increase, T-test, p=0.0013; ZR-75-1 cells: 81% increase, T-test, p=0.0002 and HCC1954 cells 
77% increase, T-test, p=0.0108). It was also increased by 43% in the BCL3 SiRNA treated  SKBR3 cells 
com pared to controls but this change was found to be insignificant (Figure 6 .IOC, T-test, p>0.05). 
Furtherm ore, BCL3 inhibition resulted in a significant 20% up-regulation o f TIMP2  in the SKBR3 cells 
(Figure 6 .10C, T-test, p=0.03). This, however, was not observed in any o f the o ther cell lines tested. These 
data indicate that, similarly to observations m ade in the M G 1361 m urine cell line (see Chapter 5, section 
5 .2.10), suppression o f BCL3 resulted in the up-regulation o f m em bers o f the TIM P  family o f genes in 
both ERBB2- and EGFR-positive human breast cancer cell lines. This up-regulation did not necessarily 
correlate w ith  the BCL3-mediated m otility phenotype as up-regulation o f TIMP1 was also observed in the  
HCC1954 cells.
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A num ber of the o ther targets identified in the M G 1361 m icroarray w ere also analysed in the  
human cell lines. There w ere no significant changes in any of the targets analysed in the ERBB2-negative, 
M D A -M B -231  or ZR-75-1 cells (Figure 6.11A&B, T-test for all comparisons, p>0.05). In the HCC1954 and 
SKBR3 cells, very small but significant changes w ere observed in the expression o f the Rho GDP 
dissociation inhibitor, ARHGDIB  that has previously been shown to be a metastases inhibitor in human 
cancer (Gildea, Seraj et al. 2002) (Figure 6.11C&D). However, the changes w ere inconsistent across the  
tw o  cell lines, w ith  BCL3 suppression resulting in an increase in ARHGDIB  in the HCC1954 cells (Figure 
6.11D) and a decrease in the SKBR3 cells (Figure 6.11C), indicating tha t changes in the expression of this 
gene are unlikely to be responsible for the observed BCL3-dependent m otility  phenotype. A significant 
increase in SPHK2 was also observed in the HCC1954 cells (Figure 6.11D). However, as this gene has only 
previously been shown to enhance EGF-stimulated m otility and as HCC1954 cells did not dem onstrate a 
BCL3-mediated m otility  phenotype, it is unlikely to be involved in regulating m otility  in response to BCL3 
suppression.
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Figure 6.9: QRT-PCR analysis o f  N M E genes in BCL3 suppressed human breast cancer cell lines 
RNA was harvested from M DA-M B-231, ZR-75-1, SKBR3 and HCC1954 cells that had been transfected 
with BCL3 or control SiRNA for 48 hours. QRT-PCR analysis directed against NME1, NME2, and NME4 
was performed. BCL3 suppression had no significant effect on the mRNA expression of any of the genes 
analysed in the MDA-MB-231 (A), ZR-75-1 (B) or SKBR3 (C) cell lines. BCL3 suppression resulted in a 
significant increase in NME2  mRNA expression in the HCC1954 cells (*=T-test, p=0.0154). Data 
represent three independent transfection experiments and error bars represent ± SEM. Graphs 
highlighted with a red title indicate cell lines in which suppression of BCL3 was previously shown to 
induce a m otility phenotype.
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Figure 6 .10: BCL3 suppression increases the mRNA expression o f  T IM P genes in hum an breast 
cancer cell lines
RNA was harvested from M D A -M B -231, ZR-75-1, SKBR3 and HCC1954 cells that had been transfected 
with BCL3 or control SiRNA for 48 hours. QRT-PCR analysis directed against TIMP1 and TIMP2  was 
perform ed. BCL3 suppression resulted in a significant increase in TIMP1 mRNA expression in the 
M DA -M B -231 (A), ZR-75-1 (B) and HCC1954 (D) cells (T-test, *=p<0.05, **= p < 0 .01 ) but not in the 
SKBR3 cells (C, T-test, p>0.05). TIMP2  mRNA expression was significantly increased in response to 
BCL3 suppression in the SKBR3 (C, T-test, *=p<0.05) cells but not in any other cell line tested (A, B & 
D, T-test, p>0.05). Data represent three independent transfection experiments and error bars 
represent ± SEM. Graphs highlighted with a red title indicate cell lines in which suppression of BCL3 
was previously shown to induce a m otility phenotype.
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Figure 6.11: QRT-PCR analysis o f  m otility-related genes in BCL3 suppressed human breast cancer cell 
lines
RNA was harvested from MDA-MB-231, ZR-75-1, SKBR3 and HCC1954 cells that had been transfected 
with BCL3 or control SiRNA for 48 hours. QRT-PCR analysis directed against motility-related genes that 
had previously been identified in chapter 5 was performed. BCL3 suppression had no significant effects 
on any of the genes analysed in the MDA-MB-231 (A) or ZR-75-1 (B) cells (T-test for all comparisons, 
p>0.05). A significant reduction ARHGDIB mRNA expression was observed in SKBR3 cells in response to 
BCL3 suppression (C, T-test, **=p<0.01). In the HCC1954 cells, BCL3 suppression resulted in a significant 
increase SPHK2 and ARHGDIB (D, T-test, *=p<0.05). Data represent three independent transfection 
experiments and error bars represent ± SEM. Graphs highlighted with a red title indicate cell lines in 
which suppression of BCL3 was previously shown to induce a motility phenotype.
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6.3 Discussion
This chapter has focussed on evaluating w hether the anti-tum ourigenic effects o f BCL3 
suppression on ERBB2-positive m urine breast tumours can be recapitulated in m ore clinically relevant 
human tum our-derived breast cancer cell lines. As NF-kB has previously been shown to be activated  
dow nstream  o f EGFR and ERBB2 (Biswas, Cruz et al. 2000; Biswas, Shi et al. 2004), the effect o f BCL3 
suppression specifically on cell types over-expressing these receptors was analysed.
6.3.1 BCL3 suppression reduces the viability and migratory capacity of both EGFR- and
ERBB2-positive human breast cancer cell lines
In contrast to  previous studies in M G 1361 murine m am m ary tum our cells, suppression o f BCL3 
was found to significantly reduce the viability o f three of the four cell lines tested, which included both 
EGFR and ERBB2-positive subtypes (Figure 6.4). These data imply that in some human breast cancers, 
BCL3 may have a m ore pronounced effect on tum our cell viability in situ than previous data generated  
from  mouse models have suggested. In support of this hypothesis, BCL3 has previously been shown to  
prom ote the proliferation and survival of a variety of cell types (Ong, Hackbarth et al. 1998; Rebollo, 
D um outier e t al. 2000; W esterheide, Mayo et al. 2001; Dolgachev, Thomas et al. 2007). Some reports  
have proposed th a t it elicits this response via activation of the CYCLIN D1 prom oter (W esterheide, Mayo  
et al. 2001; Park, Chung et al. 2006). However, QRT-PCR analysis o f the cell lines assessed here did not 
reveal any BCL3-mediated changes in CYCLIN D1 gene expression, suggesting a d ifferent, yet unknown, 
mechanism is responsible for the reduced proliferation observed.
In concordance w ith  previous experiments in murine M G 1361 cells, suppression o f BCL3 also
reduced the m igratory capacity o f the same three cell lines. This was not an artefact o f reduced cell
survival, as loss o f BCL3 did not affect cell viability in low serum, Boyden cham ber conditions. NF-kB has 
previously been im plicated in prom oting the invasive properties o f ERBB2-positive cells (M erkhofer, 
Cogswell e t al. 2010). How ever, this is the first tim e that BCL3 has been shown to m odulate the  m otility  
of human breast cancer cells, although it was recently shown to prom ote the migration of human 
m elanom a cells via activation o f the N-cadherin prom oter (Massoumi, Kuphal et al. 2009). Effects on this 
prom oter have not been evaluated in the present study but could be assessed in the future as a potential 
BCL3-mediated mechanism to  induce cell migration.
Having identified tha t suppression of BCL3 had anti-m etastatic effects on human cell lines, 
QRT-PCR analysis o f m etastases-related targets identified in the m icroarray from  chapter 5 was 
perform ed. This revealed that, similarly to the M G 1361 murine m am m ary tum our cell line, e ither TIMP1 
or TIMP2  w ere  consistently up-regulated in response to BCL3 suppression across all the cell lines 
analysed, suggesting a possible mechanism by which BCL3 mediates a pro-invasive phenotype. In order
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to investigate this possibility further, a num ber o f future experim ents could be perform ed, including ChIP 
on the TIM P  prom oters to establish which BCL3 m ediated changes in NF-kB DNA binding are observed or 
SiRNA suppression of both BCL3 and TIMPs to determ ine w hether this abolishes the BCL3-mediated 
phenotype.
O f note, both the viability and invasive capacity o f HCC1954 cells w ere  consistently unaffected  
in response to BCL3 suppression. A num ber o f possible reasons for this could be proposed. Firstly as 
these cells w ere  shown to have relatively high BCL3 expression (Figure 6.1), it is feasible that a 70%  
suppression o f BCL3 from  such high constitutive levels is not enough to result in a noticeable phenotype. 
Secondly, it is possible that although these cells have high levels of BCL3 mRNA and express both EGFR 
and ERBB2 receptors, they may have very low levels of NF-kB subunits for BCL3 to co-operate w ith. This, 
however, is an unlikely hypothesis, as a previous study dem onstrated that HCC1954 cells have a similar 
NF-kB DNA binding activity to SKBR3 cells (Yamaguchi, Ito et al. 2009) which w ere shown to respond to 
BCL3 suppression. A final possibility is that ERBB2 may preferentially signal via alternative pathways to 
elicit grow th and m otility responses in these cells. Indeed, ERBB2 has previously been shown to induce 
proliferation via activation of the PI3K pathway independently o f NF-kB signalling (M erkhofer, Cogswell 
et al. 2010).
One o f the m ajor observations from  data presented in this chapter was that BCL3 m ediated a 
profound effect on the proliferation and m otility o f both ERBB2- and EGFR-positive cell lines. Of 
particular interest was the significant response to BCL3 inhibition displayed by 'trip le negative' M DA-M B- 
231 cells, a disease subtype that has a poor prognosis and is currently difficult to  trea t (reviewed in De 
Laurentiis, Cianniello e t al. 2010). This effect was particularly rem arkable considering the comparatively 
low constitutive expression o f BCL3 in these cells (Figure 6.1). W ork from  Pratt e t al. (2009) suggested 
that human ERBB2-positive luminal cancers preferentially express NF-kB subunits involved in the  
canonical pathway whereas a large percentage of basal tum ours, which are generally EGFR-positive, 
express constituents o f the  non-canonical pathway. It is possible that due to its involvem ent in both NF- 
kB signalling pathways, BCL3 may be able to influence the progression o f both of these disease subtypes.
6.3.2 Summary
In sum mary, this chapter has established that suppression o f BCL3 can reduce the viability and 
m otility  o f both ERBB2- and EGFR-positive human breast cancer cell lines. Resistance to current therapies 
such as trastuzam ab, the first-line therapy for ERBB2-positve breast cancer, is prevalent (Cobleigh, Vogel 
et al. 1999; Vogel, Cobleigh et al. 2001; Vogel, Cobleigh et al. 2002; reviewed in Nahta and Esteva 2006) 
Mechanisms involved in this resistance can include the up-regulation of o ther members of the EGF- 
fam ily o f receptors (Ritter, Perez-Torres et al. 2007; Dua, Zhang et al. 2010). Results from this chapter 
dem onstrate that therapeutic inhibition of BCL3 could potentially block the downstream  effects o f both
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the ERBB2 and EGFR oncogenic pathways, reducing the possibility o f resistance. Taken together with  
data from  all previous chapters, these results make BCL3 a very attractive therapeutic target for both 
ERBB2-positve and EGFR-positive breast cancers.
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7.1 General Discussion
The m am m ary gland is a highly specialised organ that undergoes well co-ordinated cycles of 
cell proliferation, differentiation and program med cell death w ith each successive pregnancy. However, 
partly due to its function during pregnancy, this organ is also highly susceptible to  cancer with one in 
nine w om en in the western world developing breast cancer at some point in the ir life-tim e (Bray, 
McCarron et al. 2004).
NF-kB is up-regulated in a num ber o f human malignancies, including breast cancer. This family 
of transcription factors regulate genes involved in many pro-oncogenic processes including cell 
proliferation , cell survival, angiogenesis, m otility and invasion, and as such there  has been much interest 
in the use o f NF-kB inhibitors in the trea tm en t o f cancer. However, sustained global inhibition of NF-kB is 
likely to have serious adverse consequences on normal tissues, particularly those of the im m une system. 
An ideal trea tm en t strategy would be to selectively block the cancer-prom oting functions of NF-kB whilst 
ensuring tha t its normal physiological functions are retained. One possible way of achieving this could be 
to  target modifying NF-kB co-factors, such as BCL3.
W ith  this in mind, the aim o f this thesis was to: (1) determ ine the effect o f BCL3 deletion on 
norm al m am m ary tissue in the context o f the pregnancy cycle, w ith particular emphasis on involution 
w here it has previously been shown to be up-regulated; (2) evaluate the role o f BCL3 in the initiation and 
progression o f ERBB2-driven murine m am m ary carcinogenesis; and (3) assess the effect o f BCL3 
suppression on hum an breast cancer cell lines representing d ifferent subtypes o f the disease.
7.2 The role of BCL3 during the murine pregnancy cycle
Results from  chapter 3 of this thesis dem onstrated that although Bcl3 is a downstream  
transcriptional target o f the principle in itiator o f involution, STAT3, deletion o f this NF-kB co-factor had 
very little effect on the gross morphology or function o f the m am m ary gland throughout the pregnancy 
cycle. A subtle BCL3 dose-dependent effect was observed during involution w hereby Bcl3+/' mice had 
increased apoptotic bodies in comparison w ith  both Bcl3+/+ and B cU 1' mice, but this was very transient 
and had no lasting effect on the morphology or function of the gland. From these results, it would  
appear tha t the transient, STAT3 m ediated, increase in Bcl3 expression observed at the onset of 
involution (Chapter 3; Clarkson, W ayland et al. 2004) is a redundant pathway tha t can probably be 
com pensated fo r by the altered DNA binding and transcriptional activation o f various NF-kB subunits. 
Alterations in the  protein expression of p50 and p52 were not observed by IHC in the  absence o f BCL3, in 
comparison w ith  heterozygous mice, but it is highly likely that changes in BCL3 expression could perturb  
the DNA-binding activities o f these subunits. The idea of com pensatory mechanisms occurring following
199
Chapter 7: General Discussion
the loss of involution regulators is not hugely surprising as even in the absence of STAT3 itself, involution 
was still able to proceed, albeit w ith considerably delayed kinetics (Chapman, Lourenco et al. 1999).
It has previously been shown that constitutive knock out o f several members or upstream  
regulators of the NF-kB fam ily results in severe morphological disruption across a num ber o f organs and 
in some cases embryonic lethality (for review Gerondakis, G rum ont e t al. 2006). In the m am m ary gland 
specifically, inhibition o f NF-kB activity has been shown to have considerable effects on lobuloalveolar 
developm ent during pregnancy (Cao, Bonizzi e t al. 2001) and delayed apoptosis during involution  
(Baxter, Came e t al. 2006). Furtherm ore, experim ents involving the up-regulation of NF-kB signalling 
have shown th a t this transcription factor is essential for m aintaining the normal epithelial architecture 
during ductal developm ent (Brantley, Chen et al. 2001). These genetically engineered mouse models 
provide substantial evidence that therapeutic targeting of NF-kB in disease could have severe 
consequences on normal tissues. M ice lacking BCL3 are viable w ith only m inor immunological defects 
rendering them  m ore susceptible to certain pathogens (Franzoso, Carlson et al. 1997; Schwarz, 
Krim penfort et al. 1997). This observation, together w ith results from  chapter 3 o f this thesis, suggests 
that, unlike global inhibition o f NF-kB, loss o f BCL3 has little effect on norm al tissues.
7.3 The role of BCL3 in breast carcinogenesis
Having established th a t depletion o f BCL3 had only very mild effects on normal mammary  
epithelium , the  role o f BCL3 in breast cancer initiation and progression was investigated in the hope that 
inhibiting this NF-kB co-factor would block the tum our-prom oting function o f NF-kB, whilst allowing it to  
retain most o f its norm al physiological functions. To examine this notion, the effect o f BCL3 deletion on 
ERBB2-driven m am m ary tum ou r initiation and progression was examined.
7.3.1 BCL3 and murine ERBB2-driven mammary tumour initiation
The first observation tha t became apparent from  studies utilising M M T V /N 2 tum our models 
was that loss o f BCL3 resulted in a considerable delay in the form ation o f ERBB2-driven mammary  
tum ours (Chapter 4 ). This finding is significant as it implies that BCL3 activity is essential for optimal 
ERBB2-mediated cell transform ation . As BCL3 has been shown to prom ote cell proliferation in a number 
of contexts (see C hapter 1: General Introduction, section 1.4.5.2), this delay in tum our latency was 
initially thought to be due to  a BCL3-dependent decrease in cell proliferation via reduced CYCLIN D1 
activity. H ow ever, this was found not to be the case as no alterations in pre-neoplastic cell proliferation, 
apoptosis or Cyclin D1 gene expression were observed.
Although the  precise mechanism behind this BCL3-mediated delay in m am m ary tum our 
initiation was not established in this thesis, a num ber of hypotheses could be proposed to explain it (see 
Figure 7.1 for proposed m odel). Firstly, it is possible that loss o f BCL3 delays the tyrosine kinase
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activation of the w ild-type Neu  transgene. M am m ary tum ours induced by the w ild-type Neu (M M T V /N 2) 
transgene have increased NEU intrinsic tyrosine kinase activity in comparison w ith adjacent tissue, and it 
is thought that this activation is the rate limiting step in tum our induction (Guy, W ebster et al. 1992). It 
has subsequently been shown that activation o f NEU in transgenic mice often occurs through a somatic 
m utation located within the transgene itself (Siegel, Dankort et al. 1994). However, 35% of tum ours lack 
these somatic m utations and yet still possess intrinsic NEU tyrosine kinase activity suggesting that 
activation can also occur via a different mechanism such as up-regulation o f EGFR fam ily ligands (Siegel, 
Dankort e t al. 1994). Interestingly, a positive feedback loop involving the activation o f NF-kB by 
ERBB2/NEU and a subsequent NF-KB-dependent transcriptional up-regulation o f the  EGFR fam ily ligand, 
heregulin, has been previously identified (Frensing, Kaltschmidt et al. 2008). NEU/ERBB2 activation is 
often m ediated by heterodim erisation w ith other ligand-bound EGFR fam ily m em bers, such as ERBB3 
(Carraway, Sliwkowski e t al. 1994; Sliwkowski, Schaefer et al. 1994) which has been found to be over­
expressed in conjunction with NEU/ERBB2 in both the M M T V /N 2 model and hum an breast cancer (Siegel, 
Ryan et al. 1999). It is therefore feasible that loss of BCL3 could prevent the  NF-KB-mediated up- 
regulation o f EGFR family ligands such as heregulin, resulting in reduced ERBB2(NEU)/ERBB3 
heterodim erisation and thus delayed constitutive ERBB2/NEU kinase activation and m am m ary tum our 
form ation (Figure 7.1). This notion is supported by the observation that although BCL3 deletion resulted 
in a striking delay in the initiation of m am m ary tum ours in w ild-type Neu  (M/V47V/A/2)-expressing mice, 
no com parable delay was found in the initiation of tum ours driven by the activated form of the  
transgene (M M T V /N K ). The discrepancies betw een the tw o models could be accounted for if the primary  
function o f BCL3 was to prom ote the kinase activation of the N 2 transgene. This hypothesis is purely 
speculative and further experim ents analysing the effect o f BCL3 on the kinase activity o f NEU/ERBB2 
and the transcriptional regulation of EGFR fam ily ligands should be perform ed in the future to investigate 
it further.
A second possible hypothesis to explain the delay in tum our initiation is that BCL3 depletion  
may perturb NF-KB-mediated effects on stem or progenitor cell populations within pre-neoplastic tissue. 
M am m ary stem cells are functionally defined as those cells that are able to regenerate full glands after 
transplantation into a cleared fat pad whereas progenitors are usually com m itted to a specific cell 
lineage (lum inal or m yoepithelial) (Kordon and Smith 1998; Stingl, Eaves et al. 2001; Stingl, Eirew et al. 
2006). M am m ary  stem or progenitor cells are considered likely targets for oncogenic transformation  
enabling them  to initiate tum ours that resemble the progenitor or stem cell from  which they were  
derived (review ed in Stingl and Caldas 2007). In the M M T V /N 2 mouse m odel, virtually all epithelial 
tum our cells have been shown to exhibit the luminal progenitor marker, CD61, suggesting that the target 
cell for m alignant transform ation in this model is the luminal progenitor (Vaillant, Asselin-Labat et al.
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2008). It is possible that depletion o f BCL3 alters NF-kB signalling to reduce the size of this population 
and thus reduce the num ber o f potential cell targets in which further oncogenic events, such as the 
acquisition o f constitutive NEU kinase activity, can occur (Figure 7.1). In support o f this idea, NF-kB has 
previously been shown to be activated in the luminal progenitor cell population (Pratt, Tibbo et al. 2009). 
Furtherm ore, inhibition of canonical NF-kB activity specifically reduced the form ation of luminal ERBB2- 
positive neoplasias, but had no effect on the form ation o f basally derived lesions following a chemical 
carcinogenesis protocol (Pratt, Tibbo et al. 2009). These findings suggest that NF-kB signalling is o f prime 
im portance in luminal progenitor cells and that depletion o f an NF-kB co-factor, such as BCL3, could 
disturb the m aintenance o f this cell population. This hypothesis is currently being investigated in the 
laboratory by perform ing in vitro colony-forming cell assays on pre-neoplastic prim ary cells from  Bc/37 
/M M T V /N 2 and BcI3+/+/M M T V /N 2 mice. This assay identifies progenitor cells that produce discrete 
colonies o f m am m ary cells in low density adherent cultures (Stingl, Eaves et al. 2001 Stingl, Eirew 2006) 
and can there fo re  be used to establish the effect o f BCL3 on this cell population.
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Figure 7.1: Proposed m odel fo r  the BCL3 m ediated  effects on breast cancer in itiation  and progression
BcI3'/ '/M M T V /N 2 tumours show delayed initiation in comparison to BcI3+/* /M M T V /N 2 tumours. This could 
be due to delayed NEU kinase activation within the luminal progenitor pool. W hen BCL3 is present (top set 
of diagrams), NF-KB-mediated transcriptional up-regulation of EGFR-family ligands can occur to promote 
constitutive NEU kinase activation (from N2 cells to NK cells). Furthermore, a normal sized luminal 
progenitor cell population (light blue cells) is maintained in which kinase activation can occur, resulting in 
the initiation and growth of a kinase active tum our. However, loss o f BCL3 (bottom  set o f diagrams), could 
result in a reduced tum our initiating luminal progenitor cell pool and reduced transcriptional up-regulation 
of EGFR-family ligands which, as a result, may delay constitutive luminal progenitor kinase activation and 
subsequent tum our initiation. In addition, Bcl3'l~ /M M TV /N 2 tumours show delayed metastatic progression 
in comparison to BcI3*/+/M M T V /N 2 tumours. This may be due to multiple effects of BCL3 on the tum our 
cells and the tum our microenvironment. W hen BCL3 is present, the luminal progenitor pool, from which 
metastases are likely to originate, continues to be well maintained (light blue cells). Also, BCL3 promotes 
the intrinsic motility and invasive properties of tum our cells and furtherm ore, it may promote the NF-KB- 
m ediated recruitm ent of metastases promoting inflam m atory cells to the tum our microenvironment. 
However, loss of BCL3 reduces the intrinsic motility and invasive properties of tum our cells. In addition, it 
may also reduce the luminal progenitor cell pool and suppress a metastases-promoting inflammatory 
tum our microenvironm ent, collectively resulting in delayed metastatic disease progression.
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7.3.2 BCL3 and murine ERBB2-driven metastatic progression
The second and possibly most exciting observation from  studies assessing the role o f BCL3 in 
ERBB2-driven carcinogenesis was the marked effect it had on m etastatic progression. Although deletion  
of BCL3 did not affect the growth o f established tumours, it did result in a considerable reduction in both 
the frequency and size of metastatic lung lesions in BcI3'/'/M M T V /N 2 mice in comparison with controls 
(Chapter 4). These results were supported by in vitro Boyden cham ber experim ents, which revealed that 
BCL3 suppression reduced both the invasive and migratory capacity o f M G 1361  cells, and, furtherm ore, 
by tail vein experim ents that showed BCL3 inhibition to reduce the ability o f cells to  extravasate and seed 
in the lungs (Chapter 5). These findings are highly significant and clinically relevant, as m ortality from  
breast cancer is most commonly attributed to organ-specific metastases rather than to the primary 
tum our. Thus, the identification of pathways involved in m etastatic progression is extrem ely valuable in 
the developm ent o f new targeted therapies.
NF-kB activation is commonly associated w ith cell proliferation and survival. However, results 
from  chapters 4 and 5 o f this thesis show that loss o f BCL3 in m urine ERBB2-positive tum our cells has a 
more pronounced phenotypic effect on cell motility, invasion and metastases rather than on cell 
proliferation in this context. Interestingly, a recent study by M erkhofer et al. (2010) dem onstrated that 
dow n-regulation o f canonical NF-kB activity in ERBB2-positive human breast cancer cells specifically 
resulted in a decrease in cancer cell invasion, but had no effect on cell proliferation (M erkhofer, Cogswell 
et al. 2010). It is possible that a similar mechanism may occur in the m urine tum our cells utilised in this 
thesis, w hereby inhibition o f BCL3 alters canonical NF-kB transcriptional activity to specifically suppress 
m otility, invasion and metastases w ithout having a noticeable effect on proliferation. Interestingly, 
however, BCL3 suppression in one human ERBB2-positive cell line resulted in the inhibition o f both 
proliferation and m otility (Chapter 6 and see section 7 .3.3  below), indicating that, in some contexts, 
modulation o f NF-kB downstream  of ERBB2 can have effects on both o f the these processes.
Both In vitro and in vivo experim ents perform ed in chapter 5 showed tha t the reduced ability of 
BCL3-deficient cells to metastasize to the lung was, at least in part, due to an intrinsic cell autonomous 
effect that was independent o f the tum our microenvironm ent. However, the question o f w hether BCL3 
may also regulate broader processes such as cancer-related inflam m ation to m ediate disease 
progression remains unanswered. This is an im portant clinical question, as inflam m atory breast cancer is 
an aggressive form  of invasive breast cancer that has poor prognosis (reviewed in Robertson, Bondy et 
al. 2010).
During cancer-related inflam m ation, transcription factors are up-regulated that m ediate the  
production o f pro-inflam m atory cytokines and chemokines in tum our cells which recruit and activate 
various inflam m atory cells. The resulting inflam m atory tum our m icroenvironm ent facilitates cancer
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progression by prom oting processes such as angiogenesis, cell m igration, invasion and metastases 
(reviewed in M antovani, Allavena e t al. 2008). Studies targeting NF-kB have dem onstrated that this 
signalling pathway is heavily involved in promoting an inflam m atory tum our microenvironm ent and 
therefore disease progression in various cancer models (Greten, Eckmann e t al. 2004; Luo, M aeda et al. 
2004; Pikarsky, Porat et al. 2004). Recently, inhibition of NF-kB specifically in m am m ary epithelial cells 
was shown to reduce the proportion o f infiltrating tum our associated macrophages (TAMs) in an ERBB2- 
driven m urine breast cancer model (Liu, Sakamaki et al. 2010). The recruitm ent o f TAMs has previously 
been shown to prom ote the m etastatic progression o f m urine m am m ary tum ours via a suggested 
mechanism involving the enhancem ent o f angiogenesis (Lin, Nguyen et al. 2001; Lin and Pollard 2007). It 
is possible tha t loss o f BCL3 may also inhibit the NF-KB-mediated recruitm ent o f TAMs or o ther immune 
cells to delay m am m ary tum our progression (Figure 7.1). M oreover, as BCL3 was constitutively deleted in 
all cells in the  mouse models utilised in this thesis, it is likely that NF-kB signalling intrinsic to immune 
cells would also be de-regulated, which could further delay the normal m etastatic progression of 
m am m ary tum ours.
Experiments performed in M M T V /N 2 or M M T V /N K  mouse models have addressed the effect of 
global constitutive deletion of BCL3 across all tissues w ithin the animal. Although these experiments 
have provided substantial evidence to implicate BCL3 in m am m ary tum our initiation and progression, 
they do not determ ine the effect o f BCL3 inhibition on discrete stages during tum our developm ent and 
progression. This leaves unanswered the question of w hether short-term  inhibition o f BCL3 in late stages 
of tum our developm ent can prevent the progression to metastatic disease, which is clinically relevant as 
it addresses the situation in which a patient is likely to present. Furtherm ore, although some m am m ary  
epithelial cell specific effects have been dem onstrated in vitro and in tail vein experim ents, the in vivo 
experim ents presented in this thesis w ere unable to discriminate betw een the effects of BCL3 on 
m am m ary epithelial cells versus the surrounding inflam m atory cells. One experim ent that could 
potentially address both o f these issues would be to create an inducible transgenic model in which Bcl3 
expression could be inhibited specifically in m am m ary epithelial cells at defined times during 
tumourigenesis. Such a model has recently been developed to determ ine the effect o f inducible NF-kB 
inhibition in the context of PyVT-driven m am m ary tumourigenesis (Connelly, Barham et al. 2010). This 
model dem onstrated that inhibition of NF-kB for a single week a fter primary tum ours had developed 
resulted in reduced tum our burden, providing evidence that modulation of this signalling pathway could 
be an effective therapeutic trea tm en t strategy for patients presenting with established breast tumours.
The discovery that global deletion of BCL3 reduces the occurrence of m etastatic lung lesions in 
an ERBB2-driven m urine breast cancer model is extrem ely exciting. However, a m ajor lim itation to the  
use of this m odel is its inability to accurately reflect all o f the known sites of metastases in human breast
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cancer, such as the brain, liver and in particular bone. In fact there is a distinct lack of models available in 
which to investigate the effect o f a particular variable on bone metastases. Carefully selected sub-lines of 
cells generated from  some spontaneous murine m am m ary carcinomas have been shown to have a high 
incidence o f bone metastasis upon transplantation into the m am m ary fa t pad (Lelekakis, Moseley et al. 
1999; Li, Schem et al. 2008). Alternatively, intracardiac injection o f hum an breast cancer cell lines into 
mice has also been shown to produce bone metastases. Although the  la tter m ethod has the added 
advantage o f enabling the investigator to use human cells representing an appropriate subtype of the  
disease (Yoneda 2000), intracardiac metastasis models are lim ited in th a t they do not encompass the  
early stages o f the metastatic process. The future developm ent o f new  ERBB2-driven mouse models of 
breast cancer that metastasize to the bone could aid in determ ining w h eth er BCL3 contributes to this 
clinically relevant process.
7.3.3 BCL3 and human breast cancer
Having dem onstrated that BCL3 plays a prom inent role in prom oting the initiation and 
progression o f ERBB2-driven murine breast carcinoma, the question of w hether it could have similar pro- 
tum ourigenic effects in human breast cancer cells was addressed. Similarly to in vitro studies in murine 
M G 1361 cell lines, suppression of BCL3 resulted in a reduction in the m otility o f three out o f the four cell 
lines tested. Additionally, in contrast w ith both in vitro  and in vivo murine studies, depletion of BCL3 also 
resulted in a considerable reduction in the viability o f the same three cell lines indicating that 
therapeutic BCL3 inhibition in situ may have m ore pronounced effects on early tumourigenesis than  
previous data generated in m urine models have suggested. The discrepancies betw een results in murine  
and human cell lines highlight the im portance o f substantiating observations in animal models with  
experim ents on human tissues and indicate tha t further in vitro and in vivo studies utilising human cells 
are warranted to establish a b etter understanding o f BCL3 in human disease.
A key observation from  chapter 6 was that suppression of BCL3 inhibited the proliferative and 
migratory capacity o f both ERBB2-positive and EGFR-positive human breast cancer cells, suggesting that 
it may be a useful target in the trea tm en t o f both subtypes o f the disease. Excitingly, the basal-like, 
'trip le-negative' M D A -M B -231 cell line responded particularly well to  BCL3 inhibition. This is a significant 
observation, as triple-negative breast cancers are extrem ely difficult to  trea t because of the ir lack of 
classical m olecular therapeutic targets (reviewed in Gluz, Liedtke et al. 2009; De Laurentiis, Cianniello et 
al. 2010). It would be o f great value to substantiate this prelim inary observation by performing both 
orthotopic and tail vein transplants w ith M DA-M B-231 cells in the presence or absence of BCL3. Indeed, 
these experim ents could be perform ed w ith cell lines displaying a variety o f m olecular and diagnostic 
markers in order to gain a greater understanding of the breadth o f breast cancer subtypes that BCL3 may 
be able to m odulate.
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7.3.4 BCL3 and the transcriptional regulation of TIMPs
Having identified that BCL3 was able to regulate m etastatic properties o f both murine and 
human breast cancer cells, m icroarray analysis and subsequent QRT-PCR experim ents were perform ed in 
an a ttem p t to  identify metastases-related gene targets o f BCL3. These studies identified TIMP1 and 
TIM P2  to  be consistently up-regulated following the inhibition o f BCL3 in most cell lines tested. TIMPS 
act to inhibit M M Ps that are known to prom ote breast cancer invasion and metastases (Talvensaari- 
M attila , Paakko et al. 1998; Li, Cao et al. 2004; W u, W u et al. 2008; Zhang, Cao et al. 2008; Garcia, 
Gonzalez-Reyes et al. 2010; reviewed in Duffy, M aguire et al. 2000). Furtherm ore, they are critical 
regulators o f m atrix turnover at different stages of m am m ary gland developm ent, including post- 
lactational involution (Talhouk, Bissell et al. 1992; Fata, Leco e t al. 1999).
Previous analysis o f the role o f TIMPs in breast cancer has revealed a complex association with  
the disease. Over-expression of systemic TIM P1 in the context o f tw o  established m urine m am m ary  
carcinogenesis models resulted in reduced tum our burden and metastases whereas m am m ary specific 
over-expression was ineffective against m am m ary tumourigenesis (Yamazaki, Akahane et al. 2004). Up- 
regulation o f T IM P2 in the m urine m am m ary gland resulted in reduced M M T V /W n tl-in d u c e d  m am m ary  
tum ourigenesis and angiogenesis (Blavier, Lazaryev et al. 2006). In spite o f the  inhibitory effect o f TIMPs 
on M M Ps, high expression o f TIM P1 or TIM P2 in primary human breast tum ours has been found to 
correlate w ith  increased metastases and poor prognosis (Gonzalez, Pidal e t al. 2007; Vizoso, Gonzalez et 
al. 2007). This paradox could m erely be due to co-upregulation o f TIMPs and M M Ps in breast cancer. 
However, as well as inhibiting M M Ps, TIM P1 has also been shown to  have o ther pro-tumourigenic  
functions on cell proliferation, survival and angiogenesis. Thus, the overall clinical relevance of the  
association betw een BCL3 and TIMPs observed in this thesis remains to be determ ined.
7.4 Future perspectives: targeting BCI3 as a therapeutic treatment in breast 
cancer?
Currently ERBB2-positive breast cancers are routinely treated  w ith  the  ERBB2 monoclonal 
antibody trastuzum ab (Herceptin). However, resistance to this trea tm en t is prevalent resulting in a 
clinical need for new or adjuvant therapies for the disease. Data presented in this thesis provide 
com pelling evidence for the use o f the NF-kB co-factor, BCL3, as a therapeutic target in the treatm ent of 
m etastatic ERBB2-positve breast cancer. Additionally, work perform ed in human breast cancer cell lines 
suggests tha t inhibition o f BCL3 in the clinic may also have anti-tum ourigenic effects on EGFR-positive 
tum ours, including those characterised as aggressive triple-negative breast cancer, which are currently  
very difficult to  trea t. These observations are especially appealing in the light o f findings that depletion
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of BCL3 in otherw ise normal m am m ary tissue had minim al effects on the gross morphology or function 
of the gland throughout the pregnancy cycle.
Therapeutic targeting o f BCL3 alone may be o f some benefit to patients presenting w ith certain 
tum our subtypes. However, it is likely tha t inhibition o f BCL3 would be of most benefit as an adjuvant 
trea tm en t in com bination w ith o ther established targeted therapies, such as trastuzum ab. Furtherm ore, 
as NF-kB has previously been shown to be activated in response to both chem otherapy (Piret and Piette 
1996; W ang, M ayo et al. 1996; Das and W hite  1997; Wang, Abbruzzese e t al. 1999; Dong, Sclabas et al. 
2002; Nakanishi and Toi 2005) and horm onal treatm ents (Zhou, Yau et al. 2007; reviewed in Zhou, 
Eppenberger-Castori e t al. 2005), future investigation into the therapeutic efficacy of adjuvant BCL3 
inhibition to  prevent resistance to such treatm ents is w arranted. In addition, as BCL3 suppression 
appears to  have therapeutic  effects on both the initiation and m etastatic progression of the disease, 
determ ination  o f which tum our stage would most benefit from  BCL3 blockade requires thorough 
investigation in the  future.
The overall feasibility o f designing drugs to target BCL3 in human breast cancer is at present 
unknown. How ever, w ork currently being undertaken in the laboratory is focused on developing 
inhibitors o f BCL3-p50 interactions in the hope of blocking the pro-carcinogenic functions o f NF-kB whilst 
having m inim al effects on the function o f normal tissues. Evaluation o f the efficacy and toxicity o f these 
com pounds in vitro  and in vivo will help provide insight into the overall potential o f the use of BCL3 
inhibitors in the  fu tu re  trea tm en t o f breast cancer.
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Accession Definition Symbol Fold Change Adj.P.Val
NM 010518.2
Mus musculus insulin-like growth factor binding protein 5 
(IgfbpS), mRNA. Igfbp5 2.97133279 6.03 E-09
NM 001034870.2
Mus musculus serine (or cysteine) peptidase inhibitor, clade A, 
member 3H (Serpina3h), mRNA. Serpina3h 2.41783564 7.07E-09
NM 133859.2 Mus musculus olfactomedin-like 3 (0lfml3), mRNA. Olfml3 2.12292535 2.38E-07
XM 620286.3
PREDICTED: Mus musculus sterile alpha motif domain 
containing 9-like, transcript variant 1 (Samd9l), mRNA. Samd9l 2.08956242 1.01E-07
NM_010357.1
Mus musculus glutathione S-transferase, alpha 4 (Gsta4), 
mRNA. Gsta4 2.05521505 1.64E-07
XM 001471686.1
PREDICTED: Mus musculus hypothetical protein LOC100038882 
(LOC100038882), mRNA. LOC100038882 2.05061997 6.7E-08
NM 011909.1 Mus musculus ubiquitin specific peptidase 18 (Uspl8), mRNA. Uspl8 2.04878197 1.73E-08
NM 009525.2
Mus musculus wingless-related MMTV integration site 5B 
(Wnt5b), mRNA. Wnt5b 2.00367246 1.69E-08
NM 018734.2
Mus musculus guanylate nucleotide binding protein 3 (Gbp3), 
mRNA. Gbp3 1.89624311 1.21E-07
NM 011909.1 Mus musculus ubiquitin specific peptidase 18 (Uspl8), mRNA. Uspl8 1.87007214 2.75E-07
NM 011905.2 Mus musculus toll-like receptor 2 (Tlr2), mRNA. Tlr2 1.85170934 1.9E-08
NM 015760.4 Mus musculus NADPH oxidase 4 (Nox4), mRNA. Nox4 1.83705572 3.52E-08
NM 010476.3
Mus musculus hydroxysteroid (17-beta) dehydrogenase 7 
(Hsdl7b7), mRNA. Hsdl7b7 1.83588125 1.38E-05
NM 010260.1
Mus musculus guanylate nucleotide binding protein 2 (Gbp2), 
mRNA. Gbp2 1.83593557 2.75E-07
NM 018734.3
Mus musculus guanylate nucleotide binding protein 3 (Gbp3), 
mRNA. Gbp3 1.81971394 4.56E-06
XM 001480051.1
PREDICTED: Mus musculus similar to ubiquitin specific protease 
UBP43 (LOC100048346), mRNA. LOC100048346 1.79704349 7.75E-07
NM 009831.2 Mus musculus cyclin G1 (Ccngl), mRNA. Ccngl 1.77702745 5.46E-07
XM 001476984.1
PREDICTED: Mus musculus similar to CKLF-like MARVEL 
transmembrane domain containing 3 (LOC100046883), mRNA. LOC100046883 1.76722793 1.9E-08
NM 010501.1
Mus musculus interferon-induced protein with 
tetratricopeptide repeats 3 (Ifit3), mRNA. Ifit3 1.76463698 6.86E-05
NM 009242.1
Mus musculus secreted acidic cysteine rich glycoprotein 
(Sparc), mRNA. Sparc 1.75497040 3.65E-07
NM 008176.1 Mus musculus chemokine (C-X-C motif) ligand 1 (Cxcll), mRNA. Cxcll 1.73927182 1.14E-06
NM 145980.1
Mus musculus RIKEN cDNA 8430408G22 gene 
(8430408G22Rik), mRNA. 8430408G22Rik 1.73876121 2.75E-07
NM 011701.3 Mus musculus vimentin (Vim), mRNA. Vim 1.73720397 3.01E-06
NM 011653.1 Mus musculus tubulin, alpha 1A (Tubala), mRNA. Tubala 1.73132655 0.000145
NM 011315.3 Mus musculus serum amyloid A 3 (Saa3), mRNA. Saa3 1.72597098 3.97E-08
NM 007987.1
Mus musculus Fas (TNF receptor superfamily member 6) (Fas), 
mRNA. Fas 1.713925 7.5E-07
NM 009242.1
Mus musculus secreted acidic cysteine rich glycoprotein 
(Sparc), mRNA. Sparc 1.68534646 3.99E-07
NM 008538.2
Mus musculus myristoylated alanine rich protein kinase C 
substrate (Marcks), mRNA. Marcks 1.68201040 1.66E-07
NM 016979.1 Mus musculus protein kinase, X-linked (Prkx), mRNA. Prkx 1.68089838 1.82E-07
NM 011358.1
Mus musculus splicing factor, arginine/serine-rich 2 (SC-35) 
(Sfrs2), mRNA. Sfrs2 1.66087302 6.68E-06
NM 009338.3
Mus musculus acetyl-Coenzyme A acetyltransferase 2 (Acat2), 
mRNA. Acat2 1.66072993 9.85E-05
NM 008137.3
Mus musculus guanine nucleotide binding protein, alpha 14 
(Gnal4), mRNA. Gnal4 1.65204690 2.16E-06
NM 016979.1 Mus musculus protein kinase, X-linked (Prkx), mRNA. Prkx 1.65102362 9.44E-08
NM 011852.2
Mus musculus 2'-5' oligoadenylate synthetase 1G (Oaslg), 
mRNA. Oaslg 1.64491530 5.06E-05
NM 172659.2
Mus musculus solute carrier family 2 (facilitated glucose 
transporter), member 6 (Slc2a6), mRNA. Slc2a6 1.63792834 1.8E-06
NM 026178.2
Mus musculus monocyte to macrophage differentiation- 
associated (Mmd), mRNA. Mmd 1.63170217 9.44E-08
NM 009749.1 Mus musculus brain expressed X-linked 2 (Bex2), mRNA. Bex2 1.62918940 1.33E-06
NM 010169.3
Mus musculus coagulation factor II (thrombin) receptor (F2r), 
mRNA. F2r 1.62838591 2.45E-07
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NM 029662.1
Mus musculus major facilitator superfamily domain containing 
2 (Mfsd2), mRNA. Mfsd2 1.61818558 4.83E-06
NM 019440.2 Mus musculus interferon inducible GTPase 2 (Iigp2), mRNA. Iigp2 1.60666438 1.97E-05
NM 021301.1
Mus musculus solute carrier family 15 ( H + / p e p t i d e  
transporter), member 2 (Slcl5a2), mRNA. Slcl5a2 1.60124172 2.97E-07
NM 178697.4
Mus musculus chloride channel calcium activated 5 (Clca5), 
mRNA. Clca5 1.59354163 0.000395
NM 016850.2 Mus musculus interferon regulatory factor 7 (Irf7), mRNA. Irf7 1.58855323 6.8E-06
NM 007898.2
Mus musculus phenylalkylamine Ca2+ antagonist (emopamil) 
binding protein (Ebp), mRNA. Ebp 1.58180773 5.6E-06
NM 008332.2
Mus musculus interferon-induced protein with 
tetratricopeptide repeats 2 (Ifit2), mRNA. Ifit2 1.57294217 7.96E-06
NM 011854.1
Mus musculus 2'-5' oligoadenylate synthetase-like 2 (0asl2), 
mRNA. Oasl2 1.57120421 0.000188
NM 011358.1
Mus musculus splicing factor, arginine/serine-rich 2 (SC-35) 
(Sfrs2), mRNA. Sfrs2 1.57098753 0.00057
NM 145569.2
Mus musculus methionine adenosyltransferase II, alpha 
(Mat2a), mRNA. Mat2a 1.56974192 0.000479
NM 026464.2 Mus musculus WD repeat domain 55 (Wdr55), mRNA. Wdr55 1.54201664 1.19E-06
NM 009223.2 Mus musculus stannin (Snn), mRNA. Snn 1.54185649 2.54E-06
NM 027127.2
Mus musculus RIKEN cDNA 2310016C16 gene (2310016C16Rik), 
mRNA. 2310016C16Rik 1.54092402 7.14E-05
NM 009750.1
Mus musculus nerve growth factor receptor (TNFRSF16) 
associated protein 1 (Ngfrapl), mRNA. Ngfrapl 1.52939660 3.2E-07
NM 008987.2 Ptx3 1.52783719 1.08E-06
NM 139144.2
Mus musculus O-linked N-acetylglucosamine (GlcNAc) 
transferase (UDP-N-acetylglucosamine:polypeptide-N- 
acetylglucosaminyl transferase) (Ogt), mRNA. Ogt 1.52611585 7.87E-06
NM 018738.3 Mus musculus interferon gamma induced GTPase (Igtp), mRNA. Igtp 1.52353419 6.86E-05
NM 011852.2
Mus musculus 2'-5‘ oligoadenylate synthetase 1G (Oaslg), 
mRNA. Oaslg 1.51872619 0.000133
NM 018865.2
Mus musculus WNT1 inducible signaling pathway protein 1 
(Wispl), mRNA. Wispl 1.50788748 1.14E-06
NM 008908.1 Mus musculus peptidylprolyl isomerase C (Ppic), mRNA. Ppic 1.50524768 1.37E-06
NM 175319.2
Mus musculus RIKEN cDNA C330005M16 gene 
(C330005M16Rik), mRNA. C330005M16Rik 1.50289505 1.74E-05
NM 016753.4 Mus musculus latexin (Lxn), mRNA. Lxn 1.49648075 1.1E-05
NM 025703.2
Mus musculus transcription elongation factor A (Sll)-like 8 
(Tceal8), mRNA. Tceal8 1.49563819 2.64E-05
NM 020010.2 Mus musculus cytochrome P450, family 51 (Cyp51), mRNA. Cyp51 1.49060967 8.85E-05
NM 001037279.1
Mus musculus RIKEN cDNA 2700094K13 gene (2700094K13Rik), 
transcript variant 2, mRNA. 2700094K13Rik 1.48399067 1.19E-06
NM 029619.2
Mus musculus methionine sulfoxide reductase B2 (Msrb2), 
mRNA. Msrb2 1.47544783 8.96E-07
XM 001478939.1
PREDICTED: Mus musculus similar to human protein 
homologous to DROER protein (LOC100042777), mRNA. LOC100042777 1.46823359 1.39E-06
NM 009283.3
Mus musculus signal transducer and activator of transcription 1 
(Statl), mRNA. Statl 1.46653524 2.67E-05
NM 021604.2 Mus musculus agrin (Agrn), mRNA. Agrn 1.46204424 3.13E-05
NM 001013025.2
Mus musculus transforming growth factor, beta receptor 
associated protein 1 (Tgfbrapl), mRNA. Tgfbrapl 1.45907682 6.59E-06
NM 173374.3
Mus musculus splicing factor, arginine/serine-rich 1 (ASF/SF2) 
(Sfrsl), transcript variant 1, mRNA. Sfrsl 1.45808209 0.000505
NM 025365.2 Mus musculus prickle homolog 4 (Drosophila) (Prickle4), mRNA. Prickle4 1.45769414 0.000447
NM 172641.2
Mus musculus RIKEN cDNA 9930023K05 gene (9930023K05Rik), 
mRNA. 9930023K05Rik 1.45752667 1.23E-05
NM 018770 Igsf4a 1.45291781 1.78E-05
NM 009160.1 Mus musculus surfactant associated protein D (Sftpd), mRNA. Sftpd 1.45229249 3.53E-06
NM 009226.4
Mus musculus small nuclear ribonucleoprotein D1 (Snrpdl), 
mRNA. Snrpdl 1.45015453 3.68E-05
NM 018815.1 Mus musculus nucleoporin 210 (Nup210), mRNA. Nup210 1.44780234 1.73E-05
NM 175565.3
Mus musculus carnitine deficiency-associated gene expressed 
in ventricle 3 (Cdv3), transcript variant CDV3A, mRNA. Cdv3 1.44498734 0.000895
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NM 027878.2
Mus musculus RIKEN cDNA 1200002N14 gene 
(1200002N14Rik), mRNA. 1200002N14Rik 1.44285751 2.59E-06
NM 027127.1
Mus musculus RIKEN cDNA 2310016C16 gene (2310016C16Rik), 
mRNA. 2310016C16Rik 1.44209610 0.00013
NM 011014.2 Mus musculus opioid receptor, sigma 1 (Oprsl), mRNA. Oprsl 1.44133286 0.000133
NM 025284.3 Mus musculus thymosin, beta 10 (TmsblO), mRNA. TmsblO 1.43578153 0.000117
NM 011150.2
Mus musculus lectin, galactoside-binding, soluble, 3 binding 
protein (Lgals3bp), mRNA. Lgals3bp 1.43273450 5.79E-05
NM 175401.3
Mus musculus F-box and WD-40 domain protein 17 (Fbxwl7), 
mRNA. Fbxwl7 1.43270636 2.06E-05
NM 009320.3
Mus musculus solute carrier family 6 (neurotransmitter 
transporter, taurine), member 6 (Slc6a6), mRNA. Slc6a6 1.42872470 0.000347
NM 175103.2 Mus musculus bolA-like 2 (E. coli) (Bola2), mRNA. Bola2 1.42642792 1.22E-05
NM 025866.3 Mus musculus cell division cycle associated 7 (Cdca7), mRNA. Cdca7 1.42177050 0.000357
NM 027127.2
Mus musculus RIKEN cDNA 2310016C16 gene (2310016C16Rik), 
mRNA. 2310016C16Rik 1.42115487 1.87E-05
NM 027342.1
Mus musculus RIKEN cDNA 2310056P07 gene (2310056P07Rik), 
mRNA. 2310056P07Rik 1.41611108 8.32E-06
NM 015807.1 Mus musculus 5',3'-nucleotidase, cytosolic (Nt5c), mRNA. Nt5c 1.41357951 6.49E-05
NM 033270.1 Mus musculus E2F transcription factor 6 (E2f6), mRNA. E2f6 1.41221845 2.3E-05
NM 007951.1
Mus musculus enhancer of rudimentary homolog (Drosophila) 
(Erh), mRNA. Erh 1.41081835 7.56E-05
NM 009964.1 Mus musculus crystallin, alpha B (Cryab), mRNA. Cryab 1.40993264 9.69E-05
NM 133888.2
Mus musculus sphingomyelin phosphodiesterase, acid-like 3B 
(Smpdl3b), mRNA. Smpdl3b 1.40729464 4.09E-05
NM 020557.3 Tyki 1.40471196 3.43E-05
NM 001001979.1 Mus musculus multiple EGF-like-domains 10 (MegflO), mRNA. MegflO 1.40345666 4.19E-05
NM 206958.1
Mus musculus latent transforming growth factor beta binding 
protein 1 (Ltbpl), transcript variant 2, mRNA. Ltbpl 1.40329585 0.000157
NM 026405.3
Mus musculus RAB32, member RAS oncogene family (Rab32), 
mRNA. Rab32 1.40311396 1.5E-06
NM 013640.2
Mus musculus proteasome (prosome, macropain) subunit, beta 
type 10 (PsmblO), mRNA. PsmblO 1.40277209 0.000324
NM 008113.3
Mus musculus Rho GDP dissociation inhibitor (GDI) gamma 
(Arhgdig), mRNA. Arhgdig 1.39840941 1.36E-05
NM 007527.2 Mus musculus Bcl2-associated X protein (Bax), mRNA. Bax 1.39755720 8.3E-06
NM 028798.2 Mus musculus cysteine-rich C-terminal 1 (Crctl), mRNA. Crctl 1.39632536 4.57E-05
Appendix 1: Top 100 largest fold increases in gene expression following Bcl3 suppression
Statistical differences in microarray data w ere  determ ined by T-tests to  obtain adjusted p-values. Data 
that achieved significance at p^O.Ol (1691 genes) w ere ranked according to fold change. Table 
represents the top 100 largest fold increases in gene expression following Bcl3 suppression.
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NM 011931.3
Mus musculus ring finger and WD repeat domain 2 (Rfwd2), 
mRNA. Rfwd2 0.700836811 2.32E-06
NM 146247 BC024814 0.700329214 1.4E-05
NM 001037136.1
Mus musculus centaurin, gamma 2 (Centg2), transcript variant 
2, mRNA. Centg2 0.700186671 0.000268
NM 011261.2 Mus musculus reelin (Rein), mRNA. Rein 0.700089841 2.39E-05
NM 176933.3 Mus musculus dual specificity phosphatase 4 (Dusp4), mRNA. Dusp4 0.698987264 0.000119
NM 008970.2 Mus musculus parathyroid hormone-like peptide (Pthlh), mRNA. Pthlh 0.698620159 1.1E-05
NM 011949.3
Mus musculus mitogen-activated protein kinase 1 (Mapkl), 
transcript variant 1, mRNA. Mapkl 0.698007364 1.22E-05
NM 178143.1
Mus musculus protein kinase, AMP-activated, alpha 2 catalytic 
subunit (Prkaa2), mRNA. Prkaa2 0.697439604 1.55E-05
NM 009711.3 Mus musculus artemin (Artn), mRNA. Artn 0.697368865 0.000315
NM 011690.2 Mus musculus valyl-tRNA synthetase (Vars), mRNA. Vars 0.697349947 1.36E-05
NM 019703.3 Mus musculus phosphofructokinase, platelet (Pfkp), mRNA. Pfkp 0.696954938 2.32E-06
NM 007669.3
Mus musculus cyclin-dependent kinase inhibitor 1A (P21) 
(Cdknla), mRNA. Cdknla 0.695655894 2.64E-05
NM 033149.2
Mus musculus UDP-Gal:betaGlcNAc beta 1,3- 
galactosyltransferase, polypeptide 5 (B3galt5), mRNA. B3galt5 0.695064007 1.73E-06
NM 008813.2
Mus musculus ectonucleotide 
pyrophosphatase/phosphodiesterase 1 (Enppl), mRNA. Enppl 0.693475568 0.000122
NM 019738.1 Mus musculus nuclear protein 1 (Nuprl), mRNA. Nuprl 0.692882883 0.00253
NM 177700.3 Mus musculus ATM interactor (Atmin), mRNA. Atmin 0.691091469 3.93E-06
NM 026708.1 Mus musculus TLC domain containing 1 (Tlcdl), mRNA. Tlcdl 0.690931482 1.37E-06
NM 028800.2 Mus musculus serine/threonine kinase 40 (Stk40), mRNA. Stk40 0.690583076 2.65E-05
NM 028792.2 Mus musculus Josephin domain containing 1 (Josdl), mRNA. Josdl 0.689936154 5.37E-07
NM 011065.2 Mus musculus period homolog 1 (Drosophila) (Perl), mRNA. Perl 0.689232835 4.2E-05
NM 145447.2
Mus musculus feline leukemia virus subgroup C cellular receptor 
family, member 2 (Flvcr2), mRNA. Flvcr2 0.687823971 3.01E-06
NM 177474.4
Mus musculus DNA segment, Chr 19, Brigham 8i Women's 
Genetics 1357 expressed (D19Bwgl357e), mRNA. D19Bwgl357e 0.687695199 4.48E-06
NM 020625.3
Mus musculus zinc finger and BTB domain containing 22 
(Zbtb22), mRNA. Zbtb22 0.687138009 2.44E-06
NM 008488.1
Mus musculus Rho guanine nucleotide exchange factor (GEF) 1 
(Arhgefl), mRNA. Arhgefl 0.687039628 4.54E-05
NM 021389.4
Mus musculus SH3-domain kinase binding protein 1 (Sh3kbpl), 
mRNA. Sh3kbpl 0.68623856 3.53E-06
NM 019990.4 Mus musculus START domain containing 10 (StardlO), mRNA. StardlO 0.686059288 0.000226
NM 019703.3 Mus musculus phosphofructokinase, platelet (Pfkp), mRNA. Pfkp 0.685854901 2.12E-05
NM 033601.1 Mus musculus B-cell leukemia/lymphoma 3 (Bcl3), mRNA. Bcl3 0.685150317 6.49E-06
NM 001081170.1
Mus musculus phosphofurin acidic cluster sorting protein 2 
(Pacs2), mRNA. Pacs2 0.685027721 0.000114
NM 009801.3 Mus musculus carbonic anhydrase 2 (Car2), mRNA. Car2 0.683701875 1.59E-05
NM 008813.3
Mus musculus ectonucleotide 
pyrophosphatase/phosphodiesterase 1 (Enppl), mRNA. Enppl 0.683462757 7.08E-05
NM 144792.2 Tmem23 0.682853068 8.99E-05
NM 181323.2
Mus musculus RIKEN cDNA C130090K23 gene (C130090K23Rik), 
mRNA. C130090K23Rik 0.681467093 5.14E-07
NM 008681 Ndrl 0.680753991 1.59E-05
NM 177700.3 Mus musculus ATM interactor (Atmin), mRNA. Atmin 0.679744904 7.01E-06
NM 009075.2 Mus musculus ribose 5-phosphate isomerase A (Rpia), mRNA. Rpia 0.679578242 1.85E-06
NM 009943.2
Mus musculus cytochrome c oxidase, subunit VI a, polypeptide 
2 (Cox6a2), nuclear gene encoding mitochondrial protein, 
mRNA. Cox6a2 0.679086681 8.19E-05
NM 016797.4 Mus musculus syntaxin 7 (Stx7), mRNA. Stx7 0.678871722 2.69E-06
NM 144500.3 Mus musculus oxysterol binding protein-like 2 (Osbpl2), mRNA. Osbpl2 0.678063267 1.13E-05
NM 030706.1
Mus musculus tripartite motif protein 2 (Trim2), mRNA. 
XM_984114 XM_984144 XM_984172 XM_984200 XM_984238 
XM 984275 XM 984313 Trim2 0.670811372 2.48E-06
NM 011319.2 Mus musculus seryl-aminoacyl-tRNA synthetase (Sars), mRNA. Sars 0.670135938 1.16E-05
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NM 133898.3
Mus musculus RIKEN cDNA B230342M21 gene 
(B230342M21Rik), mRNA. B230342M21Rik 0.66497052 1.46E-05
XM 001478602.1
PREDICTED: Mus musculus similar to FOG (LOC100047651), 
mRNA. LOC100047651 0.664444308 1.22E-05
NM 053093.1 Mus musculus tachykinin 4 (Tac4), mRNA. Tac4 0.661766682 2.75E-07
NM 001039089.1
Mus musculus sel-1 suppressor of lin-12-like (C. elegans) (Selll), 
transcript variant 1, mRNA. Selll 0.661523227 5.83E-05
NM 024189.5 Mus musculus YY1 associated factor 2 (Yaf2), mRNA. Yaf2 0.660863464 5.14E-07
NM 026407.2 Mus musculus transmembrane protein 39a (Tmem39a), mRNA. Tmem39a 0.660246118 1.49E-06
NM 146017.3
Mus musculus gamma-aminobutyric acid (GABA-A) receptor, pi 
(Gabrp), mRNA. Gabrp 0.659560984 7.87E-06
NM 029999.3 Mus musculus limb-bud and heart (Lbh), mRNA. Lbh 0.656620181 1.29E-05
NM 007671.2
Mus musculus cydin-dependent kinase inhibitor 2C (pl8, 
inhibits CDK4) (Cdkn2c), mRNA. Cdkn2c 0.65577269 7.62E-06
NM 007836.1
Mus musculus growth arrest and DNA-damage-inducible 45 
alpha (Gadd45a), mRNA. Gadd45a 0.655468024 0.003813
NM 175682.2
Mus musculus RIKEN cDNA 9930021D14 gene (9930021D14Rik), 
mRNA. 9930021D14Rik 0.653137082 1.39E-05
NM 013842.2 Mus musculus X-box binding protein 1 (Xbpl), mRNA. Xbpl 0.65256871 2.15E-05
XM 001476512.1
PREDICTED: Mus musculus similar to aquaporin 5 
(LOC100046616), mRNA. LOC100046616 0.652065529 3.14E-07
NM 026270.3 Mus musculus AKT1 substrate 1 (proline-rich) (Aktlsl), mRNA. A ktls l 0.651461739 5.37E-07
NM 145525.2 Mus musculus oxysterol binding protein-like 6 (0sbpl6), mRNA. Osbpl6 0.649423786 2.15E-05
NM 008609.3
Mus musculus matrix metallopeptidase 15 (Mm pl5), mRNA. 
XM 001002221 M m pl5 0.648857872 9.42E-06
NM 019581.2 Mus musculus GTP binding protein 2 (Gtpbp2), mRNA. Gtpbp2 0.645780581 5.08E-05
NM 031185.2
Mus musculus A kinase (PRKA) anchor protein (gravin) 12 
(Akapl2), mRNA. Akapl2 0.64338736 0.000218
NM 176933.4 Mus musculus dual specificity phosphatase 4 (Dusp4), mRNA. Dusp4 0.641765708 2.69E-06
NM 025371.1 Mus musculus aminoacylase 1 (Acyl), mRNA. Acyl 0.639844887 2.94E-06
NM 009996.2 Cyp24al 0.638027453 1.09E-05
NM 009067.3 Mus musculus ralA binding protein 1 (Ralbpl), mRNA. Ralbpl 0.637552358 5.25E-05
NM 177725.3 Mus musculus leucine rich repeat containing 8A (Lrrc8a), mRNA. Lrrc8a 0.636764017 2.35E-05
NM 016865.2
Mus musculus HIV-1 tat interactive protein 2, homolog (human) 
(Htatip2), mRNA. Htatip2 0.630846189 2.45 E-07
NM 177725.2 Lrrc8 0.62980998 5.08E-05
NM 012037.2
Mus musculus vesicle amine transport protein 1 homolog (T 
californica) (Vatl), mRNA. V atl 0.62944579 1.22E-05
NM 026551.3
Mus musculus dephospho-CoA kinase domain containing 
(Dcakd), mRNA. Dcakd 0.629215025 1.5E-07
NM 016865.2
Mus musculus HIV-1 tat interactive protein 2, homolog (human) 
(Htatip2), mRNA. Htatip2 0.628100399 6.68E-06
NM 146017.3
Mus musculus gamma-aminobutyric acid (GABA-A) receptor, pi 
(Gabrp), mRNA. Gabrp 0.623849993 6E-07
NM 139200.4
Mus musculus pleckstrin homology, Sec7 and coiled-coil 
domains, binding protein (Pscdbp), mRNA. Pscdbp 0.623443765 7.09E-07
NM 029999.3 Mus musculus limb-bud and heart (Lbh), mRNA. Lbh 0.621850147 4.52E-07
NM 029631.2
Mus musculus abhydrolase domain containing 14b (Abhdl4b), 
mRNA. Abhdl4b 0.617769673 4.22E-07
NM 011177.1 Mus musculus kallikrein related-peptidase 6 (Klk6), mRNA. Klk6 0.617232496 4.34E-05
NM 016916.3
Mus musculus bladder cancer associated protein homolog 
(human) (Blcap), mRNA. Blcap 0.6156729 3.43 E-07
NM 146028.4 Mus musculus SH3 and cysteine rich domain 2 (Stac2), mRNA. Stac2 0.615165971 2.63E-06
XM 128174.2 2310001L23Rik 0.611471068 2.75E-07
NM 054087.2
Mus musculus solute carrier family 19 (thiamine transporter), 
member 2 (Slcl9a2), mRNA. Slcl9a2 0.601620614 3.53E-07
NM 153114.2 Mus musculus otospiralin (Otos), mRNA. Otos 0.600159002 2.21E-06
NM 133977.2 Mus musculus transferrin (Trf), mRNA. Trf 0.600055342 0.000108
NM 008077.2 Gadl 0.600044412 4.61E-06
NM 019990.4 Mus musculus START domain containing 10 (StardlO), mRNA. StardlO 0.57952738 2.48E-06
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NM 153163.3
Mus musculus Ca2+-dependent activator protein for secretion 2 
(Cadps2), mRNA. Cadps2 0.575340229 1.38E-07
NM 028048.2
Mus musculus solute carrier family 25, member 35 (Slc25a35), 
mRNA. Slc25a35 0.571399095 3.38E-08
NM 007913.5 Mus musculus early growth response 1 (Egrl), mRNA. Egrl 0.570325872 4.48E-06
NM 026514.2
Mus musculus CDC42 effector protein (Rho GTPase binding) 3 
(Cdc42ep3), mRNA. Cdc42ep3 0.56449874 1.23E-07
NM 011690.2 Mus musculus valyl-tRNA synthetase (Vars), mRNA. Vars 0.563426171 3.14E-07
NM 015786.1 Mus musculus histone cluster 1, Hlc (Histlhlc), mRNA. Histlhlc 0.555481545 3.97E-08
NM 015828.2 Mus musculus glucosamine (Gne), mRNA. Gne 0.55258075 6.2E-08
NM 008597.3 Mus musculus matrix Gla protein (Mgp), mRNA. Mgp 0.538368212 3.98E-07
NM 008077.4 Mus musculus glutamic acid decarboxylase 1 (Gadl), mRNA. Gadl 0.526076848 2.16E-06
NM 016974.1
Mus musculus D site albumin promoter binding protein (Dbp), 
mRNA. Dbp 0.521269471 7.52E-07
NM 022964.3
Mus musculus linker for activation of T cells family, member 2 
(Lat2), transcript variant 2, mRNA. Lat2 0.512946377 1.86E-08
NM 177613.2
Mus musculus cell division cycle 34 homolog (S. cerevisiae) 
(Cdc34), mRNA. XM_922814 XM_922817 Cdc34 0.455351144 1.73E-08
NM_030175.3
Mus musculus RIKEN cDNA 4930507C10 gene (4930507C10Rik), 
mRNA. 4930507C10Rik 0.453174903 3.14E-07
NM 021564.2 Mus musculus fetuin beta (Fetub), transcript variant 1, mRNA. Fetub 0.442456892 4.16E-10
NM 029148.1
Mus musculus thioredoxin domain containing 13 (Txndcl3), 
mRNA. XM_902134 XM_902137 XM_925631 XM_925632 
XM 925633 Txndcl3 0.433792905 3.48E-10
NM 022020.2 Mus musculus retinol binding protein 7, cellular (Rbp7), mRNA. Rbp7 0.427226393 4.16E-10
NM 029148.1
Mus musculus thioredoxin domain containing 13 (Txndcl3), 
mRNA. XM_902134 XM_902137 XM_925631 XM_925632 
XM 925633 Txndcl3 0.394442169 2.8E-09
NM 053078.3
Mus musculus DNA segment, human D4S114 (D0H4S114), 
mRNA. D0H4S114 0.382487875 3.48E-10
XM 001478127.1
PREDICTED: Mus musculus similar to Cell division cycle 34 
homolog (S. cerevisiae) (LOC100046898), mRNA. LOC100046898 0.261074911 2.02E-11
Appendix 2: Top 100 largest fold decreases in gene expression following Bcl3 suppression
Statistical differences in m icroarray data w ere  determ ined by T-tests to  obtain adjusted p-values. Data 
that achieved significance at p<0.01 (1691 genes) w ere  ranked according to fold change. Table 
represents the top  100 largest fold decreases in gene expression following Bcl3 suppression.
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